WO1999032454A9 - Nitrogen containing heteroaromatics with ortho-substituted p1's as factor xa inhibitors - Google Patents

Nitrogen containing heteroaromatics with ortho-substituted p1's as factor xa inhibitors

Info

Publication number
WO1999032454A9
WO1999032454A9 PCT/US1998/026427 US9826427W WO9932454A9 WO 1999032454 A9 WO1999032454 A9 WO 1999032454A9 US 9826427 W US9826427 W US 9826427W WO 9932454 A9 WO9932454 A9 WO 9932454A9
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
pyrazole
carboxyamide
methoxyphenyl
aminomethyl
Prior art date
Application number
PCT/US1998/026427
Other languages
French (fr)
Other versions
WO1999032454A1 (en
Inventor
Robert A Galemmo Jr
Donald J P Pinto
Lori L Bostrom
Karen Anita Rossi
Original Assignee
Du Pont Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Pharm Co filed Critical Du Pont Pharm Co
Priority to AU17244/99A priority Critical patent/AU1724499A/en
Priority to IL13663798A priority patent/IL136637A0/en
Priority to CA002314401A priority patent/CA2314401A1/en
Priority to BR9813835-9A priority patent/BR9813835A/en
Priority to JP2000525391A priority patent/JP2001526268A/en
Priority to EP98962082A priority patent/EP1042299A1/en
Publication of WO1999032454A1 publication Critical patent/WO1999032454A1/en
Publication of WO1999032454A9 publication Critical patent/WO1999032454A9/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18One oxygen or sulfur atom
    • C07D231/20One oxygen atom attached in position 3 or 5
    • C07D231/22One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18One oxygen or sulfur atom
    • C07D231/20One oxygen atom attached in position 3 or 5
    • C07D231/22One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C07D231/24One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms having sulfone or sulfonic acid radicals in the molecule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/041,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • This invention relates generally to nitrogen containing heteroaromatics, with ortho-substituted PI groups, which are inhibitors of trypsin-like serine protease enzymes, especially factor Xa, pharmaceutical compositions containing the same, and methods of using the same as anticoagulant agents for treatment and prevention of thromboembolic disorders.
  • R 1 represents the basic termini
  • U is an alkylene or heteroatom linker
  • V may be a heterocycle
  • the right hand portion of the molecule represents the acidic termini .
  • the presently claimed compounds do not contain the acidic termini of WO 95/18111.
  • Himmelsbach et al depict cell aggregation inhibitors which are 5-membered heterocycles of the formula:
  • heterocycle may be aromatic and groups A-B-C- and F-E-D- are attached to the ring system.
  • A-B-C- can be a wide variety of substituents including a basic group attached to an aromatic ring.
  • the F-E-D- group would appear to be an acidic functionality which differs from the present invention. Furthermore, use of these compounds as inhibitors of factor Xa is not discussed.
  • R 1 may be pyrrolidine or piperidine and A may be a basic group including amino and amidino.
  • Baker et al do not indicate that A can be a substituted ring system like that contained in the presently claimed heteroaromatics .
  • R 1 represents a nitrogen containing ring system or a nitrogen substituted cyclobutane
  • A may be a basic group including amino and amidino.
  • Baker et al do not indicate that A can be a substituted ring system like that contained in the presently claimed heteroaromatics .
  • R 1 can be a substituted aryl group
  • Z is a two carbon linker containing at least one heteroatome
  • X is a heterocycle
  • Y is an optional linker
  • W is an amidino or guanidino containing group.
  • cytokine inhibitors useful for inhibiting angiogenesis .
  • These inhibitors include imidazoles of the formula:
  • Ri is a variety of heteroaryl groups
  • R 4 is phenyl, naphthyl, or a heteroaryl group
  • R 2 can be a wide variety of groups .
  • Jackson et al do not teach inhibition of factor Xa. Furthermore, the imidazoles of Jackson et al are not considered part of the present invention.
  • Activated factor Xa whose major practical role is the generation of thrombin by the limited proteolysis of prothrombin, holds a central position that links the intrinsic and extrinsic activation mechanisms in the final common pathway of blood coagulation.
  • the generation of thrombin, the final serine protease in the pathway to generate a fibrin clot, from its precursor is amplified by formation of prothrombinase complex (factor Xa, factor V, Ca2 + and phospholipid) . Since it is calculated that one molecule of factor Xa can generate 138 molecules of thrombin (Elodi, S., Varadi, K. : Optimization of condi tions for the catalytic effect of the factor IXa-factor VIII Complex: Probable role of the complex in the amplification of blood coagulation.
  • inhibition of factor Xa may be more efficient than inactivation of thrombin in interrupting the blood coagulation system.
  • one object of the present invention is to provide novel nitrogen containing aromatic heterocycles, with ortho-substituted PI groups, which are useful as factor Xa inhibitors or pharmaceutically acceptable salts or prodrugs thereof .
  • It is another object of the present invention to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt or prodrug form thereof.
  • ring M contains, in addition to J, 0-3 N atoms, provided that if M contains 2 N atoms then R lb is not present and if M contains 3 N atoms then R l and R lb are not present;
  • J is N or NH
  • E is selected from phenyl, pyridyl, pyrimidyl , pyrazinyl, pyridazinyl, and piperidinyl substituted with 1-2 R;
  • R is selected from H, Cl, F, Br, I, (CH 2 ) t OR 3 , C 1 -. 4 alkyl, OCF 3 , CF 3 , C(0)NR 7 R 8 , and (CR 8 R 9 ) t NR 7 R 8 ;
  • G is absent or is selected from NHCH 2 , OCH 2 , and SCH2, provided that when s is 0 , then G is attached to a carbon atom on ring M;
  • Z is selected from a C ⁇ _ 4 alkylene, (CH 2 ) r O (CH 2 ) r >
  • R la and R lb are independently absent or selected from - ⁇ CH 2 ) r -R 1' , -CT ⁇ CH-R i NCH 2 R 1 ", OCH 2 R 1 ", SCH2R 1 ", NH(CH 2 ) 2 (CH 2 ) t R l 0 O(CH 2 ) 2 (CH 2 ) t R 1 0 and S (CH 2 ) 2 (CH 2 ) t R x 0-
  • R la and R lb when attached to adjacent carbon atoms, together with the atoms to which they are attached form a 5-8 membered saturated, partially saturated or unsaturated ring substituted with 0-2 R 4 and which contains from 0-2 heteroatoms selected from the group consisting of N, 0, and S;
  • R 1 " is selected from H, CH(CH 2 OR 2 ) 2 , C(0)R 2c , C(0)NR 2 R 2a , S(0)R 2b , S(0) 2 R 2b , and S0 2 NR 2 R 2a ;
  • R 2 at each occurrence, is selected from H, CF 3 , C ⁇ _ 6 alkyl, benzyl, C 3 - 6 carbocyclic residue substituted with 0-2 R b , and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R 4b ;
  • R 2a is selected from H, CF 3 , C - alkyl, benzyl, C 3 _ 6 carbocyclic residue substituted with 0-2 R b , and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R b ;
  • R 2b is selected from CF 3 , C 1 - 4 alkoxy, C ⁇ _ 6 alkyl, benzyl, C 3 _ 5 carbocyclic residue substituted with 0-2 R b , and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R 4b ;
  • R 2c is selected from CF 3 , OH, C 1 - 4 alkoxy, C ⁇ _6 alkyl, benzyl, C 2 -6 carbocyclic residue substituted with 0-2 R b , and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R 4b ;
  • R 2 and R 2a combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring substituted with 0-2 R 4b which contains from 0-1 additional heteroatoms selected from the group consisting of N, 0, and S;
  • R 2 and R 2a together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring substituted with 0-2 R b and containing from 0-1 additional heteroatoms selected from the group consisting of N, 0, and S;
  • R 3 at each occurrence, is selected from H, C ⁇ _ 4 alkyl, and phenyl ;
  • R 3a at each occurrence, is selected from H, C 1 - 4 alkyl, and phenyl;
  • R 3b at each occurrence, is selected from H, C 1 - 4 alkyl, and phenyl ;
  • R 3c at each occurrence, is selected from C 1 - 4 alkyl, and phenyl;
  • A is selected from: C 3 - 10 carbocyclic residue substituted with 0-2 R 4 , and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R 4 ;
  • B is selected from:
  • Y is selected from:
  • one R 4 is a 5-6 membered aromatic heterocycle containing from 1-4 heteroatoms selected from the group consisting of N, O, and S;
  • one R 4a is a 5-6 membered aromatic heterocycle containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-1 R 5 ;
  • R 5 at each occurrence, is selected from CF 3 , C ⁇ _e alkyl, phenyl substituted with 0-2 R 6 , and benzyl substituted with 0-2 R 6 ;
  • R 7 at each occurrence, is selected from H, OH, C]__ 6 alkyl, C ⁇ _ 6 alkylcarbonyl , C -s alkoxy, C ⁇ _ 4 alkoxycarbonyl , (CH 2 ) n -phenyl, C 6 - 10 aryloxy, C 6 - 10 aryloxycarbonyl, C 6 - 10 arylmethylcarbonyl , C ⁇ _ 4 alkylcarbonyloxy C 1 -.
  • R 8 at each occurrence, is selected from H, C ⁇ - 6 alkyl and (CH 2 ) n -phenyl;
  • R 7 and R 8 combine to form a 5 or 6 membered saturated, ring which contains from 0-1 additional heteroatoms selected from the group consisting of N, 0, and S;
  • R 9 at each occurrence, is selected from H, C ⁇ - 6 alkyl and (CH 2 ) n -phenyl ;
  • n at each occurrence, is selected from 0, 1, 2, and 3;
  • n 0, 1, and 2;
  • p at each occurrence, is selected from 0, 1, and 2 ;
  • r at each occurrence, is selected from 0, 1, 2, and 3;
  • s at each occurrence, is selected from 0, 1, and 2;
  • t at each occurrence, is selected from 0, 1, 2, and 3;
  • D-E-G- (CH 2 ) s ⁇ and -Z-A-B are not both benzamidines .
  • groups D-E- and -Z-A-B are attached to adjacent atoms on the ring;
  • R is selected from H, Cl, F, Br, I, (CH 2 ) t OR 3 , C 1 - 4 alkyl, OCF 3 , CF 3 , C(0)NR 7 R 8 , and (CR 8 R 9 ) t NR 7 R 8 ;
  • Z is selected from a CH 2 0, OCH 2 , CH 2 NH, NHCH 2 , C(0), CH 2 C(0),
  • A is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R 4 ; phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, 1, 2 , 3 -oxadiazolyl , 1, 2, 4-oxadiazolyl, 1, 2, 5-oxadiazolyl, 1, 3 , 4-oxadiazolyl, 1,2, 3-thiadiazolyl, 1, 2 , 4-thiadiazolyl,
  • Y is NR 2 R 2a , provided that X-Y do not form a N-N or O-N bond; alternatively, Y is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R 4a ; cylcopropyl, cyclopentyl, cyclohexyl, phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl , morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, isoxazolinyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, 1, 2 , 3-oxadiazolyl, 1, 2, 4-oxadiazolyl, 1, 2 , 5-oxadiazolyl,
  • Y is selected from the following bicyclic heteroaryl ring systems:
  • K is selected from O, S, NH, and N.
  • the present invention provides novel compounds of formulae Ila-IIf: wherein;
  • Z is selected from a C(O), CH 2 C(0), C(0)CH 2 , NHC(O), C(0)NH, C(0)N(CH 3 ), CH 2 S(0) 2 , S(0) 2 (CH 2 ), S0 2 NH, and NHS0 2 , provided that Z does not form a N-N or NCH 2 N bond with ring M or group A.
  • the present invention provides novel compounds of formulae Ila-IIf, wherein;
  • E is phenyl substituted with R or 2-pyridyl substituted with R;
  • D is selected from NH 2 , NHCH 3 , CH 2 NH 2 , CH 2 NHCH 3 , CH(CH 3 )NH 2 , and C(CH 3 ) 2 NH 2 , provided that D is substituted ortho to ring M on E; and,
  • R is selected from H, OCH 3 , Cl, and F.
  • the present invention provides novel compounds of formulae Ila-IIf, wherein;
  • D-E is selected from 2-aminophenyl, 2-methylaminophenyl, 2- aminomethylphenyl , 4-methoxy-2-aminophenyl , 4-methoxy-2- (methylamino)phenyl, 4-methoxy-2-aminomethylphenyl , 4- methoxy-2- (methylaminomethyl) henyl , 4-methoxy-2- ( 1- aminoethyl) phenyl, 4-methoxy-2- (2-amino-2-propyl)phenyl, 4-Cl-2-aminophenyl, 4-Cl-2- (methylamino) phenyl, 4-C1-2- aminomethylphenyl, 4-C1-2- (methylaminomethyl) phenyl , 4- Cl-2- (1-aminoethyl) phenyl, 4-C1-2- (2-amino-2- propyl)phenyl , 4-F-2-aminophenyl, 4-F-2- (methylamino)phenyl,
  • the present invention provides novel compounds of formulae Ila-IIf, wherein;
  • Z is C(0)CH 2 and CONH, provided that Z does not form a N-N bond with group A;
  • A is selected from phenyl, pyridyl, and pyrimidyl, and is substituted with 0-2 R ;
  • B is selected from X-Y, phenyl, pyrrolidino, morpholino,
  • R 4 at each occurrence, is selected from OH, (CH 2 ) r OR 2 , halo, Ci_ 4 alkyl, (CH 2 ) r NR 2 R 2a , and (CF 2 ) r CF 3 ;
  • R 4a is selected from C ⁇ _ alkyl, CF 3 , S(0) p R 5 , S0 2 NR 2 R 2 , and l-CF 3 -tetrazol-2-yl;
  • R 5 at each occurrence, is selected from CF 3 , C 1 - 6 alkyl, phenyl, and benzyl;
  • X is CH 2 or C(O);
  • Y is selected from pyrrolidino and morpholino .
  • the present invention provides novel compounds of formulae Ila-IIf, wherein;
  • A is selected from the group: phenyl, 2-pyridyl, 3-pyridyl, 2-pyrimidyl, 2-Cl-phenyl, 3-Cl-phenyl, 2-F-phenyl, 3-F- phenyl, 2-methylphenyl, 2-aminophenyl, and 2- methoxyphenyl ,- and,
  • B is selected from the group: 2-CF3-phenyl, 2-
  • the present invention provides novel compounds of formulae Ila-IIf, wherein;
  • E is phenyl substituted with R or 2-pyridyl substituted with R;
  • D is selected from NH 2 , NHCH 3 , CHNH 2 , CH 2 NHCH 3 , CH(CH 3 )NH 2 , and C(CH 3 ) 2 NH 2 , provided that D is substituted ortho to ring M on E; and,
  • R is selected from H, OCH 3 , Cl, and F;
  • Z is C(0)CH 2 and CONH, provided that Z does not form a N-N bond with group A;
  • A is selected from phenyl, pyridyl, and pyrimidyl, and is substituted with 0-2 R 4 ; and, B is selected from X-Y, phenyl, pyrrolidino, morpholino,
  • R 4 at each occurrence, is selected from OH, (CH2) ⁇ O R2 ' halo, C ⁇ - 4 alkyl, (CH 2 ) r NR 2 R 2 , and (CF 2 ) r CF 3 ;
  • R 4a is selected from C ⁇ _ 4 alkyl, CF 3 , S(0) p R 5 , S ⁇ 2 NR 2 R 2a , and l-CF 3 -tetrazol-2-yl;
  • R 5 at each occurrence, is selected from CF 3 , C ⁇ - 6 alkyl, phenyl, and benzyl;
  • X is CH 2 or C(O);
  • Y is selected from pyrrolidino and morpholino.
  • the present invention provides novel compounds of formulae Ila-IIf, wherein;
  • D-E is selected from 2-aminophenyl, 2-methylaminophenyl, 2- aminomethylphenyl, 4-methoxy-2-aminophenyl, 4-methoxy-2- (methylamino)phenyl, 4-methoxy-2-aminomethylphenyl, 4- methoxy-2- (methylaminomethyl) phenyl, 4-methoxy-2- (1- aminoethyl)phenyl, 4-methoxy-2- (2-amino-2-propyl)phenyl, 4-Cl-2-aminophenyl, 4-C1-2- (methylamino)phenyl, 4-C1-2- aminomethylphenyl, 4-Cl-2- (methylaminomethyl) phenyl, 4- Cl-2- (1-aminoethyl)phenyl, 4-C1-2- (2-amino-2- propyl)phenyl , 4-F-2-aminophenyl, _4-F-2- (methylamino)phenyl, 4-F-2-a
  • A is selected from the group: phenyl, 2-pyridyl, 3-pyridyl, 2-pyrimidyl, 2-Cl-phenyl, 3-Cl-phenyl, 2-F-phenyl, 3-F- phenyl, 2-methylphenyl, 2-aminophenyl, and 2- methoxyphenyl ; and,
  • B is selected from the group: 2-CF3-phenyl, 2- (aminosulfonyl) phenyl, 2- (methylaminosulfonyl) phenyl, 2- (dimethyla inosulfonyl) phenyl, 1-pyrrolidinocarbonyl, 2- (methylsulfonyl)phenyl, 4-morpholino, 2- (1' -CF3 ⁇ tetrazol- 2-yl) phenyl, 4-morpholinocarbonyl , 2-methyl-l-imidazolyl, 5-methyl-l-imidazolyl, 2-methylsulfonyl-1-imidazolyl and, 5-methyl-1,2, 3-triazolyl.
  • the present invention provides a novel compound of formula Ha.
  • the present invention provides a novel compound of formula lib.
  • the present invention provides a novel compound of formula He
  • the present invention provides a novel compound of formula lid.
  • the present invention provides a novel compound of formula He.
  • the present invention provides a novel compound of formula Hf [ 16 ] In another even more preferred embodiment , the present invention provides novel compounds of formulae Ila-IIf , wherein;
  • E is phenyl substituted with R or pyridyl substituted with R;
  • R is selected from H, Cl , F, OR 3 , CH 3 , CH 2 CH 3 , 0CF 3 , CF 3 , NR 7 R 8 , and CH 2 NR 7 R 8 ;
  • Z is selected from C(O), CH 2 C(0), C(0)CH 2 , NHC(O), and C(0)NH, provided that Z does not form a N-N bond with ring M or group A;
  • R la and R lb are independently absent or selected from
  • R 1 ' is selected from H, C 1 -. 3 alkyl, halo, (CF 2 ) r CF 3 , OR 2 , NRR , C(0)R 2c , (CF 2 ) r C0 2 R 2c , S(0) p R 2b , NR 2 (CH 2 ) r OR 2 , NR 2 C(0)R 2b , NR 2 C(0) 2 R 2b , C(0)NR 2 R 2a , S ⁇ 2 NR 2 R 2a , and NR S0 2 R 2b ;
  • A is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R 4 ; phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, and imidazolyl;
  • Y is NR 2 R 2a , provided that X-Y do not form a N-N or 0-N bond;
  • Y is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R 4a ; phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, isoxazolinyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, 1, 2 , 3 -oxadiazolyl, 1, 2, 4-oxadiazolyl, 1, 2 , 5-oxadiazolyl, 1, 3 , 4-oxadiazolyl, 1,2, 3-thiadiazolyl , 1,2, 4-thiadiazolyl , 1,2, 5-thiadiazolyl, 1, 3 , 4-thiadiazolyl , 1, 2 ,
  • R 5 at each occurrence, is selected from CF 3 , C 1 - 6 alkyl, phenyl substituted with 0-2 R 6 , and benzyl substituted with 0-2 R 6 ;
  • R 7 is selected from H, OH, C ⁇ _ 6 alkyl, C ⁇ _ 6 alkylcarbonyl, C - ⁇ alkoxy, C ⁇ _ 4 alkoxycarbonyl, benzyl, C ⁇ -io aryloxy, C ⁇ -io aryloxycarbonyl, C ⁇ -io arylmethylcarbonyl, C 1 - 4 alkylcarbonyloxy C ⁇ - 4 alkoxycarbonyl, C 6 - 10 arylcarbonyloxy C ⁇ _ 4 alkoxycarbonyl, C 1 -6 alkylaminocarbonyl, phenylaminocarbonyl , and phenyl C 1 - 4 alkoxycarbonyl;
  • R 8 at each occurrence, is selected from H, C 1 - 6 alkyl and benzyl ;
  • R 7 and R 8 combine to form a morpholino group
  • R 9 at each occurrence, is selected from H, C ⁇ _ 6 alkyl and benzyl.
  • the present invention provides novel compounds of formulae Ila-IIf, wherein;
  • E is phenyl substituted with R or 2-pyridyl substituted with R;
  • R is selected from H, Cl, F, OCH 3 , CH 3 , OCF 3 , CF 3 , NH 2 , and CH 2 NH 2 ;
  • Z is selected from a C(0)CH 2 and C(0)NH, provided that Z does not form a N-N bond with group A;
  • Rla _ s selected from H, CH 3 , CH2CH3 , Cl, F, CF3 , OCH3 , NR 2 R 2a , S(0) p R 2b , CH 2 S(0) p R 2 , CH 2 NR 2 S(0) p R b , C(0)R 2c , CH 2 C(0)R 2 , C(0)NR 2 R 2a , and S0 2 NR 2 R 2 a ;
  • Rlb s selected from H, CH 3 , CH 2 CH 3 , Cl, F, CF 3 , OCH 3 , NR 2 R 2a , S(0) p R 2b , CH 2 S(0) p R 2b , CH 2 NR 2 S(0) p R 2b , C(0)R 2c , CH 2 C(0)R 2c , C(0)NR 2 R 2a , and S0 2 NR 2 R 2a ;
  • A is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R 4 ; phenyl, pyridyl, pyrimidyl, furanyl, thiophenyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, and imidazolyl;
  • B is selected from: Y and X-Y;
  • Y is NR 2 R 2a , provided that X-Y do not form a N-N or 0-N bond;
  • Y is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R 4a ; phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, isoxazolinyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, 1, 2, 3-oxadiazolyl, 1, 2, 4-oxadiazolyl, 1, 2 , 5-oxadiazolyl, 1, 3 , 4-oxadiazolyl, 1,2, 3-thiadiazolyl, 1, 2 , 4-thiadiazolyl, 1, 2, 5-thiadiazolyl, 1, 3 , 4-thiadiazolyl, 1, 2, 3 -triazo
  • R 2 at each occurrence, is selected from H, CF 3 , CH 3 , benzyl, and phenyl;
  • R 2a at each occurrence, is selected from H, CF 3 , CH 3 , benzyl, and phenyl
  • R 2b at each occurrence, is selected from CF 3 , OCH 3 , CH 3 , benzyl, and phenyl
  • R 2c at each occurrence, is selected from CF 3 , OH, OCH 3 , CH 3 , benzyl, and phenyl;
  • R 2 and R a combine to form a 5 or 6 membered saturated, partially unsaturated, or unsaturated ring which contains from 0-1 additional heteroatoms selected from the group consisting of N, 0, and S;
  • R 3 at each occurrence, is selected from H, CH 3 , CH 2 CH 3 , and phenyl;
  • R 3a at each occurrence, is selected from H, CH 3 , CH 2 CH 3 , and phenyl ;
  • R 4 at each occurrence, is selected from OH, Cl , F, CH 3 ,
  • R 4a at each occurrence, is selected from OH, Cl, F, CH 3 ,
  • R 5 at each occurrence, is selected from CF 3 , C -e alkyl, phenyl substituted with 0-2 R 6 , and benzyl substituted with 1 R 6 ;
  • R 6 at each occurrence, is selected from H, OH, OCH 3 , Cl, F, CH 3 , CN, N0 2 , NR 2 R 2 , CH 2 NR 2 R 2 , and S0 2 NR 2 R 2a ;
  • R 7 at each occurrence, is selected from H and C ⁇ _ 3 alkyl
  • R 8 at each occurrence, is selected from H, CH 3 , and benzyl;
  • R 9 at each occurrence, is selected from H, CH 3 , and benzyl; and, t, at each occurrence, is selected from 0 and 1.
  • the present invention provides novel compounds of formulae Ila-IIf, wherein;
  • D is selected from NR 7 R 8 , and CH 2 NR 7 R 8 , provided that D is substituted ortho to ring M on E;
  • R la is absent or is selected from H, CH 3 , CH 2 CH 3 , Cl, F, CF 3 , OCH 3 , NR 2 R 2a , S(0) p R 2b , C(0)NR 2 R 2a , CH 2 S(0) p R 2b , CH 2 NR 2 S(0) p R 2b , C(0)R 2c , CH 2 C(0)R 2c , and S0 2 NR 2 R 2a ;
  • R lb is absent or is selected from H, CH 3 , CH 2 CH 3 , Cl, F, CF 3 , OCH 3 , NR 2 R 2a , S(0) p R 2b , C(0)NR 2 R 2a , CH 2 S(0) p R 2b , CH 2 NR 2 S(0) p R 2b , C(0)R 2b , CH 2 C(0)R 2b , and S0 2 NR 2 R 2a ;
  • A is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R 4 ; phenyl, pyridyl, and pyrimidyl;
  • B is selected from: Y and X-Y;
  • X is selected from -C(O)- and 0;
  • Y is NR 2 R 2 , provided that X-Y do not form a 0-N bond;
  • Y is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R 4a ; phenyl, piperazinyl, pyridyl, pyrimidyl, morpholinyl, pyrrolidinyl, imidazolyl, and 1,2,3- triazolyl;
  • R 2 at each occurrence, is selected from H, CF 3 , CH 3 , benzyl, and phenyl;
  • R 2 at each occurrence, is selected from H, CF 3 , CH 3 , benzyl, and phenyl;
  • R 2b at each occurrence, is selected from CF 3 , OCH 3 , CH 3 , benzyl, and phenyl;
  • R 2c at each occurrence, is selected from CF 3 , OH, OCH 3 , CH 3 , benzyl, and phenyl;
  • R 2 and R 2a combine to form a ring system selected from pyrrolidinyl, piperazinyl and morpholino;
  • R 4 at each occurrence, is selected from Cl, F, CH 3 , NR 2 R 2a , and CF 3 ;
  • R a at each occurrence, is selected from Cl, F, CH 3 , S0 2 NR 2 R 2a , S(0) P R 5 , and CF 3 ;
  • R 5 at each occurrence, is selected from CF 3 and CH 3 ,-
  • R 7 at each occurrence, is selected from H, CH 3 , and CH 2 CH 3 ;
  • R 8 at each occurrence, is selected from H and CH 3 .
  • Specifically preferred compounds of the present invention are selected from the group:
  • the present invention provides novel pharmaceutical compositions, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt form thereof.
  • the present invention provides a novel method for treating or preventing a thromboembolic disorder, comprising: administering to ⁇ a patient in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt form thereof .
  • the compounds herein described may have asymmetric centers .
  • Compounds of the present invention containing an asymmetrically substituted atom may be isolated in optically active or racemic forms . It is well known in the art how to prepare optically active forms, such as by resolution of racemic forms or by synthesis from optically active starting materials.
  • substituted means that any one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound.
  • 2 hydrogens on the atom are replaced.
  • Keto substituents are not present on aromatic moieties.
  • the present invention is intended to include all isotopes of atoms occurring in the present compounds.
  • Isotopes include those atoms having the same atomic number but different mass numbers.
  • isotopes of hydrogen include tritium and deuterium.
  • isotopes of carbon include C-13 and C-14.
  • any variable e.g., R6
  • its definition at each occurrence is independent of its definition at every other occurrence.
  • R 6 at each occurrence is selected independently from the definition of R 6 .
  • combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
  • alkyl is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms.
  • alkyl include, but are not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, n-pentyl, and s-pentyl.
  • Hydroalkyl is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, substituted with
  • haloalkyl examples include, but are not limited to, trifluoromethyl, trichloromethyl , pentafluoroethyl, and pentachloroethyl .
  • Alkoxy represents an alkyl group as defined above with the indicated number of carbon atoms attached through an oxygen bridge . Examples of alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy, n-pentoxy, and s-pentoxy.
  • Cycloalkyl is intended to include saturated ring groups, such as cyclopropyl, cyclobutyl, or cyclopentyl.
  • Alkenyl is intended to include hydrocarbon chains of either a straight or branched configuration and one or more unsaturated carbon-carbon bonds which may occur in any stable point along the chain, such as ethenyl and propenyl .
  • Alkynyl is intended to include hydrocarbon chains of either a straight or branched configuration and one or more triple carbon-carbon bonds which may occur in any stable point along the chain, such as ethynyl and propynyl .
  • Halo or “halogen” as used herein refers to fluoro, chloro, bromo, and iodo; and "counterion” is used to represent a small, negatively charged species such as chloride, bromide, hydroxide, acetate, and sulfate.
  • carbocycle or “carbocyclic residue” is intended to mean any stable 3- to 7-membered monocyclic or bicyclic or 7-to 13-membered bicyclic or tricyclic, any of which may be saturated, partially unsaturated, or aromatic.
  • carbocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, cyclooctyl, [3.3.0]bicyclooctane, [4.3.0]bicyclononane, [4.4. O]bicyclodecane,
  • heterocycle or “heterocyclic system” is intended to mean a stable 5-to 7-membered monocyclic or bicyclic or 7-to 10-membered bicyclic heterocyclic ring which is saturated partially unsaturated or unsaturated (aromatic) , and which consists of carbon atoms and from 1 to 4 heteroatoms independently selected from the group consisting of N, 0 and S and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring.
  • the nitrogen and sulfur heteroatoms may optionally be oxidized.
  • the heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom which results in a stable structure.
  • the heterocyclic rings described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable.
  • a nitrogen in the heterocycle may optionally be quaternized. It is preferred that when the total number of S and O atoms in the heterocycle exceeds 1, then these heteroatoms are not adjacent to one another. It is preferred that the total number of S and 0 atoms in the heterocycle is not more than 1.
  • aromatic heterocyclic system or “heteroaryl” is intended to mean a stable 5-to 7-membered monocyclic or bicyclic or 7-to 10-membered bicyclic heterocyclic aromatic ring which consists of carbon atoms and from 1 to 4 heterotams independently selected from the group consisting of N, 0 and S. It is preferred that the total number of S and 0 atoms in the aromatic heterocycle is not more than 1.
  • heterocycles include, but are not limited to, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl , benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzi idazolinyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H, 6H-1, 5, 2-dithiazinyl, dihydrofuro [2, 3 -b] tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, lH-indazolyl, indolenyl,
  • Preferred heterocycles include, but are not limited to, pyridinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrrolidinyl, imidazolyl, indolyl, benzimidazolyl, lH-indazolyl, oxazolidinyl, benzotriazolyl, benzisoxazolyl, oxindolyl, benzoxazolinyl, and isatinoyl. Also included are fused ring and spiro compounds containing, for example, the above heterocycles.
  • phrases "pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • pharmaceutically acceptable salts refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof.
  • pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
  • the pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
  • such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like.
  • inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like
  • organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic,
  • the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods.
  • such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred.
  • Lists of suitable salts are found in Remington ' s Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, PA, 1985, p. 1418, the disclosure of which is hereby incorporated by reference.
  • Prodrugs are intended to include any covalently bonded carriers which release the active parent drug according to formula (I) in vivo when such prodrug is administered to a mammalian subject.
  • Prodrugs of a compound of formula (I) are prepared by modifying functional groups present in the compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compound.
  • Prodrugs include compounds of formula (I) wherein a hydroxy, amino, or sulfhydryl group is bonded to any group that, when the prodrug or compound of formula (I) is administered to a mammalian subject, cleaves to form a free hydroxyl, free amino, or free sulfhydryl group, respectively.
  • prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups in the compounds of formula (I) , and the like.
  • More preferred prodrugs are where R 7 is OH, methoxy, ethoxy, benzyloxycarbonyl, methoxycarbonyl, and methylcarbonyloxymethoxycarbonyl
  • Solid compound and “stable structure” are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent .
  • “Substituted” is intended to indicate that one or more hydrogens on the atom indicated in the expression using “substituted” is replaced with a selection from the indicated group (s ) , provided that the indicated atom's normal valency is not exceeded, and that the substitution results in a stable compound.
  • “Therapeutically effective amount” is intended to include an amount of a compound of the present invention or an amount of the combination of compounds claimed effective to inhibit HIV infection or treat the symptoms of HIV infection in a host .
  • the combination of compounds is preferably a synergistic combination. Synergy, as described for example by Chou and Talalay, Adv.
  • Enzyme Regul . 22:27-55 (1984) occurs when the effect (in this case, inhibition of HIV replication) of the compounds when administered in combination is greater than the additive effect of the compounds when administered alone as a single agent.
  • a synergistic effect is most clearly demonstrated at suboptimal concentrations of the compounds. Synergy can be in terms of lower cytotoxicity, increased antiviral effect, or some other beneficial effect of the combination compared with the individual components .
  • the compounds of the present invention can be prepared in a number of ways known to one skilled in the art of organic synthesis.
  • the compounds of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or by variations thereon as appreciated by those skilled in the art. Preferred methods include, but are not limited to, those described below.
  • the reactions are performed in a solvent appropriate to the reagents and materials employed and suitable for the transformations being effected. It will be understood by those skilled in the art of organic synthesis that the functionality present on the molecule should be consistent with the transformations proposed. This will sometimes require a judgment to modify the order of the synthetic steps or to select one particular process scheme over another in order to obtain a desired compound of the invention.
  • the compounds of Formula I in which ring M is pyrrole can be prepared by the procedures described in Schemes 1-9.
  • Scheme 1 is shown how to prepare pyrroles in which the group Q-E is attached to the pyrrole nitrogen, wherein Q is a functionality that can be converted into D of Formula I, R e is functionality that can be converted into Z-A-B of Formula I and R f is or can be converted into R l of Formula I.
  • Oxidation of a furan with bromine in acetic acid can afford a 2,5- diacetoxydihydrofuran which can react with amine Q-E-NH2 to afford a pyrrole.
  • Derivatives which contain a sulfur atom attached to the pyrrole ring can be obtained by direct sulfonation with pyridine sulfur trioxide complex to give the sulfonic acids or treatment with copper (II) thiocyanate (J " . Het. Chem . 1988, 25, 431) followed by the reduction of the intermediate thiocyanate with sodium borohydride to give a mercaptan.
  • Pyrroles which contain a 3-amino substituent can be prepared from the acids by treatment with phosphoryl azide and triethylamine to effect a Curtius rearrangement to afford the isocyanates (J " . Med. Chem . 1981, 24 , 33) which upon hydrolysis can yield 3- aminopyrroles .
  • Pyrroles which contain a sulfur atom at C-3 can be prepared from the acids by employing the Hunsdiecker procedure to give the 3-bromo derivatives.
  • Halogen-metal exchange at low temperature with an alkyllithium reagent can afford the 3-lithio derivative which can be quenched with a variety of electrophiles, such as ⁇ 8 to afford thiols directly or Cu(SCN)2 to afford a thiocyanate which can be reduced with sodium borohydride.
  • the thiols can further be oxidized to the sulfonic acid derivatives by an oxidant such as KMn ⁇ 4 .
  • R e Z-A-B precursor
  • acidic hydrolysis can selectively hydrolyze the C-3 ester. Heating should then effect decarboxylation.
  • Hydrolysis of the 2-carboxylic acid can be achieved under basic conditions. Curtius rearrangement of the acid as described previously can afford the amino derivatives.
  • basic hydrolysis and decarboxylation can afford the C-2 unsubstituted pyrroles. These pyrroles can undergo electrophilic substitution to afford thiols (Cu(SCN) 2 , then NaBH 4 ) and sulfonic acids (pyridine SO 3 complex or chlorosulfonic acid) .
  • R la group contained in Formula I can be derived either from the remaining ester or from R f .
  • the thiol and sulfonic acid derivatives can also be derived form the C-2 acids by manipulation of the carboxylic acid group as described previously.
  • the Hunsdiecker procedure can be used to prepare the 3 -bromopyrroles .
  • Halogen metal exchange with t-BuLi at low temperature followed by quenching with copper isocyanate should introduce an isocyanate group at C-3.
  • This intermediate can be reduced with sodium borohydride to afford the 3-mercaptopyrroles .
  • the carboxylic acids can be decarboxylated to afford pyrroles which can be N- protected with a bulky protecting group such as triisopropylsilyl (TIPS) . This bulky group directs electrophilic substitution to C-3 of the pyrrole ring.
  • TIPS triisopropylsilyl
  • reaction with copper isocyanate followed by sodium borohydride reduction and then fluoride induced TIPS deprotection can afford 3-mercaptopyrroles.
  • Sulfonation of N-protected pyrrole with pyridine sulfur trioxide complex can again be directed to C-3 of the pyrrole to afford, after TIPS deprotection, the 3- sulfonic acids .
  • aldehydes and ketones can be allowed to react with the enolates of additional ketones to afford intermediate aldol addition products which under acidic conditions cyclize to form pyrroles.
  • the reacting partners in this approach can be of wide scope and can be chosen so -that one skilled in the art will be able to prepare varied pyrroles .
  • Another very general method of pyrrole synthesis useful for preparing compounds of the present invention is the Paal- Knorr reaction shown in Scheme 6.
  • This reaction involves the reacting 1, 4-diketones or 1, 4-ketoaldehydes with primary amines to afford pyrroles.
  • the starting 1, 4-diketones and 1, 4-ketoaldehydes can be prepared using standard enolate chemistry or by other procedures which are familiar to those skilled in the art of organic synthesis .
  • the reaction is of wide scope and the starting materials can be chosen so that a variety of pyrroles can be prepared.
  • the acid can be combined with amine H 2 N-A-B in the presence of a suitable peptide coupling agent, such as BOP-Cl, HBTU or DCC.
  • a suitable peptide coupling agent such as BOP-Cl, HBTU or DCC.
  • the ester can be directly coupled with an aluminum reagent, prepared by the addition of trimethylaluminum to the amine H 2 N-A-B.
  • an aluminum reagent prepared by the addition of trimethylaluminum to the amine H 2 N-A-B.
  • the acid can be reduced to the alcohol.
  • the alcohol can be oxidized to the aldehyde by a number of procedures, two preferred methods of which are the Swern oxidation and oxidation with pyridinium chlorochromate (PCC) .
  • the aldehyde may be directly prepared by direct formylation of the pyrrole ring by the Vilsmeier-Haack procedure in certain cases , as described in previous schemes. Reductive amination of the aldehyde with an appropriate amine H 2 N-A-B and sodium cyanoborohydride can then afford the amine linked compounds.
  • Treatment with an organometallic species can afford the alcohol.
  • These reagents should readily react with aldehydes to afford alcohols . Oxidation of the alcohol by any of a number of procedures, such as the Swern oxidation or PCC oxidation, can afford the ketones-linked compounds.
  • Additional compounds of Formula I in which the linking group m/z contains a nitrogen atom attached to ring M can be prepared by the procedures described in Scheme 8.
  • the amines can be converted to sulfonamides (Formula I, m/z-NHS02 ⁇ ) by treatment with an appropriate sulfonyl chloride B-A-SO2CI in the presence of a base such as triethylamine.
  • Additional compounds of Formula I in which the linking group Z contains a sulfur atom attached to ring M can be prepared by the procedures described in Scheme 9.
  • N- Substituted imidazole derivatives can be made by the general procedure shown in Scheme 10, wherein V is either V or a precusor of (CH 2 ) n V, V is nitro, amino, thio, hydroxy, sulfonic acid, sulfonic ester, sulfonyl chloride, ester, acid, or halide, n is 0 and 1, and PG is either a hydrogen or a protecting group.
  • Substitution can be achieved by coupling an imidazole with a halogen containing fragment Q-E-G-Hal in the presence of a catalyst, such as base, Cu/CuBr/base, or Pd/base, followed by conversion of V to (CH 2 ) n N- Then, Q can be converted to D, and finally V can be converted to -Z-A-B following the procedures outlined in Schemes 7-9. Alternatively, V can be converted to Z-A-B followed by deprotection of N. This product can then be coupled as before to obtain the desired imidazole.
  • a catalyst such as base, Cu/CuBr/base, or Pd/base
  • 1, 2-Disubstituted and 1, 5-disubstituted imidazole derivatives can be made by the general procedures described in Scheme 12, wherein R l is either a hydrogen or an alkyl group and U is aldehyde, ester, acid, amide, amino, thiol, hydroxy, sulfonic acid, sulfonic ester, sulfonyl chloride, or methylene halide.
  • Step a involves coupling in the presence of a catalyst, such as base, Cu/CuBr/base, or Pd/base.
  • R lb When R lb is a hydrogen, it can be deprotonated with a lithium base and trapped by formate, formamide, carbon dioxide, sulfonyl chloride (sulfur dioxide and then chlorine) , or isocyanate to give 1, 2-disubstituted imidazoles (Route bl) . Also, in Route bl when R lb is CH 3 , it can be oxidized with Se ⁇ 2 , Mn ⁇ 2 , NaI ⁇ 4 /cat. RI1CI 3 , or NBS to form U.
  • R lb When R lb is hydrogen, sequential deprotonation and quenching with a lithium base and trimethysilyl chloride, followed by a second deprotonation with a lithium base and quenching with formate, formamide, carbon dioxide, sulfonyl chloride (sulfur dioxide and then chlorine), or isocyanate can afford 1, 5-disubstituted imidazoles (Route b2 ) .
  • R lb When R lb is not hydrogen, the procedure of Route b2 can again be used to form 1, 5-disubstituted imidazoles (Route b3 ) .
  • the tetrazole compounds of the present invention where Z is -CONH- can be prepared as exemplified in Scheme 18.
  • An appropiately substituted amine can be acylated with ethyl oxalyl chloride.
  • the resulting amide can be converted to the tetrazole either by the methods described by Duncia (J. Org. Chem . 1991, 2395-2400) or Thomas ( Synthesis 1993, 767-768) .
  • the amide can be converted to the iminoyl chloride first and the reacted with a 3 to form the 5-carboethoxytetrazole (J". Org. Chem . 1993, 58, 32-35 and Bioorg . & Med. Chem . Lett . 1996, 6, 1015-1020) .
  • the 5-carboethoxytetrazole can then be further modified as described in Scheme 7.
  • the tetrazole compounds of the present invention where Z is -CO- can also be prepared via iminoyl chloride ⁇ Chem. Ber. 1961, 94, 1116 and J. Org. Chem. 1976, 41 , 1073) using an appropriately substituted acyl chloride as starting material.
  • the ketone-linker can be reduced to compounds wherein Z is alkyl .
  • tetrazole compounds of the present invention wherein Z is -S0 2 NH-, -S-, -S(0)-, SO 2 - can be prepared from the thiol prepared as shown in Scheme 20. Appropiately substituted thioisocyanate can be reacted with sodium azide to give the 5- thiotetrazole (J " . Org. Chem . 1967, 32, 3580-3592). The thio- compound can be modified as described in Scheme 9.
  • tetrazole compounds of the present invention wherein Z is -O- can be prepared via the same method described in Scheme 20 by using appropiately substituted isocyanate as the starting material.
  • the hydroxy compound can be modified si ilarily to the thiols described in Scheme 9.
  • the tetrazole compounds of the present invention wherein Z is -NH-, -NHCO-, -NHS0 2 - can be prepared from 5- aminotetrazole, which can be prepared by Smiles Rearrangement as shown in Scheme 21.
  • the thio-compound prepared as described in Scheme 20 can be alkylated with 2- chloroacetamide .
  • the resulting compound can then be refluxed in ethanolic sodium hydroxide to give the corresponding 5- amino-tetrazole ( Chem . Pharm. Bull . 1991, 39, 3331-3334) .
  • the resulting 5-amino-tetrazole can then be alkylated or acylated to form the desired products.
  • Pyrazoles of Formula I can be prepared by the condensation of an appropriately substituted hydrazine with a variety of diketo esters. Condensations of this type typically afford a mixture of pyrazole regioisomers which can be effectively separated via silica gel column chromatography. The esters can be converted to Z-A-B as previously described.
  • pyrazoles wherein the 4-position is substituted can be prepared by bromination (bromine or NBS in either dichloromethane or acetic acid) of the initial pyrazole. Conversion of 4-bromo-pyrazole to 4-carboxylic acid pyrazole can be accomplished by a number of methods commonly known to those in the art of organic synthesis . Further manipulations as previously described can afford pyrazoles of the present invention.
  • Pyrazoles can also be prepared according to method described in Scheme 25.
  • the bromo-pyrazoles are formed as in Scheme 24.
  • QE can then be coupled using palladium catalysed Suzuki cross-coupling methodology. Further modification is achieved as previously described.
  • 5-substituted phenylpyrazoles can be prepared by the method shown in Scheme 26. Conversion of the 5-hydroxy pyrazole to its triflate (triflie anhydride, lutidine in dichloromethane) or bromide (P0Br3) followed by palladium Suzuki cross-coupling with an apppropriately substituted phenylboronic acid should then afford 5-substituted pyrazoles Conversion of this intermediate to the 4-bromo derivative followed by its carbonylation as described in Scheme 24 should then afford the appropriate ester which can be further afford the compounds of formula I.
  • l-Substituted-1,2, 3-triazoles of the present invention can be prepared by the treatment of an appropriately substituted azide with a variety of dipolarophiles ( Tetrahedron 1971, 21, 845 and J. Amer . Chem. Soc . 1951, 73 , 1207) as shown in Scheme 27. Typically a mixture of regioisomers are obtained which can be easily separated and elaborated to the triazole carboxylic acids . Further transformations as previously described can then afford the compounds of the present invention.
  • 1, 2, 4-Triazoles of the present invention can be obtained by the methodology of Huisgen et al (Liebigs Ann . Chem . 1962, 653 , 105) by the cycloaddition of nitriliminium species (derived from the treatment of triethylamine and chloro hydrazone) and an appropriate nitrile dipolarophile (Scheme 28) .
  • This methodology provides a wide variety of 1,2,4 triazoles with a varied substitution pattern at the 1, 3, and 5 positions.
  • Triazoles can also be prepared by the methodology of Zecchi et al ( Synthesis 1986 , 9, 772 ) by an aza Wittig condensation (Scheme 29 ) .
  • the thiono-urea intermediate can be oxidized directly to the 2-H triazole which can then be converted to the ester and modified as previously described.
  • the thiono-urea intermediate can also be oxidized to the sulfonyl chloride by methods shown previously.
  • the imidazole core shown in Scheme 32 can be prepared by the condensation of 3-cyanoaniline with n-butylglyoxylate to afford the imine which can then be treated with TosylMIC in basic methanol to afford the desired imidazole compound. Coupling of the ester under standard conitions then affords a variety of analogs which then can be further manipulated to afford e.g. the benzylamine or the benzamidines .
  • the chemistry of Table A can be carried out in aprotic solvents such as a chlorocarbon, pyridine, benzene or toluene, at temperatures ranging from -20 ' c to the reflux point of the solvent and with or without a trialkylamine base.
  • aprotic solvents such as a chlorocarbon, pyridine, benzene or toluene
  • the coupling chemistry of Table B can be carried out by a variety of methods .
  • the Grignard reagent required for Y is prepared from a halogen analog of Y in dry ether, dimethoxyethane or tetrahydrofuran at 0 C to the reflux point of the solvent. This Grignard reagent can be reacted directly under very controlled conditions, that is low temeprature (- 20 C or lower) and with a large excess of acid chloride or with catalytic or stoichiometric copper bromide*dimethyl sulfide complex in dimethyl sulfide as a solvent or with a variant thereof.
  • the ether and thioether linkages of Table C can be prepared by reacting the two components in a polar aprotic solvent such as acetone, dimethylformamide or dimethylsulfoxide in the presence of a base such as potassium carbonate, sodium hydride or potassium t-butoxide at temperature ranging from ambient temperature to the reflux point of the solvent used.
  • a polar aprotic solvent such as acetone, dimethylformamide or dimethylsulfoxide
  • a base such as potassium carbonate, sodium hydride or potassium t-butoxide
  • the thioethers of Table C serve as a convenient starting material for the preparation of the sulfoxide and sulfone analogs of Table D.
  • a combination of wet alumina and oxone can provide a reliable reagent for the oxidation of the thioether to the sulfoxide while m-chloroperbenzoic acid oxidation will give the sulfone.
  • Rxn Q D is to be then a transformation that may be us ed is :
  • Table E several methods of transforming a functional group Q into group D of Formula 1 are shown. While not all possible functional groups for Q and D are listed and the synthetic methods suggested are not comprehensive, Table E is meant to illustrate strategies and transformations available to a practitioner skilled in the art of organic synthesis for preparing compounds of Formula 1.
  • reaction 1 of Table E the transformation of a nitrile into an amidine by the Pinner methodology is shown; in reaction 2 the " direct reduction of a nitrile by a hydride reducing agent to a methylene amine is illustrated.
  • reaction 3 the utility of a carboxylic acid, which may be readily derived from its ester or a nitrile if necessary, in the preparation of a methylene amine is shown.
  • This synthetic route is exceptionally flexible because of the several stable intermediates prepared en route to the final product.
  • formation of an activated analog such as the mixed anhydride, allows for the mild reduction of the acid to the methylene alcohol, this may in turn be transformed into a leaving group by sulfonylation or halogenation or protected with a suitable protecting group to be transformed later in the synthesis as the chemistry demands .
  • displacement by an efficient nitrogen nucleophile, such as azide anion can again provide another suitably stable analog, -the methylene azide- which may be used as a protected form of the methylene amine or transformed directly into the methylene amine group by reduction.
  • Reaction 4 addresses the problem of appending the amine functionality directly through a bond to group E of Formula 1.
  • the carboxylic acid provides a convenient entre into this selection for group D.
  • the well- know Curtius rearrangement is illustrated here; an activated acid analog can be used to form an acyl azide which upon thermal decomposition is rearranged to the corresponding isocyanate.
  • the isocyanate intermediate may then be captured as a stable carbamate by the addition of a suitable alcohol and further heating. This carbamate can be used as a stable protecting group for the amine or cleaved directly to the desired D. Alternatively, it may be convenient to quench the isocyanate intermediate with water to give the amine directly.
  • Other features of the invention will become apparent in the course of the following descriptions of exemplary embodiments which are given for illustration of the invention and are not intended to be limiting thereof.
  • Part B Ethyl 2-N- (methoxy) imino-4-oxopentanoate: A mixture of ethyl pentanoate-2 , 4-dione (24.5 g, 154.9 mmol) and methoxyamine hydrogen chloride (13.58 g, 162.6 mmol) in ethanol (100 mL) was allowed to stand over activated 3 A molecular sieves (75 g) at ambient temperature for 18h. Following removal of the molecular sieves by filtration, dichloromethane (100 mL) was added and the reaction filtered. The resulting solution was evaporated and the residue applied to a silica gel column. The title compound was isolated in a homogenous form by elution with 5:1 hexane: ethyl acetate to give 9.09 g of product.
  • Ethyl 3-methyl-1- (2-carboxy-4-methoxyphenyl) -1H- pyrazole-5-carboxylate and ethyl 5-methyl-l- (2-carboxy-4- ethoxyphenyl) -lH-pyrazole-3-carboxylate Ethyl 2-N- ( ethoxy) imino-4-oxopentanoate (1.0 g, 5.35 mmol) and crude 2- carboxy-4-methoxyphenylhydrazine (5.83 g) in acetonitrile (40 mL) and acetic acid (5 mL) was stirred at ambient temperature for 3 h then heated at reflux for an additional 3 h.
  • Part D Ethyl 3-methyl-1- (2-hydroxymethyl-4-methoxyphenyl) -1H- pyrazole-5-carboxylate and ethyl 5-methyl-1- (2-hydroxymethyl- 4-methoxyphenyl) -lH-pyrazole-3-carboxylate:
  • the mixture of regioisomers prepared in part C (1.28 g, 4.2 mmol) was dissolved in tetrahydrofuran (60 mL) and cooled to 0°C. To the cold solution was added N-methylmorpholine (0.42 g, 4.2 mmol) and isobutylchloroformate (0.57 g, 4.2 mmol).
  • reaction was stirred for 30 min at 0°C, the precipitate removed by filtration and the cold solution poured immediately into a cold (5°C) solution of sodium borohydride (0.48 g, 12.6 mmol) in water (20 mL) and tetrahydrofuran (20 mL) .
  • the reaction was allowed to thaw to room temperature over 18 h.
  • the reaction mixture was evaporated, partitioned between ethyl acetate (100 mL) and IN hydrochloric acid (50 mL) , then washed with 5% sodium bicarbonate (50 mL) and brine (50 mL) .
  • the organic layer was dried and evaporated; three products were isolated by elution of the crude mixture from a silica gel column with 2:1 hexane: ethyl acetate.
  • the first product to elute was a ring closed lactone (0.14 g) ; ESI mass spectrum analysis m/z (relative intensity) 245 (M+H, 100) .
  • the second product isolated was ethyl 3-methyl-1- (2-hydroxymethyl-4- methoxyphenyl) -lH-pyrazole-5-carboxylate (0.18 g) as determined by proton NMR nOe experiments; ESI mass spectrum analysis m/z (relative intensity) 291 (M+H, 100).
  • the third product to elute was the regioisomer ethyl 5-methyl-l- (2- hydroxymethyl-4-methoxyphenyl) -lH-pyrazole-3-carboxylate (0.14 g) ; ESI mass spectrum analysis m/z (relative intensity) 291 (M+H, 100) .
  • the final product was purified further by hplc utilizing gradient elution with a mixture of water : acetonitrile with 0.05% trifluoroacetic acid on a reverse phase C18 (60 A) column; HRMS (M+H) + calc . m/z: 492.170551, obs m/z: 492.169327.
  • Part B 3-Trifluoromethyl-1- (2-hydroxymethyl-4-methoxyphenyl) - 5- (furan-2-yl) -IH-pyrazole: 3-Trifluoromethyl-1- (2-carboxy-4- methoxyphenyl) -5- (furan-2-yl) -IH-pyrazole (3.55 g, 10.1 mmol) in tetrahydrofuran (100 mL) was cooled to 0°C then N- methylmorpholine (1.02 g, 10.1 mmol) and isobutyl chloroformate (1.38 g, 10.1 mmol) were added.
  • reaction mixture was stirred for 30 min at 0°C, filtered and added immediately to a cold solution of sodium borohydride (1.15 g, 30.2 mmol) in water (50 mL) and tetrahydrofuran (50 mL) .
  • the reaction mixture was evaporated, partitioned between ethyl acetate (100 mL) and I .
  • hydrochloric acid 50 mL
  • the organic layer was dried and evaporated then purified further by flash chromatography using 4:1 hexane : ethyl acetate as the eluent .
  • Part D 3-Trifluoromethyl-1- (2-azidomethyl-4-methoxyphenyl) - IH-pyrazole-5-carboxylic acid: To 1.43 g of 3- trifluoromethyl-1- (2-azidomethyl-4-methoxyphenyl) -5- (furan-2- yl) -IH-pyrazole (3.9 mmol) in acetone (60 mL) was added potassium permaganate (5.0 g, 27.5 m mol) in water (60 mL) . The reaction was heated at 60°C for 3 h, then cooled to ambient temperature and isopropyl alcohol (60 mL) added.
  • Part B 3-Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1, 1] -biphen-4- yl) ) carboxyamide*TFA: 3-Trifluoromethyl-1- (2-azidomethyl-4- methoxyphenyl) -lH-pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl-
  • Part A 3 -Trif luoromethyl-1- (2 -azidomethyl -4 -methoxyphenyl ) - lH-pyrazole-5- (N- (2 ' -N-tertbutylsulf amido- [1,1] -biphen-4- yl) ) carboxyamide : 3-Trif luoromethyl-1- (2-azidomethyl-4- me thoxyphenyl ) -lH-pyrazole-5-carboxylic acid chloride and 4- ( 2-N-tertbutylsulfonamido) phenyl aniline were treated as described in Example 4, Part F to give 3-trif luoromethyl-1- (2- azidomethyl- 4 -methoxyphenyl) -IH-pyrazole- 5- (N- (4- (2-N- tertbutylsulf amidophenyl ) phenyl ) carboxyamide .
  • the product was purified further by a column of flash Si ⁇ 2 (50 g) eluting with 5-10 % MeOH in CHCI 3 to give 0.24 g of 3-trifluoromethyl-1- (2-azidomethyl-4- methoxyphenyl ) -lH-pyrazole-5- (N- (4-N- carboxylpyrrolidino) phenyl) carboxyamide; LRMS ES+ (M+H) + : 514 m/z.
  • Part D 3 -Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl ) - lH-pyrazole-5- (N- (4-N- carboxylpyrrolidino) phenyl) carboxyamide*TFA: A mixture of 3- trifluoromethyl-1- (2-azidomethyl-4-methoxyphenyl) -IH-pyrazole- 5- (N- (4-N-carboxylpyrrolidino) phenyl) carboxyamide (0.24 g, 0.27 mmol) and SnCl 2 »2H 2 0 (0.24 g, 0.95 mmol) in MeOH (20 mL) was stirred for 18 h.
  • Example 12 N-Benzyl-4- (3-trif luoromethyl-1- (2 -aminomethyl -4- methoxyphenyl) -lH-pyrazole-5- carboxyamido ) piperidine • TFA 3-Trifluoromethyl-1- (2-azidomethyl-4-methoxyphenyl) -1H- pyrazole-5-carboxylic acid prepared in Part B of Example 8 was coupled with N-Benzyl-4-aminopiperidine according to the procedure in Part C of Example 8. The title compound was prepared and purified by the method outlined in Part D of Example 8; mp 116.1 °C; HRMS (M+H) + : 488.2266 m/z.
  • the azidomethyl group was reduced to the aminomethyl group with SnCl 2 »2H 2 ⁇ by the method outlined in Part D of Example 8.
  • the crude reduction product was then refluxed in trifluoroacetic acid (10 mL) for 1 h to remove the t-butyl protecting group.
  • the title compound was isolated by HPLC utilizing gradient elution with a mixture of water: acetonitrile with 0.05% trifluoroacetic acid on a reverse phase C18 (60 A) column; mp 101 °C; HRMS (M+H) + : 552.1120 m/z.
  • the azidomethyl group was reduced to the aminomethyl group with SnCl 2 *2H 2 ⁇ by the method outlined in Part D of Example 8.
  • the crude reduction product was then refluxed in trifluoroacetic acid (10 mL) for 1 h to remove the t-butyl protecting group.
  • the title compound was isolated by HPLC utilizing gradient elution with a mixture of water : acetonitrile with 0.05% trifluoroacetic acid on a reverse phase C18 (60 A) column; mp 118.7 °C; HRMS (M+H) + : 570.1038 m/z.
  • the azidomethyl group was reduced to the aminomethyl group with SnCl 2 ⁇ 2H 2 ⁇ by the method outlined in Part D of Example 8.
  • the crude reduction product was then refluxed in trifluoroacetic acid (10 mL) for 1 h to remove the t-butyl protecting group.
  • the title compound was isolated by HPLC utilizing gradient elution with a mixture of water :acetonitrile with 0.05% trifluoroacetic acid on a reverse phase C18 (60 A) column; mp 115.8 °C; HRMS (M+H) + : 552.1111 m/z.
  • Part A 4-Amino-N- ( (N' -methylsulfonyl) iminoyl)pyrrolidine : 4-Nitrobenzonitrile (5.4 g, 36.5 mmol) in anhydrous methyl acetate (200 mL) and MeOH (20 mL) was cooled to 0 °C and treated with a stream of dry HCI gas for 1 h. The reaction was securely stoppered and left to stand at 5 °C in a refrigerator for 24 h. The solvent was removed and the reaction was evaporated repeatedly (5 x) with Et 2 ⁇ to remove the last traces of free HCI. There was obtained 28.6 g of the imidate as an HCI salt.
  • the free base of the amidine prepared above was formed by suspending the product in IN NaOH (250 mL) and extracting this suspension with CHCI 3 (3 x) . The material was dried and evaporated to give 4.49 g of product.
  • Part B 3-Trifluoromethyl-1- (2-aminomethyl-4-fluorophenyl) - IH-pyrazole-5- (N- (4- (N- ( (N' - methylsulfonyl) iminoly) pyrrolidino) )phenyl) carboxyamide*
  • FA 3-Trifluoromethyl-1- (2-azidomethyl-4- fluorophenyl) -lH-pyrazole-5-carboxylic acid was prepared from 3-fluoro-6-aminobenzoic acid by essentially the same method used for 3-trifluoromethyl-1- (2-azidomethyl-4-methoxyphenyl) - lH-pyrazole-5-carboxylic acid in Parts A and B of Example 8.
  • the resulting mixture was heated at 65 'C for 40 min. Additional KMn ⁇ 4 (1.39 g, 8.8 mmol) was added, and the reaction continued heating at 65 "C for 35 min.
  • the reaction mixture was cooled and filtered through celite, using EtOH and acetone to rinse the celite. The filtrate was concentrated to approx. half its original volume and treated with aq. sodium bisulfite to remove residual KMn ⁇ 4 .
  • the resulting mixture was extracted with EtOAc, and the organic layer was removed, dried over Na 2 S0 4 , filtered, and evaporated to yield crude product (1.50 g) .
  • the aqueous layer was cooled in ice, acidified with IM HCI (6 mL) and extracted with EtOAc (containing a small amount of EtOH) . Before separating, both layers were filtered through celite and treated with sat NaHC0 3 (1.5 mL) . The aqueous layer was removed and extracted twice with EtOAc/EtOH. Solid NaCI was added both times to aid separation of the emulsion. The aqueous layer was extracted with CHCI 3 , adjusted to pH 5 with IM HCI, and extracted twice with CHCl 3 /EtOH. The final 6 organic layers were combined, dried over Na 2 S0 4 , filtered, and evaporated to yield a second batch of product (2.43 g, 68%). The first batch of product was chromatographed on silica gel (0-30% MeOH/CHCl 3 ) to yield clean product (0.95 g, 27%). 1H NMR (DMSO) ⁇ 7.34 (m, 4H) ,
  • Triethylamine 150 ⁇ l , 1.1 mmol
  • 4-amino-2 ' t- butylamino
  • sulfonyl- [1, 1 '] -biphenyl 190 mg, 0.62 mmol
  • 4-dimethylaminopyridine 20 mg, 0.16 mmol
  • the reaction was extracted with dilute brine solution, ice- cooled IM HCI, and sat. NaHCC> 3 .
  • the organic layer was dried over MgS ⁇ 4 , filtered, and evaporated to yield crude product (371 mg) .
  • the title compound was prepared from l-[2- ( (aminomethyl) phenyl) -5- (3-f luoro-2 ' -methylsulfonyl- [1,1']- biphen-4-yl) ) aminocarbonyl ] -3- (trif luoromethyl) pyrazole trifluoroacetic acid salt (prepared in Example 34) and N-Boc glycine according to the procedure in Example 29; HRMS (M+H) + : 590.1495 m/z.
  • the acid chloride was dissolved in dry CH 2 CI 2 and cooled to 0°C, and cone. aq. NH 3 (2.0 mL) was added over 20 min. The resulting mixture was stirred at room temperature for 18 h. The reaction was diluted with CH 2 CI 2 and extracted with water. The aqueous layer was extracted with CHCI 3 , MeOH/CH 2 Cl 2 , and CH 2 C1 2 . All of the organics were combined and extracted with sat. NaHC03 (2x) , IM HCI, and sat. NaCI.
  • Ethyl 1- (2-cyanophenyl) -5-tetrazole carboxylate To a solution of anthranilonitrile (10.00 g) and Et ⁇ N (13.21 mL) in CH2CI2 (250 mL) was added ethyloxalyl chloride (9.92 mL) in a dropwise fashion over 30 minutes. The reaction was stirred at RT under N2 for 3 h. The reaction mixture was filtered. The filtrate was washed with water (2 x 150 mL) and brine (1 x 150 mL) , filtered through phase separatory paper and evaporated. The residue was dissolved in 60 mL of CH2CI2 and 300 mL of hexane was added.
  • Cobalt chloride (0.098 g ) was added to 1- (2 ' -cyanophenyl) -5- [ [ (2 '-methylsulfonyl) -3-fluoro- [1,1' ] -biphen-4- yl] aminocarbonyl] -tetrazole (0.35 g) and sodium borohydride (0.072 g) in DMF (5 mL) .
  • the reaction was stirred at room temperature for 16 h.
  • the resulting mixture was stirred at room temperature for 16 h.
  • 6M HCI (5 mL) was added over 5 min.
  • the quenched reaction was stirred at room temperature for 3.5 h, diluted with EtOAc and water.
  • Methyl 3- (thiomethoxy)pyrazole-5-carboxylate A mixture of methyl 4, 4-bis (thiomethoxy) -2-oxo-3-butenoate (9.9 g, 48 mmol) and hydrazine monohydrate (2.6 mL, 53 mmol) in 200 mL of glacial acetic acid was stirred at 100 °C for 18 h. The reaction was cooled and concentrated. The residue was taken up in ethyl acetate, washed with sat'd aq NaHC0 3 and brine, dried (MgS0 4 ) and concentrated.
  • Methyl 1- [2-formylphenyl] -3- (thiomethoxy) pyrazole-5- carboxylate To a solution of methyl 3- (thiomethoxy) pyrazole- 5-carboxylate (0.87 g, 5.05 mmol) in 20 mL of 1,4-dioxane was added 2-formylphenyl boronic acid (1.13 g, 7.58 mmol), pyridine (0.82 mL, 10.1 mmol), crushed 4 A molecular sieves and cupric acetate (1.38 g, 7.58 mmol) . The flask was equipped with a drying tube and the mixture was allowed to stir at ambient temperature under an air atmosphere for 18 h.
  • Example 42 [2- (aminomethyl) henyl] -3-methysulfonyl-5- [ (2- fluoro) - (2 • -methylsulfonyl- [1,1'] -biphen-4- y1 ) aminocarbonyl] pyrazole•TFA
  • Triazololactone A solution of (2-azidophenyl)methyl propiolate (10.7 g, 53.2 mmol) in 100 mL of toluene was stirred at 100°C for 18 h. The reaction was cooled and concentrated and the residue was purified by flash chromatography (elution with 1:1 hexanes/ethyl acetate) to afford 1.4 g (13%) of the title compound.
  • X H NMR (CDCI3) ⁇ 8.38 (s, IH) , 8.04 (d, IH) , 7.63 (m, IH) , 7.54 (m, 2H) , 5.16 (s, 2H) .
  • Methyl 1- [2-methylphenyl]pyrazole-5-carboxylate A neat mixture of methyl pyruvate (11.37 mL, 125.9 mmol) and dimethylformamide dimethylacetal (16.72 mL, 125.9 mmol) was stirred at 80°C for 24 h. The mixture was cooled and concentrated. A portion of the residue (4.00 g, 25.45 mmol) was dissolved in 50 mL of glacial acetic acid and then there was added o-tolylhydrazine hydrochloride (4.44 g, 27.99 mmol). This mixture was stirred at 100°C for 18 h and then was cooled and concentrated.
  • Part D 1- (2- (N-Boc-aminomethyl )phenyl) -3-trifluoromethyl-5- [ ( (2-fluoro) - (2 ' -hydroxymethylsilyloxymethyl) -[1,1'] -biphen-4- yl) aminocarbonyl]pyrazole: To a solution of 1- (2- (N-Boc- aminomethyl)phenyl) -3-trifluoromethylpyrazol-5-yl-carboxylic acid (0.768 g, 2 mmol) in CH2CI2 (50 mL) was added DMF (1 drop) and oxalyl chloride (0.381 g, 3 mmol), and the resulting mixture was stirred at room temperature for 1.5 hours .
  • Part E 1- (2- (aminomethyl) phenyl) -3-trifluoromethyl-5- [ ( (2- fluoro) - (2 ' -pyrrolidinomethyl) -[1,1'] -biphen-4- yl) aminocarbonyl] pyrazole, TFA salt: To a solution of l-(2- (N-Boc-aminomethyl) phenyl) -3-trifluoromethyl-5- [ ( (2-fluoro) - (2 ' -hydroxymethyl) -[1,1'] -biphen-4-yl) aminocarbonyl] pyrazole (150 mg, 0.26 mmol) in THF (5 mL) was added CS2CO3 (167 mg, 0.51 mmol) and MsCl (4 mg, 0.39 mmol).
  • D is at the 2-position and is
  • each entry in each table is intended to be paired with each formulae at the start of the table .
  • example 1 is intended to be paired with each of formulae a-bbbb
  • example 1 is intended to be paired with each of formulae a-bbbb.

Abstract

The present application describes nitrogen containing heteroaromatics with ortho-substituted P1's and derivatives thereof of Formula (I) or pharmaceutically acceptable salt or prodrug forms thereof, wherein J is N or NH and D is substituted ortho to G on E and may be CH2NH2, which are useful as inhibitors of factor Xa.

Description

TITLE Nitrogen Containing Heteroaro atics with Ortho-Substituted
PI ' s as Factor Xa Inhibitors
FIELD OF THE INVENTION This invention relates generally to nitrogen containing heteroaromatics, with ortho-substituted PI groups, which are inhibitors of trypsin-like serine protease enzymes, especially factor Xa, pharmaceutical compositions containing the same, and methods of using the same as anticoagulant agents for treatment and prevention of thromboembolic disorders.
BACKGROUND OF THE INVENTION WO 95/18111 addresses fibrinogen receptor antagonists, containing basic and acidic termini, of the formula:
Figure imgf000002_0001
wherein R1 represents the basic termini, U is an alkylene or heteroatom linker, V may be a heterocycle, and the right hand portion of the molecule represents the acidic termini . The presently claimed compounds do not contain the acidic termini of WO 95/18111. In U.S. Patent No. 5,463,071, Himmelsbach et al depict cell aggregation inhibitors which are 5-membered heterocycles of the formula:
Figure imgf000002_0002
wherein the heterocycle may be aromatic and groups A-B-C- and F-E-D- are attached to the ring system. A-B-C- can be a wide variety of substituents including a basic group attached to an aromatic ring. The F-E-D- group, however, would appear to be an acidic functionality which differs from the present invention. Furthermore, use of these compounds as inhibitors of factor Xa is not discussed.
Baker et al, in U.S. Patent No. 5,317,103, discuss 5-HTχ agonists which are indole substituted five-membered heteroaromatic compounds of the formula:
Figure imgf000003_0001
wherein R1 may be pyrrolidine or piperidine and A may be a basic group including amino and amidino. Baker et al, however, do not indicate that A can be a substituted ring system like that contained in the presently claimed heteroaromatics .
Baker et al, in WO 94/02477, discuss 5-HTι agonists which are imidazoles, triazoles, or tetrazoles of the formula:
Figure imgf000003_0002
wherein R1 represents a nitrogen containing ring system or a nitrogen substituted cyclobutane, and A may be a basic group including amino and amidino. Baker et al, however, do not indicate that A can be a substituted ring system like that contained in the presently claimed heteroaromatics .
Illig et al, in WO 97/47299, illustrate amidino and guanidino heterocycle protease inhibitors of the formula:
R1-Z-X-Y-W
wherein R1 can be a substituted aryl group, Z is a two carbon linker containing at least one heteroatome, X is a heterocycle, Y is an optional linker and W is an amidino or guanidino containing group. Compounds of this sort are not considered part of the present invention.
Jackson et al, in WO 97/32583, describe cytokine inhibitors useful for inhibiting angiogenesis . These inhibitors include imidazoles of the formula:
Rt Ji
wherein Ri is a variety of heteroaryl groups, R4 is phenyl, naphthyl, or a heteroaryl group, and R2 can be a wide variety of groups . Jackson et al do not teach inhibition of factor Xa. Furthermore, the imidazoles of Jackson et al are not considered part of the present invention.
Activated factor Xa, whose major practical role is the generation of thrombin by the limited proteolysis of prothrombin, holds a central position that links the intrinsic and extrinsic activation mechanisms in the final common pathway of blood coagulation. The generation of thrombin, the final serine protease in the pathway to generate a fibrin clot, from its precursor is amplified by formation of prothrombinase complex (factor Xa, factor V, Ca2+ and phospholipid) . Since it is calculated that one molecule of factor Xa can generate 138 molecules of thrombin (Elodi, S., Varadi, K. : Optimization of condi tions for the catalytic effect of the factor IXa-factor VIII Complex: Probable role of the complex in the amplification of blood coagulation.
Thromb. Res . 1979, 15, 617-629), inhibition of factor Xa may be more efficient than inactivation of thrombin in interrupting the blood coagulation system.
Therefore, efficacious and specific inhibitors of factor Xa are needed as potentially valuable therapeutic agents for the treatment of thromboembolic disorders. It is thus desirable to discover new factor Xa inhibitors.
SUMMARY OF THE INVENTION Accordingly, one object of the present invention is to provide novel nitrogen containing aromatic heterocycles, with ortho-substituted PI groups, which are useful as factor Xa inhibitors or pharmaceutically acceptable salts or prodrugs thereof .
It is another object of the present invention to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt or prodrug form thereof.
It is another object of the present invention to provide a method for treating thromboembolic disorders comprising administering to a host in need of such treatment a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt or prodrug form thereof. These and other objects, which will become apparent during the following detailed description, have been achieved by the inventors' discovery that compounds of formula (I):
Figure imgf000005_0001
I or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, B, D, E, G, J, M, Rla, Rlb, and s are defined below, are effective factor Xa inhibitors.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
[1] Thus, in a first embodiment, the present invention provides novel compounds of formula I :
Figure imgf000005_0002
I or a stereoisomer or pharmaceutically acceptable salt thereof , wherein; ring M contains, in addition to J, 0-3 N atoms, provided that if M contains 2 N atoms then Rlb is not present and if M contains 3 N atoms then Rl and Rlb are not present;
J is N or NH;
D is selected from CN, C ( =NR8 ) NR7R9 , NHC (=NR8 ) NR7R9 ,
NR8CH(=NR7), C(0)NR7R8, and (CR8R9) tNR7R8, provided that D is substituted ortho to G on E;
E is selected from phenyl, pyridyl, pyrimidyl , pyrazinyl, pyridazinyl, and piperidinyl substituted with 1-2 R;
R is selected from H, Cl, F, Br, I, (CH2)tOR3, C1-.4 alkyl, OCF3, CF3, C(0)NR7R8, and (CR8R9) tNR7R8;
G is absent or is selected from NHCH2 , OCH2, and SCH2, provided that when s is 0 , then G is attached to a carbon atom on ring M;
Z is selected from a Cχ_4 alkylene, (CH2) rO (CH2) r >
(CH2)rNR3(CH2)r, (CH2 ) rC (0) (CH2 ) r, (CH2 ) rC (0) 0 (CH2) r, (CH2)r0C(0) (CH2)r, (CH2) rC (0) NR3 (CH2 ) r . (CH2)rNR3C(0) (CH2)r, (CH2) r0C (0) 0 (CH2) r, (CH2)rOC(0)NR3(CH2)r, (CH2) rNR3C (0) 0 (CH2) r,
(CH2)rNRC(0)NR (CH2)r, (CH2 ) rS (O) p (CH2) r, (CH2)rS02NR3(CH2)r, (CH2 ) rNR S02 (CH2 ) r, and (CH2)rNR3S0NR3 (CH2)r, provided that Z does not form a N- N, N-O, N-S, NCH2N, NCH20, or NCH2S bond with ring M or group A;
Rla and Rlb are independently absent or selected from -{CH2)r-R1', -CT^CH-Ri NCH2R1", OCH2R1", SCH2R1", NH(CH2)2(CH2)tRl0 O(CH2)2(CH2)tR10 and S (CH2) 2 (CH2) tRx0-
alternatively, Rla and Rlb, when attached to adjacent carbon atoms, together with the atoms to which they are attached form a 5-8 membered saturated, partially saturated or unsaturated ring substituted with 0-2 R4 and which contains from 0-2 heteroatoms selected from the group consisting of N, 0, and S;
R1' is selected from H, C1-3 alkyl, -F, Cl, Br, I, -CN, -CHO, (CF2)rCF3, (CH2)rOR2, NR2R2a, C(0)R2c, 0C(0)R2, (CF2)rC02R2c, S(0)pR2b, NR2(CH2)rOR2, CH (=NR2 ) NR2R2a, NR2C(0)R2b, NR2C(0)NHR2b, NR2C(0) R2a, OC (0) NR2aR2b, C(0)NR2R2a, C(0)NR2 (CH2)rOR2, S02NR2R2a, NR2S0R2b, C3_6 carbocyclic residue substituted with 0-2 R4, and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R4;
R1" is selected from H, CH(CH2OR2)2, C(0)R2c, C(0)NR2R2a, S(0)R2b, S(0)2R2b, and S02NR2R2a;
R2, at each occurrence, is selected from H, CF3 , Cι_6 alkyl, benzyl, C3-6 carbocyclic residue substituted with 0-2 Rb, and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R4b;
R2a, at each occurrence, is selected from H, CF3, C - alkyl, benzyl, C3_6 carbocyclic residue substituted with 0-2 Rb, and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 Rb;
R2b, at each occurrence, is selected from CF3, C1-4 alkoxy, Cι_6 alkyl, benzyl, C3_5 carbocyclic residue substituted with 0-2 Rb, and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R4b;
R2c, at each occurrence, is selected from CF3, OH, C1-4 alkoxy, Cι_6 alkyl, benzyl, C2-6 carbocyclic residue substituted with 0-2 Rb, and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R4b;
alternatively, R2 and R2a combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring substituted with 0-2 R4b which contains from 0-1 additional heteroatoms selected from the group consisting of N, 0, and S;
alternatively, R2 and R2a, together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring substituted with 0-2 Rb and containing from 0-1 additional heteroatoms selected from the group consisting of N, 0, and S;
R3, at each occurrence, is selected from H, Cι_4 alkyl, and phenyl ;
R3a, at each occurrence, is selected from H, C1-4 alkyl, and phenyl;
R3b, at each occurrence, is selected from H, C1-4 alkyl, and phenyl ;
R3c, at each occurrence, is selected from C1-4 alkyl, and phenyl;
A is selected from: C3-10 carbocyclic residue substituted with 0-2 R4, and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R4;
B is selected from:
X-Y, NR2R2a, C(=NR )NR2R2a, NR2C (=NR2) NR2R2a,
C3-10 carbocyclic residue substituted with 0-2 R4a, and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R4a;
X is selected from Cι_ alkylene, -CR2 (CR2R2b) (CH2) t~, -C(0)-, -C(=NR1")-, -CR2(NR1"R2)-, -CR2(0R2)-, -CR2(SR2)-, -C(0)CR2R2a-, -CR2R2aC(0), -S(0)p-, -S (0)pCR2R2a-, -CR2R2 S(0)p-, -S(0)2NR2-, -NR2S(0)2-, -NR2S (0) 2CR2R2a- , -CR2R2aS(0)2NR2-, -NR2S(0)2NR2-, -C(0)NR2-, -NR2C(0)-, -C(0)NR2CR2R2a-, -NR2C(0)CR2R2a-, -CR2R2aC (0) NR2-,
-CR2R2aNR2C(0)-, -NR2C(0)0-, -OC(0)NR2-, -NR2C (0) NR2- , -NR2-, -NR2CR2R2a-, -CR2R2aNR2-, 0, -CR2R2aO-, and -OCR2R2a- ;
Y is selected from:
(CH2)rNR2R2a, provided that X-Y do not form a N-N, 0-N, or S-N bond,
C3-.10 carbocyclic residue substituted with 0-2 Ra, and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R4a;
R4, at each occurrence, is selected from H, =0, {CΗ.2 ) r0R2 , F, Cl, Br, I, C1-4 alkyl, -CN, N02 , (CH2) rNR2R2a, (CH2)rC(0)R2c, NR2C(0)R2b, C(0)NR2R2a, NR2C (0) NR2R2a, CH(=NR2)NR2R2a, CH(=NS(0) R5)NR2R2a, NHC (=NR2 ) NR2R2a, C(0)NHC(=NR2)NR2R2a, S02NR2R2a, NR2S0NR2R2 , NR2S02-Cι_4 alkyl, NR2S02R5, S(0)pR5, (CF2)rCF3, NO^R1", OO^R1", SCH2R1", N(CH2)2(CH2)tRl0 o(CH2)2(CH2)tR10 and
Figure imgf000009_0001
alternatively, one R4 is a 5-6 membered aromatic heterocycle containing from 1-4 heteroatoms selected from the group consisting of N, O, and S;
R4a, at each occurrence, is selected from H, =0, (CH2)rOR2,
(CH2)r-F, (CH2)r-Br, (CH2)r-Cl, Cl, Br, F, I, C1-4 alkyl, -CN, N02, (CH2)rNR2R2a, (CH2)rC(0)R2c, NR2C(0)R2b, C(0)NR2R2a, C(0)NH(CH2)2NR2R2a, NR2C (0) NR2R2 , CH(=NR2)NR2R2a, NHC(=NR2)NR2R2a, S02NR2R2a, NR2S02NR2R2a, NR2S02-Cι_4 alkyl, C (0)NHSO2-Cι_ alkyl, NR2S02R5, S(0)pR5, and (CF2)rCF3;
alternatively, one R4a is a 5-6 membered aromatic heterocycle containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-1 R5;
R4b, at each occurrence, is selected from H, =0, (CH2)rOR3 F, Cl, Br, I, Ci-4 alkyl, -CN, N02 , (CH2) rNR3R3a, (CH2)rC(0)R3, (CH2)rC(0)OR3c, NR3C(0)R3a, C(0)NR3R3a, NR3C(0)NR3R3a, CH(=NR3)NR3R3a, NR3C (=NR3 ) NR3R3a, S02NR3R3a, NR3S02NR3R3a, NR3S02-Cι_4 alkyl, NR3S02CF3, NR3S02-phenyl, S(0)pCF3, S(0)p-Cι_4 alkyl, S (0) p-phenyl, and (CF2)rCF3;
R5, at each occurrence, is selected from CF3 , Cι_e alkyl, phenyl substituted with 0-2 R6, and benzyl substituted with 0-2 R6;
R6, at each occurrence, is selected from H, OH, (CH2)rOR2< halo, C1-4 alkyl, CN, N02, (CH2) rNR2R2a, (CH2) rC (0) R2b, NRC(0)R2b, NR2C(0)NR2R2a, CH(=NH)NH2, NHC(=NH)NH2, S02NR2R2a, NR2S02NR2R2a, and NR2S02Cι_4 alkyl;
R7, at each occurrence, is selected from H, OH, C]__6 alkyl, Cχ_6 alkylcarbonyl , C -s alkoxy, Cχ_4 alkoxycarbonyl , (CH2) n-phenyl, C6-10 aryloxy, C6-10 aryloxycarbonyl, C6-10 arylmethylcarbonyl , Cχ_4 alkylcarbonyloxy C1-.4 alkoxycarbonyl, Cδ-io arylcarbonyloxy Cχ_4 alkoxycarbonyl, Cι_6 alkylaminocarbonyl, phenylaminocarbonyl , and phenyl Cι_4 alkoxycarbonyl;
R8, at each occurrence, is selected from H, Cχ-6 alkyl and (CH2) n-phenyl;
alternatively, R7 and R8 combine to form a 5 or 6 membered saturated, ring which contains from 0-1 additional heteroatoms selected from the group consisting of N, 0, and S;
R9, at each occurrence, is selected from H, Cι-6 alkyl and (CH2) n-phenyl ;
n, at each occurrence, is selected from 0, 1, 2, and 3;
m, at each occurrence, is selected from 0, 1, and 2;
p, at each occurrence, is selected from 0, 1, and 2 ;
r, at each occurrence, is selected from 0, 1, 2, and 3;
s, at each occurrence, is selected from 0, 1, and 2; and,
t, at each occurrence, is selected from 0, 1, 2, and 3;
provided that D-E-G- (CH2) s~ and -Z-A-B are not both benzamidines .
[2] In a preferred embodiment, the present invention provides novel compounds of formulae Ia-Ih:
Figure imgf000011_0001
Id Ie If
Figure imgf000011_0002
wherein, groups D-E- and -Z-A-B are attached to adjacent atoms on the ring;
R is selected from H, Cl, F, Br, I, (CH2)tOR3, C1-4 alkyl, OCF3, CF3, C(0)NR7R8, and (CR8R9) tNR7R8 ;
Z is selected from a CH20, OCH2, CH2NH, NHCH2, C(0), CH2C(0),
C(0)CH2, NHC(O), C(0)NH, CH2S(0)2, S(0) (CH2), S02NH, and NHSO2, provided that Z does not form a N-N, N-0, NCH2N, or NCH2O bond with ring M or group A;
A is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R4; phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, 1, 2 , 3 -oxadiazolyl , 1, 2, 4-oxadiazolyl, 1, 2, 5-oxadiazolyl, 1, 3 , 4-oxadiazolyl, 1,2, 3-thiadiazolyl, 1, 2 , 4-thiadiazolyl,
1, 2, 5-thiadiazolyl, 1, 3 , 4-thiadiazolyl, 1, 2 , 3 -triazolyl, 1,2, 4-triazolyl, 1, 2 , 5-triazolyl, 1, 3 , 4-triazolyl, benzofuranyl, benzothiofuranyl, indolyl, benzimidazolyl, benzoxazolyl, benzthiazolyl, indazolyl, benzisoxazolyl, benzisothiazolyl, and isoindazolyl;
B is selected from: Y, X-Y, NR2R2a, C (=NR2)NR2R2a, and NR2C(=NR2)NR2R2a;
X is selected from C3.-4 alkylene, -C(O)-, -C(=NR)-,
-CR2(NR2R2a)-, -C(0)CR2R2 -, -CR2R2aC(0), -C(0)NR2-, -NR2C(0)-, -C(0)NR2CR2R2a-, -NR2C (0) CR2R2a- , -CR2R2aC(0)NR2-, -CR2R2aNR2C(0)-, -NR2C (0)NR2- , -NR2-, -NR2CR2R2a-, -CR2R2aNR2-, 0, -CR2R2a0-, and -0CR2R2a-;
Y is NR2R2a, provided that X-Y do not form a N-N or O-N bond; alternatively, Y is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R4a; cylcopropyl, cyclopentyl, cyclohexyl, phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl , morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, isoxazolinyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, 1, 2 , 3-oxadiazolyl, 1, 2, 4-oxadiazolyl, 1, 2 , 5-oxadiazolyl, 1, 3 , 4-oxadiazolyl, 1,2, 3-thiadiazolyl , 1,2, 4-thiadiazolyl ,
1,2, 5-thiadiazolyl, 1, 3 , 4-thiadiazolyl , 1, 2 , 3-triazolyl , 1,2, 4-triazolyl, 1, 2 , 5-triazolyl, 1, 3 , 4-triazolyl, benzofuranyl, benzothiofuranyl, indolyl, benzimidazolyl, benzoxazolyl , benzthiazolyl, indazolyl, benzisoxazolyl , benzisothiazolyl, and isoindazolyl;
alternatively, Y is selected from the following bicyclic heteroaryl ring systems:
Figure imgf000013_0001
K is selected from O, S, NH, and N.
[3] In a more preferred embodiment, the present invention provides novel compounds of formulae Ila-IIf:
Figure imgf000014_0001
wherein;
Z is selected from a C(O), CH2C(0), C(0)CH2, NHC(O), C(0)NH, C(0)N(CH3), CH2S(0)2, S(0)2(CH2), S02NH, and NHS02 , provided that Z does not form a N-N or NCH2N bond with ring M or group A.
[4] In an even more preferred embodiment, the present invention provides novel compounds of formulae Ila-IIf, wherein;
E is phenyl substituted with R or 2-pyridyl substituted with R;
D is selected from NH2, NHCH3, CH2NH2 , CH2NHCH3 , CH(CH3)NH2, and C(CH3)2NH2, provided that D is substituted ortho to ring M on E; and,
R is selected from H, OCH3 , Cl, and F.
[5] In a further preferred embodiment, the present invention provides novel compounds of formulae Ila-IIf, wherein;
D-E is selected from 2-aminophenyl, 2-methylaminophenyl, 2- aminomethylphenyl , 4-methoxy-2-aminophenyl , 4-methoxy-2- (methylamino)phenyl, 4-methoxy-2-aminomethylphenyl , 4- methoxy-2- (methylaminomethyl) henyl , 4-methoxy-2- ( 1- aminoethyl) phenyl, 4-methoxy-2- (2-amino-2-propyl)phenyl, 4-Cl-2-aminophenyl, 4-Cl-2- (methylamino) phenyl, 4-C1-2- aminomethylphenyl, 4-C1-2- (methylaminomethyl) phenyl , 4- Cl-2- (1-aminoethyl) phenyl, 4-C1-2- (2-amino-2- propyl)phenyl , 4-F-2-aminophenyl, 4-F-2- (methylamino)phenyl, 4-F-2-aminomethylphenyl , 4-F-2- (methylaminomethyl) phenyl, 4-F-2- (1-aminoethyl) phenyl, and 4-F-2- (2-amino-2-propyl) phenyl .
[6] In another even more preferred embodiment, the present invention provides novel compounds of formulae Ila-IIf, wherein;
Z is C(0)CH2 and CONH, provided that Z does not form a N-N bond with group A;
A is selected from phenyl, pyridyl, and pyrimidyl, and is substituted with 0-2 R ; and,
B is selected from X-Y, phenyl, pyrrolidino, morpholino,
1, 2, 3-triazolyl, and imidazolyl, and is substituted with 0-1 R4 ;
R4, at each occurrence, is selected from OH, (CH2)rOR2, halo, Ci_4 alkyl, (CH2) rNR2R2a, and (CF2)rCF3;
R4a is selected from Cι_ alkyl, CF3, S(0)pR5, S02NR2R2 , and l-CF3-tetrazol-2-yl;
R5, at each occurrence, is selected from CF3, C1-6 alkyl, phenyl, and benzyl;
X is CH2 or C(O); and,
Y is selected from pyrrolidino and morpholino . [7] In another further preferred embodiment, the present invention provides novel compounds of formulae Ila-IIf, wherein;
A is selected from the group: phenyl, 2-pyridyl, 3-pyridyl, 2-pyrimidyl, 2-Cl-phenyl, 3-Cl-phenyl, 2-F-phenyl, 3-F- phenyl, 2-methylphenyl, 2-aminophenyl, and 2- methoxyphenyl ,- and,
B is selected from the group: 2-CF3-phenyl, 2-
(aminosulfonyl)phenyl, 2- (methylaminosulfonyl) phenyl, 2- (dimethylaminosulfonyl) phenyl, 1-pyrrolidinocarbonyl, 2- (methylsulfonyl)phenyl, 4-morpholino, 2- (1 ' -CF3~tetrazol- 2-yl)phenyl, 4-morpholinocarbonyl, 2-methyl-l-imidazolyl, 5-methyl-l-imidazolyl, 2-methylsulfonyl-1-imidazolyl and, 5-methyl-1,2, 3-triazolyl.
[8] In another even more preferred embodiment, the present invention provides novel compounds of formulae Ila-IIf, wherein;
E is phenyl substituted with R or 2-pyridyl substituted with R;
D is selected from NH2, NHCH3, CHNH2, CH2NHCH3 , CH(CH3)NH2, and C(CH3)2NH2, provided that D is substituted ortho to ring M on E; and,
R is selected from H, OCH3, Cl, and F;
Z is C(0)CH2 and CONH, provided that Z does not form a N-N bond with group A;
A is selected from phenyl, pyridyl, and pyrimidyl, and is substituted with 0-2 R4; and, B is selected from X-Y, phenyl, pyrrolidino, morpholino,
1, 2, 3-triazolyl, and imidazolyl, and is substituted with 0-1 R4a;
R4, at each occurrence, is selected from OH, (CH2)ΓOR2' halo, Cι-4 alkyl, (CH2) rNR2R2 , and (CF2)rCF3;
R4a is selected from Cι_4 alkyl, CF3 , S(0)pR5, Sθ2NR2R2a, and l-CF3-tetrazol-2-yl;
R5, at each occurrence, is selected from CF3 , Cχ-6 alkyl, phenyl, and benzyl;
X is CH2 or C(O); and,
Y is selected from pyrrolidino and morpholino.
[9] In another further preferred embodiment, the present invention provides novel compounds of formulae Ila-IIf, wherein;
D-E is selected from 2-aminophenyl, 2-methylaminophenyl, 2- aminomethylphenyl, 4-methoxy-2-aminophenyl, 4-methoxy-2- (methylamino)phenyl, 4-methoxy-2-aminomethylphenyl, 4- methoxy-2- (methylaminomethyl) phenyl, 4-methoxy-2- (1- aminoethyl)phenyl, 4-methoxy-2- (2-amino-2-propyl)phenyl, 4-Cl-2-aminophenyl, 4-C1-2- (methylamino)phenyl, 4-C1-2- aminomethylphenyl, 4-Cl-2- (methylaminomethyl) phenyl, 4- Cl-2- (1-aminoethyl)phenyl, 4-C1-2- (2-amino-2- propyl)phenyl , 4-F-2-aminophenyl, _4-F-2- (methylamino)phenyl, 4-F-2-aminomethylphenyl, 4-F-2- (methylaminomethyl)phenyl, 4-F-2- (1-aminoethyl) phenyl, and 4-F-2- (2-amino-2-propyl) phenyl;
A is selected from the group: phenyl, 2-pyridyl, 3-pyridyl, 2-pyrimidyl, 2-Cl-phenyl, 3-Cl-phenyl, 2-F-phenyl, 3-F- phenyl, 2-methylphenyl, 2-aminophenyl, and 2- methoxyphenyl ; and,
B is selected from the group: 2-CF3-phenyl, 2- (aminosulfonyl) phenyl, 2- (methylaminosulfonyl) phenyl, 2- (dimethyla inosulfonyl) phenyl, 1-pyrrolidinocarbonyl, 2- (methylsulfonyl)phenyl, 4-morpholino, 2- (1' -CF3~tetrazol- 2-yl) phenyl, 4-morpholinocarbonyl , 2-methyl-l-imidazolyl, 5-methyl-l-imidazolyl, 2-methylsulfonyl-1-imidazolyl and, 5-methyl-1,2, 3-triazolyl.
[10] In a still further preferred embodiment, the present invention provides a novel compound of formula Ha.
[11] In another still further preferred embodiment, the present invention provides a novel compound of formula lib.
[12] In another still further preferred embodiment, the present invention provides a novel compound of formula He
[13] In another still further preferred embodiment, the present invention provides a novel compound of formula lid.
[14] In another still further preferred embodiment, the present invention provides a novel compound of formula He.
[15] In another still further preferred embodiment, the present invention provides a novel compound of formula Hf [ 16 ] In another even more preferred embodiment , the present invention provides novel compounds of formulae Ila-IIf , wherein;
D is selected from -CN, C ( =NR8 ) NR7R9 , C ( 0) NR7R8 , NR7R8 , and
CH2NR7R8 , provided that D is substituted ortho to ring M on E;
E is phenyl substituted with R or pyridyl substituted with R;
R is selected from H, Cl , F, OR3, CH3 , CH2CH3 , 0CF3 , CF3, NR7R8 , and CH2NR7R8;
Z is selected from C(O), CH2C(0), C(0)CH2, NHC(O), and C(0)NH, provided that Z does not form a N-N bond with ring M or group A;
Rla and Rlb are independently absent or selected from
-(CH2)r~R10 NCH2R1", OCH2R1", SCH2R1", N(CH2)2(CH2)tR1 O(CH2)2(CH2)tR10 and S (CH2) 2 (CH2) tR1', or combined to form a 5-8 membered saturated, partially saturated or unsaturated ring substituted with 0-2 R4 and which contains from 0-2 heteroatoms selected from the group consisting of N, 0, and S;
R1', at each occurrence, is selected from H, C1-.3 alkyl, halo, (CF2)rCF3, OR2, NRR , C(0)R2c, (CF2) rC02R2c, S(0)pR2b, NR2(CH2)rOR2, NR2C(0)R2b, NR2C(0)2R2b, C(0)NR2R2a, Sθ2NR2R2a, and NR S02R2b;
A is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R4; phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, and imidazolyl; B is selected from: Y, X-Y, NR2R2a, C (=NR2 )NR2R2a, and NR2C(=NR2)NR2R2a;
X is selected from CH2 , -CR2 (CR2R2b) (CH2) t- , -C(0)-, -C(=NR)-, -CH(NR2R2a)-, -C(0)NR2-, -NR2CtO)-, -NR2C (0) NR2- , -NR2-, and 0;
Y is NR2R2a, provided that X-Y do not form a N-N or 0-N bond;
alternatively, Y is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R4a; phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, isoxazolinyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, 1, 2 , 3 -oxadiazolyl, 1, 2, 4-oxadiazolyl, 1, 2 , 5-oxadiazolyl, 1, 3 , 4-oxadiazolyl, 1,2, 3-thiadiazolyl , 1,2, 4-thiadiazolyl , 1,2, 5-thiadiazolyl, 1, 3 , 4-thiadiazolyl , 1, 2 , 3-triazolyl, 1, 2, 4-triazolyl, 1, 2 , 5-triazolyl, and 1, 3 , 4-triazolyl;
R4, at each occurrence, is selected from =0, OH, Cl, F, Cι_4 alkyl, (CH2) r R2R2a, (CH2) rC (0) R2b, NR2C(0)R2b, C(0)NR2R2a, CH(=NH)NH2, NHC (=NH)NH2 , S02NR2R2a, NR2S02-Cι_4 alkyl, NR2S02R5, S(0)pR5, and (CF2)rCF3;
Ra, at each occurrence, is selected from =0, OH, Cl, F, C1-.4 alkyl, (CH2) rNR2R2a, (CH2) rC (0) R2b, NR2C(0)R2b, C(0)NR2R2a, CH(=NH)NH2, NHC(=NH)NH2, S02NR2R2a, NR2S02-Cι_4 alkyl, NR2S02R5, S(0)pR5, (CF2)rCF3, and l-CF3-tetrazol-2-yl;
R5, at each occurrence, is selected from CF3, C1-6 alkyl, phenyl substituted with 0-2 R6, and benzyl substituted with 0-2 R6; R6, at each occurrence, is selected from H, =0, OH, OR2, Cl, F, CH3, CN, N02, (CH2)rNR2R2a, (CH2 ) rC (0) R2b, NR2C(0)R2b, CH(=NH)NH2, NHC(=NH)NH2, and S02NR2R2a;
R7, at each occurrence, is selected from H, OH, Cι_6 alkyl, Cι_6 alkylcarbonyl, C -β alkoxy, Cχ_4 alkoxycarbonyl, benzyl, Cδ-io aryloxy, Cβ-io aryloxycarbonyl, Cβ-io arylmethylcarbonyl, C1-4 alkylcarbonyloxy Cχ-4 alkoxycarbonyl, C6-10 arylcarbonyloxy Cι_4 alkoxycarbonyl, C1-6 alkylaminocarbonyl, phenylaminocarbonyl , and phenyl C1-4 alkoxycarbonyl;
R8, at each occurrence, is selected from H, C1-6 alkyl and benzyl ; and
alternatively, R7 and R8 combine to form a morpholino group; and,
R9, at each occurrence, is selected from H, Cι_6 alkyl and benzyl.
[17] In a another further preferred embodiment, the present invention provides novel compounds of formulae Ila-IIf, wherein;
E is phenyl substituted with R or 2-pyridyl substituted with R;
R is selected from H, Cl, F, OCH3 , CH3 , OCF3 , CF3 , NH2 , and CH2NH2 ;
Z is selected from a C(0)CH2 and C(0)NH, provided that Z does not form a N-N bond with group A;
Rla _s selected from H, CH3 , CH2CH3 , Cl, F, CF3 , OCH3 , NR2R2a, S(0)pR2b, CH2S(0)pR2 , CH2NR2S(0)pR b, C(0)R2c, CH2C(0)R2 , C(0)NR2R2a, and S02NR2R2a; Rlb s selected from H, CH3 , CH2CH3 , Cl, F, CF3 , OCH3 , NR2R2a, S(0)pR2b, CH2S(0)pR2b, CH2NR2S(0)pR2b, C(0)R2c, CH2C(0)R2c, C(0)NR2R2a, and S02NR2R2a;
A is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R4; phenyl, pyridyl, pyrimidyl, furanyl, thiophenyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, and imidazolyl;
B is selected from: Y and X-Y;
X is selected from CH2 , -CR2 (CR2R2b) -, -C(O)-, -C(=NR)-, -CH(NR2R2a)-, -C(0)NR2-, -NR2C(0)-, -NR2C (0) NR2- , -NR2-, and O;
Y is NR2R2a, provided that X-Y do not form a N-N or 0-N bond;
alternatively, Y is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R4a; phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, isoxazolinyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, 1, 2, 3-oxadiazolyl, 1, 2, 4-oxadiazolyl, 1, 2 , 5-oxadiazolyl, 1, 3 , 4-oxadiazolyl, 1,2, 3-thiadiazolyl, 1, 2 , 4-thiadiazolyl, 1, 2, 5-thiadiazolyl, 1, 3 , 4-thiadiazolyl, 1, 2, 3 -triazolyl, 1, 2, 4-triazolyl, 1, 2 , 5-triazolyl, and 1, 3 , 4-triazolyl;
R2, at each occurrence, is selected from H, CF3 , CH3, benzyl, and phenyl;
R2a, at each occurrence, is selected from H, CF3, CH3, benzyl, and phenyl; R2b, at each occurrence, is selected from CF3 , OCH3 , CH3 , benzyl, and phenyl;
R2c, at each occurrence, is selected from CF3, OH, OCH3 , CH3 , benzyl, and phenyl;
alternatively, R2 and Ra combine to form a 5 or 6 membered saturated, partially unsaturated, or unsaturated ring which contains from 0-1 additional heteroatoms selected from the group consisting of N, 0, and S;
R3, at each occurrence, is selected from H, CH3 , CH2CH3 , and phenyl;
R3a, at each occurrence, is selected from H, CH3, CH2CH3 , and phenyl ;
R4, at each occurrence, is selected from OH, Cl , F, CH3 ,
CH2CH3, NR2R2 , CH2NR2R2 , C(0)R2b, NR2C(0)R2b, C(0)NR2R2a, and CF3;
R4a, at each occurrence, is selected from OH, Cl, F, CH3 ,
CH2CH3, NR2R2a, CH2NR2R2 , C(0)R2b, C(0)NR2R2a, S02NR2R2a, S(0)pR5, CF3, and l-CF3-tetrazol-2-yl;
R5, at each occurrence, is selected from CF3, C -e alkyl, phenyl substituted with 0-2 R6, and benzyl substituted with 1 R6;
R6, at each occurrence, is selected from H, OH, OCH3, Cl, F, CH3, CN, N02, NR2R2 , CH2NR2R2 , and S02NR2R2a;
R7, at each occurrence, is selected from H and Cχ_3 alkyl;
R8, at each occurrence, is selected from H, CH3, and benzyl;
R9, at each occurrence, is selected from H, CH3, and benzyl; and, t, at each occurrence, is selected from 0 and 1.
[18] In a another still further preferred embodiment, the present invention provides novel compounds of formulae Ila-IIf, wherein;
D is selected from NR7R8 , and CH2NR7R8, provided that D is substituted ortho to ring M on E;
Rla is absent or is selected from H, CH3, CH2CH3 , Cl, F, CF3 , OCH3, NR2R2a, S(0)pR2b, C(0)NR2R2a, CH2S(0)pR2b, CH2NR2S(0)pR2b, C(0)R2c, CH2C(0)R2c, and S02NR2R2a;
Rlb is absent or is selected from H, CH3, CH2CH3, Cl, F, CF3 , OCH3, NR2R2a, S(0)pR2b, C(0)NR2R2a, CH2S(0)pR2b, CH2NR2S(0)pR2b, C(0)R2b, CH2C(0)R2b, and S02NR2R2a;
A is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R4; phenyl, pyridyl, and pyrimidyl;
B is selected from: Y and X-Y;
X is selected from -C(O)- and 0;
Y is NR2R2 , provided that X-Y do not form a 0-N bond;
alternatively, Y is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R4a; phenyl, piperazinyl, pyridyl, pyrimidyl, morpholinyl, pyrrolidinyl, imidazolyl, and 1,2,3- triazolyl;
R2, at each occurrence, is selected from H, CF3, CH3, benzyl, and phenyl; R2 , at each occurrence, is selected from H, CF3 , CH3 , benzyl, and phenyl;
R2b, at each occurrence, is selected from CF3 , OCH3 , CH3 , benzyl, and phenyl;
R2c, at each occurrence, is selected from CF3, OH, OCH3, CH3, benzyl, and phenyl;
alternatively, R2 and R2a combine to form a ring system selected from pyrrolidinyl, piperazinyl and morpholino;
R4, at each occurrence, is selected from Cl, F, CH3 , NR2R2a, and CF3 ;
Ra, at each occurrence, is selected from Cl, F, CH3, S02NR2R2a, S(0)PR5, and CF3 ;
R5, at each occurrence, is selected from CF3 and CH3 ,-
R7, at each occurrence, is selected from H, CH3, and CH2CH3; and,
R8, at each occurrence, is selected from H and CH3.
[19] Specifically preferred compounds of the present invention are selected from the group:
3-Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (2 '-sulfamido- [1,1' ] -biphen-4-yl) ) carboxyamide;
3-Ethyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (2 ' -sulfamido- [1,1'] -biphen-4-yl) ) carboxyamide;
3-Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (2 ' -sulfamido- [1, 1 ' ] -biphen-4- yl) ) carboxyamide; -Methyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (2 ' -sulfamido- [1,1'] -biphen-4- yl ) ) carboxyamide ; -Ethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -lH-pyrazole- 5- (N- (2 ' -sulfamido- [1,1'] -biphen-4-yl) ) carboxyamide; -Trifluoromethyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) - lH-pyrazole-5-(N- (2 ' -sulfamido- [1,1' ] -biphen-4- yl) ) carboxyamide; -Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (2 ' -methylsulfonyl- [1,1'] -biphen-4-yl) ) carboxyamide; -Ethyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (2 ' -methylsulfonyl- [1,1'] -biphen-4-yl) ) carboxyamide; -Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (2 ' -methylsulfonyl- [1,1'] -biphen-4- yl) ) carboxyamide; -Methyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5-(N-(2 ' -methylsulfonyl- [1, 1' ]-biphen-4- yl ) ) carboxyamide; -Ethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -lH-pyrazole- 5- (N- (2 ' -methylsulfonyl- [1,1'] -biphen-4-yl) ) carboxyamide , -Trifluoromethyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) lH-pyrazole-5- (N- (2 ' -methylsulfonyl- [1, 1 ' ] -biphen-4- yl ) ) carboxyamide; -Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (3-fluoro-2 ' -sulfamido- [1,1'] -biphen-4-yl) ) carboxyamide;-Ethyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (3- fluoro-2 ' -sulfamido- [1,1'] -biphen-4-yl) ) carboxyamide; -Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -sulfamido- [1,1' ] -biphen-4- yl) ) carboxyamide; -Methyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -sulfamido- [1,1' ] -biphen-4- yl ) ) carboxyamide; -Ethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -lH-pyrazole- 5- (N- (3-fluoro-2 ' -sulfamido- [1, 1 ' ]-biphen-4- yl) ) carboxyamide; -Trifluoromethyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (3-fluoro-2 ' -sulfamido- [1 , 1 ' ] -biphen-4- yl) ) carboxyamide; -Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- ( 3 -fluoro-2 '-methylsulfonyl- [1,1' ]-biphen-4- yl ) ) carboxyamide,--Ethyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (3- fluoro-2 ' -methylsulfonyl- [1,1 ' ] -biphen-4- yl) ) carboxyamide; -Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1'] -biphen- 4-y1 ) ) carboxyamide; -Methyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1'] -biphen- 4-yl) ) carboxyamide; -Ethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -lH-pyrazole- 5- (N- (3-fluoro-2 ' -methylsulfonyl- [1, 1 ' ] -biphen-4- yl) ) carboxyamide; -Trifluoromethyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1']- biphen-4-yl) ) carboxyamide; -Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (4- (1-pyrrolidinocarbonyl) phenyl) carboxyamide; -Ethyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (4- ( 1-pyrrolidinocarbonyl) phenyl ) carboxyamide; -Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (4- (1- pyrrolidinocarbonyl) phenyl) carboxyamide; -Methyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (4-(l- pyrrolidinocarbonyl) phenyl ) carboxyamide ; -Ethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -lH-pyrazole- 5- (N- (4- ( 1-pyrrolidinocarbonyl) phenyl) carboxyamide; -Trifluoromethyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) - lH-pyrazole-5-(N-(4-(l- pyrrolidinocarbonyl ) phenyl) carboxyamide; -Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (2-fluoro-4- ( 1-pyrrolidinocarbonyl) phenyl) carboxyamide;-Ethyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (2- fluoro-4- ( 1-pyrrolidinocarbonyl) phenyl) carboxyamide ; -Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (2-fluoro-4- (1- pyrrolidinocarbonyl ) henyl ) carboxyamide; -Methyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (2-fluoro-4- (1- pyrrolidinocarbonyl) phenyl) carboxyamide ; -Ethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -lH-pyrazole- 5- (N- (2-fluoro-4- (1-pyrrolidinocarbonyl) carboxyamide ; -Trifluoromethyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (2-fluoro-4- (1- pyrrolidinocarbonyl ) phenyl ) carboxyamide; -Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (5- ( (2-sulfamido) phenyl )pyridin-2-yl) carboxyamide; -Ethyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (5- ( (2-sulfamido) phenyl )pyridin-2-yl) carboxyamide; -Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (5- ( (2-sulfamido)phenyl)pyridin-2- y1 ) carboxyamide; -Methyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (5- ( (2-sulfamido)phenyl)pyridin-2- yl) carboxyamide; -Ethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -lH-pyrazole- 5- (N- (5- ( (2-sulfamido)phenyl)pyridin-2-yl) carboxyamide; -Trifluoromethyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (5- ( (2-sulfamido) phenyl) pyridin-2- yl) carboxyamide,--Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (5- ( (2-methylsulphonyl)phenyl)pyridin-2-yl) carboxyamide;-Ethyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (5- (2-methylsulphonyl) phenyl) pyridin-2 -yl ) carboxyamide ; -Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (5- ( (2-methylsulphonyl) phenyl) pyridin-2- yl) carboxyamide; -Methyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (5- ( (2-methylsulphonyl) phenyl) pyridin-2- yl) carboxyamide; -Ethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -lH-pyrazole-
5- (N- (5- ( (2-methylsulphonyl) phenyl-) pyridin-2- yl) carboxyamide; -Trifluoromethyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (5- ( (2-methylsulphonyl) phenyl) pyridin-2- yl) carboxyamide; -Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (5- ( (2-sulfamido) phenyl)pyrimidin-2-yl) carboxyamide; -Ethyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (5- ( (2-sulfamido) phenyl)pyrimidin-2-yl) carboxyamide; -Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (5- ( (2-sulfamido) phenyl)pyrimidin-2- yl ) carboxyamide ; -Methyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (5- ( (2-sulfamido) phenyl) pyrimidin-2- yl ) carboxyamide; -Ethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -lH-pyrazole- 5- (N- (5- ( ( 2-sulfamido) phenyl )pyrimidin-2-yl) carboxyamide ; -Trifluoromethyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (5- ( (2-sulfamido) phenyl) pyrimidin-2- yl) carboxyamide; -Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (5- ( (2-methylsulphonyl) phenyl )pyrimidin-2- yl ) carboxyamide ; -Ethyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (5- (2-methylsulphonyl) phenyl) pyrimidin-2-yl) carboxyamide ; -Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (5- ( (2-methylsulphonyl) phenyl)pyrimidin-2- yl ) carboxyamide; -Methyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (5- ( (2-methylsulphonyl) phenyl) pyrimidin-2- yl) carboxyamide; -Ethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -lH-pyrazole- 5- (N- (5- ( (2-methylsulphonyl) phenyl)pyrimidin-2- yl) carboxyamide; -Trifluoromethyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (5- ( (2-methylsulphonyl) phenyl) pyrimidin- 2-yl) carboxyamide; -Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (4- ( (2-methyl) imidazo-1-yl) phenyl) carboxyamide; -Ethyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (4- ( (2-methyl) imidazo-1-yl) phenyl ) carboxyamide; -Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (4- ( (2-methyl) imidazo-1- yl) henyl) carboxyamide; -Methyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (4- ( (2-methyl) imidazo-1- yl)phenyl) carboxyamide; -Ethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -IH-pyrazole- 5- (N- (4- ( (2-methyl) imidazo-1-yl) phenyl) carboxyamide; -Trifluoromethyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) - IH-pyrazole-5- (N- (4- ( (2-methyl) imidazo-1- yl)phenyl) carboxyamide; -Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (4- ( (5-methyl) imidazo-1-yl) phenyl) carboxyamide; -Ethyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (4- ( (5-methyl) imidazo-1-yl)phenyl) carboxyamide; -Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (4- ( (5-methyl) imidazo-1- yl)phenyl) carboxyamide; -Methyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (4- ( (5-methyl) imidazo-1- y1)phenyl) carboxyamide; -Ethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -lH-pyrazole- 5- (N- (4- ( (5-methyl) imidazo-1-yl)phenyl) carboxyamide; -Trifluoromethyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (4- ( (5-methyl) imidazo-1- yl)phenyl) carboxyamide; -Methyl-l- (2-aminomethyl-4-methoxyphenyl) -IH-pyrazole-5- (N- (2-fluoro-4- ( (2-methyl) imidazo-1-yl)phenyl) carboxyamide;-Ethyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (2- fluoro-4- ( (2-methyl) imidazo-1-yl)phenyl) carboxyamide; -Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (2-fluoro-4- ( (2-methyl) imidazo-1- yl)phenyl) carboxyamide; -Methyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (2-fluoro-4- ( (2-methyl) imidazo-1- yl)phenyl) carboxyamide; -Ethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -lH-pyrazole- 5- (N- (2-fluoro-4- ( (2-methyl) imidazo-1- yl)phenyl) carboxyamide; -Trifluoromethyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (2-fluoro-4- ( (2-methyl) imidazo-1- yl)phenyl) carboxyamide; -Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (2-fluoro-4- ( (5-methyl) imidazo-1-yl) phenyl) carboxyamide; -Ethyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (2- fluoro-4- ( (5-methyl) imidazo-1-yl)phenyl) carboxyamide; 3 -Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (2-fluoro-4- ( (5-methyl) imidazo-1- yl ) phenyl) carboxyamide,- 3-Methyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (2-fluoro-4- ( (5-methyl) imidazo-1- yl ) phenyl ) carboxyamide;
3-Ethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -lH-pyrazole- 5- (N- (2-fluoro-4- ( (5-methyl) imidazo-1- yl ) phenyl ) carboxyamide ; and,
3 -Trifluoromethyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (2-fluoro-4- ( (5-methyl) imidazo-1- yl ) phenyl ) carboxyamide,-
and pharmaceutically acceptable salts thereof.
[20] More specifically preferred compounds of the present invention are selected from the group:
3-Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (2 ' -sulfamido- [1,1'] -biphen-4-yl) ) carboxyamide;
5-Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-3- (N- (2 ' -sulfamido- [1,1'] -biphen-4-yl) ) carboxyamide;
3-Methyl-l- (2-N,N-dimethylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (2 ' -N-methylsulfamido- [1, 1 ' ] -biphen-4- yl ) ) carboxyamide;
3 -Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -sulfamido- [1, 1] -biphen-4- yl ) ) carboxyamide;
3-Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1, 1] -biphen-4- yl) ) carboxyamide;
3 -Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (2 ' -methylsulfonyl- [1, 1] -biphen-4- yl) ) carboxyamide; 3-Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (2 ' -sulfamido- [1,1] -biphen-4- yl) ) carboxyamide;
3 -Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N-(4-N- pyrrolidinocarbonyl ) phenyl ) carboxyamide ; N-Benzylsulfonyl-4- (3 -trifluoromethyl-1- (2-aminomethyl-4- methoxyphenyl) -IH-pyrazole-5-carboxyamido) piperidine;
3 -Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (5- (2 ' -sulfonamido) phenyl )pyrid-2- yl ) carboxyamide;
3 -Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (5- (pyrid-2-yl) ) pyrid-2-yl) carboxyamide;
N-Benzyl-4- (3 -trifluoromethyl-1- (2-aminomethyl-4- methoxyphenyl) -lH-pyrazole-5-carboxyamido) piperidine;
N-Phenylsulfonyl-4- (3-trifluoromethyl-1- (2-aminomethyl-4- methoxyphenyl) -IH-pyrazole-5-carboxyamido) piperidine ;
3 -Trifluoromethyl-1- (2-aminomethyl-4-chlorophenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1'] -biphen-
4-yl) ) carboxyamide;
3 -Trifluoromethyl-1- (2-aminomethyl-4-chlorophenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -sulfamido- [1,1'] -biphen-4- yl ) ) carboxyamide; 3-Trifluoromethyl-1- (2-aminomethyl-5-chlorophenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1'] -biphen- 4-yl ) ) carboxyamide;
3 -Trifluoromethyl-1- (2-aminomethyl-4-chlorophenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -sulfamido- [1, 1 ' ]-biphen-4- yl) ) carboxyamide;
3 -Trifluoromethyl-1- (2-aminomethyl-4-fluorophenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1'] -biphen- 4-yl ) ) carboxyamide;
3-Trifluoromethyl-1- (2-aminomethyl-4-fluorophenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -sulfamido- [1,1'] -biphen-4- yl ) ) carboxyamide;
3-Trifluoromethyl-1- (2-aminomethyl-5-fluorophenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1'] -biphen-
4-yl ) ) carboxyamide; 3-Trifluoromethyl-1- (2-aminomethyl-5-fluorophenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -sulfamido- [1,1' ] -biphen-4- yl ) ) carboxyamide;
3-Trifluoromethyl-1- (2-aminomethyl-4, 5-difluorophenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1'] -biphen- 4-yl) ) carboxyamide;
3-Trifluoromethyl-1- (2-aminomethyl-4 , 5-difluorophenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -sulfamido- [1,1'] -biphen-4- yl ) ) carboxyamide; -Trifluoromethyl-1- (2-aminomethyl-3 -fluorophenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1'] -biphen- 4-yl ) ) carboxyamide ; -Trifluoromethyl-1- ( 2-aminomethyl-3-fluorophenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -sulfamido- [1,1'] -biphen-4- yl ) ) carboxyamide; -Trifluoromethyl-1- (2-aminomethyl-4-fluorophenyl) -1H- pyrazole-5- (N- (4- (2-methylsulfonyl- [1,1' ] -biphen-4- yl) ) carboxyamide; -Trifluoromethyl-1- (2-aminomethyl-4-fluorophenyl) -1H- pyrazole-5- (N- (4- (2-sulfamido- [1,1'] -biphen-4- yl) ) carboxyamide ; -Trifluoromethyl-1- (2-aminomethyl-4-fluorophenyl) -1H- pyrazole-5- (N- (4- (N- ( (N' - methylsulfonyl) iminoly) pyrrolidino) ) phenyl ) carboxyamide ; -Trifluoromethyl-1- (2- (N-glycyl) aminomethyl-4-methoxyphenyl) - lH-pyrazole-5-(N- (3-fluoro-2 ' -methylsulfonyl- [1, 1 ' ]- biphen-4-yl ) ) carboxyamide ; -Trifluoromethyl-1- (2- (N-phenylacetyl) aminomethyl-4- methoxyphenyl ) -lH-pyrazole-5- (N- (3-fluoro-2 ' - methylsulfonyl- [1,1'] -biphen-4-yl) ) carboxyamide; - (Trifluoromethyl) -1- (2- (aminomethyl) phenyl) -lH-pyrazole-5- (N- (2 ' -methylsulfonyl- [1,1'] -biphen-4-yl) ) carboxyamide; -Trifluoromethyl-1- (2- (aminomethyl ) phenyl ) -lH-pyrazole-5- (N- (2 ' -aminosulfonyl- [1,1' ] -biphen-4-yl) ) carboxyamide; -Trifluoromethyl-1- (2- (aminomethyl) phenyl) -lH-pyrazole-5- (N- ( 3-fluoro-2 ' -aminosulfonyl- [1,1'] -biphen-4- yl ) ) carboxyamide ; -Trifluoromethyl-1- (2- (aminomethyl)phenyl) -lH-pyrazole-5- (N- (3-fluoro-2" -methylsulfonyl- [1,1' ]-biphen-4- yl) ) carboxyamide; -Trifluoromethyl-1- (2- (N- (glycyl) aminomethyl) phenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1'] -biphen- 4-yl) ) carboxyamide; -Trifluoromethyl-1- (2- ( (N- (N- methylglycyl) aminomethyl) phenyl) -IH-pyrazole-5- (N- (3- fluoro-2 ' -methylsulfonyl- [1,1'] -biphen-4- y1) ) carboxyamide; -Trifluoromethyl-1- (2-carboxamidophenyl) -lH-pyrazole-5- (N- (3- fluoro-2 ' -methylsulfonyl- [1, 1 ' ] -biphen-4- yl) ) carboxyamide; 3 -Trifluoromethyl-1- (2-cyanophenyl) -lH-pyrazole-5- (N- (3- fluoro-2 ' -methylsulfonyl- [1,1'] -biphen-4- yl ) ) carboxyamide;
1- (2 ' -Aminomethylphenyl) -5- [ [ (2 ' -methylsulfonyl) -3-fluoro- [1,1'] -biphen-4-yl]aminocarbonyl] -tetrazole;
1- (2 ' -Aminomethylphenyl) -5- [ (2 ' -aminosulfonyl- [1,1'] -biphen-4- yDaminocarbonyl] -tetrazole;
1- [2- (Aminomethyl) phenyl] -3-thiomethoxy-5- [ (2-fluoro) - (2 ' - methylsulfonyl- [1, 1 ' ] -biphen-4-yl) aminocarbonyl] pyrazole; l-[2- (Aminomethyl) phenyl] -3-methysulfonyl-5- [ (2-fluoro) -(2 ' - methylsulfonyl- [1, 1 ' ] -biphen-4-yl) aminocarbonyl]pyrazole;
1- [2- (Aminomethyl) phenyl] -5- [ (2-fluoro) - (2 ' -methylsulfonyl- [1,1'] -biphen-4-yl) aminocarbonyl] triazole; 1- [2- (Aminomethyl) phenyl] -5- [ (2-fluoro) - (2 ' -methylsulfonyl- [1,1'] -biphen-4-yl) aminocarbonyl] pyrazole;
1- [2- (Aminomethyl) phenyl] -3-trifluoromethyl-5- [ ( (2-fluoro) - (2 ' -pyrrolidinomethyl) - [1,1'] -biphen-4- yl) aminocarbonyl] pyrazole; and,
1- [2- (Aminomethyl) phenyl] -3-trifluoromethyl-5- [ ( (2-fluoro) - (2 ' -hydroxymethyl) - [1 , 1 ' ] -biphen-4- yl ) aminocarbonyl] pyrazole; and pharmaceutically acceptable salts thereof,
In a second embodiment, the present invention provides novel pharmaceutical compositions, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt form thereof.
In a third embodiment, the present invention provides a novel method for treating or preventing a thromboembolic disorder, comprising: administering to^ a patient in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt form thereof . DEFINITIONS The compounds herein described may have asymmetric centers . Compounds of the present invention containing an asymmetrically substituted atom may be isolated in optically active or racemic forms . It is well known in the art how to prepare optically active forms, such as by resolution of racemic forms or by synthesis from optically active starting materials. Many geometric isomers of olefins, C=N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. Cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms. All chiral, diastereomeric, racemic forms and all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomeric form is specifically indicated. All processes used to prepare compounds of the present invention and intermediates made therein are considered to be part of the present invention. The term "substituted, " as used herein, means that any one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound. When a substitent is keto (i.e., =0), then 2 hydrogens on the atom are replaced. Keto substituents are not present on aromatic moieties.
The present invention is intended to include all isotopes of atoms occurring in the present compounds. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include tritium and deuterium. Isotopes of carbon include C-13 and C-14.
When any variable (e.g., R6) occurs more than one time in any constituent or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown to be substituted with 0-2 R6, then said group may optionally be substituted with up to two R6 groups and R6 at each occurrence is selected independently from the definition of R6. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
When a bond to a substituent is shown to cross a bond connecting two atoms in a ring, then such substituent may be bonded to any atom on the ring. When a substituent is listed without indicating the atom via which such substituent is bonded to the rest of the compound of a given formula, then such substituent may be bonded via any atom in such substituent. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds .
As used herein, "alkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms. Examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, n-pentyl, and s-pentyl. "Haloalkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, substituted with
1 or more halogen (for example -CVFW where v = 1 to 3 and w = 1 to (2v+l) ) . Examples of haloalkyl include, but are not limited to, trifluoromethyl, trichloromethyl , pentafluoroethyl, and pentachloroethyl . "Alkoxy" represents an alkyl group as defined above with the indicated number of carbon atoms attached through an oxygen bridge . Examples of alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy, n-pentoxy, and s-pentoxy. "Cycloalkyl" is intended to include saturated ring groups, such as cyclopropyl, cyclobutyl, or cyclopentyl. Alkenyl" is intended to include hydrocarbon chains of either a straight or branched configuration and one or more unsaturated carbon-carbon bonds which may occur in any stable point along the chain, such as ethenyl and propenyl . "Alkynyl" is intended to include hydrocarbon chains of either a straight or branched configuration and one or more triple carbon-carbon bonds which may occur in any stable point along the chain, such as ethynyl and propynyl . "Halo" or "halogen" as used herein refers to fluoro, chloro, bromo, and iodo; and "counterion" is used to represent a small, negatively charged species such as chloride, bromide, hydroxide, acetate, and sulfate. As used herein, "carbocycle" or "carbocyclic residue" is intended to mean any stable 3- to 7-membered monocyclic or bicyclic or 7-to 13-membered bicyclic or tricyclic, any of which may be saturated, partially unsaturated, or aromatic. Examples of such carbocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, cyclooctyl, [3.3.0]bicyclooctane, [4.3.0]bicyclononane, [4.4. O]bicyclodecane,
[2.2.2]bicyclooctane, fluorenyl, phenyl, naphthyl, indanyl, adamantyl , and tetrahydronaphthyl . As used herein, the term "heterocycle" or "heterocyclic system" is intended to mean a stable 5-to 7-membered monocyclic or bicyclic or 7-to 10-membered bicyclic heterocyclic ring which is saturated partially unsaturated or unsaturated (aromatic) , and which consists of carbon atoms and from 1 to 4 heteroatoms independently selected from the group consisting of N, 0 and S and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The nitrogen and sulfur heteroatoms may optionally be oxidized. The heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom which results in a stable structure. The heterocyclic rings described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable. A nitrogen in the heterocycle may optionally be quaternized. It is preferred that when the total number of S and O atoms in the heterocycle exceeds 1, then these heteroatoms are not adjacent to one another. It is preferred that the total number of S and 0 atoms in the heterocycle is not more than 1. As used herein, the term "aromatic heterocyclic system" or "heteroaryl" is intended to mean a stable 5-to 7-membered monocyclic or bicyclic or 7-to 10-membered bicyclic heterocyclic aromatic ring which consists of carbon atoms and from 1 to 4 heterotams independently selected from the group consisting of N, 0 and S. It is preferred that the total number of S and 0 atoms in the aromatic heterocycle is not more than 1.
Examples of heterocycles include, but are not limited to, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl , benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzi idazolinyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H, 6H-1, 5, 2-dithiazinyl, dihydrofuro [2, 3 -b] tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, lH-indazolyl, indolenyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl , isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl, morpholinyl, naphthyridinyl , octahydroisoquinolinyl , oxadiazolyl, 1, 2 , 3-oxadiazolyl, 1, 2 , 4-oxadiazolyl, 1,2,5- oxadiazolyl, 1, 3 , 4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolidinyl, pyrimidinyl, phenanthridinyl , phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl , pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, tetrahydrofuranyl , tetrahydroisoquinolinyl , tetrahydroquinolinyl, 6H-1 , 2, 5-thiadiazinyl, 1,2,3- thiadiazolyl , 1, 2, 4-thiadiazolyl, 1, 2, 5-thiadiazolyl, 1,3,4- thiadiazolyl , thianthrenyl , thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl, 1, 2, 3-triazolyl, 1, 2, 4-triazolyl, 1, 2, 5-triazolyl, 1, 3, 4-triazolyl, and xanthenyl. Preferred heterocycles include, but are not limited to, pyridinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrrolidinyl, imidazolyl, indolyl, benzimidazolyl, lH-indazolyl, oxazolidinyl, benzotriazolyl, benzisoxazolyl, oxindolyl, benzoxazolinyl, and isatinoyl. Also included are fused ring and spiro compounds containing, for example, the above heterocycles. The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
As used herein, "pharmaceutically acceptable salts" refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like.
The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington ' s Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, PA, 1985, p. 1418, the disclosure of which is hereby incorporated by reference.
"Prodrugs" are intended to include any covalently bonded carriers which release the active parent drug according to formula (I) in vivo when such prodrug is administered to a mammalian subject. Prodrugs of a compound of formula (I) are prepared by modifying functional groups present in the compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compound. Prodrugs include compounds of formula (I) wherein a hydroxy, amino, or sulfhydryl group is bonded to any group that, when the prodrug or compound of formula (I) is administered to a mammalian subject, cleaves to form a free hydroxyl, free amino, or free sulfhydryl group, respectively. Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups in the compounds of formula (I) , and the like. Preferred prodrugs are amidine prodrugs wherein D is C(=NR7)NH2 or its tautomer C(=NH)NHR7 and R7 is selected from OH, Cι_4 alkoxy, C6_χo aryloxy, Cχ_4 alkoxycarbonyl, Cβ-io aryloxycarbonyl, C6_ιo arylmethylcarbonyl , C1-4 alkylcarbonyloxy C1-4 alkoxycarbonyl, and Cβ-io arylcarbonyloxy Cι_4 alkoxycarbonyl . More preferred prodrugs are where R7 is OH, methoxy, ethoxy, benzyloxycarbonyl, methoxycarbonyl, and methylcarbonyloxymethoxycarbonyl .
"Stable compound" and "stable structure" are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent .
"Substituted" is intended to indicate that one or more hydrogens on the atom indicated in the expression using "substituted" is replaced with a selection from the indicated group (s ) , provided that the indicated atom's normal valency is not exceeded, and that the substitution results in a stable compound. When a substituent is keto (i.e., =0) group, then 2 hydrogens on the atom are replaced. "Therapeutically effective amount" is intended to include an amount of a compound of the present invention or an amount of the combination of compounds claimed effective to inhibit HIV infection or treat the symptoms of HIV infection in a host . The combination of compounds is preferably a synergistic combination. Synergy, as described for example by Chou and Talalay, Adv. Enzyme Regul . 22:27-55 (1984), occurs when the effect (in this case, inhibition of HIV replication) of the compounds when administered in combination is greater than the additive effect of the compounds when administered alone as a single agent. In general, a synergistic effect is most clearly demonstrated at suboptimal concentrations of the compounds. Synergy can be in terms of lower cytotoxicity, increased antiviral effect, or some other beneficial effect of the combination compared with the individual components .
SYNTHESIS The compounds of the present invention can be prepared in a number of ways known to one skilled in the art of organic synthesis. The compounds of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or by variations thereon as appreciated by those skilled in the art. Preferred methods include, but are not limited to, those described below. The reactions are performed in a solvent appropriate to the reagents and materials employed and suitable for the transformations being effected. It will be understood by those skilled in the art of organic synthesis that the functionality present on the molecule should be consistent with the transformations proposed. This will sometimes require a judgment to modify the order of the synthetic steps or to select one particular process scheme over another in order to obtain a desired compound of the invention. It will also be recognized that another major consideration in the planning of any synthetic route in this field is the judicious choice of the protecting group used for protection of the reactive functional groups present in the compounds described in this invention. An authoritative account describing the many alternatives to the trained practitioner is Greene and Wuts (Protective Groups In Organic Synthesis, Wiley and Sons, 1991) . All references cited herein are hereby incorporated in their entirety herein by reference.
The compounds of Formula I in which ring M is pyrrole can be prepared by the procedures described in Schemes 1-9. In Scheme 1 is shown how to prepare pyrroles in which the group Q-E is attached to the pyrrole nitrogen, wherein Q is a functionality that can be converted into D of Formula I, Re is functionality that can be converted into Z-A-B of Formula I and Rf is or can be converted into Rl of Formula I. Oxidation of a furan with bromine in acetic acid can afford a 2,5- diacetoxydihydrofuran which can react with amine Q-E-NH2 to afford a pyrrole. Vilsmeier-Haack formylation with phosphorous oxychloride and DMF preferentially can acylate the pyrrole ring at C-2. Oxidation of the resulting aldehyde can give a carboxylic acid. The carboxylic acid can then be converted into amine derivatives using either the Hofmann degradation of the derived primary amide (Huisgen et. al .
Chem. Ber. 1960, 93 , 65) or the Curtius rearrangement of the derived acyl azide {J. Prakt . Chem . 1909, 42, All ) . Derivatives which contain a sulfur atom attached to the pyrrole ring can be obtained by direct sulfonation with pyridine sulfur trioxide complex to give the sulfonic acids or treatment with copper (II) thiocyanate (J". Het. Chem . 1988, 25, 431) followed by the reduction of the intermediate thiocyanate with sodium borohydride to give a mercaptan.
Scheme 1
Figure imgf000043_0001
3) heat; then I§0
Figure imgf000043_0002
In Scheme 2 is shown how to prepare pyrroles in which Q-E is attached to the 2-position, wherein Rf and R9 collectively are hydrogen or a group that can be converted into Rla and Rlb of Formula I. The Hantzsch pyrrole synthesis is a versatile reaction involving the cyclization of an appropriate β- ketoester with an α-halo ketone or aldehyde in the presence of a primary amine (Ber. Dtsch . Chem . Ges . 1890, 23 , 1474) . The β-ketoesters can be prepared from acid chlorides (X = Cl) by the addition of the magnesium anion of potassium alkylmalonate followed by decarboxylation (Synthesis 1993, 290) . Alternatively, β-ketoesters can be prepared from an appropriate aldehyde (R = H) by Reformatsky reaction with an α- bromoacetate followed by oxidation. Cyclization with an α- halo ketone or aldehyde in the presence" of a primary amine can afford pyrroles. Acidic hydrolysis of the 3-carboalkoxy pyrrole can afford the carboxylic acids . Pyrroles which contain a 3-amino substituent can be prepared from the acids by treatment with phosphoryl azide and triethylamine to effect a Curtius rearrangement to afford the isocyanates (J". Med. Chem . 1981, 24 , 33) which upon hydrolysis can yield 3- aminopyrroles . Pyrroles which contain a sulfur atom at C-3 can be prepared from the acids by employing the Hunsdiecker procedure to give the 3-bromo derivatives. Halogen-metal exchange at low temperature with an alkyllithium reagent can afford the 3-lithio derivative which can be quenched with a variety of electrophiles, such as ≤8 to afford thiols directly or Cu(SCN)2 to afford a thiocyanate which can be reduced with sodium borohydride. The thiols can further be oxidized to the sulfonic acid derivatives by an oxidant such as KMnθ4.
Scheme 2
K+-02CCH2C02Rh
Figure imgf000044_0001
(R = Cl, H) 2 ) oxidation (R = H )
Figure imgf000044_0002
R9NH,
Figure imgf000044_0003
Ag+ salts , Br2
Figure imgf000044_0004
then NaBH In Scheme 3 is shown how to prepare pyrroles in which Q-E is attached to the 3 -position . This scheme relies upon the extremely versatile Knorr pyrrole synthesis , which involves condensation of α-aminoketones with β-ketoesters . The α- aminoketones can be prepared from β-ketoesters (Scheme 2) by nitrosation followed by reduction with zinc/acetic acid. Condensation of α-aminoketones with appropriate β-ketoesters can afford good yields of pyrroles.- These intermediates are very versatile and can be converted into pyrroles with a wide variety of substituents with varying substitution patterns. For cases wherein Re (Z-A-B precursor) is at the 2-position, acidic hydrolysis can selectively hydrolyze the C-3 ester. Heating should then effect decarboxylation. Hydrolysis of the 2-carboxylic acid can be achieved under basic conditions. Curtius rearrangement of the acid as described previously can afford the amino derivatives. To prepare compounds with a sulfur atom attached to C-2, basic hydrolysis and decarboxylation can afford the C-2 unsubstituted pyrroles. These pyrroles can undergo electrophilic substitution to afford thiols (Cu(SCN)2, then NaBH4) and sulfonic acids (pyridine SO3 complex or chlorosulfonic acid) . The Rla group contained in Formula I can be derived either from the remaining ester or from Rf. Alternatively, the thiol and sulfonic acid derivatives can also be derived form the C-2 acids by manipulation of the carboxylic acid group as described previously.
Scheme 3
Figure imgf000046_0001
Figure imgf000046_0002
Figure imgf000046_0003
In Scheme 4 is shown how to prepare pyrroles in which Q-E is attached to the 3-position. Cyclization of α-aminoketones as described previously with β-ketoesters can afford pyrroles. Hydrolysis under basic conditions can selectively hydrolyze the C-2 ester which upon heating should undergo decarboxylation to afford 2-unsubstituted pyrroles. The C-3 ester can then be hydrolyzed under acidic conditions to afford the 3-carboxypyrroles . Curtius rearrangement under conditions described previously can afford the 3-aminopyrroles . The carboxylic acids can be used to prepare the 3-mercapto and 3- sulfonic acid derivatives . The Hunsdiecker procedure can be used to prepare the 3 -bromopyrroles . Halogen metal exchange with t-BuLi at low temperature followed by quenching with copper isocyanate should introduce an isocyanate group at C-3. This intermediate can be reduced with sodium borohydride to afford the 3-mercaptopyrroles . Alternatively, the carboxylic acids can be decarboxylated to afford pyrroles which can be N- protected with a bulky protecting group such as triisopropylsilyl (TIPS) . This bulky group directs electrophilic substitution to C-3 of the pyrrole ring. Thus, reaction with copper isocyanate followed by sodium borohydride reduction and then fluoride induced TIPS deprotection can afford 3-mercaptopyrroles. Sulfonation of N-protected pyrrole with pyridine sulfur trioxide complex can again be directed to C-3 of the pyrrole to afford, after TIPS deprotection, the 3- sulfonic acids .
Scheme 4
Figure imgf000048_0001
LiOH or NaOH, heat (-C0 )
Figure imgf000048_0002
Another general method of pyrrole synthesis that can be used to prepare compounds of the present invention is shown in Scheme 5. This approach (Cushman et. al . J. Org. Chem. 1996, 61, 4999) uses N-protected α-aminoketones and N-protected α- aminoaldehydes which are readily available from α-amino acids by initial preparation of the N-methoxy-N-methylamides followed by addition of an alkyl Grignard reagent (to produce ketones) or by reduction with a hydride reducing agent such as lithium aluminum hydride or diisobutylaluminum hydride. These aldehydes and ketones can be allowed to react with the enolates of additional ketones to afford intermediate aldol addition products which under acidic conditions cyclize to form pyrroles. The reacting partners in this approach can be of wide scope and can be chosen so -that one skilled in the art will be able to prepare varied pyrroles .
Scheme 5
t _ _ 1 ) Base
2) HCI
Figure imgf000049_0001
( PG = protecting group )
Figure imgf000049_0002
Another very general method of pyrrole synthesis useful for preparing compounds of the present invention is the Paal- Knorr reaction shown in Scheme 6. This reaction involves the reacting 1, 4-diketones or 1, 4-ketoaldehydes with primary amines to afford pyrroles. The starting 1, 4-diketones and 1, 4-ketoaldehydes can be prepared using standard enolate chemistry or by other procedures which are familiar to those skilled in the art of organic synthesis . The reaction is of wide scope and the starting materials can be chosen so that a variety of pyrroles can be prepared.
Scheme 6
Figure imgf000049_0003
N-E-Q , NR9 ) In Scheme 7 is shown how the compounds of Schemes 1-6 wherein Re is a carboxylic ester group can be converted into compounds containing the Z-A-B residue. For the amide linker (Formula I, Z = -CONH-), when Re = carboalkoxy, it can be hydrolyzed to the acid under either basic or acidic conditions depending on the substitution pattern, as described previously. Formation of the acid chloride with thionyl chloride followed by the addition of an appropriate amine H2 - A-B can afford the amide-linked compounds. Alternatively, the acid can be combined with amine H2N-A-B in the presence of a suitable peptide coupling agent, such as BOP-Cl, HBTU or DCC. In another method the ester can be directly coupled with an aluminum reagent, prepared by the addition of trimethylaluminum to the amine H2N-A-B. To form ether- or thioether-linked compounds of Formula I (Z = -CH2O-, -CH2S-) the acid can be reduced to the alcohol. Preferred procedures for this transformation are reduction with borane THF complex, or a procedure involving the reduction of the mixed anhydride with sodium borohydride (IBCF=isobutyl chloroformate and NMM=N-methylmorpholine) . Completion of the ether and thioether linked compounds of Formula I can readily be accomplished by the Mitsonobu protocol with an appropriate phenol, thiophenol or hydroxy- or mercaptoheterocycle HX-A-B (X = 0,S) (Formula I, A = aryl or heteroaryl) . Other ethers or thioethers (X = 0,S) can be prepared following initial conversion of the alcohol to a suitable leaving group, such as tosylate. Where X = S, thioethers can be further oxidized to prepare the sulfones (Formula I, Z = -CH2SO2-) . To prepare the amine-linked compounds of Formula I (Z = -CH2NH-) the alcohol can be oxidized to the aldehyde by a number of procedures, two preferred methods of which are the Swern oxidation and oxidation with pyridinium chlorochromate (PCC) . Alternatively, the aldehyde may be directly prepared by direct formylation of the pyrrole ring by the Vilsmeier-Haack procedure in certain cases , as described in previous schemes. Reductive amination of the aldehyde with an appropriate amine H2N-A-B and sodium cyanoborohydride can then afford the amine linked compounds.
The aldehyde also can be used to prepare the ketone- linked compounds of Formula I (Z = -COCH2-) - Treatment with an organometallic species can afford the alcohol. The organometallic species (wherein M = magnesium or zinc) can preferably be prepared from the corresponding halide by treatment with metallic magnesium or zinc. These reagents should readily react with aldehydes to afford alcohols . Oxidation of the alcohol by any of a number of procedures, such as the Swern oxidation or PCC oxidation, can afford the ketones-linked compounds.
Scheme 7
Rla -E' ΓΛ'Y A-I
Figure imgf000052_0001
0
BH3 , or IBCF, NMM; then NaBH
Figure imgf000052_0002
TsCl, base; then
HX-A-B, base
(X = 0,S) oxidation
Figure imgf000052_0003
Ln-M-CH2A-B
(M Mg, Zn)
oxidation
Figure imgf000052_0004
Figure imgf000052_0005
Additional compounds of Formula I in which the linking group m/z contains a nitrogen atom attached to ring M can be prepared by the procedures described in Scheme 8. The amines can be converted to sulfonamides (Formula I, m/z-NHS02~) by treatment with an appropriate sulfonyl chloride B-A-SO2CI in the presence of a base such as triethylamine. The amines can be converted into amides (Formula I, Z = -NHCO-) by treatment with an appropriate acid chloride Cl-CO-A-B in the presence of a base or by treatment with an appropriate carboxylic acid HO- CO-A-B in the presence of a suitable peptide coupling agent, such as DCC, HBTU or BOP. The amines can also be converted into amine-linked compounds (Formula I, Z = -NHCH2-) by reductive amination with an appropriate aldehyde OHC-A-B.
Scheme 8
t
Figure imgf000053_0001
Additional compounds of Formula I in which the linking group Z contains a sulfur atom attached to ring M can be prepared by the procedures described in Scheme 9. Treatment of sulfonic acids with phosphorous pentachloride followed by treatment with an appropriate amine H2N-A-B can afford sulfonamide-linked compounds (Formula I, Z = -SO2NH-) . The thiols can be alkylated with a suitable alkylating reagent in the presence of a base to afford thioethers (Formula I, Z = -SCH2-) . These compounds can be further oxidized by a variety of reagents to afford the sulfone-linked compounds (Formula I, Z = -SO2CH2-) •
Scheme 9
Figure imgf000054_0001
Q-
Figure imgf000054_0002
Compounds of Formula I wherein ring M is an imidazole can be formed using procedures described in Schemes 10-16. N- Substituted imidazole derivatives can be made by the general procedure shown in Scheme 10, wherein V is either V or a precusor of (CH2)nV, V is nitro, amino, thio, hydroxy, sulfonic acid, sulfonic ester, sulfonyl chloride, ester, acid, or halide, n is 0 and 1, and PG is either a hydrogen or a protecting group. Substitution can be achieved by coupling an imidazole with a halogen containing fragment Q-E-G-Hal in the presence of a catalyst, such as base, Cu/CuBr/base, or Pd/base, followed by conversion of V to (CH2 ) nN- Then, Q can be converted to D, and finally V can be converted to -Z-A-B following the procedures outlined in Schemes 7-9. Alternatively, V can be converted to Z-A-B followed by deprotection of N. This product can then be coupled as before to obtain the desired imidazole.
Scheme 10
Figure imgf000054_0003
One way to make amidino-phenyl-imidazole derivatives is shown in Scheme 11. 4-Imidazole carboxylic acid can be treated with thionyl chloride and then coupled with H2N-A-B in the presence of a base and then be heated with 3- fluorobenzonitrile in the presence of a base. The Pinner reaction using standard procedures known to those of skill in the art can be used to form the amidino group.
Scheme 11
Figure imgf000055_0001
Pinner
Figure imgf000055_0003
Figure imgf000055_0002
1, 2-Disubstituted and 1, 5-disubstituted imidazole derivatives can be made by the general procedures described in Scheme 12, wherein Rl is either a hydrogen or an alkyl group and U is aldehyde, ester, acid, amide, amino, thiol, hydroxy, sulfonic acid, sulfonic ester, sulfonyl chloride, or methylene halide. Step a involves coupling in the presence of a catalyst, such as base, Cu/CuBr/base, or Pd/base. When Rlb is a hydrogen, it can be deprotonated with a lithium base and trapped by formate, formamide, carbon dioxide, sulfonyl chloride (sulfur dioxide and then chlorine) , or isocyanate to give 1, 2-disubstituted imidazoles (Route bl) . Also, in Route bl when Rlb is CH3, it can be oxidized with Seθ2, Mnθ2, NaIθ4/cat. RI1CI3, or NBS to form U. When Rlb is hydrogen, sequential deprotonation and quenching with a lithium base and trimethysilyl chloride, followed by a second deprotonation with a lithium base and quenching with formate, formamide, carbon dioxide, sulfonyl chloride (sulfur dioxide and then chlorine), or isocyanate can afford 1, 5-disubstituted imidazoles (Route b2 ) . When Rlb is not hydrogen, the procedure of Route b2 can again be used to form 1, 5-disubstituted imidazoles (Route b3 ) .
Scheme 12
Figure imgf000056_0001
A preferred way of making 1, 2-disubstituted and 1,5- disubstituted imidazole derivatives is shown in Scheme 13. Imidazole can be heated with 3-fluorobenzonitrile in the presence of a base. The coupled product can then be treated with an alkyl lithium base and quenched with ClCθ2Me to give the 1, 2-disubstituted compound. Further treatment with a solution prepared of H2N-A-B in trimethylaluminum can give the amide, which can be further modified via the Pinner reaction to form the desired compound. The 1, 5-disubstituted compounds can be made using the same procedure, except that the initial anion is protected and a second anion is formed which is then quenched as noted above. Further modifications can follow the same procedures as the 1, 2-disubstituted compounds. Scheme 13
Figure imgf000057_0001
Another way of making 1, 2-disubstituted imidazole derivatives is described in Scheme 14. By reacting an N- substituted imidazole with a cyanate, the amide can be obtained. This amide can then be coupled with group B as will be described later.
Scheme 14
Figure imgf000057_0002
Another means of making 1, 5-disubstituted imidazole derivatives is described in Scheme 15. Alkylation with 2- bromoethylacetate and subsequent reaction with Gold's reagent in the presence of a base, such as NaOMe, or LDA, can form ester substituted imidazoles which can be further modified as previously discribed.
Scheme 15
Figure imgf000058_0001
A general procedure to make 2 , 4, 5-trisubstituted or 4,5- disubstituted imidazole derivatives is shown in Scheme 16. After metal halogen exchange of the Q-E-G fragment, it can be reacted with the amide shown, brominated with NBS and cyclized with excess NH3 and RlCC>2H to afford an imidazole. This can then be modified as before.
Scheme 16
Figure imgf000058_0002
A general procedure to make 4, 5-disubstituted triazole derivatives is described in Scheme 17. Ethyl propiolate can be substituted in the presence of Cul/Pd and then reacted with N 3 to form a triazole . The triazole can be converted as described previously. Scheme 17
Figure imgf000059_0001
The tetrazole compounds of the present invention where Z is -CONH- can be prepared as exemplified in Scheme 18. An appropiately substituted amine can be acylated with ethyl oxalyl chloride. The resulting amide can be converted to the tetrazole either by the methods described by Duncia (J. Org. Chem . 1991, 2395-2400) or Thomas ( Synthesis 1993, 767-768) . The amide can be converted to the iminoyl chloride first and the reacted with a 3 to form the 5-carboethoxytetrazole (J". Org. Chem . 1993, 58, 32-35 and Bioorg . & Med. Chem . Lett . 1996, 6, 1015-1020) . The 5-carboethoxytetrazole can then be further modified as described in Scheme 7.
The tetrazole compounds of the present invention where Z is -CO- can also be prepared via iminoyl chloride { Chem. Ber. 1961, 94, 1116 and J. Org. Chem. 1976, 41 , 1073) using an appropriately substituted acyl chloride as starting material. The ketone-linker can be reduced to compounds wherein Z is alkyl .
Scheme 18
0 O Cl Cl-^ C02Et HN" C02Et ■ ccl
QE — NH2 N C02Et I
CH2Cl, /Et,N E(2 EQ
Figure imgf000060_0001
The methods described in Scheme 18 can also be used to synthesize compounds where the E-Q is linked to the carbon atom of the tetrazole as shown in Scheme 19. The 5- substituted tetrazole can then be alkylated or acylated to give the desired products.
Scheme 19
Figure imgf000060_0002
The tetrazole compounds of the present invention wherein Z is -S02NH-, -S-, -S(0)-, SO2- can be prepared from the thiol prepared as shown in Scheme 20. Appropiately substituted thioisocyanate can be reacted with sodium azide to give the 5- thiotetrazole (J". Org. Chem . 1967, 32, 3580-3592). The thio- compound can be modified as described in Scheme 9.
The tetrazole compounds of the present invention wherein Z is -O- can be prepared via the same method described in Scheme 20 by using appropiately substituted isocyanate as the starting material. The hydroxy compound can be modified si ilarily to the thiols described in Scheme 9.
Scheme 20
N— N
NCS NaN3 N ^N^ 5^ SH
E0- CHC13 /H20 EQ
The tetrazole compounds of the present invention wherein Z is -NH-, -NHCO-, -NHS02- can be prepared from 5- aminotetrazole, which can be prepared by Smiles Rearrangement as shown in Scheme 21. The thio-compound prepared as described in Scheme 20 can be alkylated with 2- chloroacetamide . The resulting compound can then be refluxed in ethanolic sodium hydroxide to give the corresponding 5- amino-tetrazole ( Chem . Pharm. Bull . 1991, 39, 3331-3334) . The resulting 5-amino-tetrazole can then be alkylated or acylated to form the desired products.
Scheme 21
Figure imgf000061_0001
Pyrazoles of Formula I (such as those described in Scheme 22) can be prepared by the condensation of an appropriately substituted hydrazine with a variety of diketo esters. Condensations of this type typically afford a mixture of pyrazole regioisomers which can be effectively separated via silica gel column chromatography. The esters can be converted to Z-A-B as previously described.
Alternatively, if in Scheme 22, the starting diketone contains CH3 in place of CC>2Et, then the resulting methyl pyrazole can be separated and oxidized as in Route bl in Scheme 12 to form the pyrazole carboxylic acid. Scheme 22
Figure imgf000062_0001
When ketoimidates are used for condensations with hydrazines the corresponding pyrazole amino esters are obtained ( Scheme 23 ) . Conversion of these intermediates to the final compounds of formula I can then be accomplished by the protection of the amino functionality with a suitable protecting group or by derivatization (e . g . sulfonamide) and then modifying the ester as previously noted.
Scheme 23
Figure imgf000062_0002
Me2S02Cl pyridine
Figure imgf000062_0003
As shown in Scheme 24, pyrazoles wherein the 4-position is substituted can be prepared by bromination (bromine or NBS in either dichloromethane or acetic acid) of the initial pyrazole. Conversion of 4-bromo-pyrazole to 4-carboxylic acid pyrazole can be accomplished by a number of methods commonly known to those in the art of organic synthesis . Further manipulations as previously described can afford pyrazoles of the present invention. Scheme 24
Figure imgf000063_0001
Pyrazoles can also be prepared according to method described in Scheme 25. The bromo-pyrazoles are formed as in Scheme 24. QE can then be coupled using palladium catalysed Suzuki cross-coupling methodology. Further modification is achieved as previously described.
Scheme 25
Figure imgf000063_0002
B(OH)2 Pd ( PPh3 ) 4 , 2N Na2C03 EQ
Figure imgf000063_0003
5-substituted phenylpyrazoles can be prepared by the method shown in Scheme 26. Conversion of the 5-hydroxy pyrazole to its triflate (triflie anhydride, lutidine in dichloromethane) or bromide (P0Br3) followed by palladium Suzuki cross-coupling with an apppropriately substituted phenylboronic acid should then afford 5-substituted pyrazoles Conversion of this intermediate to the 4-bromo derivative followed by its carbonylation as described in Scheme 24 should then afford the appropriate ester which can be further afford the compounds of formula I.
Scheme 26
Figure imgf000064_0001
1) POBr3 or Tf20, lutidine
2) QE-B(OH)2, Pd(PPh3)4, 2N Na2C03
Figure imgf000064_0002
l-Substituted-1,2, 3-triazoles of the present invention can be prepared by the treatment of an appropriately substituted azide with a variety of dipolarophiles ( Tetrahedron 1971, 21, 845 and J. Amer . Chem. Soc . 1951, 73 , 1207) as shown in Scheme 27. Typically a mixture of regioisomers are obtained which can be easily separated and elaborated to the triazole carboxylic acids . Further transformations as previously described can then afford the compounds of the present invention.
Scheme 27
hydrolysis Ag20
Figure imgf000064_0003
1, 2, 4-Triazoles of the present invention can be obtained by the methodology of Huisgen et al (Liebigs Ann . Chem . 1962, 653 , 105) by the cycloaddition of nitriliminium species (derived from the treatment of triethylamine and chloro hydrazone) and an appropriate nitrile dipolarophile (Scheme 28) . This methodology provides a wide variety of 1,2,4 triazoles with a varied substitution pattern at the 1, 3, and 5 positions.
Scheme 28
Figure imgf000065_0001
1 , 2 , 4 Triazoles can also be prepared by the methodology of Zecchi et al ( Synthesis 1986 , 9, 772 ) by an aza Wittig condensation (Scheme 29 ) .
Scheme 29
Figure imgf000065_0002
1,2, 4-Triazoles wherein the -E-D(Q) substituent is at the 5-position of the triazole can be obtained as shown in Scheme 30. Scheme 3 0
Figure imgf000066_0001
1, 3 , 4-Triazoles of the present invention can be obtained via the methodology of Moderhack et al (J". Prakt . Chem . 1996, 338, 169) . As shown in Scheme 31, this reaction involves the condensation of a carbazide with an appropriately substituted commercially available thioisocyanate to form the cyclic thiourea derivative. Alkylation or nucleophilic displacement reactions on the thiono-urea intermediate can then afford a thio-alkyl or aryl intermediate which can be hydrolysed, oxidized and decarboxylated to the 5-H 2-thio-triazole intermediate which can be converted to the compounds of the present invention. Alternatively the thiono-urea intermediate can be oxidized directly to the 2-H triazole which can then be converted to the ester and modified as previously described. The thiono-urea intermediate can also be oxidized to the sulfonyl chloride by methods shown previously.
Scheme 31
Figure imgf000066_0002
The imidazole core shown in Scheme 32 can be prepared by the condensation of 3-cyanoaniline with n-butylglyoxylate to afford the imine which can then be treated with TosylMIC in basic methanol to afford the desired imidazole compound. Coupling of the ester under standard conitions then affords a variety of analogs which then can be further manipulated to afford e.g. the benzylamine or the benzamidines .
Scheme 32
Figure imgf000067_0001
Figure imgf000067_0002
Compounds of the present invention wherein AB is a biphenylamine or similar amine may be prepared as shown in Scheme 33. 4-Bromoaniline can be protected as Boc-derivative and coupled to a phenylboronic acid under Suzuki conditions (Bioorg. Med. Chem . Lett . 1994, 189) . Deprotection with TFA provides the aminobiphenyl compound. Other similar amines wherein A and/or B are heterocycles can be prepared by the same method using appropiately substituted boronic acids and arylbromide. The bromoaniline can also be linked to the core ring structures first as described above, and then undergo a Suzuki reaction to give the desired product.
Scheme 33
Figure imgf000068_0001
Compounds of the present invention wherein A-B is A-X-Y can be prepared like the piperazine derivative shown in Scheme 34.
Scheme 34
Figure imgf000068_0002
Scheme 35 shows how one can couple cyclic groups wherein X=NH, O, or S.
Scheme 35
reduction
Figure imgf000068_0003
Halo Base, DMF
Figure imgf000068_0004
X = NH, 0, S
When B is defined as X-Y, the following description applies. Groups A and B are available either through commercial sources, known in the literature or readily synthesized by the adaptation of standard procedures known to practioners skilled in the art of organic synthesis . The required reactive functional groups appended to analogs of A and B are also available either through commercial sources, known in the literature or readily synthesized by the adaptation of standard procedures known to practioners skilled in the art of organic synthesis. In the tables that follow the chemistry required to effect the coupling of A to B is outlined.
Table A: Preparation of Amide, Ester, Urea, Sulfonamide and Sulfamide linka es between A and B,
Figure imgf000069_0001
Figure imgf000070_0001
Figure imgf000071_0001
The chemistry of Table A can be carried out in aprotic solvents such as a chlorocarbon, pyridine, benzene or toluene, at temperatures ranging from -20 'c to the reflux point of the solvent and with or without a trialkylamine base.
Table B: Preparation of ketone linkages between A and
B.
Figure imgf000071_0002
The coupling chemistry of Table B can be carried out by a variety of methods . The Grignard reagent required for Y is prepared from a halogen analog of Y in dry ether, dimethoxyethane or tetrahydrofuran at 0 C to the reflux point of the solvent. This Grignard reagent can be reacted directly under very controlled conditions, that is low temeprature (- 20 C or lower) and with a large excess of acid chloride or with catalytic or stoichiometric copper bromide*dimethyl sulfide complex in dimethyl sulfide as a solvent or with a variant thereof. Other methods available include transforming the Grignard reagent to the cadmium reagent and coupling according to the procedure of Carson and Prout (Org. Syn. Col. Vol. 3 (1955) 601) or a coupling mediated by Fe(acac)3 according to Fiandanese et al . (Tetrahedron Lett., (1984) 4805), or a coupling mediated by manganese (II) catalysis (Cahiez and Laboue, Tetrahedron Lett., 33(31), (1992) 4437). Table C: Preparation of ether and thioether linkages between A and B
Figure imgf000072_0001
The ether and thioether linkages of Table C can be prepared by reacting the two components in a polar aprotic solvent such as acetone, dimethylformamide or dimethylsulfoxide in the presence of a base such as potassium carbonate, sodium hydride or potassium t-butoxide at temperature ranging from ambient temperature to the reflux point of the solvent used.
Table D: Preparation of -SO- and -S02- linkages from
Figure imgf000072_0002
The thioethers of Table C serve as a convenient starting material for the preparation of the sulfoxide and sulfone analogs of Table D. A combination of wet alumina and oxone can provide a reliable reagent for the oxidation of the thioether to the sulfoxide while m-chloroperbenzoic acid oxidation will give the sulfone.
Table E : Methods of Preparing Group E
Rxn Q D is to be then a transformation that may be us ed is :
1 -CN -C ( =NH) NH2 NH2 i) HCI MeOH /
E ii) NH3OAc, MeOH ^ NH
2 -CN -CH2NH2
Figure imgf000073_0001
Et2O
3 -C02H -CH2NH2 i) iBuOC(O)Cl
Figure imgf000073_0002
4 -C02H -NH2 i) iBuOC(O)Cl
Figure imgf000073_0003
In Table E several methods of transforming a functional group Q into group D of Formula 1 are shown. While not all possible functional groups for Q and D are listed and the synthetic methods suggested are not comprehensive, Table E is meant to illustrate strategies and transformations available to a practitioner skilled in the art of organic synthesis for preparing compounds of Formula 1. In reaction 1 of Table E the transformation of a nitrile into an amidine by the Pinner methodology is shown; in reaction 2 the" direct reduction of a nitrile by a hydride reducing agent to a methylene amine is illustrated. In reaction 3, the utility of a carboxylic acid, which may be readily derived from its ester or a nitrile if necessary, in the preparation of a methylene amine is shown. This synthetic route is exceptionally flexible because of the several stable intermediates prepared en route to the final product. As outlined, formation of an activated analog, such as the mixed anhydride, allows for the mild reduction of the acid to the methylene alcohol, this may in turn be transformed into a leaving group by sulfonylation or halogenation or protected with a suitable protecting group to be transformed later in the synthesis as the chemistry demands . Once the methylene alcohol is so activated, displacement by an efficient nitrogen nucleophile, such as azide anion, can again provide another suitably stable analog, -the methylene azide- which may be used as a protected form of the methylene amine or transformed directly into the methylene amine group by reduction. Reaction 4 addresses the problem of appending the amine functionality directly through a bond to group E of Formula 1. Once again, the carboxylic acid provides a convenient entre into this selection for group D. The well- know Curtius rearrangement is illustrated here; an activated acid analog can be used to form an acyl azide which upon thermal decomposition is rearranged to the corresponding isocyanate. The isocyanate intermediate may then be captured as a stable carbamate by the addition of a suitable alcohol and further heating. This carbamate can be used as a stable protecting group for the amine or cleaved directly to the desired D. Alternatively, it may be convenient to quench the isocyanate intermediate with water to give the amine directly. Other features of the invention will become apparent in the course of the following descriptions of exemplary embodiments which are given for illustration of the invention and are not intended to be limiting thereof.
EXAMPLES
Example 1
3 -Methyl- 1- ( 2 -aminomethyl - -methoxyphenyl ) - lH-pyrazole-
5- (N- (2 ' -sulfamido- [1,1'] -biphen-4-yl) ) carboxyamide, trifluoroacetic acid salt
Part A: 2-Carboxy-4-methoxyphenylhydrazine: 2-Nitro-5- methoxybenzoic acid (5.0 g) in methanol (150 mL) was shaken under an atmosphere of hydrogen (50 psi) in the presence of 10% palladium on carbon catalyst (0.5 g) until hydrogen uptake ceased (ca. 3 h) . The methanol solution was purge with nitrogen, filtered through a pad of Celite® and evaporated. There was obtained 4.2 g (25.1 mmol) of the aniline; ESI mass spectrum analysis m/z (relative intensity) 168 (M+H, 100) .
The aniline prepared above (4.2 g, 25.1 mmol) in concentrated hydrochloric acid (50 mL) was cooled to 0°C and sodium nitrite (2.08 g, 30.2 mmol) in cold water (20 mL) was added dropwise. This mixture was stirred at 0°C for 30 min - 1 h then tin (II) chloride dihydrate (17.0 g, 75.4 mmol) in cold concentrated hydrochloric acid (25 mL) was added dropwise. This mixture was allowed to thaw to ambient temperature over 3-5 h then filtered and air dried for several more. The filter cake was broken up and dried further in a vacuum oven at 60°C overnight. There was obtained 8.76 g of 2-carboxy-4- methoxyphenylhydrazine tin salt.
Part B: Ethyl 2-N- (methoxy) imino-4-oxopentanoate: A mixture of ethyl pentanoate-2 , 4-dione (24.5 g, 154.9 mmol) and methoxyamine hydrogen chloride (13.58 g, 162.6 mmol) in ethanol (100 mL) was allowed to stand over activated 3 A molecular sieves (75 g) at ambient temperature for 18h. Following removal of the molecular sieves by filtration, dichloromethane (100 mL) was added and the reaction filtered. The resulting solution was evaporated and the residue applied to a silica gel column. The title compound was isolated in a homogenous form by elution with 5:1 hexane: ethyl acetate to give 9.09 g of product.
Part C: Ethyl 3-methyl-1- (2-carboxy-4-methoxyphenyl) -1H- pyrazole-5-carboxylate and ethyl 5-methyl-l- (2-carboxy-4- ethoxyphenyl) -lH-pyrazole-3-carboxylate: Ethyl 2-N- ( ethoxy) imino-4-oxopentanoate (1.0 g, 5.35 mmol) and crude 2- carboxy-4-methoxyphenylhydrazine (5.83 g) in acetonitrile (40 mL) and acetic acid (5 mL) was stirred at ambient temperature for 3 h then heated at reflux for an additional 3 h. The reaction was cooled to ambient temperature, diluted with methylene chloride (150 mL) and filtered. The filtrate was evaporated and the product isolated by flash chromatography by elution with 10% methanol in chloroform. This material (1.28 g) co-eluted as a mixture of regiosiomers as evident by proton NMR. ESI mass spectrum analysis m/zr (relative intensity) 306 (M+H, 100) .
Part D: Ethyl 3-methyl-1- (2-hydroxymethyl-4-methoxyphenyl) -1H- pyrazole-5-carboxylate and ethyl 5-methyl-1- (2-hydroxymethyl- 4-methoxyphenyl) -lH-pyrazole-3-carboxylate: The mixture of regioisomers prepared in part C (1.28 g, 4.2 mmol) was dissolved in tetrahydrofuran (60 mL) and cooled to 0°C. To the cold solution was added N-methylmorpholine (0.42 g, 4.2 mmol) and isobutylchloroformate (0.57 g, 4.2 mmol). The reaction was stirred for 30 min at 0°C, the precipitate removed by filtration and the cold solution poured immediately into a cold (5°C) solution of sodium borohydride (0.48 g, 12.6 mmol) in water (20 mL) and tetrahydrofuran (20 mL) . The reaction was allowed to thaw to room temperature over 18 h. The reaction mixture was evaporated, partitioned between ethyl acetate (100 mL) and IN hydrochloric acid (50 mL) , then washed with 5% sodium bicarbonate (50 mL) and brine (50 mL) . The organic layer was dried and evaporated; three products were isolated by elution of the crude mixture from a silica gel column with 2:1 hexane: ethyl acetate. The first product to elute was a ring closed lactone (0.14 g) ; ESI mass spectrum analysis m/z (relative intensity) 245 (M+H, 100) . The second product isolated was ethyl 3-methyl-1- (2-hydroxymethyl-4- methoxyphenyl) -lH-pyrazole-5-carboxylate (0.18 g) as determined by proton NMR nOe experiments; ESI mass spectrum analysis m/z (relative intensity) 291 (M+H, 100). The third product to elute was the regioisomer ethyl 5-methyl-l- (2- hydroxymethyl-4-methoxyphenyl) -lH-pyrazole-3-carboxylate (0.14 g) ; ESI mass spectrum analysis m/z (relative intensity) 291 (M+H, 100) .
Part E: Ethyl 3-methyl-l- (2-azidomethyl-4-methoxyphenyl) -1H- pyrazole-5-carboxylate: Ethyl 3-methyl-l- (2-hydroxymethyl-4- methoxyphenyl) -lH-pyrazole-5-carboxylate (0.18 g, 0.62 mmol) was dissolved in chloroform (20 mL) then methanesulfonyl chloride (0.3 g, 2.6 mmol) and triethylamine (0.26 g, 2.6 mmol) added. The reaction was complete in 6 h; it was evaporated, dissolved in ethyl acetate (100 mL) , washed with IN hydrochloric acid (50 mL) and brine (50 mL) , dried and evaporated to give 0.22 g of product.
The mesylate prepared above (0.22 g, 0.6 mmol) and sodium azide (0.12 g, 1.79 mmol) were dissolved in dimethylformamide (15 mL) and heated for 1.5 h at 60°C, then diluted with brine (50 mL) , extracted with ethyl acetate (100 mL) , dried and evaporated. There was obtained 0.11 g of ethyl 3-methyl-l- (2- azidomethyl-4-methoxyphenyl) -IH-pyrazole-5-carboxylate; ESI mass spectrum analysis m/z (relative intensity) 316 (M+H, 100) .
Part F: 3-Methyl-l- (2-azidomethyl-4-methoxyphenyl) -1H- pyrazole-5-carboxylic acid: Ethyl 3-methyl-l- (2-azidomethyl- 4-methoxyphenyl) -lH-pyrazole-5-carboxylate (0.11 g, 0.35 mmol) in ethanol (2 mL) and water (2 mL) was stirred with 50% sodium hydroxide (3 drops) at 45°C and followed by TLC (1:1 hexane: ethyl acetate) . When all of the ester was consumed the reaction was cooled, diluted with brine and washed with ethyl ether (25 mL) . The aqueous layer was acidified with IN hydrochloric acid (pH = 1) , extracted with ethyl acetate (2x 30 mL) , dried and evaporated. There was obtained 3-methyl-l- (2-azidomethyl-4-methoxyphenyl) -lH-pyrazole-5-carboxylic acid (0.06 g) ; ESI mass spectrum analysis m/z (relative intensity) 285 (M+H, 100) .
Part G: 3-Methyl-l- (2-azidomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (4- (2-N-t- butylsulfamido) phenyl)phenyl) carboxyamide : 3-Methyl-l- (2- azidomethyl-4-methoxyphenyl) -lH-pyrazole-5-carboxylic acid (0.60 g, 0.21 mmol) in dichloromethane (5 mL) was cooled to 0°C and oxalyl chloride (0.21 mL of a 2M solution in dichloromethane) and dimethyl formamide (1 drop) were added. The reaction was complete inside of 1 h; it was evaporated and pumped on to remove residual HCI. There was obtained 0.17 g of the acid chloride.
To the acid chloride prepared above (0.17 g, 0.50 mmol) in dichloromethane (3 mL) was added dropwise to an ice-cold solution of 4- (2-N-tertbutylsulfonamido) phenyl aniline (0.15 g, 0.51 mmol), pyridine (0.39 g, 4.4 mmol) and 4,4- dimethylaminopyridine (0.09 g, 0.7 mmol) in dichloromethane (15 mL) . The reaction was allowed to warm to ambient temperature over 18 h, then evaporated, dissolved in ethyl acetate (30 mL) , washed with IN hydrochloric acid (20 mL) and dried. Silica gel flash chromatography, eluting with a gradient of 2:1 to 1:1 hexane: ethyl acetate, gave 0.09 g of 3- methyl-1- (2-azidomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (4- (2-N-t-butylsulfamido) phenyl)phenyl) carboxyamide; ESI mass spectrum analysis m/z (relative intensity) 572 (M+H, 100) .
Part H: 3-Methyl-l- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (2' -sulfamido- [1, 1 ' ] -biphen-4- yl) ) carboxyamide*TFA: 3-Methyl-l- (2-azidomethyl-4- methoxyphenyl) -lH-pyrazole-5- (N- (2 ' -N-t-butylsulfamido- [1, 1' ] - biphen-4-yl) ) carboxyamide (0.09 g, 0.16 mmol) was stirred with tin(II) chloride dihydrate (0.11 g, 0.47 mmol) in methanol (10 mL) . When the reaction was complete by TLC (1:1 hexane: ethyl acetate) it was evaporated to give a crude mixture of the aminomethyl product and tin salts weighing 0.39 g. The material was heated at reflux in trifluoroacetic acid (10 mL) for 45 min then evaporated. The residue was partitioned between IN sodium hydroxide (30 mL) and ethyl acetate (30 mL) . The ethyl acetate solution was dried and evaporated to give 0.04 g of crude product. This material was purified further by hplc utilizing gradient elution with a mixture of water:acetonitrile with 0.05% trifluoroacetic acid on a reverse phase C18 (60 A) column to give 0.010 g of the title compound; mp 184.3°C; HRMS (M+H) + calc . m/z: 492.170551, obs m/z: 492.171712.
Example 2 5-Methyl-1- ( 2-aminomethyl-4-methoxyphenyl ) -IH-pyrazole-
3- (N- (2 ' -sulfamido- [1,1'] -biphen-4 -yl ) ) carboxyamide, trifluoroacetic acid salt
The regioisomeric acid prepared in Example 1, ethyl 5- methyl-1- (2-hydroxymethyl-4-methoxyphenyl) -lH-pyrazole-3- carboxylate (0.14 g, 0.48 mmol), was transformed into the azidomethyl analog, coupled with 4- (2-N- tertbutylsulfonamido) phenyl aniline and transformed into 5- methyl-1- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-3- (N- (4- (2-sulfamido)phenyl)phenyl) carboxyamide by the same procedures described in Example 1. The final product was purified further by hplc utilizing gradient elution with a mixture of water : acetonitrile with 0.05% trifluoroacetic acid on a reverse phase C18 (60 A) column; HRMS (M+H) + calc . m/z: 492.170551, obs m/z: 492.169327.
Example 3 3-methyl-l- ( 2-N, N-dimethylaminomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (2 ' -N-methylsulfamido- [1, 1' ] -biphen-4- yl) ) carboxyamide, trifluoroacetic acid salt
3-Methyl-l- (2-azidomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (2 ' -N-t-butylsulfamido- [1,1'] -biphen-4-yl) ) carboxyamide (0.09 g, 0.16 mmol), prepared in Example 1, was stirred with tin(II) chloride dihydrate (0.11 g, 0.47 mmol) in methanol (10 mL) . When the reaction was complete by TLC (1:1 hexane: ethyl acetate) it was evaporated to give a crude mixture of the aminomethyl product and tin salts weighing 0.39 g. A portion of the crude reduction product (0.1 g, 0.20 mmol) prepared above was stirred at ambient temperature with methyl iodide (0.2 mL) , and potassium hydrogen carbonate (solid, 0.2 g) in methanol (4 mL) at ambient temperature. After 18 h the reaction was evaporated and stirred with chloroform (30 mL) , filtered and evaporated again to give 0.28 g of crude product. The material from above was heated at reflux in trifluoroacetic acid (10 mL) for 45 min then evaporated. The residue was partitioned between IN sodium hydroxide (30 mL) and ethyl acetate ( 30 mL) . The ethyl acetate solution was dried and evaporated to give crude product . This material was purified further by hplc utilizing gradient elution with a mixture of water : acetonitrile with 0 . 05% trifluoroacetic acid on a reverse phase C18 ( 60 A) column to give the title compound; mp 114 . 5°C ; HRMS (M+H) + calc . m/ z : 534 .217502 , obs m/z : 534 .218000 .
Example 4 3 -Trif luoromethyl - 1 - ( 2 -aminomethyl -4 -methoxyphenyl ) - IH- pyrazole- 5 - ( N- ( 3 - f luoro-2 ' - sulf amido- [ 1 , 1 ] -biphen-4 - yl ) ) carboxyamide , trifluoroacetic acid salt
Part A : 3 -Trif luoromethyl-1- ( 2 -carboxy-4 -methoxyphenyl ) -5- ( furan-2-yl ) -IH-pyrazole : Crude 2-carboxy-4- methoxyphenylhydrazine (8.88 g) , prepared in Example 1, and 4,4,4-trifluoro-l-(2-furyl)-l,3-butanedione (7.4 g, 135.9 mmol) in acetic acid (150 mL) was heated at 100°C for 4 h. The hot reaction mixture was evaporated and the residue stirred in a biphasic mixture of water (150 mL) and chloroform (150 mL) . The layers were filtered and separated, the solid percipitate washed several times with additional chloroform (3x 50 mL) and the chloroform layer and washings combined, dried and evaporated. There was obtained 3.55 g of 3- trifluoromethyl-1- (2-carboxy-4-methoxyphenyl) -5- (furan-2-yl) - IH-pyrazole; ESI (-ve) mass spectrum analysis m/z (relative intensity) 351 (M-H, 100) .
Part B: 3-Trifluoromethyl-1- (2-hydroxymethyl-4-methoxyphenyl) - 5- (furan-2-yl) -IH-pyrazole: 3-Trifluoromethyl-1- (2-carboxy-4- methoxyphenyl) -5- (furan-2-yl) -IH-pyrazole (3.55 g, 10.1 mmol) in tetrahydrofuran (100 mL) was cooled to 0°C then N- methylmorpholine (1.02 g, 10.1 mmol) and isobutyl chloroformate (1.38 g, 10.1 mmol) were added. The reaction mixture was stirred for 30 min at 0°C, filtered and added immediately to a cold solution of sodium borohydride (1.15 g, 30.2 mmol) in water (50 mL) and tetrahydrofuran (50 mL) . The reaction mixture was evaporated, partitioned between ethyl acetate (100 mL) and I. hydrochloric acid (50 mL) , then washed with 5% sodium bicarbonate (50 mL) and brine (50 mL) . The organic layer was dried and evaporated then purified further by flash chromatography using 4:1 hexane : ethyl acetate as the eluent . There was obtained 1.5 g of 3-trifluoromethyl-1- (2- hydroxymethyl-4-methoxyphenyl) -5- (furan-2-yl) -IH-pyrazole; ESI mass spectrum analysis m/z (relative intensity) 339 (M+H, 100) .
Part C: 3-Trifluoromethyl-1- (2-azidomethyl-4-methoxyphenyl) -5- (furan-2-yl) -IH-pyrazole: To a cooled chloroform (50 mL) solution of 3-trifluoromethyl-1- (2-hydroxymethyl-4- methoxyphenyl) -5- (furan-2-yl) -IH-pyrazole (1.5 g, 4.44 mmol) and triethylamine (1.79 g, 17.7 mmol) was added a chloroform solution (10 mL) of methanesulfonyl chloride (2.03 g, 17.7 mmol) . The reaction was complete in 4 h. It was evaporated, dissolved in ethyl acetate (100 mL) and the ethyl acetate solution washed with cold 5% NaHSθ4 (50 mL) and cold saturated NaHCθ3 (50 mL) . The organic layer was dried and evaporated to give 2.1 g of the mesylate which was used immediately in the next reaction; ESI mass spectrum analysis m/z (relative intensity) 417 (M+H, 100).
A mixture of the mesylate prepared above (2.1 g, 5.05 mmol) and sodium azide (0.98 g, 15.1 mmol) in dimethylformamide (40 mL) was heated at 60°C for 2 h. The reaction mixture was cooled, diluted with brine (100 mL) and extracted with ethyl acetate (100 mL) . The ethyl acetate extract was washed with water (5x 50 mL) then dried and evaporated. There was obtained 1.43 g of 3-trifluoromethyl-l- (2-azidomethyl-4-methoxyphenyl) -5- (furan-2-yl) -IH-pyrazole; ESI mass spectrum analysis m/z (relative intensity) 364 (M+H, 100) .
Part D: 3-Trifluoromethyl-1- (2-azidomethyl-4-methoxyphenyl) - IH-pyrazole-5-carboxylic acid: To 1.43 g of 3- trifluoromethyl-1- (2-azidomethyl-4-methoxyphenyl) -5- (furan-2- yl) -IH-pyrazole (3.9 mmol) in acetone (60 mL) was added potassium permaganate (5.0 g, 27.5 m mol) in water (60 mL) . The reaction was heated at 60°C for 3 h, then cooled to ambient temperature and isopropyl alcohol (60 mL) added. This mixture was stirred for 18 h then filtered through a Celite® pad and washed with copious amounts of isopropyl alcohol. The combined filtrates were evaporated," the residue dissolved in IN NaOH (50 mL) and washed with ethyl ether (2x 50 mL) . The basic layer was acidified with IN HCI (75 mL) and solid NaCI added. The suspension was extracted with EtOAc (3x 100 mL) ; the extracts were dried and evaporated. There was obtained 0.91 g of 3-trifluoromethyl-1- (2-azidomethyl-4-methoxyphenyl) - lH-pyrazole-5-carboxylic acid; ESI (-ve) mass spectrum analysis m/z (relative intensity) 340 (M-H, 100) .
Part E: 3-Trifluoromethyl-1- (2-azidomethyl-4-methoxyphenyl) - lH-pyrazole-5-carboxylic acid chloride: 3-Trifluoromethyl-1- (2-azidomethyl-4-methoxyphenyl) -lH-pyrazole-5-carboxylic acid (1.09 g, 3.2 mmol) in dichloromethane (50 mL) was stirred at 0°C with oxalyl chloride from 3.2 mL of a 2M dichloromethane solution of the reagent and a catalytic amount of DMF (3 drops) . The reaction was complete in 3 h, then evaporated and pumped on to remove residual reagent. There was obtained 1.04 g (2.9 mmol) of 3-trifluoromethyl-1- (2-azidomethyl-4- methoxyphenyl) -lH-pyrazole-5-carboxylic acid chloride.
Part F: 3-Trifluoromethyl-1- (2-azidomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (2-fluoro-4- (2-N-tertbutylsulfamido- [1, 1] - biphen-4-yl) ) carboxyamide: 3-Trifluoromethyl-1- (2- azidomethyl-4-methoxyphenyl) -IH-pyrazole-5-carboxylic acid chloride prepared above (0.52 g, 1.45 mmol) in dichloromethane (10 mL) was added dropwise to an ice-cold solution of 2- fluoro-4- (2-N-tertbutylsulfonamido)phenyl aniline (0.56 g, 1.74 mmol), pyridine (1.14 g, 14.5 mmol.) and 4,4- dimethylaminopyridine (0.21 g, 1.74 mmol) in dichloromethane (30 mL) . The reaction was allowed to warm to ambient temperature over 18 h, then evaporated, dissolved in ethyl acetate (100 mL) , washed with IN hydrochloric acid (50 mL) and dried. Silica gel flash chromatography, eluting with 4:1 hexane:ethyl acetate, gave 0.28 g of 3-trifluoromethyl-1- (2- azidomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (2-fluoro-4- (2- N-tertbutylsulfamidophenyl)phenyl) carboxyamide; ESI (-ve) mass spectrum analysis m/z (relative intensity) 644 (M-H, 100) .
Part G: 3-Trifluoromethyl-1- (2-aminomethyl-4-methoxyphen-1- yl) -lH-pyrazole-5- (N- (2-fluoro-4- (2-sulfamido- [1,1] -biphen-4- yl) ) carboxyamide*TFA: 3-Trifluoromethyl-1- (2-azidomethyl-4- methoxyphenyl) -lH-pyrazole-5- (N- (2-fluoro-4- (2-N- tertbutylsulfamidophenyl)phenyl) carboxyamide (0.28 g, 0.43 mmol) and tin (II) chloride dihydrate (0.29 g, 1.3 mmol) was stirred in methanol (30 mL) for 18 h. The reaction was evaporated and the reduction product (0.60 g) was carried on to the next step without further processing.
The product prepared above was refluxed in trifluoroacetic acid (20 mL) for 30 min, then evaporated. The residue was suspened in IN NaOH (30 mL) , extracted with EtOAc (3x 50 mL) , dried and evaporated. This material was purified further by hplc utilizing gradient elution with a mixture of water: acetonitrile with 0.05% trifluoroacetic acid on a reverse phase C18 (60 A) column to give the title compound; mp 103.2 °C; ESI ESI mass spectrum analysis m/z (relative intensity) 564.2 (M+H, 100).
Example 5 3-Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1, 1] -biphen- 4-yl)) carboxyamide, trifluoroacetic acid salt
Part A: 3-Trifluoromethyl-1- (2-azidomethyl-4-methoxyphenyl) - IH-pyrazole-5- (N- (2-fluoro-4- (2- methylsulfonylphenyl)phenyl) carboxyamide : 3-Trifluoromethyl- 1- (2-azidomethyl-4-methoxyphenyl) -lH-pyrazole-5-carboxylic acid chloride prepared in Example 4 (0.52 g, 1.45 mmol) in dichloromethane (10 mL) was added dropwise to an ice-cold solution of 2-fluoro-4- (2-methylsulfonylphenyl) aniline (0.52 g, 1.74 mmol), pyridine (1.14 g, 14.5 mmol) and 4,4- dimethylaminopyridine (0.21 g, 1.74 mmol) in dichloromethane (30 mL) . The reaction was allowed to warm to ambient temperature over 18 h, then evaporated, dissolved in ethyl acetate (100 mL) , washed with IN hydrochloric acid (50 mL) and dried. Silica gel flash chromatography, eluting with a gradient of 5:1 to 1:1 hexane:ethyl acetate, gave 0.46 g of 3- trifluoromethyl-1- (2-azidomethyl-4-methoxyphenyl) -lH-pyrazole- 5- (N- (2-fluoro-4- (2-methylsulfonylphenyl) phenyl) carboxyamide; ESI mass spectrum analysis m/z (relative intensity) 587 (M+H, 100) .
Part B: 3-Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1, 1] -biphen-4- yl) ) carboxyamide*TFA: 3-Trifluoromethyl-1- (2-azidomethyl-4- methoxyphenyl) -lH-pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl-
[1, 1] -biphen-4-yl) ) carboxyamide (0.46 g, 0.78 mmol) and tin (II) chloride dihydrate (0.53 g, 2.35 mmol) was stirred in methanol (25 mL) for 18 h. The reaction was evaporated and the residue was suspended in IN NaOH (50 mL) , extracted with EtOAc (3x 100 mL) , dried and evaporated to give 0.29 g of crude product. This material was purified further by hplc utilizing gradient elution with a mixture of water: acetonitrile with 0.05% trifluoroacetic acid on a reverse phase C18 (60 A) column to give the title compound; mp 101.5 °C; ESI mass spectrum analysis m/z (relative intensity) 563 (M+H, 100).
Example 6
3 -Trif luoromethyl- 1- ( 2 -aminomethyl-4 -methoxyphenyl ) - 1H- pyrazole-5- (N- ( 2 ' -methylsulfonyl- [ 1 , 1 ] -biphen-4 - yl ) ) carboxyamide, trifluoroacetic acid salt
Part A: 3-Trif luoromethyl-1- (2-azidomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (2 ' -methylsulfonyl- [1 , 1] -biphen-4- yl) ) carboxyamide : 3 -Trif luoromethyl-1- (2-azidomethyl-4- me thoxyphenyl) -IH-pyrazole- 5 -carboxylic acid chloride and 4- (2-methylsulfonylphenyl) aniline were treated in the manner described for Example 5 , Part A to give 3-trif luoromethyl-1 - (2-azidomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (4- (2- methylsulf onylphenyl ) phenyl ) carboxyamide . Part B: 3-Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (2 ' -methylsulfonyl- [1 , 1] -biphen-4- yl) ) carboxyamide*TFA: 3-Trifluoromethyl-1- (2-azidomethyl-4- methoxyphenyl) -lH-pyrazole-5- (N- (4-(2- methylsulfonylphenyl) phenyl) carboxyamide was treated in the same manner as Example 5, Part B to give the title compound; HRMS (M+H)+ calc. m/z: 545.147037, obs m/z: 545.145700.
Example 7
3-Trif luoromethyl-1- (2 -aminomethyl -4 -methoxyphenyl ) -IH- pyrazole-5- (N- (2 ' -sulfamido- [1, 1] -biphen-4- yl) ) carboxyamide, trifluoroacetic acid salt
Part A: 3 -Trif luoromethyl-1- (2 -azidomethyl -4 -methoxyphenyl ) - lH-pyrazole-5- (N- (2 ' -N-tertbutylsulf amido- [1,1] -biphen-4- yl) ) carboxyamide : 3-Trif luoromethyl-1- (2-azidomethyl-4- me thoxyphenyl ) -lH-pyrazole-5-carboxylic acid chloride and 4- ( 2-N-tertbutylsulfonamido) phenyl aniline were treated as described in Example 4, Part F to give 3-trif luoromethyl-1- (2- azidomethyl- 4 -methoxyphenyl) -IH-pyrazole- 5- (N- (4- (2-N- tertbutylsulf amidophenyl ) phenyl ) carboxyamide .
Part B: 3-Trif luoromethyl-1- (2-aminomethyl-4-methoxyphen-l- yl) -lH-pyrazole-5- (N- (2 ' -sulfamido- [1, 1] -biphen-4- yl) ) carboxyamide* TFA: 3 -Trif luoromethyl-1- (2-azidomethyl-4- me thoxyphenyl ) -lH-pyrazole-5- (N- (4- (2-N- tertbutylsulf amidophenyl) phenyl) carboxyamide was treated as described in Example 4, Part G to give the title compound; LRMS (M+H)+: m/z 546.2.
Example 8 3-Trif luoromethyl-1- (2 -aminomethyl -4 -methoxyphenyl) -IH- pyrazole-5- (N- (4-N- pyrrolidinocarbonyl ) phenyl ) carboxyamide • TPA
Part A: 5- (Furan-2-yl) -3-trif luoromethyl-1- ( 2 -carboxyl -4- me thoxyphenyl ) -IH-pyrazole: 3-Methoxy-6-aminobenzoic acid (23 g, 138 mmol) in cone. HCI (300 mL) was cooled to 0 °C and NaN02 (11.4 g, 165 mmol) in H2O (50 mL) was added dropwise while the temperature of the reaction was maintained below 10 °C. The reaction was stirred at or below 10 °C for 1 h, then SnCl2*H2θ (92.3 g, 413 mmol) in cone. HCI (125 mL) was added dropwise. The reaction was allowed to thaw to ambient temperature and stirred for 3 h. The precipitate was filtered and air-dried then heated in a vacuum oven for 18 h. There was obtained 71.4 g of 3-methoxy-6-hydrazinobenzoic acid entrained with tin (II) salts.
The hydrazine prepared above (71.4 g) in acetic acid (800 mL) was heated at 45 °C until dissolved, then 4,4,4- trifluoromethyl-l-(2-furyl)-l,3-butanedione (28.42 g, 138 mmol) was added and the mixture heated at reflux for 2.5 h. The reaction was cooled and evaporated to dryness. The residue was partitioned between H2O (400 mL) and CHCI3 (400 mL) and stirred for 30 min. The biphasic mixture was filtered, the layers separated and the organic layer dried (Na24) and evaporated to give 49.4 g of 5- (furan-2-yl) -3-trifluoromethyl- 1- (2-carboxyl-4-methoxyphenyl) -IH-pyrazole; LRMS (ES") M" : 351 m/z.
Part B: 3-Trifluoromethyl-1- (2-azidomethyl-4-methoxyphenyl) - IH-pyrazole-5-carboxylic acid: To a solution of 5-(furan-2- yl) -3-trifluoromethyl-1- (2-carboxyl-4-methoxyphenyl) -1H- pyrazole (49.4 g, 140.3 mmol) in THF (600 mL) at 0 °C was added N-methylmorpholine (14.9 g, 147 mmol) and isobutylchloroformate (20.1 g, 147.3 mmol). After 3 h at 0 °C, the reaction mixture was filtered into a H2θ:THF (200 mL:
200 mL) solution of NaBH (10.6 g, 280 mmol) at 0 °C. After 18 h, the reaction was quenched with IN HCI (500 mL) then the THF was removed in vaccuo . The remaining aqueous suspension was saturated with solid NaCI and extracted with EtOAc, dried (Na24) and evaporated. The crude product was recrystallized from 1-chlorobutane to give 16.8 g of benzyl alcohol product. The mother liquors were applied to a column of flash Siθ2 (500 g) and eluted with 2:1 hexane: EtOAc to give 8.7 g of benzyl alcohol product; LRMS ES+ (M+H) + : 339 m/z.
The benzyl alcohol product (8.7 g, 25.1 mmol) prepared above and Et3N (3.1 g, 30.9 mmol) in CH2C12 (200 mL) was cooled to 0 °C. Methanesulfonyl chloride (3.5 g, 30.9 mmol) in CH2CI2 (10 mL) was added dropwise. The cooling bath was removed and the reaction stirred for 3 h. A 5% solution of NaHSθ4 (200 mL) was added, the organic layer was separated, dried and evaporated to give 10.25 g of mesylate.
The mesylate (10.25 g, 24.6 mmol) from above and NaN3 (4.8 g, 73.8 mmol) in DMF (100 mL) was stirred at ambient temperature for 18 h. The reaction was diluted with brine (500 mL) , extracted with EtOAc and the extracts washed with H2O (5 x 150 mL) . The EtOAc layer was dried (Na24) and evaporated to give 8.16 of the azidomethyl compound; LRMS ES+ (M+H) + : 364 m/z.
The azidomethyl coumpound (23 g, 63.4 mmol) in acetone (400 mL) was heated at 60 °C, then KMnθ4 (50 g, 317 mmol) in H2O
(300 mL) was added. After addition was complete, the reaction was heated for 1.5 h. The cooled reaction was filtered through a pad of Celite® and evaporated. The water layer was made basic with IN NaOH (200 mL) and washed with Et2θ (3x) , then acidified with cone. HCI, saturated with solid NaCI and extracted with EtOAc (3x) . The EtOAc layer was dried and evaporated to give 15.1 g of 3-trifluoromethyl-1- (2- azidomethyl-4-methoxyphenyl) -lH-pyrazole-5-carboxylic acid; LRMS ES" (M-H)~: 340 m/z.
Part C: 3-Trifluoromethyl-1- (2-azidomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (4-N-carboxylpyrrolidino) phenyl) carboxyamide: To 3-trifluoromethyl-1- (2-azidomethyl-4-methoxyphenyl) -1H- pyrazole-5-carboxylic acid (0.44 g, 1.29 mmol) prepared above in CH2CI2 at 0 °C was added a 2M solution of oxalyl chloride in CH2CI2 (2 equivilents, 1.29 mL) followed by a drop of DMF. The ice bath was removed and the reaction stirred for 3 h then evaporated. The resulting acid chloride was combined with N- (4-aminobenzoyl)pyrrolidine (0.32 g, 1.68 mmol) and DMAP (0.47 g, 3.87 mmol) and dissolved in CH2CI2 (20 mL) . The reaction was stirred for 18 h, then evaporated and dissolved in EtOAc. The EtOAc layer was washed with IN HCI and brine, dried (Na24) and evaporated. The product was purified further by a column of flash Siθ2 (50 g) eluting with 5-10 % MeOH in CHCI3 to give 0.24 g of 3-trifluoromethyl-1- (2-azidomethyl-4- methoxyphenyl ) -lH-pyrazole-5- (N- (4-N- carboxylpyrrolidino) phenyl) carboxyamide; LRMS ES+ (M+H) + : 514 m/z.
Part D: 3 -Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl ) - lH-pyrazole-5- (N- (4-N- carboxylpyrrolidino) phenyl) carboxyamide*TFA: A mixture of 3- trifluoromethyl-1- (2-azidomethyl-4-methoxyphenyl) -IH-pyrazole- 5- (N- (4-N-carboxylpyrrolidino) phenyl) carboxyamide (0.24 g, 0.27 mmol) and SnCl2»2H20 (0.24 g, 0.95 mmol) in MeOH (20 mL) was stirred for 18 h. The reaction was evaporated and dissolved in IN NaOH. The basic layer was extracted with EtOAc dried and evaporated. The crude product was purified further by HPLC utilizing gradient elution with a mixture of water: acetonitrile with 0.05% trifluoroacetic acid on a reverse phase C18 (60 A) column to give 31.2 mg of title compound; mp 117.5 °C; HRMS (M+H)+ calc . m/z: 488.190950, obs: 488.191005.
Example 9 N-Benzylsulfonyl-4- ( 3-trifluoromethyl-1- (2-aminomethyl- 4 -methoxyphenyl) -lH-pyrazole-5- carboxyamido) iperidine*TFA
3-Trifluoromethyl-1- (2-azidomethyl-4-methoxyphenyl) -IH- pyrazole-5-carboxylic acid prepared in Part B of Example 8 was coupled with N-Benzylsulfonyl-4-aminopiperidine according to the procedure in Part C of Example 8. The title compound was prepared and purified by the method outlined in Part D of Example 8; mp 98.3 °C; HRMS (M+H) + calc. m/z: 552.189236 obs: 552.188800. Example 10 3-Trif luoromethyl-1- (2 -aminomethyl -4 -methoxyphenyl ) -1H- pyrazole-5- (N- (5- (2 ' -sulf onamido) phenyl) pyrid-2- yl) carboxyamide* TFA
3-Trif luoromethyl-1- (2-azidomethyl-4-methoxyphenyl) -1H- pyrazole-5-carboxylic acid prepared in Part B of Example 8 was coupled with 2-amino-5- ( (2-N-t- butylsulfonamido) phenyl )pyridine according to the procedure in Part C of Example 8. The azidomethyl group was reduced to the aminomethyl group with SnCl2*2H2θ by the method outlined in Part D of Example 8. The crude reduction product was then refluxed in trifluoroacetic acid (10 mL) for 1 h to remove the t-butyl protecting group. The title compound was isolated by HPLC utilizing gradient elution with a mixture of water : acetonitrile with 0.05% trifluoroacetic acid on a reverse phase C18 (60 A) column; mp 86.6 °C; HRMS (M+H)+ calc. m/z: 547.137535, obs: 547.138200.
Example 11
3-Trif luoromethyl-1- (2 -aminomethyl -4 -methoxyphenyl) -1H- pyrazole-5- (N- (5- (pyrid-2-yl) )pyrid-2- yl) carboxyamide* TFA
3-Trif luoromethyl-1- (2-azidomethyl-4-methoxyphenyl) -1H- pyrazole-5-carboxylic acid prepared in Part B of Example 8 was coupled with 2-amino-5- (pyrid-2-yl)pyridine according to the procedure in Part C of Example 8. The title compound was prepared and purified by the method outlined in Part D of Example 8; mp 48.2 °C; HRMS (M+H)+: 469.1602 m/z.
Example 12 N-Benzyl-4- (3-trif luoromethyl-1- (2 -aminomethyl -4- methoxyphenyl) -lH-pyrazole-5- carboxyamido ) piperidine • TFA 3-Trifluoromethyl-1- (2-azidomethyl-4-methoxyphenyl) -1H- pyrazole-5-carboxylic acid prepared in Part B of Example 8 was coupled with N-Benzyl-4-aminopiperidine according to the procedure in Part C of Example 8. The title compound was prepared and purified by the method outlined in Part D of Example 8; mp 116.1 °C; HRMS (M+H)+: 488.2266 m/z.
Example 13 N-Phenylsulfonyl-4- (3-trifluoromethyl-1- (2 -aminomethyl- 4 -methoxyphenyl) -lH-pyrazole-5- carboxyamido ) piperidine •TFA
3-Trifluoromethyl-1- (2-azidomethyl-4-methoxyphenyl) -1H- pyrazole-5-carboxylic acid prepared in Part B of Example 8 was coupled with N-phenylsulfonyl-4-aminopiperidine according to the procedure in Part C of Example 8. The title compound was prepared and purified by the method outlined in Part D of Example 8; mp 103 °C; HRMS (M+H)+: 538.1729 m/z.
Example 14
3 -Trif luoromethyl-1- ( 2 -aminomethyl-4 -chlorophenyl ) -1H- pyrazole- 5 - (N- ( 3 -f luoro-2 ' -methylsulfonyl- [ 1 , 1 ' ] - biphen-4 -yl ) ) carboxyamide * TFA
3 -Trif luoromethyl-1- (2-azidomethyl-4-chlorophenyl ) -1H- pyrazole-5-carboxylic acid was prepared from 3-chloro-6- aminobenzoic acid by essentially the same method used for 3- trif luoromethyl-1- ( 2 -azidomethyl-4 -methoxyphenyl) -lH-pyrazole- 5-carboxylic acid in Parts A and B of Example 8. This compound was coupled with 2-f luoro-4- ( (2- methansulfonyl) phenyl) aniline according to the procedure in Part C of Example 8. The title compound was prepared and purified by the method outlined in Part D of Example 8 ; mp 97.5 °C; HRMS (M+H) + : 567 .0891 m/z .
Example 15 3-Trifluoromethyl-1- ( 2-aminomethyl-4-chlorophenyl ) -1H- pyrazole-5- (N- (3-fluoro-2 • -sulfamido- [1, 1 ' ] -biphen-4- yl) ) carboxyamide* FA
3-Trifluoromethyl-1- (2-azidomethyl--4-chlorophenyl) -1H- pyrazole-5-carboxylic acid was prepared from 3-chloro-6- aminobenzoic acid by essentially the same method used for 3- trifluoromethyl-1- (2-azidomethyl-4-methoxyphenyl) -lH-pyrazole- 5-carboxylic acid in Parts A and B of Example 8. This compound was coupled with 2-fluoro-4- ( (2-N-t- butylsulfonamido) phenyl) aniline according to the procedure in Part C of Example 8. The azidomethyl group was reduced to the aminomethyl group with SnCl2»2H2θ by the method outlined in Part D of Example 8. The crude reduction product was then refluxed in trifluoroacetic acid (10 mL) for 1 h to remove the t-butyl protecting group. The title compound was isolated by HPLC utilizing gradient elution with a mixture of water: acetonitrile with 0.05% trifluoroacetic acid on a reverse phase C18 (60 A) column; mp 128 °C; HRMS (M+H)+: 568.0832 m/z.
Example 16 3-Trifluoromethyl-1- ( 2-aminomethyl-5-chlorophenyl ) -1H- pyrazole-5- (N- (3-fluoro-2 • -methylsulfonyl- [1,1']- biphen-4-yl) ) carboxyamide*TFA
3-Trifluoromethyl-1- (2-azidomethyl-5-chlorophenyl) -1H- pyrazole-5-carboxylic acid was prepared from 4-chloro-6- aminobenzoic acid by essentially the same method used for 3- trifluoromethyl-1- (2-azidomethyl-4-methoxyphenyl) -lH-pyrazole- 5-carboxylic acid in Parts A and B of Example 8. This compound was coupled with 2-fluoro-4- ( (2- methansulfonyl) phenyl) aniline according to the procedure in Part C of Example 8. The title compound was prepared and purified by the method outlined in Part D of Example 8; mp 99.7 °C; HRMS (M+H)+: 567.0859 m/z.
Example 17 3 - Tri f luoromethyl - 1 - ( 2 -aminomethyl - 4 - chlorophenyl ) - 1H- pyrazole - 5 - ( N- ( 3 - f luoro - 2 ' - sul f amido - [ 1 , 1 ' ] -biphen-4 - yl) ) carboxyamide*TFA
3-Trifluoromethyl-1- (2-azidomethyl-S-chlorophenyl) -1H- pyrazole-5-carboxylic acid was prepared from 4-chloro-6- aminobenzoic acid by essentially the same method used for 3- trifluoromethyl-1- (2-azidomethyl-4-methoxyphenyl) -lH-pyrazole- 5-carboxylic acid in Parts A and B of Example 8. This compound was coupled with 2-fluoro-4- ( (2-N-t- butylsulfonamido) phenyl) aniline according to the procedure in Part C of Example 8. The azidomethyl group was reduced to the aminomethyl group with SnCl2*2H2θ by the method outlined in Part D of Example 8. The crude reduction product was then refluxed in trifluoroacetic acid (10 mL) for 1 h to remove the t-butyl protecting group. The title compound was isolated by HPLC utilizing gradient elution with a mixture of water: acetonitrile with 0.05% trifluoroacetic acid on a reverse phase C18 (60 A) column; mp 127.4 °C; HRMS (M+H)+: 568.0837 m/z.
Example 18 3-Trifluoromethyl-1- (2 -aminomethyl-4-fluorophenyl ) -1H- pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1']- biphen-4-yl )) carboxyamide*TFA
3-Trifluoromethyl-1- (2-azidomethyl-4-fluorophenyl) -1H- pyrazole-5-carboxylic acid was prepared from 3-fluoro-6- aminobenzoic acid by essentially the same method used for 3- trifluoromethyl-1- (2-azidomethyl-4-methoxyphenyl) -lH-pyrazole- 5-carboxylic acid in Parts A and B of Example 8. This compound was coupled with 2-fluoro-4- ( (2- methansulfonyl)phenyl) aniline according to the procedure in Part C of Example 8. The title compound was prepared and purified by the method outlined in Part D of Example 8; mp 125 °C; HRMS (M+H)+: 551.1177 m/z.
Example 19 3-Trif luoromethyl-1- (2 -aminomethyl-4 -fluorophenyl) -1H- pyrazole-5- (N- (3-f luoro-2 * -sulfamido- [1,1'] -biphen-4- yl) ) carboxyamide*TFA
3-Trifluoromethyl-1- (2-azidomethyl-4-fluorophenyl) -1H- pyrazole-5-carboxylic acid was prepared from 3-fluoro-6- aminobenzoic acid by essentially the same method used for 3- trifluoromethyl-1- (2-azidomethyl-4-methoxyphenyl) -lH-pyrazole- 5-carboxylic acid in Parts A and B of Example 8. This compound was coupled with 2-fluoro-4- ( (2-N-t- butylsulfonamido) phenyl) aniline according to the procedure in Part C of Example 8. The azidomethyl group was reduced to the aminomethyl group with SnCl2*2H2θ by the method outlined in Part D of Example 8. The crude reduction product was then refluxed in trifluoroacetic acid (10 mL) for 1 h to remove the t-butyl protecting group. The title compound was isolated by HPLC utilizing gradient elution with a mixture of water:acetonitrile with 0.05% trifluoroacetic acid on a reverse phase C18 (60 A) column; mp 113.1 °C; HRMS (M+H) + : 552.1112 m/z.
Example 20 3-Trif luoromethyl-1- ( 2 - aminomethyl - 5 - fluorophenyl ) -1H- pyrazole-5- (N- (3-f luoro-2 -methylsulfonyl- [1, 1 ] - biphen-4 -yl )) carboxyamide* TFA
3 -Trif luoromethyl-1- (2-azidomethyl-5-f luorophenyl) -1H- pyrazole-5-carboxylic acid was prepared from 4-fluoro-6- aminobenzoic acid by essentially the same method used for 3- trif luoromethyl-1- (2 -azidomethyl-4 -methoxyphenyl) -lH-pyrazole- 5-carboxylic acid in Parts A and B of Example 8. This compound was coupled with 2-f luoro-4- ( (2- methansulfonyl) phenyl) aniline according to the procedure in Part C of Example 8. The title compound was prepared and purified by the method outlined in Part D of Example 8; mp 97.2 °C; HRMS (M+H) + : 551.1179 m/z.
Example 21 3-Trif luoromethyl-1- (2 -aminomethyl- 5 -f luorophenyl ) -1H- pyrazole-5- (N- (3-f luoro-2 ' -sulfamido- [1,1'] -biphen-4 - yl) ) carboxyamide*TFA
3 -Trifluoromethyl-1- (2-azidomethyl-5-fluorophenyl) -1H- pyrazole-5-carboxylic acid was prepared from 4-fluoro-6- aminobenzoic acid by essentially the same method used for 3- trifluoromethyl-1- (2-azidomethyl-4-methoxyphenyl) -lH-pyrazole- 5-carboxylic acid in Parts A and B of Example 8. This compound was coupled with 2-fluoro-4- ( (2-N-t- butylsulfonamido) phenyl) aniline according to the procedure in Part C of Example 8. The azidomethyl group was reduced to the aminomethyl group with SnCl2»2H2θ by the method outlined in Part D of Example 8. The crude reduction product was then refluxed in trifluoroacetic acid (10 mL) for 1 h to remove the t-butyl protecting group. The title compound was isolated by HPLC utilizing gradient elution with a mixture of water: acetonitrile with 0.05% trifluoroacetic acid on a reverse phase C18 (60 A) column; mp 101 °C; HRMS (M+H)+: 552.1120 m/z.
Example 22 3-Trif luoromethyl-1- ( 2 -aminomethyl-4 , 5-dif luorophenyl) - lH-pyrazole-5- (N- (3-f luoro-2 ' -methylsulfonyl- [1,1']- biphen-4 -yl )) carboxyamide* TFA
3 -Trif luoromethyl-1- (2 -azidomethyl-4, 5-dif luorophenyl) -1H- pyrazole-5-carboxylic acid was prepared from 3 , 4-difluoro-6- aminobenzoic acid by essentially the same method used for 3- trif luoromethyl-1- (2-azidomethyl-4-methoxyphenyl) -lH-pyrazole- 5-carboxylic acid in Parts A and B of Example 8. This compound was coupled with 2-f luoro-4- ( (2- methansulfonyl) phenyl) aniline according to the procedure in Part C of Example 8. The title compound was prepared and purified by the method outlined in Part D of Example 8; HRMS (M+H)+: 569.1082 m/z.
Example 21 3-Trifluoromethyl-1- ( 2 -aminomethyl-4 , 5-difluorophenyl) -
IH-pyrazole- 5- (N- (3-fluoro-2 ' -sulfamido- [1,1' ] -biphen-
4-yl) ) carboxyamide*TFA
3-Trifluoromethyl-1- (2-azidomethyl-4 , 5-difluorophenyl) -1H- pyrazole-5-carboxylic acid was prepared from 3 , 4-difluoro-6- aminobenzoic acid by essentially the same method used for 3- trifluoromethyl-1- (2-azidomethyl-4-methoxyphenyl) -lH-pyrazole- 5-carboxylic acid in Parts A and B of Example 8. This compound was coupled with 2-fluoro-4- ( (2-N-t- butylsulfonamido)phenyl) aniline according to the procedure in Part C of Example 8. The azidomethyl group was reduced to the aminomethyl group with SnCl2*2H2θ by the method outlined in Part D of Example 8. The crude reduction product was then refluxed in trifluoroacetic acid (10 mL) for 1 h to remove the t-butyl protecting group. The title compound was isolated by HPLC utilizing gradient elution with a mixture of water : acetonitrile with 0.05% trifluoroacetic acid on a reverse phase C18 (60 A) column; mp 118.7 °C; HRMS (M+H)+: 570.1038 m/z.
Example 24 3-Trifluoromethyl-1- ( 2 -aminomethyl-3-fluorophenyl ) -1H- pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1, 1 • ] - biphen-4-yl) ) carboxyamide*TFA
3-Trifluoromethyl-1- (2-azidomethyl-3-fluorophenyl) -1H- pyrazole-5-carboxylic acid was prepared from 2-fluoro-6- aminobenzoic acid by essentially the same method used for 3- trifluoromethyl-1- (2-azidomethyl-4-methoxyphenyl) -lH-pyrazole- 5-carboxylic acid in Parts A and B of Example 8. This compound was coupled with 2-fluoro-4- ( (2- methansulfonyl)phenyl) aniline according to the procedure in Part C of Example 8. The title compound was prepared and purified by the method outlined in Part D of Example 8; mp 105.1 °C; HRMS (M+H) + : 551.1180 m/z.
Example 25 3-Trifluoromethyl-1- (2-aminomethyl-3-fluorophenyl) -1H- pyrazole-5- (N- (3-fluoro-2 -sulfamido- [1, 1 ' ] -biphen-4- yl) ) carboxyamide* FA
3-Trifluoromethyl-1- (2-azidomethyl-3-fluorophenyl) -IH- pyrazole-5-carboxylic acid was prepared from 2-fluoro-6- aminobenzoic acid by essentially the same method used for 3- trifluoromethyl-1- (2-azidomethyl-4-methoxyphenyl) -lH-pyrazole- 5-carboxylic acid in Parts A and B of Example 8. This compound was coupled with 2-fluoro-4- ( (2-N-t- butylsulfonamido) phenyl) aniline according to the procedure in Part C of Example 8. The azidomethyl group was reduced to the aminomethyl group with SnCl2 φ2H2θ by the method outlined in Part D of Example 8. The crude reduction product was then refluxed in trifluoroacetic acid (10 mL) for 1 h to remove the t-butyl protecting group. The title compound was isolated by HPLC utilizing gradient elution with a mixture of water :acetonitrile with 0.05% trifluoroacetic acid on a reverse phase C18 (60 A) column; mp 115.8 °C; HRMS (M+H) + : 552.1111 m/z.
Example 26 3-Trifluoromethyl-1- (2-aminomethyl-4-fluorophenyl) -1H- pyrazole-5- (N- (4- (2-methylsulfonyl- [1,1'] -biphen-4- yl) ) carboxyamide*TFA
3-Trifluoromethyl-1- (2-azidomethyl-4-fluorophenyl) -1H- pyrazole-5-carboxylic acid was prepared from 3-fluoro-6- aminobenzoic acid by essentially the same method used for 3- trifluoromethyl-1- (2-azidomethyl-4-methoxyphenyl) -lH-pyrazole- 5-carboxylic acid in Parts A and B of Example 8. This compound was coupled with 4- ( (2-methansulfonyl)phenyl) aniline according to the procedure in Part C of Example 8. The title compound was prepared and purified by the method outlined in Part D of Example 8; mp 110.3 °C; HRMS (M+H)+: 533.1265 m/z.
Example 27 3-Trifluoromethyl-1- (2 -aminomethyl-4 -fluorophenyl ) -IH- pyrazole- 5- (N- (4- (2 -sulfamido- [1,1*] -biphen-4 - yl) ) carboxyamide*TFA
3 -Trifluoromethyl-1- (2-azidomethyl -A-fluorophenyl) -1H- pyrazole-5-carboxylic acid was prepared from 3-fluoro-6- aminobenzoic acid by essentially the same method used for 3- trifluoromethyl-1- (2-azidomethyl-4-methoxyphenyl) -lH-pyrazole- 5-carboxylic acid in Parts A and B of Example 8. This compound was coupled with 4-((2-N-t- butylsulfonamido) phenyl) aniline according to the procedure in Part C of Example 8. The azidomethyl group was reduced to the aminomethyl group with SnCl2*2H2θ by the method outlined in Part D of Example 8. The crude reduction product was then refluxed in trifluoroacetic acid (10 mL) for 1 h to remove the t-butyl protecting group. The title compound was isolated by HPLC utilizing gradient elution with a mixture of water: acetonitrile with 0.05% trifluoroacetic acid on a reverse phase C18 (60 A) column; mp 136.8 °C; HRMS (M+H)+: 534.1227 m/z.
Example 28 3-Trifluoromethyl-1- (2 -aminomethyl-4-fluorophenyl ) -1H- pyrazole-5-(N-(4- (N- ( (N1 - methylsulfonyl) iminoly) pyrrolidino) ) phenyl) carboxyamide* TFA
Part A: 4-Amino-N- ( (N' -methylsulfonyl) iminoyl)pyrrolidine : 4-Nitrobenzonitrile (5.4 g, 36.5 mmol) in anhydrous methyl acetate (200 mL) and MeOH (20 mL) was cooled to 0 °C and treated with a stream of dry HCI gas for 1 h. The reaction was securely stoppered and left to stand at 5 °C in a refrigerator for 24 h. The solvent was removed and the reaction was evaporated repeatedly (5 x) with Et2θ to remove the last traces of free HCI. There was obtained 28.6 g of the imidate as an HCI salt. This material was dissolved in anhydrous MeOH (100 mL) and pyrrolidine (40.1 mmol, 2.85 g) added. The reaction was stirred for 18 h, then evaporated and stirred in IN HCI (150 mL) ; the insoluable material was removed by filtration then the HCI solution evaporated. The residue was dried by the azeotropic removal of H2O with EtOH and there was obtained 7.44 g of the amidine product; LRMS ES+ (M+H)+: 220.1 m/z.
The free base of the amidine prepared above was formed by suspending the product in IN NaOH (250 mL) and extracting this suspension with CHCI3 (3 x) . The material was dried and evaporated to give 4.49 g of product.
To 3.1 g of the free base of the amidine prepared above (14.2 mmol) in CH2C12 (100 mL) at 0 °C was added DMAP (2.1 g, 17 mmol) followed by methanesulfonyl chloride (1.95 g, 17 mmol) in CH2CI2 (25 mL) . After 18 h at ambient temperature, the reaction was washed with IN HCI (2 x) , IN NaOH and brine, dried and evaporated. There was obtained 3.6 g of the mesylation product; LRMS ES+ (M+H)+: 298.1.
The mesyltion product (3.6 g, 12 mmol) and SnC12*2H20 (8.12 g, 36 mmol) in EtOH (100 mL) was heated at reflux for 2 h. The solvent was removed and the residue par ioned between IN NaOH (150 mL) and CH2C12 (100 mL) . The aqueous layer was extracted with CH2C12 (2 x 100 mL) , dried (Na2S04) and evaporated to give 2.7 g of 4-amino-N- ( (N' - methylsulfonyl) iminoyl)pyrrolidine; LRMS ES+ (M+H) + : 268.1 m/z.
Part B: 3-Trifluoromethyl-1- (2-aminomethyl-4-fluorophenyl) - IH-pyrazole-5- (N- (4- (N- ( (N' - methylsulfonyl) iminoly) pyrrolidino) )phenyl) carboxyamide* FA: 3-Trifluoromethyl-1- (2-azidomethyl-4- fluorophenyl) -lH-pyrazole-5-carboxylic acid was prepared from 3-fluoro-6-aminobenzoic acid by essentially the same method used for 3-trifluoromethyl-1- (2-azidomethyl-4-methoxyphenyl) - lH-pyrazole-5-carboxylic acid in Parts A and B of Example 8. This compound was coupled with 4-amino-N- ( (N' - methylsulfonyl) iminoyl)pyrrolidine, prepared in Part A of Example 28, according to the procedure in Part C of Example 8. The title compound was prepared and purified by the method outlined in Part D of Example 8; mp 138.4 °C; HRMS (M+H) + : 553.1640 m/z.
Example 29
3-Trifluoromethyl-1- (2- (N-glycyl) aminomethyl-4- methoxyphenyl) -lH-pyrazole-5- (N- (3-fluoro-2 ' - methylsulfonyl- [1,1'] -biphen-4-yl ) ) carboxyamide*TFA
3-Trifluoromethyl-1- (2- (N-glycyl) aminomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1'] -biphen-4- yl) ) carboxyamide*TFA: A mixture of 3-Trifluoromethyl-1- (2- aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (3-fluoro-2 ' - methylsulfonyl- [1,1' ] -biphen-4-yl) ) carboxyamide*TFA (prepared in Example 5, 0.15 g, 0.22 mmol),N-Boc glycine (0.039 g, 0.22 mmol) and HBTU (0.084 g, 0.22 mmol) in DMF (3 mL) were cooled to 0 °C and NMM (0.075 g, 0.75 mmol) added. After 6 h, the reaction was diluted with brine and extracted with EtOAc. The EtOAc layer was washed with 5% NaHS04 and brine (5 x) then dried (MgS04) and evaporated to give 0.14 g of product; LRMS ES+ (M+H)+: 720.4 m/z.
The product from above was stirred in 5% TFA in CH2CI2 (20 mL) for 18 h. The reaction was evaporated and the product purified by HPLC utilizing gradient elution with a mixture of water :acetonitrile with 0.05% trifluoroacetic acid on a reverse phase C18 (60 A) column to give 0.087 g of the title compound; mp 92.5 °C; HRMS (M+H)+: 620.160000 m/z.
Example 30
3 -Trif luoromethyl- 1- ( 2 - (N-phenylacetyl ) aminomethyl-4 - methoxyphenyl ) -lH-pyrazole- 5 - ( N- ( 3 -f luoro-2 ' - methylsulfonyl - [ 1 , 1 ' ] -biphen-4 -yl ) ) carboxyamide
3-Trif luoromethyl-1- (2- (N-phenylacetyl ) aminomethyl-4 - methoxyphenyl ) -lH-pyrazole-5- (N- (3-f luoro-2 ' -methylsulf onyl- [1, 1 ' ] -biphen-4 -yl) ) carboxyamide : A mixture of 3- Trif luoromethyl-1- (2 -aminomethyl-4 -methoxyphenyl) -lH-pyrazole- 5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1'] -biphen-4- yl) ) carboxyamide*TFA (prepared in Example 5, 0.15 g, 0.22 mmol) and Et3N (0.068 g, 0.66 mmol) in CH2C1 (10 mL) was cooled to 0 °C and phenylacetyl chloride (0.22 mol in 1 mL of CH2CI2) was added dropwise. The reaction was complete in 3 h. It was diluted with more CH2CI2 then washed with IN HCI, dried and evaporated. The residue was purified further by MPLC on a 200g column of flash Siθ2 by elution with 1:1 Hexane : EtOAc . Fractions (25 mL) were collected and the product isolated in tubes 44-75. There was obtained 0.086 g of the desired product; mp 179-181 °C; HRMS (M+H) + : 681.1786 m/z.
Example 31 3- (Trifluoromethyl) -1- (2- (aminomethyl) phenyl) -1H- pyrazole-5- (N- (2 ■ -methylsulfonyl- [1,1'] -biphen-4- yl ) ) carboxyamide •TFA
2- [5- (2-Furyl) -3- (trifluoromethyl) -lH-pyrazol-l-yl]benzoic acid: 4, 4,4-Trifluoro-l- (2-furyl) -1, 3-butanedione (2.4 mL, 16 mmol) was added to 2-hydrazinobenzoic acid (3.01 g, 16 mmol) in acetic acid (20 mL) and heated at reflux for 25 h. The reaction was cooled, diluted with EtOAc, and extracted twice with water. The organic layer was dried over a2Sθ4, filtered, and evaporated to yield a thick red paste (5.71 g, >100%) . ^H NMR (CDCI3) δ 8.18 (dd, IH, J = 7.7, J' = 1.8), 7.74 (td, IH, J = 7.7, J' = 1.4), 7.65 (td, IH, J = 7.7, J' = 1.5), 7.50 (dd, IH, J = 7.3, J' = 1.1), 7.35 (m, IH) , 6.89 (s, IH) , 6.28 (m, IH) , 5.76 (d, IH, J = 3.3) .
2- [5- (2-Furyl) -3- (trifluoromethyl) -lH-pyrazol-l-yl]benzamide: 2- [5- (2-Furyl) -3- (trifluoromethyl) -lH-pyrazol-l-yl]benzoic acid (5.13 g, 16 mmol) was dissolved in thionyl chloride (25 mL) and heated at reflux for 2 h. The excess thionyl chloride was evaporated, and the resulting acid chloride was placed under high vacuum. The acid chloride was then redissolved in CH2CI2 (25 mL) and cooled to 0*C. Cone, aqueous NH3 (6 mL)was added portionwise over 30 min. The resulting mixture was stirred at 0"C for 30 min, then at room temperature for 1 h. The reaction was diluted with water and extracted with CH2CI2
(3x) . The organic layers were combined and extracted with 2M Na23. The organic layer was dried over gSθ4 , filtered, and evaporated to yield the desired product (4.76 g, 93%). ^H NMR (CDCI3) δ 7.98 (dd, IH, J = 7.3, J'- = 2.2), 7.67 (m, 2H) , 7.41
(m, 2H) , 6.96 (s, IH) , 6.28 (m, IH) , 5.89 (bs, IH) , 5.67 (d, IH, J = 2.9) .
2- [5- (2-Furyl) -3- (trifluoromethyl) -lH-pyrazol-1- yl]benzonitrile: 2- [5- (2-Furyl) -3- (trifluoromethyl) -1H- pyrazol-l-yl]benzamide (6.73 g, 21 mmol) and triethylamine (5.8 mL, 42 mmol) were combined in dry CH2CI2 (55 mL) under argon and cooled to O'C. Trichloroacetyl chloride (2.7 mL, 24 mmol) in CH2CI2 (15 mL) was added dropwise over 30 min. The resulting solution was stirred at O'C for 20 min, then at room temperature for 65 min. The reaction was quenched with a small amount of water, then partitioned between IM HCI and CH2CI2 • The organic layer was removed and extracted with sat . NaHC03, then dried over Na24, filtered, and evaporated to yield crude product (6.66 g) . The crude product was chromatographed on silica gel (30-40% EtOAc/hexanes ) to yield a yellow solid (6.51 g, >100%) . E NMR (CDCI3) δ 7.79 (m, 2H) ,
7.64 (m, 2H) , 7.39 (d, IH, J = 1.8), 6.96 (s, IH) , 6.37 (m, IH) , 6.04 (d, IH, J = 3.7) .
2- [5- (2-Furyl) -3- (trifluoromethyl) -lH-pyrazol-1- yl] benzylamine : Cobalt chloride (1.76 g, 13.6 mmol) was added to 2- [5- (2-furyl) -3- (trifluoromethyl) -lH-pyrazol-1- yllbenzonitrile (4.12 g, 13.6 mmol) and sodium borohydride (1.03 g, 27.2 mmol) in DMF (40 mL) . The reaction turned black and became warm. An ice bath was added and the reaction was stirred at O'C for 45 min, then at room temperature for 23 h. Additional sodium borohydride (0.25 g, 6.6 mmol) was added and the resulting mixture was stirred at room temperature for 6 h. A room temperature water bath was added, and the reaction was quenched with water (10 mL) over 10 min, then MeOH (20 mL) , then 6M HCI (20 mL) over 15 min. The quenched reaction was stirred at room temperature for 16 h, diluted with EtOAc, and extracted with water and 0. IM HCI. The resulting emulsion was filtered through celite, and the organic layer was removed, dried over Na24, filtered, and evaporated to yield crude product (857 mg) . The aqueous layers were combined and neutralized (pH 8) with solid a23 (6.9 g) . Addition of EtOAc yielded another emulsion, which was filtered through celite. The organic layer was removed, and the aqueous layer was extracted again with EtOAc. The organic layers were combined, dried over Na2S04, filtered, and evaporated to yield a second batch of crude product (3.55 g) . The two batches of crude product were combined and chromatographed on silica gel (0-10% MeOH/CHCl3) to yield the desired product (3.77 g, 90%). XH NMR (CDC13) δ 7.59 (m, 2H) , 7.38 (m, 2H) , 7.33 (d, IH, J =
7.3), 6.96 (s, IH) , 6.27 (m, IH) , 5.59 (d, IH, J = 3.6), 3.51 (s, 2H) .
t-Butyl 2- [5- (2-furyl) -3- (trifluoromethyl) -lH-pyrazol-1- yl]benzylcarbamate: Triethylamine (2.6 mL, 18.7 mmol) and di- t-butyl dicarbonate (4.0 g, 18.4 mmol) were added to 2- [5- (2- furyl) -3- (trifluoromethyl) -lH-pyrazol-l-yl]benzylamine (3.77 g, 12.3 mmol) in THF (60 mL) and stirred at room temperature for 17 h. The reaction was concentrated, diluted with Et2θ, and extracted with water (2x) . The aqueous layers were combined and extracted with Et2θ. The organic layers were combined, dried over MgS04, filtered, and evaporated to yield crude product (5.58 g) . The crude product was chromatographed on silica gel (10-20% EtOAc/hexanes) to yield a waxy solid (3.82 g, 76%). XH NMR (CDCI3) δ 7.57 (m, 2H) , 7.43 (m, 2H) ,
7.32 (d, IH, J = 7.7), 6.95 (s, IH) , 6.28 (m, IH) , 5.66 (d, IH, J = 3.3), 4.82 (bs, IH) , 4.01 (bd, 2H, J = 6.2), 1.39 (s, 9H) .
1- (2- ( [ (t-Butoxycarbonyl) amino]methyl)phenyl) -3- (trifluoromethyl) -lH-pyrazol-l-yl-5-carboxylic acid: t-Butyl 2- [5- (2-furyl) -3- (trifluoromethyl) -lH-pyrazol-1- y1]benzylcarbamate (3.77 g, 9.2 mmol) was dissolved in t-BuOH (60 mL) . A 5% aqueous solution of NaH24 (40 mL) was added, followed by portionwise addition of solid KMnθ4 (5.86 g, 37 mmol) over 25 min. The resulting mixture was heated at 65 'C for 40 min. Additional KMnθ4 (1.39 g, 8.8 mmol) was added, and the reaction continued heating at 65 "C for 35 min. The reaction mixture was cooled and filtered through celite, using EtOH and acetone to rinse the celite. The filtrate was concentrated to approx. half its original volume and treated with aq. sodium bisulfite to remove residual KMnθ4. The resulting mixture was extracted with EtOAc, and the organic layer was removed, dried over Na2S04, filtered, and evaporated to yield crude product (1.50 g) . The aqueous layer was cooled in ice, acidified with IM HCI (6 mL) and extracted with EtOAc (containing a small amount of EtOH) . Before separating, both layers were filtered through celite and treated with sat NaHC03 (1.5 mL) . The aqueous layer was removed and extracted twice with EtOAc/EtOH. Solid NaCI was added both times to aid separation of the emulsion. The aqueous layer was extracted with CHCI3, adjusted to pH 5 with IM HCI, and extracted twice with CHCl3/EtOH. The final 6 organic layers were combined, dried over Na2S04, filtered, and evaporated to yield a second batch of product (2.43 g, 68%). The first batch of product was chromatographed on silica gel (0-30% MeOH/CHCl3) to yield clean product (0.95 g, 27%). 1H NMR (DMSO) δ 7.34 (m, 4H) ,
7.16 (d, IH) , 6.81 (bs, IH) , 3.79 (bd, 2H) , 1.32 (s, 9H) .
1- [2- ( ( [ (t-Butoxycarbonyl) amino]methyl)phenyl) -5- (2 ' - methylsufonyl- [1, 1 ' ] -biphen-4-yl) ) aminocarbonyl] -3- (trifluoromethyl)pyrazole: Oxalyl chloride (90 μl, 1.0 mmol) and DMF (2 drops) were added to l-(2-([(t- butoxycarbonyl) amino]methyl)phenyl) -3- (trifluoromethyl) -1H- pyrazol-1-yl-5-carboxylic acid (200 mg, 0.52 mmol) in CH2CI2 (5 mL) and the resulting solution was stirred for 90 min at room temperature. The solvents were evaporated and the resulting compound was placed briefly under high vacuum before redissolving in CH2CI2 (5 mL) . Triethylamine (220 μl, 1.6 mmol) , 4-amino-2 ' -methylsulfonyl- [1,1' ] -biphenyl hydrochloride (177 mg, 0.62 mmol), and 4-dimethylaminopyridine (20 mg, 0.16 mmol) were added, and the resulting solution was stirred for 23 h at room temperature. The reaction was extracted with ice-cooled IM HCI, then sat. NaHCC>3. The organic layer was dried over MgS04, filtered, and evaporated to yield crude product (241 mg) . The crude product was chromatographed on silica gel (30-40% EtOAc/hexanes) to yield the desired product (64 mg, 20%). NMR (CDCI3) δ 8.21 (d, IH, J = 8.1), 7.58 (m,
5H) , 7.35 (m, 8H) , 7.18 (s, IH) , 4.16 (d, 2H, J = 5.8), 2.59 (s, 3H) , 1.33 (s, 9H) .
3- (Trifluoromethyl) -1- (2- (aminomethyl)phenyl) -lH-pyrazole-5- (N- (2 ' -methylsulfonyl- [1,1'] -biphen-4-yl) ) carboxyamide trifluoroacetic acid salt: TFA (1 mL) was added to l-[2- ( ( [ (t-butoxycarbonyl) amino]methyl)phenyl) -5- (2 ' -methylsufonyl- [1,1'] -biphen-4-yl) ) aminocarbonyl] -3- (trifluoromethyl) pyrazole (64 mg, 0.10 mmol) in CH2CI2 (1 mL) and stirred at room temperature for 21 h. The reaction was evaporated and purified by reverse phase prep. HPLC (15-70% MeCN/H2O/0.5% TFA) to yield the desired product (30 mg, 46%) . !H NMR (DMSO) d 10.79 (s, IH) , 8.16 (bs, 2H) , 8.04 (d, IH, J = 7.7), 7.77 (s, IH) , 7.71 (td, IH, J = 5.8), 7.64 (m, 6H) , 7.51 (m, IH) , 7.45 (d, IH, J = 7.6), 7.34 (m, 3H) , 3.79 (bm, 2H) , 2.78 (s, 3H) . 19F NMR (DMSO) d -61.22, -73.97. HRMS calc. C25H22N4O3F3S: 515.1365; found, 515.1359.
Example 32 3-Trifluoromethyl-1- (2- (aminomethyl) phenyl) -1H- pyrazole-5- (N- (2 -aminosulfonyl- [1,1'] -biphen-4- yl ) ) carboxyamide•TFA
1- [2-( ( [ (t-Butoxycarbonyl) amino]methyl)phenyl) -5- (2 ' -(t- butylamino) sulfonyl- [1,1'] -biphen-4-yl) ) aminocarbonyl] -3-
(trifluoromethyl) yrazole: Oxalyl chloride (90 μl, 1.0 mmol) and DMF (2 drops) were added to l-(2-([_(t- butoxycarbonyl) amino]methyl)phenyl) -3- (trifluoromethyl) -1H- pyrazol-l-yl-5-carboxylic acid (Example 31 Part A, 200 mg, 0.52 mmol) in CH2CI2 (5 mL) and the resulting solution was stirred for 95 min at room temperature. The solvents were evaporated and the resulting compound was placed briefly under high vacuum before redissolving in CH2CI2 (5 mL) . Triethylamine (150 μl , 1.1 mmol), 4-amino-2 ' ( t- butylamino) sulfonyl- [1, 1 '] -biphenyl (190 mg, 0.62 mmol), and 4-dimethylaminopyridine (20 mg, 0.16 mmol) were added, and the resulting solution was stirred for 23 h at room temperature. The reaction was extracted with dilute brine solution, ice- cooled IM HCI, and sat. NaHCC>3. The organic layer was dried over MgSθ4, filtered, and evaporated to yield crude product (371 mg) . The crude product was chromatographed on silica gel (30% EtOAc/hexanes) to yield the desired product (74 mg, 21%) . !H NMR (CDC13) δ 8.64 (bs, IH) , 8.15 (dd, IH, J = 7.7, J' =
1.5), 7.45 (m, 10H) , 7.25 (d, IH, J = 6.9), 7.20 (s, IH) , 5.33 (bs, IH) , 4.15 (d, 2H, J = 5.8), 3.49 (bs, IH) , 1.34 (s, 9H) , 0.97 (s, 9H) .
3 -Trifluoromethyl-1- (2- (aminomethyl ) phenyl ) -lH-pyrazole-5- (N- (2 ' -aminosulfonyl- [1,1'] -biphen-4-yl) ) carboxyamide trifluoroacetic acid salt: TFA (2 mL) was added to l-[2- ( ( [ (t-butoxycarbonyl) amino] methyl) phenyl) -5- (2 ' - (t- butylamino) sulfonyl- [1,1'] -biphen-4-yl) ) aminocarbonyl] -3- (trifluoromethyl) pyrazole (74 mg, 0.11 mmol) in CH2CI2 (1 mL) and stirred at room temperature for 19 h. Additional TFA (2 mL) was added, and the reaction continued stirring for 3 h. The reaction was evaporated and purified by reverse phase prep. HPLC (15-70% MeCN/H2O/0.5% TFA) to yield the desired product (41 mg, 59%). MR (DMSO) δ 10.75 (s, IH) , 8.17 (bs, 3H) , 7.98 (dd, IH, J = 7.3), 7.76 (s, IH) , 7.57 (m, 7H) , 7.44 (d, IH, J = 6.7), 7.32 (d, 2H, J = 8.8), 7.25 (m, 3H) 3.79 (bd, 2H, J = 5.1). 19F NMR (DMSO) δ -61.22, -73.99. HRMS calc. C24H21N5O3F3S: 516.1317; found, 516.1319.
Example 33
3-Trifluoromethyl-1- (2- (aminomethyl ) phenyl) -1H- pyrazole-5- (N- (3-fluoro-2 -aminosulfonyl- [1, 1 ' ] -biphen-
4-yl) ) carboxyamide* TFA
1- [2- ( ( [ (t-Butoxycarbonyl) amino]methyl ) phenyl ) -5- (3-fluoro-2 ' - (t-butylamino) sulfonyl- [1,1'] -biphen-4-yl) ) aminocarbonyl] -3- ( trifluoromethyl) pyrazole: Oxalyl chloride (300 μl, 3.4 mmol) and DMF (3 drops) were added to l-(2-[(t- butoxycarbonyl) amino]methylphenyl) -3- (trifluoromethyl) -1H- pyrazol-l-yl-5-carboxylic acid (Example 31 Part A, 888 mg, 2.3 mmol) in CH2CI2 (30 mL) and the resulting solution was stirred for 65 min at room temperature. The solvents were evaporated and the resulting compound was placed briefly under high vacuum before redissolving in CH2CI2 (30 mL) . 4-Amino-3- fluoro-2' -(t-butylamino)sulfonyl-[1,1' ] -biphenyl (890 mg, 2.8 mmol), and 4-dimethylaminopyridine (420 mg, 3.4 mmol) were added, and the resulting solution was stirred for 22 h at room temperature . The reaction was concentrated and chromatographed on silica gel (20-30% EtOAc/hexanes) . The fractions containing product were combined and concentrated to half the original volume, then extracted 3x with ice-cooled IM HCI, 2x with room temperature IM HCI, sat. NaHC03 , 2M HCI, and sat. NaHCθ3. The organic layer was dried over Na2S04, filtered, and evaporated to yield the desired product (600 mg, 38%) .
3-Trifluoromethyl-1- (2- (aminomethyl)phenyl) -lH-pyrazole-5- (N- (3-fluoro-2 ' -aminosulfonyl- [1, 1 ' ] -biphen-4-yl) ) carboxyamide trifluoroacetic acid salt: TFA (9 mL) was added to l-[2- ( ( [ (t-butoxycarbonyl) amino]methyl) phenyl) -5- (3-fluoro-2 ' - (t- butylamino) sulfonyl- [1,1' ] -biphen-4-yl) ) aminocarbonyl] -3- (trifluoromethyl) pyrazole (600 mg, 0.87 mmol) in CH2CI2 (3 mL) and stirred at room temperature for 18 h. The reaction was evaporated and purified by reverse phase prep. HPLC (10-70% MeCN/H2θ/0.5% TFA) to yield impure product (349 mg) . This material was again purified by reverse phase HPLC (5-70% MeCN/H2O/0.5% TFA) to yield clean product (162 mg, 35%). Any impure fractions containing product were combined and purified by reverse phase HPLC (20-60% MeCN/H2O/0.5% TFA) to yield additional product (119 mg, 26%) !H NMR (DMSO) δ 10.62 (s,
IH) , 8.16 (bs, 2H) , 7.98 (dd, IH, J = 7.0, J' = 2.2), 7.79 (s, IH) , 7.54 (m, 7H) , 7.39 (s, 2H) , 7.28 (m, 2H) , 7.15 (d, IH, J = 8.4), 3.78 (bm, 2H) . 19F NMR (DMSO) δ -61.26, -74.29,
-122 . 79 . HRMS calc . C24H20N5O3F4S : 534 . 1223 ; found, 534 . 1216 . Example 34
3-Trifluoromethyl-1- (2- (aminomethyl ) phenyl ) -IH- pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1']- biphen-4-yl) ) carboxyamide •TFA
1- [2- ( ( [ (t-Butoxycarbonyl) amino]methyl) phenyl) -5- (3-fluoro-2 ' - methylsulfonyl- [1, 1 ' ] -biphen-4-yl) ) aminocarbonyl] -3- (trifluoromethyl)pyrazole: Oxalyl chloride (320 μl, 3.7 mmol) and DMF (4 drops) were added to 1- (2- ( [ (t-butoxy carbonyl) amino]methyl)phenyl) -3- (trifluoromethyl) -lH-pyrazol- l-yl-5-carboxylic acid (Example 31 Part A, 940 mg, 2.4 mmol) in CH2CI2 (35 mL) and the resulting solution was stirred for 55 min at room temperature . The solvents were evaporated and the resulting compound was placed briefly under high vacuum before redissolving in CH2CI2 (20 mL) . 4-Amino-3-fluoro-2 ' - methylsulfonyl- [1,1" ] -biphenyl (750 mg, 2.8 mmol) in CH2C1 (15 mL) , and 4-dimethylaminopyridine (447 mg, 3.7 mmol) were added, and the resulting solution was stirred for 20 h at room temperature . The reaction was concentrated and chromatographed on silica gel (30-40% EtOAc/hexanes ) to yield impure product (802 mg) , which was purified on reverse phase prep. HPLC (10-70% MeCN/H2O/0.5% TFA) to yield clean product (645 mg, 42%) .
3-Trifluoromethyl-1- (2- (aminomethyl)phenyl) -lH-pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1'] -biphen-4-yl) ) carboxyamide trifluoroacetic acid salt: TFA (2 mL) was added to l-[2- ( ( [ (t-butoxycarbonyl) amino]methyl)phenyl) -5- (3-fluoro-2 ' - methylsulfonyl- [1,1'] -biphen-4-yl) ) aminocarbonyl] -3- (trifluoromethyl)pyrazole (132 mg, 0.21 mmol) in CH2CI2 (2 mL) and stirred at room temperature for 5 h. The reaction was evaporated and purified by reverse phase prep. HPLC (10-70% MeCN/H2O/0.5% TFA) to yield the desired product (80 mg, 59%). ^ NMR (DMSO) δ 10.65, (s, IH) , 8.16 (bs, 3H) , 8.05 (d, IH, J = 6.6), 7.79 (s, IH) , 7.73 (td, IH, J = 6.2, J" = 1.5), 7.67
(dd, IH, J = 7.7, J' = 1.5), 7.54 (m, 5H) , 7.35 (m, 2H) , 7.19 (d, IH, J = 8.0), 3.78 (bd, 2H, J = 5.5), 2.88 (s, 3H) . 19F NMR (DMSO) δ -61.26, -74.11, -122.19. HRMS calc. C25H21N4O3F4S : 533.1217; found, 533.1258.
Example 35 3-Trif luoromethyl-1- (2- (N- (glycyl) aminomethyl ) phenyl ) - lH-pyrazole-5- (N- (3-f luoro-2 * -methylsulfonyl- [1, 1 • ] - biphen-4 -yl) ) carboxyamide* FA
The title compound was prepared from l-[2- ( (aminomethyl) phenyl) -5- (3-f luoro-2 ' -methylsulfonyl- [1,1']- biphen-4-yl) ) aminocarbonyl ] -3- (trif luoromethyl) pyrazole trifluoroacetic acid salt (prepared in Example 34) and N-Boc glycine according to the procedure in Example 29; HRMS (M+H)+: 590.1495 m/z.
Example 36
3-Trif luoromethyl-1- (2- ( (N- (N- methylglycyl) aminomethyl ) phenyl ) -lH-pyrazole-5- (N- (3- f luoro-2 -methylsulfonyl- [1,1'] -biphen-4- yl) ) carboxyamide* TFA
The title compound was prepared from l-[2-
( (aminomethyl) phenyl) -5- (3-f luoro-2 ' -methylsulfonyl- [1,1']- biphen-4-yl) ) aminocarbonyl] -3- (trif luoromethyl) pyrazole trifluoroacetic acid salt (prepared in Example 34) and N-Boc- N-methyl glycine according to the procedure in Example 29; HRMS (M+H)+: 604.1655 m/z.
Example 37 3-Trif luoromethyl-1- (2-carboxamidophenyl) - IH-pyrazole - 5- (N- (3-f luoro-2 -methylsulfonyl- [1,1'] -biphen-4- yl ) ) carboxyamide
Methyl 2- [5- (2-furyl) -3- (trif luoromethyl) -lH-pyrazol-1- yl]benzoate: 2- [5- (2-furyl) -3- (trif luoromethyl) -lH-pyrazol-1- yl]benzoic acid (Example 31 Part A, 26.5 g, 82 mmol) was dissolved in SOCI2 (130 mL) and heated at reflux for 2.5 h. Excess SOCI2 was evaporated, and the residual acid chloride was placed under high vacuum. The acid chloride was cooled to 0°C, and dry MeOH (130 mL) was added. The resulting solution was allowed to warm slowly to room temperature, then stirred at room temperature for 22 h. The solvent was evaporated, and the crude product was chromatographed on silica gel (0-30% EtOAc/hexanes) to yield the desired product (22.6 g, 82%). !H NMR (CDC13) δ 8.10 (dd, IH, J = 7.3, J' = 1.9), 7.67 (m, 2H) ,
7.50 (dd, IH, J = 7.7, J' = 1.4), 7.37 (s, IH) , 6.92 (s, IH) , 6.29 (m, IH) , 5.77 (d, IH, J = 3.3), 3.62 (s, 3H) .
1- (2-Carbomethoxyphenyl) -3- (trifluoromethyl) -lH-pyrazol-1-yl] - 5-carboxylic acid: A 5% aq. solution of NaH P04 (320 mL) and water (200 mL) were added to methyl 2- [5- (2-furyl) -3- ( trifluoromethyl) -lH-pyrazol-1-yl] benzoate (23.7 g, 71 mmol) in t-BuOH (470 mL) . The reaction was immersed in a room temperature water bath, and solid KMnθ4 (55.8 g, 353 mmol) was added portionwise over 1 h. The reaction was heated at 70°C for 90 min, cooled, and filtered through celite. The celite was rinsed with acetone and EtOAc. The filtrate was concentrated to remove most of the organics, then extracted with EtOAc. The organic layer was extracted with sat. Na2Sθ3, dried over Na2S04, filtered, evaporated, and set aside. The aqueous layers were combined and neutralized to pH 6.5 with 2M HCI (100 mL) , and then extracted with EtOAc (3x) . The organic layers were combined, dried over Na2S04, filtered, and evaporated to yield clean product (14.8 g, 67%) . ^ NMR (CDCI3) δ 8.10 (dd, IH, J = 7.3, J' = 1-5), 7.64 (m, 2H) , 7.42
(dd, IH, J = 7.3, J' = 1.1), 7.31 (s, IH) , 3.69 (s, 3H) .
1- [2-Carbomethoxyphenyl-5- (3-fluoro-2 ' -methylsulfonyl- [1, 1 ' ] - biphen-4-yl) ) aminocarbonyl] -3- (trifluoromethyl)pyrazole: Oxalyl chloride (2.9 mL, 33 mmol) and DMF (10 drops) were added to 1- (2-carbomethoxyphenyl) -3- (trifluoromethyl) -1H- pyrazol-1-yl] -5-carboxylic acid (7.0 g, 22 mmol) in dry CH2CI2 (240 mL) , and the resulting solution was stirred at room temperature for 80 min. The solvents were evaporated, and the resulting compound was placed briefly under high vacuum before redissolving in CH2CI2 (240 mL) . 4-Amino-3-fluoro-2 ' - methylsulfonyl- [1, 1" ] -biphenyl hydrochloride (7.4 g, 25 mmol) and 4-dimethylaminopyridine (7.1 g, 58 mmol) were added, and the resulting solution was stirred at room temperature for 67 h. The reaction was extracted with IM HCI (2x) , then sat. NaHCθ3. The organic layer was dried over MgS04, filtered, and evaporated to yield crude product. The crude product was chromatographed on silica gel (30-50% EtOAc/hexanes) to yield the desired product (12.4 g, 99%). !H NMR (CDC13) δ 8.29 (t,
IH, J = 8.1), 8.21 (m, 2H) , 8.11 (dd, IH, J = 7.7, J' = 1.5), 7.62 (m, 5H) , 7.30 (m, 2H) , 7.14 (m, 2H) , 3.77 (s, 3H) , 2.69 (s, 3H) .
l-[2-Carboxyphenyl-5- (3-fluoro-2 ' -methylsulfonyl- [1, 1' ]- biphen-4-yl) ) aminocarbonyl] -3- (trifluoromethyl) pyrazole : IM LiOH (34 mL)was added to 1- [2-carbomethoxyphenyl-5- (3-fluoro- 2 ' -methylsulfonyl- [1,1'] -biphen-4-yl) ) aminocarbonyl] -3- (trifluoromethyl)pyrazole (12.0 g, 21 mmol) in THF (285 mL) and stirred at room temperature for 26 h. Additional IM LiOH (15 mL) was added, and the reaction continued stirring for 18 h. The resulting solution was heated at 35°C for 2.5 h, then at 50°C for 18 h. The reaction was cooled, concentrated, and partitioned between Et2θ and water. The organic layer was extracted again with water (2x) . A small amount of white solid was assumed to be product, and was added to the aqueous layer. The aqueous layers were combined, neutralized to pH 7 with 2M HCI (23 mL) , and extracted with EtOAc. Additional 2M HCI (2 mL) was added to the aqueous, which was extracted twice with EtOAc. The EtOAc layers were combined, dried over Na2S04, filtered, and evaporated to yield the desired product (10.3 g, 88%). XH NMR (CDCI3) δ 8.21 (m, 4H) , 7.75 (m, IH) , 7.60 (m,
4H) , 7.29 (m, 3H) , 7.13 (m, 2H) , 2.70 (s, 3H) .
3-Trifluoromethyl-1- (2-carboxamidophenyl) -lH-pyrazole-5- (N- (3- fluoro-2 ' -methylsulfonyl- [1,1'] -biphen-4-yl) ) carboxyamide: 1- [2-Carboxyphenyl-5- (3-fluoro-2 ' -methylsulfonyl- [1,1'] -biphen- 4-yl) ) aminocarbonyl] -3- (trifluoromethyl)pyrazole (3.0 g, 5.5 mmol) was dissolved in SOCI2 (10 mL) and heated at reflux for 2 h. Excess SOCI2 was evaporated, and the residual acid chloride was placed under high vacuum. The acid chloride was dissolved in dry CH2CI2 and cooled to 0°C, and cone. aq. NH3 (2.0 mL) was added over 20 min. The resulting mixture was stirred at room temperature for 18 h. The reaction was diluted with CH2CI2 and extracted with water. The aqueous layer was extracted with CHCI3, MeOH/CH2Cl2, and CH2C12. All of the organics were combined and extracted with sat. NaHC03 (2x) , IM HCI, and sat. NaCI. The organic layer was dried over MgS04, filtered, evaporated, and chromatographed on silica gel (30- 75% EtOAc/hexanes) to yield the desired product (794 mg, 27%) . l-H NMR (CDCI3, 400 MHz) δ 9.53 (bs, IH) , 8.25 (t, IH, J = 8.3) ,
8.20 (dd, IH, J = 7.8, J' = 1.2), 7.75 (m, IH) , 7.60 (m, 4H) , 7.45 (m, IH) , 7.29 (dd, IH, J = 7.6, J' = 1.2), 7.20 (dd, IH, J = 11.2, J' = 1.9), 7.12 (m, 2H) , 6.13 (bs, IH) , 5.68 (bs, IH) , 2.67 (s, 3H) .
Example 38 3-Trifluoromethyl-1- (2-cyanophenyl ) -lH-pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1, 1 ] -biphen-4- yl) ) carboxyamide
1- [2-Cyanophenyl-5- (3-fluoro-2 ' -methylsulfonyl- [1,1'] -biphen- 4-yl) ) aminocarbonyl] -3- (trifluoromethyl) pyrazole: l-[2- Carboxamidophenyl-5- (3-fluoro-2 ' -methylsulfonyl- [1,1' ] -biphen- 4-yl) ) aminocarbonyl] -3- (trifluoromethyl) pyrazole (Example 36, 715 mg, 1.3 mmol) and triethylamine (360 μL, 2.6 mmol) were combined in dry CH2CI2 (10 mL) and cooled to 0°C. Trichloroacetyl chloride (160 μl, 1.4 mmol) was added over 5 min.. The resulting solution was stirred at 0°C for 30 min, then at room temperature for 2 h. Additional triethylamine (200μL, 1.4 mmol) was added, and the reaction continued stirring at room temperature for 68 h. Additional trichloroacetyl chloride (20 μL, 0.2 mmol) was added. After stirring 2 h, the reaction was quenched with water. The organic layer was removed and extracted with IM HCI and sat.
NaHCθ3. A small amount of sat . NaCI was added to break up the emulsion. The organic layer was dried over Na2S04, filtered, evaporated, and chromatographed on silica gel (20-75% EtOAc/hexanes) to yield the desired product (114 mg, 17%) . IH NMR (CDC13) δ 8.25 (m, 2H) , 8.09 (bs, IH) , 7.82 (m, 2H) , 7.65
(m, 4H) , 7.35 (m, 2H) , 7.20 ( , 2H) , 2.72 (s, 3H) .
Example 39
1- (2 ' -Aminomethylphenyl) -5- [ [ (2 -methylsulfonyl) -3- fluoro- [1,1'] -biphen-4-yl] aminocarbonyl] -tetrazole TFA salt
Ethyl 1- (2-cyanophenyl) -5-tetrazole carboxylate: To a solution of anthranilonitrile (10.00 g) and EtβN (13.21 mL) in CH2CI2 (250 mL) was added ethyloxalyl chloride (9.92 mL) in a dropwise fashion over 30 minutes. The reaction was stirred at RT under N2 for 3 h. The reaction mixture was filtered. The filtrate was washed with water (2 x 150 mL) and brine (1 x 150 mL) , filtered through phase separatory paper and evaporated. The residue was dissolved in 60 mL of CH2CI2 and 300 mL of hexane was added. The solution was allowed to stand at RT for the weekend. The precipitate was filtered, rinsed with hexane, and dried under vacuum to give 17.74 g of l-(2- cyanophenyl ) -oxoacetic acid ethyl ester.
A solution of triphenylphosphine (16.83 g) in CCI4 (100 mL) was stirred at 0° C for 30 minutes. 1- (2-Cyanophenyl) - oxoacetic acid ethyl ester (7.00 g) in CCI4 (100 mL) was added and the reaction was stirred at reflux under N2 for 16 h. The reaction was cooled to RT and the precipitate filtered off. The filtrate was evaporated and dissolved in CH3CN (300 mL) . Sodium azide (2.29 g) was added and the reaction stirred at RT under N2 for 16 h. The solvent was evaporated and the residue taken up in EtOAc (100 mL) . The organic solution was washed with water (2 x 100 mL) and brine (1 x 100 mL) , dried over MgS04, and evaporated. The crude material was purified by silica gel chromatography eluting with CH2CI2 to give 3.80 g of the title compound; LRMS (ES+) M+ : 244 m/z
1- (2 ' -Aminomethylphenyl) -5- [ [ (2 ' -methylsulfonyl) -3-fluoro-
[1, 1 '] -biphen-4-yl] aminocarbonyl] -tetrazole: To a solution of [ (2 ' -methylaminosulfonyl) -3-fluoro- [1,1'] -biphen-4-yl] amine (0.32 g) in anhydrous CH2CI2 (10 mL) was added trimethylaluminum (2.12 mL, 2M in heptane) . The reaction was stirred at RT under N2 for 30 minutes. A solution of ethyl 1- (2-cyanophenyl) -5-tetrazole carboxylate (0.28 g) in anhydrous CH2CI2 (10 mL) was added and the reaction was stirred at RT under N2 for 64 h. The reaction was quenched with 5 drops of IN HCI and diluted with CH2CI2 (30 mL) . The organic solution was washed with water (2 x 25 mL) and brine (1 x 25 mL) , filtered through phase separatory paper, and evaporated. The crude material was purified by silica gel chromatography eluting with 10% EtOH/CH2Cl to give 0.35 g of l-(2'- cyanophenyl) -5- [ [ (2 ' -methylsulfonyl) -3-fluoro- [1,1'] -biphen-4- yl] aminocarbonyl] -tetrazole; LMRS (ES") M" : 461 m/z.
Cobalt chloride (0.098 g ) was added to 1- (2 ' -cyanophenyl) -5- [ [ (2 '-methylsulfonyl) -3-fluoro- [1,1' ] -biphen-4- yl] aminocarbonyl] -tetrazole (0.35 g) and sodium borohydride (0.072 g) in DMF (5 mL) . The reaction was stirred at room temperature for 16 h. The resulting mixture was stirred at room temperature for 16 h. 6M HCI (5 mL) was added over 5 min. The quenched reaction was stirred at room temperature for 3.5 h, diluted with EtOAc and water. The resulting emulsion was filtered through celite, and the organic layer was washed with IN HCI, dried over Na2Sθ4, filtered, and evaporated to yield crude product (100 mg) . The aqueous layers were combined and neutralized (pH 7) with saturate NaHC03, extracted with EtOAc. The organic layers were combined, dried over a2Sθ4, filtered, and evaporated to yield a second batch of crude product. The two batches of crude product were combined and purified by reverse phase HPLC (10- 90% MeCN/H2O/0.5% TFA) to yield 102 mg of the title compound as its TFA salt. LMRS (ES+) M+ : 467 m/z.
Example 40
1- (2 -Aminomethylphenyl) -5- [ (2 ' -aminosulfonyl- [1,1']- biphen-4-yl) aminocarbonyl] -tetrazole*TFA The title compound was prepared in an analogous fashion as its
TFA salt. LRMS (ES+) M+ : 468 m/z.
Example 41 1- [2- (Aminomethyl) phenyl] -3 -thiomethoxy- 5- [ (2-fluoro) -
(2 ' -methylsulfonyl- [1, 1 ] -biphen-4- yl) aminocarbonyl] pyrazole *TFA
Methyl 3- (thiomethoxy)pyrazole-5-carboxylate : A mixture of methyl 4, 4-bis (thiomethoxy) -2-oxo-3-butenoate (9.9 g, 48 mmol) and hydrazine monohydrate (2.6 mL, 53 mmol) in 200 mL of glacial acetic acid was stirred at 100 °C for 18 h. The reaction was cooled and concentrated. The residue was taken up in ethyl acetate, washed with sat'd aq NaHC03 and brine, dried (MgS04) and concentrated. The solid residue was recrystallized from hexanes/ethyl acetate to afford 6.0 g (73%) of the title compound. XH NMR (CDC13) δ 11.0 (broad s, IH) , 6.74 (s, IH) , 3.88 (s, 3H) , 2.48 (s, 3H) .
Methyl 1- [2-formylphenyl] -3- (thiomethoxy) pyrazole-5- carboxylate: To a solution of methyl 3- (thiomethoxy) pyrazole- 5-carboxylate (0.87 g, 5.05 mmol) in 20 mL of 1,4-dioxane was added 2-formylphenyl boronic acid (1.13 g, 7.58 mmol), pyridine (0.82 mL, 10.1 mmol), crushed 4 A molecular sieves and cupric acetate (1.38 g, 7.58 mmol) . The flask was equipped with a drying tube and the mixture was allowed to stir at ambient temperature under an air atmosphere for 18 h. The mixture was filtered through a pad of Celite and concentrated. The residue was purified by flash chromatography to afford 0.22 g (16%) of the title compound. XH NMR (CDC13) δ 9.66 (s, IH) , 8.02 (dd, IH) , 7.69 (td, IH) , 7.63 (t, IH), 7.42 (d, IH) , 6.96 (s, IH) , 3.75 (s, 3H) , 2.55 (s, 3H) .
l-[ (2- (Hydroxymethyl) phenyl] -3-thiomethoxy-5- [ (2-fluoro) - (2 ' - methylsulfonyl- [1, 1 ' ] -biphen-4-yl) aminocarbonyl] pyrazole: To a solution of methyl 1- [2-formylphenyl] -3- (thiomethoxy) pyrazole-5-carboxylate (0.48 g, 1.74 mmol) in 15 mL of methanol at 0°C was added sodium borohydride (33 mg, 0.87 mmol) . The cooling bath was removed and the reaction was stirred for 10 min and then quenched by dilution with water. The reaction mixture was extracted with ethyl acetate and the organics were washed with brine, dried (MgSθ4) and concentrated to afford 0.41 g (85%) of about a 2:1 mixture of a hydroxy ester and a seven-membered ring lactone. This mixture was used without purification. To a solution of (2- fluoro-2 ' -methylsulfonyl- [1,1'] -biphen-4-yl) amine hydrochloride (0.89 g, 2.94 mmol) in methylene chloride was added trimethylaluminum (2.95 mL of a 2.0 M solution in hexanes, 5.89 mmol) dropwise. This solution was stirred until gas evolution ceased (15-20 min) and then there was added the hydroxy ester/lactone mixture from above (0.41 g, 1.47 mmol) in methylene chloride. The resulting solution was allowed to stir at reflux for 4 h and then it was cooled and quenched by dropwise addition of sat'd aq ammonium chloride. The mixture was diluted with ethyl acetate, the layers were separated, the organic layer was washed with water and brine, dried (MgSθ4) and concentrated. The solid residue was purified by flash chromatography (elution with 1:1 hexanes/ethyl acetate) to afford 0.68 g (91%) of the title compound. LRMS (ES+) : 534.1 (M+Na)+.
l-[ (2- (Bromomethyl) phenyl] -3-thiomethoxy-5- [ (2-fluoro) - (2 '- methylsulfonyl- [1,1'] -biphen-4-yl) aminocarbonyl]pyrazole: To a solution of 1- [ (2- (hydroxymethyl)phenyl] -3-thiomethoxy-5- [ (2-fluoro) - (2 ' -methylsulfonyl- [1,1'] -biphen-4- yl) aminocarbonyl]pyrazole (0.68 g, 1.3 mmol) in 20 mL of methylene chloride was added carbon tetrabromide (1.06 g, 3.2 mmol) and triphenylphosphine (0.84 g, 3.2 mmol). The resulting solution was stirred at ambient temperature for 4 h. The reaction was diluted with ethyl acetate, washed with water and brine, dried (MgSθ4) and concentrated. The residue was purified by flash chromatography (elution with 3:1 hexanes/ethyl acetate) to afford 0.60 g (81%) of the title compound. l-[ (2- (Azidometnyl) phenyl] -3-thiomethoxy-5- [ (2-fluoro) - (2 '- methylsulfonyl- [1, 1 ' ] -biphen-4-yl) aminocarbonyl]pyrazole : To a solution of 1- [ (2- (bromomethyl)phenyl] -3-thiomethoxy-5- [ (2- fluoro) - (2 ' -methylsulfonyl- [1,1'] -biphen-4- yl) aminocarbonyl] pyrazole (0.42 g, O.73 mmol) in 5 mL of N,N- dimethylformamide was added sodium azide (0.38 g, 5.85 mmol) . This mixture was stirred at ambient temperature for 1 h and then was diluted with ethyl acetate. The organics were washed with water and brine, dried (MgS04) and concentrated to afford 0.38 g (97%) of the title compound which was used directly without purification. LRMS (ES+) : 559.1 (M+Na)+.
1- [2- (Aminomethyl)phenyl] -3-thiomethoxy-5- [ (2-fluoro) - (2 ' - methylsulfonyl- [1,1' ] -biphen-4-yl) aminocarbonyl]pyrazole, trifluoroacetic acid salt: To a solution of l-[(2-
(azidomethyl)phenyl] -3-thiomethoxy-5- [ (2-fluoro) - (2 ' - methylsulfonyl- [1, 1 ' ] -biphen-4-yl) aminocarbonyl]pyrazole (0.38 g, 0.71 mmol) in 10 mL of methanol was added tin (II) chloride (0.80 g, 4.24 mmol). The reaction mixture was stirred at reflux for 1 h and then was cooled to room temperature and diluted with ethyl acetate. The organics were washed with 5% aq sodium hydroxide and brine, dried (MgS04) and concentrated. The residue was purified by preparative HPLC (C18 reverse phase column, elution with a H2O/CH3CN gradient with 0.5% TFA) and lyophilized to afford 230 mg (52%) of the title compound as a white powder. LRMS (ES+) : 511.1 (M+H)+.
Example 42 1- [2- (aminomethyl) henyl] -3-methysulfonyl-5- [ (2- fluoro) - (2 • -methylsulfonyl- [1,1'] -biphen-4- y1 ) aminocarbonyl] pyrazole•TFA
1- [ (2- (Bromomethyl) phenyl] -3-methylsulfonyl-5- [ (2-fluoro) - (2 ' - methylsulfonyl- [1,1' ] -biphen-4-yl) aminocarbonyl] pyrazole : To a solution of 1- [ (2- (bromomethyl)phenyl] -3-thiomethoxy-5- [ (2- fluoro) - (2 ' -methylsulfonyl- [1,1'] -biphen-4- yl) aminocarbonyl]pyrazole (85 mg, 0.15 mmol) in 10 mL of methylene chloride was added m-chloroperoxybenzoic acid (130 mg of 57-86% pure material, -0.5 mmol) . The resulting solution was stirred at ambient temperature for 3 h. The reaction was diluted with ethyl acetate, washed with sat'd aq NaHCθ3 and brine, dried (MgS04) and concentrated to afford 80 mg (88%) of the title compound which was sufficiently pure to be used without purification.
1- [ (2- (Azidomethyl) phenyl] -3-methylsulfonyl-5- [ (2-fluoro) - (2 ' - methylsulfonyl- [1, 1 ' ] -biphen-4-yl) aminocarbonyl] pyrazole: To a solution of 1- [ (2- (bromomethyl)phenyl] -3-methylsulfonyl-5- [ (2-fluoro) - (2 ' -methylsulfonyl- [1, 1 ' ] -biphen-4- yl) aminocarbonyl] pyrazole (55 mg, 0.09 mmol) in 1 mL of dimethylsulfoxide was added sodium azide (30 mg, 0.45 mmol). This mixture was stirred at ambient temperature for 1 h and then was diluted with ethyl acetate. The organics were washed with water and brine, dried (MgS04) and concentrated to afford 50 mg (97%) of the title compound which was used directly without purification. LRMS (ES+) : 591.1 (M+Na)+.
1- [2- (Aminomethyl)phenyl] -3-methylsulfonyl-5- [ (2-fluoro) - (2 '- methylsulfonyl- [1,1'] -biphen-4-yl) aminocarbonyl] pyrazole, trifluoroacetic acid salt: To a solution of l-[(2- (azidomethyl) phenyl] -3-methylsulfonyl-5- [ (2-fluoro) - (2 ' - methylsulfonyl- [1, 1 ' ] -biphen-4-yl) aminocarbonyl]pyrazole (90 mg, 0.16 mmol) in 4 mL of methanol was added tin (II) chloride (0.30 g, 1.6 mmol). The reaction mixture was stirred at reflux for 1 h and then was cooled to room temperature and diluted with ethyl acetate. The organics were washed with 5% aq sodium hydroxide and brine, dried (MgS04) and concentrated. The residue was purified by preparative HPLC (C18 reverse phase column, elution with a H2O/CH3CN gradient with 0.5% TFA) and lyophilized to afford 18 mg (17%) of the title compound as a white powder. LRMS (ES+) : 543.2 (M+H)+.
Example 43
1- [2- (aminomethyl) phenyl] -5- [ (2-fluoro) - (2 * - methylsulfonyl- [1,1'] -biphen-4- yl) aminocarbonyl] triazole*TFA 2-Azidobenzyl alcohol: To a solution of 2-aminobenzyl alcohol (12.0 g, 97.4 mmol) in 50 mL of trifluoroacetic acid at 0°C was added sodium nitrite (7.39 g, 107.2 mmol). This solution was stirred for 45 min and then there was added sodium azide (6.33 g, 97.4 mmol) dropwise as a solution in water. The resulting mixture was stirred at 0°C for 45 min and then was carefully quenched by slow addition of potassium carbonate. The reaction mixture was diluted with ethyl acetate, washed with brine, dried (MgSθ4) , filtered through a pad of silica gel and concentrated to afford 10.5 g (72%) of the title compound which was used without further purification. H NMR (CDC13) δ 7.33 (m, 2H) , 7.14 (m, 2H) , 4.59 (s, 2H) , 2.69 (broad s, IH) .
(2-Azidophenyl)methyl propiolate: To a solution of 2- azidobenzyl alcohol (15.66 g, 105.1 mmol) in 200 mL of methylene chloride was added propiolic acid (7.1 mL, 115.6 mmol), dicyclohexylcarbodiimide (20.0 g, 110.3 mmol) and 4- dimethylaminopyridine (1.93 g, 15.8 mmol). The resulting mixture was allowed to stir at ambient temperature for 18h. The mixture was filtered, concentrated and the residue was purified by flash chromatography (elution with 1:1 hexanes/ethyl acetate) to afford 10.7 g (51%) of the title compound. XH NMR (CDC13) δ 7.40 (m, 2H) , 7.17 (m, 2H) , 5.20 (s, 2H) , 2.92 (s, IH) .
Triazololactone: A solution of (2-azidophenyl)methyl propiolate (10.7 g, 53.2 mmol) in 100 mL of toluene was stirred at 100°C for 18 h. The reaction was cooled and concentrated and the residue was purified by flash chromatography (elution with 1:1 hexanes/ethyl acetate) to afford 1.4 g (13%) of the title compound. XH NMR (CDCI3) δ 8.38 (s, IH) , 8.04 (d, IH) , 7.63 (m, IH) , 7.54 (m, 2H) , 5.16 (s, 2H) .
1- [ (2- (Hydroxymethyl)phenyl] -5- [ (2-fluoro) - (2 ' -methylsulfonyl- [1, 1 '] -biphen-4-yl) aminocarbonyl] triazole: To a solution of (2-fluoro-2 -methylsulfonyl- [1, 1' ] -biphen-4-yl) amine hydrochloride (2.10 g, 6.96 mmol) in methylene chloride was added trimethylaluminum (20.8 mL of a 2.0 M solution in hexanes, 41.8 mmol) dropwise. This solution was stirred until gas evolution ceased (about 30 min) and then there was added the triazololactone from above (1.4 g, 6.96 mmol) as a solution in methylene chloride. The resulting solution was allowed to stir at reflux for 18 h and then it was cooled and quenched by dropwise addition of sat'd aq ammonium chloride. The mixture was diluted with ethyl acetate, the layers were separated, the organic layer was washed with water and brine, dried (MgS04) and concentrated. The solid residue was purified by flash chromatography (elution with 3:1 ethyl acetate/hexanes) to afford 1.0 g (31%) of the title compound. LRMS (ES+) : 467.2 (M+H)+.
1- [ (2- (Bromomethyl) phenyl] -5- [ (2-fluoro) - (2 ' -methylsulfonyl- [1, 1 '] -biphen-4-yl) aminocarbonyl] triazole: To a solution of 1- [ (2- (hydroxymethyl) phenyl] -5- [ (2-fluoro) - (2 ' -methylsulfonyl- [1, 1 '] -biphen-4-yl) aminocarbonyl] triazole (0.80 g, 1.71 mmol) in 20 mL of methylene chloride was added carbon tetrabromide (2.83 g, 8.55 mmol) and triphenylphosphine (2.24 g, 8.55 mmol) . The resulting solution was stirred at ambient temperature for 18 h. The reaction was diluted with ethyl acetate, washed with water and brine, dried (MgS04) and concentrated. The residue was purified by flash chromatography (elution with 1:1 hexanes/ethyl acetate) to afford 0.80 g (89%) of the title compound. LRMS (ES+) : 529.1/531.1 (M+H)+.
1- [ (2- (Azidomethyl) phenyl] -5- [ (2-fluoro) - (2 ' -methylsulfonyl- [1,1'] -biphen-4-yl) aminocarbonyl] triazole : To a solution of 1- [ (2- (bromomethyl) phenyl] -5- [ (2-fluoroJ - (2 ' -methylsulfonyl- [1, 1 '] -biphen-4-yl) aminocarbonyl] triazole (0.25 g, 0.47 mmol) in 10 mL of N,N-dimethylformamide was added sodium azide (0.37 g, 5.6 mmol) . This mixture was stirred at 65°C for 18 h and then was cooled and diluted with ethyl acetate. The organics were washed with water and brine, dried (MgS04) and concentrated to afford 0.22 g (96%) of the title compound which was used directly without purification. LRMS (ES+) : 514.2 (M+Na)+.
1- [2- (Aminomethyl)phenyl] -5- [ (2-fluoro) - (2 ' -methylsulfonyl- [1,1'] -biphen-4-yl) aminocarbonyl] triazole, trifluoroacetic acid salt: To a solution of 1- [ (2- (azidomethyl)phenyl] -5- [ (2- fluoro) - (2 ' -methylsulfonyl- [1,1'] -biphen-4- yl) aminocarbonyl] triazole (0.22 g, 0.45 mmol) in 10 mL of absolute ethanol was added 10% palladium on carbon catalyst (25 mg) and concentrated HCI (0.04 mL, 0.45 mmol). The reaction mixture was stirred at ambient temperature under 1 atm of hydrogen for 2 h and then was filtered through a pad of Celite and concentrated. The residue was purified by preparative HPLC (C18 reverse phase column, elution with a H20/CH3CN gradient with 0.5% TFA) and lyophilized to afford 26 mg (10%) of the title compound as a white powder. LRMS (ES+) : 466.2 (M+H)+.
Example 44 1- [2- (Aminomethyl) phenyl] -5- [ (2-fluoro) - (2 - methylsulfonyl) -[1,1'] -biphen-4- yl ) aminocarbonyl] pyrazole•TFA
Methyl 1- [2-methylphenyl]pyrazole-5-carboxylate: A neat mixture of methyl pyruvate (11.37 mL, 125.9 mmol) and dimethylformamide dimethylacetal (16.72 mL, 125.9 mmol) was stirred at 80°C for 24 h. The mixture was cooled and concentrated. A portion of the residue (4.00 g, 25.45 mmol) was dissolved in 50 mL of glacial acetic acid and then there was added o-tolylhydrazine hydrochloride (4.44 g, 27.99 mmol). This mixture was stirred at 100°C for 18 h and then was cooled and concentrated. The residue was dissolved in ethyl acetate, washed with sat'd aq sodium carbonate and brine, dried (MgS04) and concentrated. The residue was purified by flash chromatography (elution with 2:1 hexanes/ethyl acetate) to afford 3.0 g (55%) of the title compound. XH NMR (CDC13) δ 7.70 (d, IH) , 7.4-7.2 (m, 4H) , 7.00 (d, IH) , 3.71 (s, 3H) , 2.00 (s, 3H) . Methyl 1- [2- (bromomethyl)phenyl]pyrazole-5-carboxylate : To a solution of methyl 1- [2-methylphenyl]pyrazole-5-carboxylate (1.00 g, 4.62 mmol) in 20 mL of carbon tetrachloride was added N-bromosuccinimide (0.823 g, 4.62 mmol) and AIBN (76 mg, 0.46 mmol) . This mixture was stirred at 80°C for 18 h. The volatiles were removed and the residue was taken up in ether, filtered through a pad of silica gel and concentrated to afford 1.3 g (95%) of the title compound which was used without further purification. LRMS (ES+) : 295.0/297.0 (M+H)+.
Methyl 1- [2- (azidomethyl)phenyl]pyrazole-5-carboxylate: To a solution of methyl 1- [2- (bromomethyl)phenyl]pyrazole-5- carboxylate (1.30 g, 4.40 mmol) in 10 mL of N,N- dimethylformamide was added sodium azide (2.86 g, 44.0 mmol) . This mixture was stirred at ambient temperature for 48 h and then was diluted with ethyl acetate. The organics were washed with water and brine, dried (MgS04) and concentrated to afford 0.80 g (71%) of the title compound which was used directly without purification. LRMS (ES+) : 280.1 (M+Na)+.
1- [ (2- (Azidomethyl)phenyl] -5- [ (2-fluoro) - (2 ' -methylsulfonyl- [1, 1 '] -biphen-4-yl) aminocarbonyl]pyrazole: To a solution of (2-fluoro-2 ' -methylsulfonyl- [1,1'] -biphen-4-yl) amine hydrochloride (0.94 g, 3.11 mmol) in 20 mL of methylene chloride was added trimethylaluminum (4.67 mL of a 2.0 M solution in hexanes, 9.33 mmol) dropwise. This solution was stirred until gas evolution ceased (about 30 min) and then there was methyl 1- [2- (azidomethyl) phenyl] pyrazole-5- carboxylate (0.80 g, 3.11 mmol) as a solution in methylene chloride. The resulting solution was allowed to stir at reflux for 18 h and then it was cooled and quenched by dropwise addition of sat'd aq ammonium chloride. The mixture was diluted with ethyl acetate, the layers were separated, the organic layer was washed with water and brine, dried (MgSθ4) , filtered through a pad of silica gel and concentrated to afford 1.0 g (67%) of the title compound. LRMS (ES+) : 513.0 (M+Na) + . 1- [2- (Aminomethyl) phenyl] -5- [ (2-fluoro) - (2 ' -methylsulfonyl- [1,1'] -biphen-4-yl) aminocarbonyl]pyrazole, trifluoroacetic acid salt: To a solution of 1- [ (2- (azidomethyl)phenyl] -5- [ (2- fluoro) - (2 ' -methylsulfonyl- [1,1'] -biphen-4- yl) aminocarbonyl] pyrazole (0.50 g, 1.0 mmol) in 20 mL of absolute ethanol was added 10% palladium on carbon catalyst (50 mg) and concentrated HCI (0.085 mL, 1.0 mmol). The reaction mixture was stirred at ambient temperature under 1 atm of hydrogen for 2 h and then was filtered through a pad of Celite and concentrated. The residue was purified by preparative HPLC (C18 reverse phase column, elution with a H2O/CH3CN gradient with 0.5% TFA) and lyophilized to afford 60 mg (10%) of the title compound as a white powder. LRMS (ES+) : 465.2 (M+H)+.
Example 45 1- [2- (Aminomethyl) phenyl] -3 -trifluoromethyl-5- [ ( (2- fluoro) - (2 ' -pyrrolidinomethyl) - [1, 1 ' ] -biphen-4- yl) aminocarbonyl] pyrazole*TFA
Part A: 2-Fluoro-4- ( (2 ' -tert- butyldimethylsilyloxymethyl)phenyl) aniline: A solution of 2- formylphenylboronic acid (5 g, 33.3 mmol) and 4-bromo-2- fluoroaniline (4.2 g, 22.2 mmol) in THF (80 mL) and aqueous Na2Cθ3 solution (2M, 80 mL) was bubbled with nitrogen for 10 minutes. After Pd(PPh3)4 (1.54 g, 1.33 mmol) was added, the resulting mixture was refluxed under nitrogen for 4 hours . The THF layer was separated and filtered through a pad of silica gel. The silica gel was washed with THF. To the combined filtrates containing 2-fluoro-4- (2 ' - formylphenyl) aniline (65 mL) was portion by portion added NaBH4 (2.2 g, 29.1 mmoL) . The resulting mixture was stirred at room temperature for 1 hour, quenched with IN HCI (10 mL) , and washed with IN HCI (100 mL x 3 ) . The combined HCI layers were neutralized with 50% NaOH to pH 12 and extracted with EtOAc (100 mL x 3) . The EtOAc layers were dried over Na2S04, concentrated, and purified by column chromatography with a graduate solvent (hexane to EtOAc) to give 2-fluoro-4- (2 ' - hydroxymethylphenyl) aniline (3.83 g, 97.6%). XH NMR (CDCI3) δ
7.53 (dd, J = 6.6 Hz, J = 2.2 Hz, IH) , 7.36-7.33 (m, 2H) , 7.25 (dd, J = 6.6 Hz, J = 2.2 Hz, IH) , 7.06 (dd, J = 12.1 Hz , J = 1.8 Hz, IH) , 6.97 (dd, J = 8.0 Hz, J = 1.8 Hz, IH) , 6.82 (t, J = 8.8 Hz, IH) , 4.63 (s, 2H) , 3.79 (bs, 2H) ; 19F NMR (CDCI3): δ -135.66 (dd, J= 12.21 Hz, J = 9.2 Hz); CIMS(CI) m/z 218
(M+H, 100%) .
To a solution of 2-fluoro-4- (2 ' -hydroxymethy1- phenyl) aniline (5 g, 23 mmol) in THF (150 mL) was added imidazole (2.35 g, 34.5 mmol) and 2'-tert- butyldimethylsilylchloride (5.18 g, 34.5 mmol), and the resulting mixture was stirred at room temperature for 24 hours. The mixture was diluted with hexane (150 mL) and washed with water (150 mL) . The organic layer was washed with brine, dried over MgSθ4, purified by column chromatography with hexane and methylenechloride (1 to 1) to give 2-fluoro-4- ( (2 ' -tert-butyldimethylsilyloxymethyl) phenyl) aniline (7.1 g, 92.8%) as a colorless oil. NMR (CDCI3) δ 7.55 (dd, J = 7.7 Hz, J = 1.1 Hz, IH) , 7.35 (dd, J = 7.4 Hz, J = 1.9 Hz, IH) ,
7.30 (dd, J = 9.1 Hz, J = 1.4 Hz, IH) , 7.20 (dd, J = 7.3 Hz, J = 1.5 Hz, IH) , 7.05 (dd, J = 12.1 Hz, J = 1.8 Hz , IH) , 6.93 (dd, J = 8.0 Hz, J = 1.4 Hz, IH) , 6.80 (dd, J = 9.1 Hz, J = 8.0 Hz, IH) , 4.60 (s 2H) , 3.77 (bs, 2H) , 0.91 (s, 9H) , 0.04 (s, 6H) ; 19F NMR (CDCI3): δ -136.04; CIMS : 332 (M+H, 100).
Part B: 1- (2-cyanophenyl) -5-furyl-3-trifluoromethylpyrazole: To a solution of 4, 4, 4-trifluoro-1- (2-furyl) -1, 3 -butanedione (2.06 g, 10 mmol) in ethanol (mL) was added hydrazine monohydrate (0.46 g, 10 mmol) . The resulting mixture was refluxed for 16 hours and dried under vacuum to give 5-furyl- 3-trifluoromethyl-3-hydroxypyrazoline in almost quantitative yield. !H NMR (CDCI3) δ 7.48 (d, J = 1.9 Hz, IH) , 6.63 (d, J =
3.7 Hz, IH) , 6.47 (dd, J = 3.7 Hz, J = 1.9 Hz, IH) , 6.16 (s, IH) , 3.48 (d, J = 17.9 Hz, IH) , 3.18 (d, J = 17.9 Hz, IH) ; 19F NMR (CDCI3) : δ-81.47; ESMS(+): 221 (M+H, 100).
To a solution of 2-fluorobenzonitrile (0.605 g, 5 mmol) and 5-furyl-3-trifluoromethyl-3-hydroxypyrazoline (1.1 g, 5 mmol) in DMF (10 mL) was added CS2CO3 (1.63 g, 5 mmol), and the resulting mixture was stirred at 110 *C for 16 hours. The mixture was diluted with EtOAc, washed with brine (x 5) , dried over MgSθ4, and purified by column chromatography with a gradient solvent (hexane to ethyl acetate) to give l-(2- cyanophenyl) -5-furyl-3-trifluoromethylpyrazole and l-(2- cyanophenyl) -3-furyl-5-trifluoromethylpyrazole (1.27 g, 83.8 %) in a ratio of 95 to 5. 1H NMR (CDCI3) δ 7.82 (dd, J = 7.7
Hz, J = 1.5 Hz, IH) , 7.77 (dd, J = 7.7 Hz, J = 1.5 Hz, IH) , 7.66 (td, J = 7.7 Hz, J = 1.1 Hz, IH) , 7.61 (d, J = 7.7 Hz,
IH) , 7.39 (d, J = 1.4 Hz, IH) , 6.96 (s, IH) , 6.37 (dd, J = 3.3 Hz, J = 1.4 Hz, IH) , 6.04 (d, J = 3.3 Hz, IH) ; 19F NMR (CDCI3): δ- 62.98; ESMS(+): 304 (M+H, 100).
Part C: 1- (2- (N-Boc-aminomethyl ) phenyl) -3- trifluoromethylpyrazol-5-yl-carboxylic acid: To a solution of 1- (2-cyanophenyl) -5-furyl-3-trifluoromethylpyrazole (1.5 g, 4.67 mmol) in DMF (20 mL) was portion by portion added ΝaBH4 (0.71 g, 18.7 mmol) and then C0CI2 (0.61 g, 4,67 mmol) at O'C. After the resulting mixture was stirred at room temperature for 18 hours, a black suspension was cooled to 0 "C and carefully acidified with 6N HCI (20 mL) . The resulting mixture was stirred at room temperature for 3 hours, and neutralized with IN NaOH to pH 14. The mixture was diluted with EtOAc (100 mL) , and filtered through a pad of sand (top layer) and Celite (bottom layer) . The filtrate was separated and the organic layer was washed with brine (5 x 10 mL) , dried over Na2S04, and concentrated to give l-(2- (aminomethyl)phenyl) -5-furyl-3-trifluoromethylpyrazole (1.4 g, 91.5%). !H NMR (CD3OD) δ 7.69-7.61 (m, 2H) , 7.52 (d, J = 1.5
Hz, IH) , 7 47 (td, J = 7.7 Hz, J = 1.1 Hz, IH) , 7.34 (d, J = 8.0 Hz, IH) , 7.07 (s, IH) , 6.34 (dd, J _= 1.8 Hz, J = 3.6 Hz, IH) , 5.75 (d, J = 3.3 Hz, IH) , 3.40 (s, 2H) ; ESMS(+): 308 (M+H, 100); To a solution of 1- (2- (aminomethyl) phenyl) -5-furyl-3- trifluoromethylpyrazole (1.4 g, 4.27 mmol) in THF (10 mL) was added a solution of (Boc)2θ (1.4 g, 6.4 mmol) in THF (10 mL) , and the resulting mixture was stirred at room temperature for 1 hour. The mixture was diluted with EtOAc (100 mL) , washed with water and brine, dried over Na2S04, and concentrated to provide crude 1- (2- (N-Boc-aminomethyl )phenyl) -5-furyl-3- trifluoromethylpyrazole. 3-H ΝMR (CDCI3) δ 7.60-7.55 (m, 2H) , 7.42 (d, J = 6.2 Hz, IH) , 7 40 (s, -IH) , 7.32 (d, J = 7.7 Hz, IH) , 6.95 (s, IH) , 6.28 (dd, J = 1.8 Hz, J = 3.3 Hz, IH) , 5.65 (d, J = 3.3 Hz, IH) , 4.01 (d, J = 6.8 Hz, 2H) , 3.40 (s, 2H) , 1.41 (s, 9H) ; 19F ΝMR (CDCI3): δ -62.76.
To a solution of crude product in acetone (20 mL) and water (20 mL) was portion by portion added KMnθ4 (3.95 g, 25 mmol) , and the resulting mixture was stirred at 60 'C for 20 minutes and then filtered through Celite. The filtrate was concentrated, acidified with IN HCI to pH 4, and extracted with EtOAc (3 x 50 mL) . The organic layer was washed with brine, dried over Νa2Sθ4, concentrated, and purified by column chromatography with 20% MeOH in dichloromethane to provide 1- (2- (N-Boc-aminomethyl) phenyl) -3-trifluoromethylpyrazol-5-yl- carboxylic acid (1.05 g, 56% for the two steps). ESMS(-): 384.2 (M-H, 100) .
Part D: 1- (2- (N-Boc-aminomethyl )phenyl) -3-trifluoromethyl-5- [ ( (2-fluoro) - (2 ' -hydroxymethylsilyloxymethyl) -[1,1'] -biphen-4- yl) aminocarbonyl]pyrazole: To a solution of 1- (2- (N-Boc- aminomethyl)phenyl) -3-trifluoromethylpyrazol-5-yl-carboxylic acid (0.768 g, 2 mmol) in CH2CI2 (50 mL) was added DMF (1 drop) and oxalyl chloride (0.381 g, 3 mmol), and the resulting mixture was stirred at room temperature for 1.5 hours . The mixture was concentrated and the residue was dissolved in THF (10 mL) . To the solution was added a solution of 2-fluoro-4- (2' - ( tert-butyldimethylsilyloxymethyl)phenyl) aniline (0.6 g, 1.8 mmoL) in THF (10 mL) and Et3Ν (1.5 mL) , and the resulting mixture was stirred at room temperature for 24 hours. The mixture was diluted with EtOAc (100 mL) , washed with water and brine, dried over MgS04, and purified on thin layer chromatography with CH2Cl2/hexane (3:2) to give 1- (2- (N-Boc- aminomethyl)phenyl ) -3-trifluoromethyl-5- [ ( (2-fluoro) - (2 ' -tert- butyldimethylsilyloxymethyl) -[1,1'] -biphen-4- yl) aminocarbonyl]pyrazole (0.49 g, 80%). To a solution of 1- (2 ' -N-Boc-aminomethylphenyl) -3- trifluoromethyl-5-[ ( (2-fluoro) - (2 ' -tert- butyldimethylsilyloxy ethyl] -[1,1'] -biphen-4- yl) aminocarbonyl] pyrazole (0.57 g, 0.93 mmol) in THF (10 mL) was added BU4ΝF (IM in THF, 3 mL) , -and the resulting solution was stirred at room temperature for 2 hours. The mixture was diluted with EtOAc (150 mL) , washed with water (20 mL) , dried over Na2S04, and purified by column chromatography with a gradient solvent (hexane to EtOAc) to give l- ( 2- (N-Boc- aminomethyl) phenyl) -3-trifluoromethyl-5- [ ( (2-fluoro) - (2 ' - hydroxymethyl) -[1,1'] -biphen-4-yl) aminocarbonyl] pyrazole (484 mg, ~ 100%). ^ ΝMR (CD3OD) δ 7.69 (t, J = 8.0 Hz, IH) , 7.55-
7.27 (m, 9H) , 7.21 (dd, J = 7.4 Hz, J = 1.8 Hz, IH) , 7.13 (dd, J = 8.4 Hz, J = 1.1 Hz, IH) , 4.46 (s, 2H) , 4.05 (s, 2H) , 1.34 (s, 9H) ; 19F ΝMR (CD3OD) : δ -64.08, -125.53; ESMS(+): 606.3
(M+Νa, 100) .
Part E: 1- (2- (aminomethyl) phenyl) -3-trifluoromethyl-5- [ ( (2- fluoro) - (2 ' -pyrrolidinomethyl) -[1,1'] -biphen-4- yl) aminocarbonyl] pyrazole, TFA salt: To a solution of l-(2- (N-Boc-aminomethyl) phenyl) -3-trifluoromethyl-5- [ ( (2-fluoro) - (2 ' -hydroxymethyl) -[1,1'] -biphen-4-yl) aminocarbonyl] pyrazole (150 mg, 0.26 mmol) in THF (5 mL) was added CS2CO3 (167 mg, 0.51 mmol) and MsCl (4 mg, 0.39 mmol). After the resulting mixture was stirred at room temperature for 18 hours and concentrated, the residue was dissolved in THF (10 mL) and treated with pyrrolidine (0.5 mL) at room temperature 8 hours. ESMS(+): 638.4 (M+H, 100). The mixture was treated with TFA/CH2CI2 (1 to 1, 10 mL) at room temperature for 5 hours, and concentrated. The residue was purified on HPLC with a gradient solvent (H2O-CH3CΝ-O .05% TFA) on C18 give the title compound (50 mg, 36% for the two steps) !H NMR (CD3OD) δ 7.80
(T, J = 8.1 HZ, IH) , 7.71-7.30 (m. 9H) , 7.27 (dd, J = 11.3 Hz, J = 1.8 Hz, IH) , 7.15 (d, J = 8.4 Hz, IH) , 4.40 (s, 2H) , 3.99 (s, 2H) , 3.42-3.34 (m, 2H) , 2.93-2.87 (m, 2H) , 2.00-1.94 (m, 4H) ; 19F NMR (CD3OD) : δ -64.22, -77.57 (TFA), -123.82; HRMS:
538.2243 for C29H28O1F4 5. Example 46
1- [2- (Aminomethyl) phenyl] -3-trifluoromethyl-5- [ ( (2- fluoro) - (2 • -hydroxymethyl) - [1, 1 ' ] -biphen-4- yl ) aminocarbonyl] pyrazole•TFA
A solution of 1- (2- (N-Boc-aminomethyl ) phenyl) -3- trifluoromethyl-5- [ ( (2-fluoro) - (2 ' - hydroxymethylsilyloxymethyl) -[1,1'] -biphen-4- yl) aminocarbonyl]pyrazole (10 mg) was treated with TFA/CH2CI2 (1 to 1, 1 mL) at room temperature for 3 hours and concentrated. The residue was purified by HPLC with a gradient solvent (H2O-CH3CΝ-O .05% TFA) on C18 to give the title compound (2 mg) . ^ NMR (CD3OD) : δ7.66-7.45 ( , 6H) ,
7.38-7.21 (m, 4H) , 7.15 (d, J = 9.5 Hz, IH) , 7,10 (d, J = 6.6 Hz, IH) , 4.39 (s, 2H) , 3.91 (s, 2H) ; 19F NMR (CD3OD) : δ
-64.23, -77.38, -125.40; ESMS(-): 483.2 (M-H, 100).
Table 1
Figure imgf000128_0001
Pyrazole-c
Figure imgf000128_0002
Figure imgf000128_0003
Pyrazole-d Pyrazole-e Pyrazole-f
Figure imgf000128_0004
Triazole Tetrazole
Unless otherwise indicated, D is at the 2-position and is
Figure imgf000128_0005
Figure imgf000129_0001
Figure imgf000130_0003
The following tables contain representative examples of the present invention. Each entry in each table is intended to be paired with each formulae at the start of the table . For example, in Table 2, example 1 is intended to be paired with each of formulae a-bbbb and in Table 3 , example 1 is intended to be paired with each of formulae a-bbbb.
The following groups are intended for group A in the following tables .
- - "B -H*" ~Ϊ →*-Q→
2-pyridyl 3-pyridyl 2-pyrimidyl
Figure imgf000130_0001
5-pyrimidyl
2-CI-p βnyl 2-F-phenyl
Figure imgf000130_0002
2,6-diF-phenyl Table 2
Figure imgf000131_0001
Figure imgf000132_0001
hh
Figure imgf000133_0001
zz aaa bbb
Figure imgf000134_0001
rrr sss ttt
Figure imgf000135_0001
zzz aaaa bbbb
Rla A B
CH3 phenyl 2- (aminosulfonyl)phenyl
CH3 phenyl 2- (methylammosulfonyl)phenyl
CH3 phenyl 1-pyrrolidinocarbonyl
CH3 phenyl 2- (methylsulfonyl)phenyl
CH3 phenyl 4-morpholino
CH3 phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl
CH3 phenyl 4-morpholinocarbonyl
CH3 phenyl 2-methyl-l-imidazolyl
CH3 phenyl 5-methyl-1-imidazolyl
CH3 phenyl 2-methylsulfonyl-1-imidazolyl
CH3 2-pyridyl 2- (aminosulfonyl)phenyl
CH3 2-pyridyl 2- (methylammosulfonyl)phenyl
CH3 2-pyridyl 1-pyrrolidinocarbonyl
CH3 2-pyridyl 2- (methylsulfonyl)phenyl
CH3 2-pyridyl 4-morpholino
CH3 2-pyridyl 2- (1' -CF3-tetrazol-2-yl) phenyl
CH3 2-pyridyl 4-morpholinocarbonyl
CH3 2-pyridyl 2-methyl-l-imidazolyl
CH3 2-pyridyl 5-methyl-1-imidazolyl
CH3 2-pyridyl 2-methylsulfonyl-1-imidazolyl
CH3 3-pyridyl 2- (aminosulfonyl)phenyl
CH3 3-pyridyl 2- (methylaminosulfonyl) phenyl
CH3 3-pyridyl 1-pyrrolidinocarbonyl CH3 3-pyridyl 2- (methylsulfonyl) phenyl CH3 3 -pyridyl 4-morpholino CH3 3 -pyridyl 2- ( 1 ' -CF3 -tetrazol-2-yl) phenyl CH3 3-pyridyl 4-morpholinocarbonyl CH3 3-pyridyl 2-methyl-1-imidazolyl CH3 3-pyridyl 5-methyl-1-imidazolyl CH3 3-pyridyl 2-methylsulfonyl-1-imidazolyl CH3 2-pyrimidyl 2- (aminosu1fonyl) phenyl CH3 2-pyrimidyl 2- (methylaminosulfonyl) phenyl CH3 2-pyrimidyl 1-pyrrolidinocarbonyl CH3 2-pyrimidyl 2- (methylsulfonyl) phenyl CH3 2-pyrimidyl 4-morpholino CH3 2-pyrimidyl 2- (1' -CF3 -tetrazol-2-yl) phenyl CH3 2-pyrimidyl 4-morpholinocarbonyl CH3 2-pyrimidyl 2-methyl-1-imidazolyl CH3 2-pyrimidyl 5-methyl-1-imidazolyl CH3 2-pyrimidyl 2-methylsulfonyl-l-imidazolyl CH3 5-pyrimidyl 2- (aminosulfonyl) phenyl CH3 5-pyrimidyl 2- (methylaminosulfonyl) phenyl CH3 5-pyrimidyl 1-pyrrolidinocarbonyl CH3 5-pyrimidyl 2- (methylsulfonyl)phenyl CH3 5-pyrimidyl 4-morpholino CH3 5-pyrimidyl 2- (1' -CF3-tetrazol-2-yl) phenyl CH3 5-pyrimidyl 4-morpholinocarbonyl CH3 5-pyrimidyl 2-methyl-l-imidazolyl CH3 5-pyrimidyl 5-methyl-1-imidazolyl CH3 5-pyrimidyl 2-methylsulfonyl-l-imidazolyl CH3 2-Cl-phenyl 2- (aminosulfonyl) phenyl CH3 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl CH3 2-Cl-phenyl 1-pyrrolidinocarbonyl CH3 2-Cl-phenyl 2- (methylsulfonyl)phenyl CH3 2-Cl-phenyl 4-morpholino CH3 2-Cl-phenyl 2- (1' -CF3-tetrazol-2-yl) phenyl CH3 2-Cl-phenyl 4-morpho1inocarbony1 CH3 2-Cl-phenyl 2-methyl-l-imidazolyl CH3 2-Cl-phenyl 5-methyl-l-imidazolyl CH3 2-Cl-phenyl 2-methylsulfonyl-l-imidazolyl CH3 2-F-phenyl 2- (aminosulfonyl) phenyl CH3 2-F-phenyl 2- (methylaminosulfonyl) phenyl CH3 2-F-phenyl 1-pyrrolidinocarbonyl CH3 2-F-phenyl 2- (methylsulfonyl)phenyl CH3 2-F-phenyl 4-morpho1ino CH3 2-F-phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl CH3 2-F-phenyl 4-morpholinocarbonyl CH3 2-F-phenyl 2-methyl-l-imidazolyl CH3 2-F-phenyl 5-methyl-l-imidazolyl CH3 2-F-phenyl 2-methylsulfonyl-l-imidazolyl CH3 2 , 6-diF-phenyl 2- (aminosulfonyl) phenyl CH3 2 , 6-diF-phenyl 2- (methylaminosulfonyl) phenyl CH3 2 , 6-diF-phenyl 1-pyrrolidinocarbonyl CH3 2 , 6-diF-phenyl 2- (methylsulfonyl) phenyl CH3 2 , 6-diF-phenyl 4-morpholino 76 CH3 2, 6-diF-phenyl 2- ( 1 ' -CF3-tetrazol-2-yl ) phenyl
77 CH3 2 , 6-diF-phenyl 4-morpholinocarbonyl
78 CH3 2, 6-diF-phenyl 2-methyl-l-imidazolyl
79 CH3 2, 6-diF-phenyl 5-methyl-l-imidazolyl
80 CH3 2 , 6-diF-phenyl 2-methylsulfonyl-l-imidazolyl
81 CH2CH3 phenyl 2- (aminosulfonyl ) phenyl
82 CH2CH3 phenyl 2- (methylammosulfonyl) phenyl
83 CH2CH3 phenyl 1-pyrro1idinocarbony1
84 CH2CH3 phenyl 2- (methylsulfonyl) phenyl
85 CH2CH3 phenyl 4-morpholino
86 CH2CH3 phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl
87 CH2CH3 phenyl 4-morpholinocarbonyl
88 CH2CH3 phenyl 2-methyl-l-imidazolyl
89 CH2CH3 phenyl 5-methyl-l-imidazolyl
90 CH2CH3 phenyl 2-methylsulfonyl-l-imidazolyl
91 CH2CH3 2-pyridyl 2- (aminosulfonyl) phenyl
92 CH2CH3 2-pyridyl 2- (methylaminosulfonyl) phenyl
93 CH2CH3 2-pyridyl 1-pyrrolidinocarbonyl
94 CH2CH3 2-pyridyl 2- (methylsulfonyl) phenyl
95 CH2CH3 2-pyridyl 4-morpholino
96 CH2CH3 2-pyridyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl
97 CH2CH3 2-pyridyl 4-morpholinocarbonyl
98 CH2CH3 2-pyridyl 2-methyl-l-imidazolyl
99 CH2CH3 2-pyridyl 5-methyl-l-imidazolyl
100 CH2CH3 2-pyridyl 2-methylsulfonyl-l-imidazolyl
101 CH2CH3 3-pyridyl 2- (aminosulfonyl) phenyl
102 CH2CH3 3-pyridyl 2- (methylaminosulfonyl) phenyl
103 CH2CH3 3-pyridyl 1-pyrrolidinocarbonyl
104 CH2CH3 3-pyridyl 2- (methylsulfonyl) phenyl
105 CH2CH3 3-pyridyl 4-morpholino
106 CH2CH3 3-pyridyl 2- ( 1 ' -CF3-tetrazol-2-yl ) phenyl
107 CH2CH3 3-pyridyl 4-morpholinocarbonyl
108 CH2CH3 3-pyridyl 2-methyl-l-imidazolyl
109 CH2CH3 3-pyridyl 5-methyl-l-imidazolyl
110 CH2CH3 3-pyridyl 2-methylsulfonyl-l-imidazolyl
111 CH2CH3 2-pyrimidyl 2- (aminosulfonyl) phenyl
112 CH2CH3 2-pyrimidyl 2- (methylaminosulfonyl ) phenyl
113 CH2CH3 2-pyrimidyl 1-pyrrolidinocarbonyl
114 CH2CH3 2-pyrimidyl 2- (methylsulfonyl) phenyl
115 CH2CH3 2-pyrimidyl 4-morpholino
116 CH2CH3 2-pyrimidyl 2- ( 1 ' -CF3-tetrazol-2-yl) phenyl
117 CH2CH3 2-pyrimidyl 4-morpholinocarbonyl
118 CH2CH3 2-pyrimidyl 2-methyl-l-imidazolyl
119 CH2CH3 2-pyrimidyl 5-methyl-l-imidazolyl
120 CH2CH3 2-pyrimidyl 2-methylsulfonyl-l-imidazolyl
121 CH2CH 5-pyrimidyl 2- (aminosulfonyl) phenyl
122 CH2CH3 5-pyrimidyl 2- (methylaminosulfonyl) phenyl
123 CH2CH3 5-pyrimidyl 1-pyrrolidinocarbonyl
124 CH2CH3 5-pyrimidyl 2- (methylsulfonyl) phenyl
125 CH2CH3 5-pyrimidyl 4-morpholino
126 CH2CH3 5-pyrimidyl 2- (1' -CF3-tetrazol-2-yl) phenyl
127 CH2CH3 5-pyrimidyl 4-morpholinocarbonyl 128 CH2CH3 5-pyrimidyl 2 -methyl-1-imidazolyl
129 CH2CH3 5-pyrimidyl 5-methyl-l-imidazolyl
130 CH2CH3 5-pyrimidyl 2-methylsulfonyl-l-imidazolyl
131 CH2CH3 2-Cl-phenyl 2- (aminosulfonyl) phenyl
132 CH2CH3 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl
133 CH2CH3 2-Cl-phenyl 1-pyrro1idinocarbony1
134 CH2CH3 2-Cl-phenyl 2- (methylsulfonyl) phenyl
135 CH2CH3 2-Cl-phenyl 4-morpho1ino
136 CH2CH3 2-Cl-phenyl 2- (l'-CF3-tetrazol-2-yl) phenyl
137 CH2CH3 2-Cl-phenyl 4-morpholinocarbonyl
138 CH2CH3 2-Cl-phenyl 2-methyl-l-imidazolyl
139 CH2CH3 2-Cl-phenyl 5-methyl-l-imidazolyl
140 CH2CH3 2-Cl-phenyl 2-methylsulfonyl-l-imidazolyl
141 CH2CH3 2-F-phenyl 2- (aminosulfonyl) phenyl
142 CH2CH3 2-F-phenyl 2- (methylaminosulfonyl) phenyl
143 CH2CH3 2-F-phenyl 1-pyrrolidinocarbonyl
144 CH2CH3 2-F-phenyl 2- (methylsulfonyl) phenyl
145 CH2CH3 2-F-phenyl 4-morpholino
146 CH2CH3 2-F-phenyl 2 - ( 1 ' -CF3 -tetrazol-2-yl ) phenyl
147 CH2CH3 2-F-phenyl 4-morpholinocarbonyl
148 CH2CH3 2-F-phenyl 2-methyl-l-imidazolyl
149 CH2CH3 2-F-phenyl 5-methyl-l-imidazolyl
150 CH2CH3 2-F-phenyl 2-methylsulfonyl-l-imidazolyl
151 CH2CH3 2 , 6-diF-phenyl 2- (aminosulfonyl) phenyl
152 CH2CH3 2 , 6-diF-phenyl 2 - (methylaminosulfonyl ) phenyl
153 CH2CH3 2 , 6-diF-phenyl 1-pyrrolidinocarbonyl
154 CH2CH3 2 , 6-diF-phenyl 2- (methylsulfonyl) phenyl
155 CH2CH3 2 , 6-diF-phenyl 4-morpholino
156 CH2CH3 2 , 6-diF-phenyl 2- ( 1 ' -CF3 -tetrazol-2-yl ) phenyl
157 CH2CH3 2 , 6-diF-phenyl 4-morpholinocarbonyl
158 CH2CH3 2 , 6-diF-phenyl 2-methyl-1-imidazolyl
159 CH2CH3 2, 6-diF-phenyl 5-methyl-l-imidazolyl
160 CH2CH3 2 , 6-diF-phenyl 2-methylsulfonyl-l-imidazolyl
161 CF3 phenyl 2- (aminosulfonyl ) phenyl
162 CF3 phenyl 2- (methylaminosulfonyl) phenyl
163 CF3 phenyl 1-pyrrolidinocarbonyl
164 CF3 phenyl 2- (methylsulfonyl) phenyl
165 CF3 phenyl 4-morpholino
166 CF3 phenyl 2 - ( 1 ' -CF3 -tetrazol-2-yl ) phenyl
167 CF3 phenyl 4-morpholinocarbonyl
168 CF3 phenyl 2-methyl-1-imidazoly1
169 CF3 phenyl 5-methyl-l-imidazolyl
170 CF3 phenyl 2-methylsulfonyl-l-imidazolyl
171 CF3 2-pyridyl 2- (aminosulfonyl ) phenyl
172 CF3 2-pyridyl 2- (methylaminosulfonyl) phenyl
173 CF3 2-pyridyl 1-pyrrolidinocarbonyl
174 CF3 2-pyridyl 2- (methylsulfonyl) phenyl
175 CF3 2-pyridyl 4-morpholino
176 CF3 2-pyridyl 2- (l'-CF3-tetrazol-2-yl) phenyl
177 CF3 2-pyridyl 4-morpho1inocarbonyl
178 CF3 2-pyridyl 2-methyl-l-imidazolyl
179 CF3 2-pyridyl 5-methyl-l-imidazolyl 180 CF3 2-pyridyl 2-methylsulfonyl-l-imidazolyl
181 CF3 3-pyridyl 2- (aminosulfonyl) phenyl
182 CF3 3-pyridyl 2- (methylaminosulfonyl) phenyl
183 CF3 3 -pyridyl 1-pyrrolidinocarbonyl
184 CF3 3-pyridyl 2- (methylsulfonyl) phenyl
185 CF3 3-pyridyl 4-morpholino
186 CF3 3-pyridyl 2-(l'-CF3-tetrazol-2-yl)phenyl
187 CF3 3-pyridyl 4-morpholinocarbonyl
188 CF3 3-pyridyl 2-methyl-1-imidazolyl
189 CF3 3-pyridyl 5-methyl-l-imidazolyl
190 CF3 3-pyridyl 2-methylsulfonyl-l-imidazolyl
191 CF3 2-pyrimidyl 2- (aminosulfonyl) phenyl
192 CF3 2-pyrimidyl 2- (methylaminosulfonyl) phenyl
193 CF3 2-pyrimidyl 1-pyrrolidinocarbonyl
194 CF3 2-pyrimidyl 2- (methylsulfonyl) phenyl
195 CF3 2-pyrimidyl 4-morpholino
196 CF3 2-pyrimidyl 2- (l'-CF3-tetrazol-2-yl) phenyl
197 CF3 2-pyrimidyl 4-morpholinocarbonyl
198 CF3 2-pyrimidyl 2-methyl-l-imidazolyl
199 CF3 2-pyrimidyl 5-methyl-l-imidazolyl
200 CF3 2-pyrimidyl 2-methylsulfonyl-l-imidazolyl
201 CF3 5-pyrimidyl 2- (aminosulfonyl) phenyl
202 CF3 5-pyrimidyl 2- (methylaminosulfonyl)phenyl
203 CF3 5-pyrimidyl 1-pyrrolidinocarbonyl
204 CF3 5-pyrimidyl 2- (methylsulfonyl) phenyl
205 CF3 5-pyrimidyl 4-morpholino
206 CF3 5-pyrimidyl 2-(l'-CF3-tetrazol-2-yl)phenyl
207 CF3 5-pyrimidyl 4-morpholinocarbonyl
208 CF3 5-pyrimidyl 2-methyl-l-imidazolyl
209 CF3 5-pyrimidyl 5-methyl-l-imidazolyl
210 CF3 5-pyrimidyl 2-methylsulfonyl-l-imidazolyl
211 CF3 2-Cl-phenyl 2- (aminosulfonyl) phenyl
212 CF3 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl
213 CF3 2-Cl-phenyl 1-pyrro1idinocarbony1
214 CF3 2-Cl-phenyl 2- (methylsulfonyl) phenyl
215 CF3 2-Cl-phenyl 4-morpholino
216 CF3 2-Cl-phenyl 2- (1 ' -CF3 -tetrazol-2-yl) phenyl
217 CF 2-Cl-phenyl 4-morpholinocarbonyl
218 CF3 2-Cl-phenyl 2-methyl-l-imidazolyl
219 CF3 2-Cl-phenyl 5-methyl-l-imidazolyl
220 CF3 2-Cl-phenyl 2-methylsulfonyl-l-imidazolyl
221 CF3 2-F-phenyl 2- (aminosulfonyl) phenyl
222 CF3 2-F-phenyl 2- (methylaminosulfonyl) phenyl
223 CF3 2-F-phenyl 1-pyrrolidinocarbonyl
224 CF3 2-F-phenyl 2- (methylsulfonyl) phenyl
225 CF3 2-F-phenyl 4-morpho1ino
226 CF3 2-F-phenyl 2- (1' -CF3-tetrazol-2-yl) phenyl
227 CF3 2-F-phenyl 4-morpholinocarbonyl
228 CF3 2-F-phenyl 2-methyl-l-imidazolyl
229 CF3 2-F-phenyl 5-methyl-1-imidazolyl
230 CF3 2-F-phenyl 2-methylsulfonyl-l-imidazolyl
231 CF3 2, 6-diF-phe: 2- (aminosulfonyl) phenyl 232 CF3 2, 6-diF-phenyl 2- (methylammosulfonyl)phenyl
233 CF3 2 , 6-diF-phenyl 1-pyrrolidinocarbonyl
234 CF3 2 , 6-diF-phenyl 2- (methylsulfonyl) phenyl
235 CF3 2 , 6-diF-phenyl 4-morpho1ino
236 CF3 2 , 6-diF-phenyl 2- (1 ' -CF3-tetrazol-2-yl)phenyl
237 CF3 2 , 6-diF-phenyl 4-morpholinocarbonyl
238 CF3 2 , 6-diF-phenyl 2-methyl-l-imidazolyl
239 CF3 2 , 6-diF-phenyl 5-methyl-l-imidazolyl
240 CF3 2 , 6-diF-phenyl 2-methylsulfonyl-1-imidazolyl
241 SCH3 phenyl 2- (aminosulfonyl)phenyl
242 SCH3 phenyl 2- (methylaminosulfonyl) phenyl
243 SCH3 phenyl 1-pyrrolidinocarbonyl
244 SCH3 phenyl 2- (methylsulfonyl) phenyl
245 SCH3 phenyl 4-morpho1ino
246 SCH3 phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl
247 SCH3 phenyl 4-morpholinocarbonyl
248 SCH3 phenyl 2-methyl-l-imidazolyl
249 SCH3 phenyl 5-methyl-l-imidazolyl
250 SCH3 phenyl 2-methylsulfonyl-1-imidazolyl
251 SCH3 2-pyridyl 2- (aminosulfonyl) phenyl
252 SCH3 2-pyridyl 2- (methylaminosulfonyl) phenyl
253 SCH3 2-pyridyl 1-pyrrolidinocarbonyl
254 SCH3 2-pyridyl 2- (methylsulfonyl) phenyl
255 SCH3 2-pyridyl 4-morpholino
256 SCH3 2-pyridyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl
257 SCH3 2-pyridyl 4-morpholinocarbonyl
258 SCH3 2-pyridyl 2-methyl-l-imidazolyl
259 SCH3 2-pyridyl 5-methyl-l-imidazolyl
260 SCH3 2-pyridyl 2-methylsulfonyl-l-imidazolyl
261 SCH3 3-pyridyl 2- (aminosulfonyl) phenyl
262 SCH3 3-pyridyl 2- (methylaminosulfonyl)phenyl
263 SCH3 3-pyridyl 1-pyrrolidinocarbonyl
264 SCH3 3-pyridyl 2- (methylsulfonyl)phenyl
265 SCH3 3-pyridyl 4-morpholino
266 SCH3 3-pyridyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl
267 SCH3 3-pyridyl 4-morpholinocarbonyl
268 SCH3 3-pyridyl 2-methyl-l-imidazolyl
269 SCH3 3-pyridyl 5-methyl-l-imidazolyl
270 SCH3 3-pyridyl 2-methylsulfonyl-l-imidazolyl
271 SCH3 2-pyrimidyl 2- (aminosulfonyl)phenyl
272 SCH3 2-pyrimidyl 2- (methylaminosulfonyl)phenyl
273 SCH3 2-pyrimidyl 1-pyrrolidinocarbonyl
274 SCH3 2-pyrimidyl 2- (methylsulfonyl)phenyl
275 SCH3 2-pyrimidyl 4-morpholino
276 SCH3 2-pyrimidyl 2- (l'-CF3-tetrazol-2-yl)phenyl
277 SCH3 2-pyrimidyl 4-morpholinocarbonyl
278 SCH3 2-pyrimidyl 2-methyl-l-imidazolyl
279 SCH3 2-pyrimidyl 5-methyl-l-imidazolyl
280 SCH3 2-pyrimidyl 2-methylsulfonyl-l-imidazolyl
281 SCH3 5-pyrimidyl 2- (aminosulfonyl)phenyl
282 SCH3 5-pyrimidyl 2- (methylaminosulfonyl)phenyl
283 SCH3 5-pyrimidyl 1-pyrrolidinocarbonyl UI ■£»• ιP>. LO LO NJ t M o UI o Π o LΠ o LΠ o LΠ
ω ω ) ω ω ω J ω t t M Kj t t M M M i KJ
LO OJ LO LO LO ) J NJ VD LD ) U3 υD υ3 CD OO OO OO OO
Ul ili W M H O VD O ooO
Figure imgf000141_0001
uι *. ) M H o ω (» s] m Lπ
Figure imgf000141_0002
W W W W W 3 3 3 )' )" )" 3 rø )' )' W W W W W W W W W W W W W W W W W W W W W W W W W W W
1 1 1 1 1 pJ pJ tr pJ pJ PJ tr pJ PJ PJ , , , ^ J J j , i , i j i j I I I I I , i i I i i i i ! i i
Ό Ό Ό Ό Ό Φ Φ Φ Φ Φ Φ Φ Φ Φ Φ m m m σι m σj m oι m oι ,ι| t ^ fι| iι) i ,ι) ,ιl ,ι) i] O θ n n n n π θ O ΩlO ϋ ϋ 'd Ό Ό
*< ^ * •< •< p p p p p p p p p p I I I I I I I I I I I I I I I I I I \ -> -1 l-1 i-* [-> -• -> t-1 t-> -1 ^ *<: ; ^ ^ ;
H fl M j hj ft ft ft ft ft ft ft ft ft ft'd O O 'O O O ' O O 'O' i i ι i ι i i i ι i H H.
H- H- H- H- H- M M M M M M M M M M μ- μ- μ- μ- μ- μ- μ- μ- μ- μ- tr tr tr tr tr tr tr tr tr tr *ϋ T •ϋ *σ O *ϋ •ϋ *ϋ *ϋ O μ- μ- μ- α a α α α Hj ^ Hj »] r| H] ^ π) Φ Φ φ φ Φ Φ φ φ Φ J J J ρJ J J pJ i J ' 3 3 3
*< •< * * *< i i i i i i i i i i p a p p a p p p p p φ φ φ φ φ φ φ φ φ φ μ- μ- O t^ O O O O Η ^ O ^ ^ ^ ^ KI ^ ^ ^ ^ ^ a a p ft ft ft ft ft ft j j p' pJ p' j aj jj M M M M M M M Mt<; ι<; > > » '<; ι<; ' '<; ^ t<; < •< • •< <
Φ Φ Φ Φ Φ Φ Φ Φ Φ Φ r-> r-- -' -' ^-' V-> i-' \-1 r-' )-' r-' M M M M M p p p p p p p p p p
^-i ^ l-' -' -' -' r-' i-' t-, -'
^
1
3 o j
O ff
O ι_ι μ-
P o
Figure imgf000141_0004
Figure imgf000141_0003
336 SOCH3 2-pyridyl 2- (1' -CF3-tetrazol-2-yl)phenyl
337 SOCH3 2-pyridyl 4-morpholinocarbonyl
338 SOCH3 2-pyridyl 2-methyl-l-imidazolyl
339 SOCH3 2-pyridyl 5-methyl-l-imidazolyl
340 SOCH3 2-pyridyl 2-methylsulfonyl-l-imidazolyl
341 SOCH3 3 -pyridyl 2- (aminosulfonyl) phenyl
342 SOCH3 3-pyridyl 2- (methylaminosulfonyl)phenyl
343 SOCH3 3-pyridyl 1-pyrrolidinocarbonyl
344 SOCH3 3 -pyridyl 2- (methylsulfonyl) phenyl
345 SOCH3 3 -pyridyl 4-morpho1ino
346 SOCH3 3 -pyridyl 2- (1 ' -CF3-tetrazol-2-yl)phenyl
347 SOCH3 3 -pyridyl 4-morpholinocarbonyl
348 SOCH3 3 -pyridyl 2-methyl-l-imidazolyl
349 SOCH3 3 -pyridyl 5-methyl-l-imidazolyl
350 SOCH3 3 -pyridyl 2-methylsulfonyl-l-imidazolyl
351 SOCH3 2-pyrimidyl 2- (aminosulfonyl)phenyl
352 SOCH3 2-pyrimidyl 2- (methylaminosulfonyl)phenyl
353 SOCH3 2-pyrimidyl 1-pyrrolidinocarbonyl
354 SOCH3 2-pyrimidyl 2- (methylsulfonyl) phenyl
355 SOCH3 2-pyrimidyl 4-morpholino
356 SOCH3 2-pyrimidyl 2- (1 ' -CF3-tetrazol-2-yl)phenyl
357 SOCH3 2-pyrimidyl 4-morpho1inocarbony1
358 SOCH3 2-pyrimidyl 2-methyl-l-imidazolyl
359 SOCH3 2-pyrimidyl 5-methyl-l-imidazolyl
360 SOCH3 2-pyrimidyl 2-methylsulfonyl-l-imidazolyl
361 SOCH3 5-pyrimidyl 2- (aminosulfonyl)phenyl
362 SOCH3 5-pyrimidyl 2- (methylaminosulfonyl)phenyl
363 SOCH3 5-pyrimidyl 1-pyrrolidinocarbonyl
364 SOCH3 5-pyrimidyl 2- (methylsulfonyl)phenyl
365 SOCH3 5-pyrimidyl 4-morpho1ino
366 SOCH3 5-pyrimidyl 2- (1' -CF3-tetrazol-2-yl) phenyl
367 SOCH3 5-pyrimidyl 4-morpholinocarbonyl
368 SOCH3 5-pyrimidyl 2-methyl-l-imidazolyl
369 SOCH3 5-pyrimidyl 5-methyl-l-imidazolyl
370 SOCH3 5-pyrimidyl 2-methylsulfonyl-l-imidazolyl
371 SOCH3 2-Cl-phenyl 2- (aminosulfonyl)phenyl
372 SOCH3 2-Cl-phenyl 2- (methylammosulfonyl)phenyl
373 SOCH3 2-Cl-phenyl 1-pyrrolidinocarbonyl
374 SOCH3 2-Cl-phenyl 2- (methylsulfonyl)phenyl
375 SOCH3 2-Cl-phenyl 4-morpholino
376 SOCH3 2-Cl-phenyl 2- (l'-CF3-tetrazol-2-yl) phenyl
377 SOCH3 2-Cl-phenyl 4-morpholinocarbonyl
378 SOCH3 2-Cl-phenyl 2-methyl-l-imidazolyl
379 SOCH3 2-Cl-phenyl 5-methyl-l-imidazolyl
380 SOCH3 2-Cl-phenyl 2-methylsulfonyl-l-imidazolyl
381 SOCH3 2-F-phenyl 2- (aminosulfonyl)phenyl
382 SOCH3 2-F-phenyl 2- (methylaminosulfonyl)phenyl
383 SOCH3 2-F-phenyl 1-pyrrolidinocarbonyl
384 SOCH3 2-F-phenyl 2- (methylsulfonyl) phenyl
385 SOCH3 2-F-phenyl 4-morpholino
386 SOCH3 2-F-phenyl 2- (l'-CF3-tetrazol-2-yl) phenyl
387 SOCH3 2-F-phenyl 4-morpholinocarbonyl 388 SOCH3 2-F-phenyl 2-methyl-1-imidazolyl
389 SOCH3 2-F-phenyl 5-methyl-1-imidazolyl
390 SOCH3 2-F-phenyl 2-methylsulfonyl-l-imidazolyl
391 SOCH3 2, 6-diF-phenyl 2- (aminosulfonyl)phenyl
392 SOCH3 2, 6-diF-phenyl 2- (methylaminosulfonyl) phenyl
393 SOCH3 2, 6-diF-phenyl 1-pyrrolidinocarbonyl
394 SOCH3 2, 6-diF-phenyl 2- (methylsulfonyl)phenyl
395 SOCH3 2, 6-diF-phenyl 4-morpholino
396 SOCH3 2, 6-diF-phenyl 2- (1 ' -CF3-tetrazol-2-yl)phenyl
397 SOCH3 2, 6-diF-phenyl 4-morpholinocarbonyl
398 SOCH3 2, 6-diF-phenyl 2-methyl-1-imidazolyl
399 SOCH3 2, 6-diF-phenyl 5-methyl-1-imidazolyl
400 SOCH3 2, 6-diF-phenyl 2-methylsulfonyl-l-imidazolyl
401 S02CH3 phenyl 2- (aminosulfonyl)phenyl
402 S02CH3 phenyl 2- (methylammosulfonyl)phenyl
403 S02CH3 phenyl 1-pyrrolidinocarbonyl
404 S02CH3 phenyl 2- (methylsulfonyl)phenyl
405 S02CH3 phenyl 4-morpholino
406 S02CH3 phenyl 2- (1 ' -CF3-tetrazol-2-yl)phenyl
407 S02CH3 phenyl 4-morpholinocarbonyl
408 S02CH3 phenyl 2-methyl-l-imidazolyl
409 S02CH3 phenyl 5-methyl-1-imidazolyl
410 S02CH3 phenyl 2-methylsulfonyl-l-imidazolyl
411 S02CH3 2-pyridyl 2- (aminosulfonyl)phenyl
412 S02CH3 2-pyridyl 2- (methylaminosulfonyl) phenyl
413 S02CH3 2-pyridyl 1-pyrrolidinocarbonyl
414 S02CH3 2-pyridyl 2- (methylsulfonyl)phenyl
415 S02CH3 2-pyridyl 4-morpholino
416 S02CH3 2-pyridyl 2- (1 ' -CF3-tetrazol-2-yl)phenyl
417 S02CH 2-pyridyl 4-morpholinocarbonyl
418 Sθ2CH3 2-pyridyl 2-methyl-l-imidazolyl
419 S02CH3 2-pyridyl 5-methyl-l-imidazolyl
420 S02CH3 2-pyridyl 2-methylsulfonyl-l-imidazolyl
421 S02CH3 3-pyridyl 2- (aminosulfonyl)phenyl
422 S02CH3 3-pyridyl 2- (methylaminosulfonyl) phenyl
423 S02CH3 3-pyridyl 1-pyrrolidinocarbonyl
424 S02CH3 3-pyridyl 2- (methylsulfonyl)phenyl
425 S02CH3 3-pyridyl 4-morpholino
426 S02CH3 3-pyridyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl
427 S02CH3 3-pyridyl 4-morpholinocarbonyl
428 S02CH3 3-pyridyl 2-methyl-l-imidazolyl
429 S02CH3 3-pyridyl 5-methyl-l-imidazolyl
430 S02CH3 3-pyridyl 2-methylsulfonyl-l-imidazolyl
431 S02CH3 2-pyrimidyl 2- (aminosulfonyl)phenyl
432 S02CH3 2-pyrimidyl 2- (methylaminosulfonyl) phenyl
433 SO2CH3 2-pyrimidyl 1-pyrro1idinocarbony1
434 S02CH3 2-pyrimidyl 2- (methylsulfonyl)phenyl
435 S02CH3 2-pyrimidyl 4-morpholino
436 S02CH3 2-pyrimidyl 2-(l'-CF3-tetrazol-2-yl)phenyl
437 S02CH3 2-pyrimidyl 4-morpholinocarbonyl
438 S02CH3 2-pyrimidyl 2-methyl-1-imidazolyl
439 S02CH3 2-pyrimidyl 5-methyl-l-imidazolyl 440 S02CH3 2-pyrimidyl 2-methylsulfonyl-l-imidazolyl
441 SO2CH3 5-pyrimidyl 2- (aminosulfonyl)phenyl
442 SO2CH3 5-pyrimidyl 2 - (methylaminosulfonyl ) phenyl
443 SO2CH3 5-pyrimidyl 1-pyrrolidinocarbonyl
444 SO2CH3 5-pyrimidyl 2- (methylsulfonyl) phenyl
445 S02CH3 5-pyrimidyl 4-morpholino
446 SO2CH3 5-pyrimidyl 2- (1' -CF3-tetrazol-2-yl) phenyl
447 S02CH3 5-pyrimidyl 4-morpholinocarbonyl
448 SO2CH3 5-pyrimidyl 2-methyl-l-imidazolyl
449 SO2CH3 5-pyrimidyl 5-methyl-l-imidazolyl
450 S02CH3 5-pyrimidyl 2-methylsulfonyl-l-imidazolyl
451 S02CH3 2-Cl-phenyl 2- (aminosulfonyl) phenyl
452 S02CH3 2-Cl-phenyl 2 - (methylaminosulfonyl ) phenyl
453 S02CH3 2-Cl-phenyl 1-pyrrolidinocarbonyl
454 SO2CH3 2-Cl-phenyl 2- (methylsulfonyl) phenyl
455 SO2CH3 2-Cl-phenyl 4-morpho1ino
456 S02CH3 2-Cl-phenyl 2- (l'-CF3-tetrazol-2-yl) phenyl
457 S02CH3 2-Cl-phenyl 4-morpho1inocarbony1
458 S02CH3 2-Cl-phenyl 2-methyl-l-imidazolyl
459 S02CH3 2-Cl-phenyl 5-methyl-l-imidazolyl
460 S02CH3 2-Cl-phenyl 2-methylsulfonyl-l-imidazolyl
461 S02CH3 2-F-phenyl 2 - (aminosulfonyl ) phenyl
462 S02CH3 2-F-phenyl 2- (methylaminosulfonyl) phenyl
463 S02CH3 2-F-phenyl 1-pyrro1idinocarbony1
464 SO2CH3 2-F-phenyl 2- (methylsulfonyl) phenyl
465 S02CH3 2-F-phenyl 4-morpho1ino
466 S02CH3 2-F-phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl
467 S02CH3 2-F-phenyl 4-morpholinocarbonyl
468 S02CH3 2-F-phenyl 2-methyl-l-imidazolyl
469 S02CH3 2-F-phenyl 5-methyl-l-imidazolyl
470 S02CH3 2-F-phenyl 2-methylsulfonyl-l-imidazolyl
471 S02CH3 2 , 6-diF-phenyl 2- (aminosulfonyl) phenyl
472 S02CH3 2 , 6-diF-phenyl 2- (methylaminosulfonyl) phenyl
473 SO2CH3 2 , 6-diF-phenyl 1-pyrro1idinocarbony1
474 S02CH3 2, 6-diF-phenyl 2 - (methylsulfonyl ) phenyl
475 S02CH3 2, 6-diF-phenyl 4-morpholino
476 S02CH3 2 , 6-diF-phenyl 2- (1' -CF3-tetrazol-2-yl) phenyl
477 S02CH3 2, 6-diF-phenyl 4-morpholinocarbonyl
478 S02CH3 2 , 6-diF-phenyl 2-methyl-l-imidazolyl
479 S02CH3 2 , 6-diF-phenyl 5-methyl-l-imidazolyl
480 S02CH3 2, 6-diF-phenyl 2-methylsulfonyl-l-imidazolyl
481 CH2NH phenyl 2- (aminosulfonyl) phenyl -S02CH3
482 CH2NH phenyl 2- (methylaminosulfonyl) phenyl -S02CH3
483 CH2NH phenyl 1-pyrrolidinocarbonyl -S02CH3
484 CH2NH phenyl 2- (methylsulfonyl) phenyl -S02CH3
485 CH2NH phenyl 4-morpholino -S02CH3
486 CH2NH phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl -S02CH3
487 CH2 H phenyl 4-morpholinocarbonyl -S02CH3
488 CH2NH phenyl 2-methyl-l-imidazolyl -S02CH3
489 CHNH phenyl 5-methyl-l-imidazolyl -S02CH3
490 CH2 H phenyl 2-methylsulfonyl-l-imidazolyl -S02CH3
491 CH H 2-pyridyl 2- (aminosulfonyl) phenyl -S02CH3
492 CH2 H 2-pyridyl 2- (methylaminosulfonyl) phenyl -Sθ2CH3
493 CH2 H 2-pyridyl 1-pyrrolidinocarbonyl -S02CH3
494 CH2NH 2-pyridyl 2- (methylsulfonyl) phenyl -S02CH3
495 CH2NH 2-pyridyl 4-morpholino -S02CH3
496 CH2NH 2-pyridyl 2- (l'-CF3 -tetrazol-2-yDphenyl -S02CH3
497 CH2NH 2-pyridyl 4-morpholinocarbonyl -S02CH3
498 CH2NH 2-pyridyl 2-methyl-l-imidazolyl -S02CH3
499 CH2 H 2-pyridyl 5-methyl-l-imidazolyl
500 CH2 H 2-pyridyl 2-methylsulfonyl-l-imidazolyl -S02CH3
501 CH2 H 3-pyridyl 2- (aminosulfonyl) phenyl -S02CH3
502 CH2 H 3-pyridyl 2- (methylaminosulfonyl) phenyl -S02CH3
503 CH2NH 3-pyridyl 1-pyrrolidinocarbonyl -S02CH3
504 CH2 H 3-pyridyl 2- (methylsulfonyl) phenyl -S02CH3
505 CH2NH 3-pyridyl 4-morpholino -S02CH3
506 CH2NH 3-pyridyl 2- (1' -CF3-tetrazol-2-yl)phenyl -S02CH3
507 CH2 H 3-pyridyl 4-morpholinocarbonyl -S02CH3
508 CH2NH 3-pyridyl 2-methyl-l-imidazolyl -S02CH3
509 CH2NH 3-pyridyl 5-methyl-l-imidazolyl -S02CH3
510 CH2NH 3-pyridyl 2-methylsulfonyl-l-imidazolyl -S02CH3
511 CH2NH 2-pyrimidyl 2- (aminosulfonyl) phenyl -S02CH3
512 CH2NH 2-pyrimidyl 2- (methylaminosulfonyl) phenyl -S02CH3 513 CH2NH 2-pyrimidyl 1-pyrrolidinocarbonyl -S02CH3
514 CH2NH 2-pyrimidyl 2- (methylsulfonyl) phenyl -S0CH3
515 CH2 H 2-pyrimidyl 4-morpho1ino -S02CH3
516 CH2NH 2-pyrimidyl 2-(l' -CF3-tetrazol-2-yl) phenyl -S02CH3
517 CH2NH 2-pyrimidyl 4-morpholinocarbonyl -Sθ2CH3
518 CH2 H 2-pyrimidyl 2-me hyl-1-imidazolyl -Sθ2CH3
519 CH2 H 2-pyrimidyl 5-methyl-1-imidazolyl -S02CH3
520 CH2 H 2-pyrimidyl 2-methylsulfonyl-l-imidazolyl -SO2CH3
521 CH2 H 5-pyrimidyl 2- (aminosulfonyl) phenyl -S02CH3
522 CH2 H 5-pyrimidyl 2- (methylaminosulfonyl)phenyl -S02CH3
523 CH2NH 5-pyrimidyl 1-pyrro1idinocarbony1 -S02CH3
524 CH2NH 5-pyrimidyl 2- (methylsulfonyl)phenyl -S02CH3
525 CH2NH 5-pyrimidyl 4-morpholino -S02CH3
526 CH2 H 5-pyrimidyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl -S02CH3
527 CH2NH 5-pyrimidyl 4-morpholinocarbonyl -S02CH3
528 CHNH 5-pyrimidyl 2-methyl-1-imidazolyl -S02CH3
529 CH2NH 5-pyrimidyl 5-methyl-l-imidazolyl -S02CH3
530 CH2 H 5-pyrimidyl 2-methylsulfonyl-l-imidazolyl -S02CH3
531 CH2 H 2-Cl-phenyl 2- (aminosulfonyl)phenyl -S02CH3
532 CH2 H 2-Cl-phenyl 2- (methylaminosulfonyl)phenyl -S02CH3
533 CH2NH 2-Cl-phenyl 1-pyrrolidinocarbonyl -S02CH3
534 CH2 H 2-Cl-phenyl 2- (methylsulfonyl)phenyl -S02CH3
535 CH2 H 2-Cl-phenyl 4-morpho1ino -S02CH3
536 CH2NH 2-Cl-phenyl 2-(l'-CF3-tetrazol-2-yl)phenyl -S02CH3
537 CH2NH 2-Cl-phenyl 4-morpho1inocarbony1 -S02CH3
538 CH2NH 2-Cl-phenyl 2-methyl-l-imidazolyl -S02CH3 539 CH2NH 2-Cl-phenyl 5 -methyl- 1-imidazolyl -S02CH3
540 CH2NH 2-Cl-phenyl 2 -methylsulfonyl-1 -imidazolyl -S02CH3
541 CH2NH 2-F-phenyl 2 - (aminosulfonyl) phenyl -S02CH3
542 CH2NH 2-F-phenyl 2 - (methylaminosulfonyl)phenyl -S02CH3
543 CH2 H 2-F-phenyl 1 -pyrrolidinocarbony1 -S02CH3
544 CH2 H 2-F-phenyl 2 - (methylsulfonyl) phenyl -S02CH3
545 CH2NH 2-F-phenyl 4 -morpholino -S02CH3
546 CH2NH 2-F-phenyl 2 - (1' -CF3-tetrazol-2-yl) phenyl -S02CH3
547 CH2 H 2-F-phenyl 4 -morpholinocarbonyl -S02CH3
548 CH2 H 2-F-phenyl 2 -methyl-1-imidazolyl -S02CH3
549 CH2 H 2-F-phenyl 5 -methyl-1-imidazolyl -S02CH3
550 CH2NH 2-F-phenyl 2 -methylsulfonyl-1-imidazolyl -S02CH3
551 CH2 H 2, 6-diF-phenyl 2 - (aminosulfonyl)phenyl -S02CH3
552 CH2NH 2, 6-diF-phenyl 2 - (methylaminosulfonyl) phenyl -S02CH3
553 CH2 H 2, 6-diF-phenyl 1 -pyrrolidinocarbonyl -S02CH3
554 CH2NH 2, 6-diF-phenyl 2 - (methylsulfonyl)phenyl -S02CH3
555 CH2NH 2, 6-diF-phenyl 4 -morpholino -S02CH3
556 CH2NH 2, 6-diF-phenyl 2 - (1 ' -CF3-tetrazol-2-yl) phenyl -S02CH3
557 CH2NH 2, 6-diF-phenyl 4 -morpholinocarbonyl -S02CH3
558 CH2NH 2, 6-diF-phenyl 2 -methyl-1-imidazolyl -S02CH3
559 CH2NH 2, 6-diF-phenyl 5 -methyl-1-imidazolyl -S02CH3
560 CH2NH 2, 6-diF-phenyl 2 -methylsulfonyl-1-imidazolyl -S02CH3
561 Cl phenyl 2 - (aminosulfonyl)phenyl
562 Cl phenyl 2 - (methylammosulfonyl) phenyl
563 Cl phenyl 1 -pyrrolidinocarbonyl
564 Cl phenyl 2 - (methylsulfonyl)phenyl
565 Cl phenyl 4 -morpholino
566 Cl phenyl 2 - (l'-CF3-tetrazol-2-yDphenyl
567 Cl phenyl 4 -morpholinocarbonyl
568 Cl phenyl 2 -methyl-1-imidazolyl
569 Cl phenyl 5 -methyl-1-imidazolyl 570 Cl phenyl 2-methylsulfonyl-l-imidazolyl
571 Cl 2-pyridyl 2- (aminosulfonyl)phenyl
572 Cl 2-pyridyl 2- (methylaminosulfonyl) phenyl
573 Cl 2-pyridyl 1-pyrrolidinocarbonyl
574 Cl 2-pyridyl 2- (methylsulfonyl)phenyl
575 Cl 2-pyridyl 4-morpholino
576 Cl 2-pyridyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl
577 Cl 2-pyridyl 4-morpholinocarbonyl
578 Cl 2-pyridyl 2-methyl-l-imidazolyl
579 Cl 2-pyridyl 5-methyl-1-imidazolyl
580 Cl 2-pyridyl 2-methylsulfonyl-l-imidazolyl
581 Cl 3-pyridyl 2- (aminosulfonyl)phenyl
582 Cl 3 -pyridyl 2- (methylaminosulfonyl) phenyl
583 Cl 3-pyridyl 1-pyrrolidinocarbonyl
584 Cl 3-pyridyl 2- (methylsulfonyl)phenyl
585 Cl 3-pyridyl 4-morpholino
586 Cl 3 -pyridyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl
587 Cl 3-pyridyl 4-morpholinocarbonyl
588 Cl 3-pyridyl 2-methyl-l-imidazolyl
589 Cl 3-pyridyl 5-methyl-l-imidazolyl
590 Cl 3 -pyridyl 2-methylsulfonyl-l-imidazolyl
591 Cl 2-pyrimidyl 2- (aminosulfonyl)phenyl
592 Cl 2-pyrimidyl 2- (methylaminosulfonyl) phenyl
593 Cl 2-pyrimidyl 1-pyrrolidinocarbonyl
594 Cl 2-pyrimidyl 2- (methylsulfonyl)phenyl
595 Cl 2-pyrimidyl 4-morpholino
596 Cl 2-pyrimidyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl
597 Cl 2-pyrimidyl 4-morpholinocarbonyl
598 Cl 2-pyrimidyl 2-methyl-l-imidazolyl
599 Cl 2-pyrimidyl 5-methyl-1-imidazolyl
600 Cl 2-pyrimidyl 2-methylsulfonyl-1-imidazolyl
601 Cl 5-pyrimidyl 2- (aminosulfonyl)phenyl
602 Cl 5-pyrimidyl 2- (methylaminosulfonyl)phenyl
603 Cl 5-pyrimidyl 1-pyrrolidinocarbonyl
604 Cl 5-pyrimidyl 2- (methylsulfonyl)phenyl
605 Cl 5-pyrimidyl 4-morpholino
606 Cl 5-pyrimidyl 2- (1 ' -CF3-tetrazol-2-yl)phenyl
607 Cl 5-pyrimidyl 4-morpholinocarbonyl
608 Cl 5-pyrimidyl 2-methyl-l-imidazolyl
609 Cl 5-pyrimidyl 5-methyl-l-imidazolyl
610 Cl 5-pyrimidyl 2-methylsulfonyl-l-imidazolyl
611 Cl 2-Cl-phenyl 2- (aminosulfonyl) phenyl
612 Cl 2-Cl-phenyl 2- (methylaminosulfonyl)phenyl
613 Cl 2-Cl-phenyl 1-pyrrolidinocarbonyl
614 Cl 2-Cl-phenyl 2- (methylsulfonyl)phenyl
615 Cl 2-Cl-phenyl 4-morpholino
616 Cl 2-Cl-phenyl 2- (1 ' -CF3-tetrazol-2-yDphenyl
617 Cl 2-Cl-phenyl 4-morpholinocarbonyl
618 Cl 2-Cl-phenyl 2-methyl-l-imidazolyl
619 Cl 2-Cl-phenyl 5-methyl-l-imidazolyl
620 Cl 2-Cl-phenyl 2-methylsulfonyl-l-imidazolyl
621 Cl 2-F-phenyl 2- (aminosulfonyl)phenyl
622 Cl 2-F-phenyl 2- (methylaminosulfonyl)phenyl
623 Cl 2-F-phenyl 1-pyrrolidinocarbonyl
624 Cl 2-F-phenyl 2- (methylsulfonyl)phenyl
625 Cl 2-F-phenyl 4-morpholino 626 Cl 2-F-phenyl 2- (1 ' -CF3-tetrazol-2-yDphenyl
627 Cl 2-F-phenyl 4-morpholinocarbonyl
628 Cl 2-F-phenyl 2-methyl-l-imidazolyl
629 Cl 2-F-phenyl 5-methyl-l-imidazolyl
630 Cl 2-F-phenyl 2-methylsulfonyl-l-imidazolyl
631 Cl 2 , 6-diF-phenyl 2- (aminosulfonyl)phenyl
632 Cl 2 , 6-diF-phenyl 2- (methylammosulfonyl) phenyl
633 Cl 2 , 6-diF-phenyl 1-pyrrolidinocarbonyl
634 Cl 2 , 6-diF-phenyl 2- (methylsulfonyl)phenyl
635 Cl 2 , 6-diF-phenyl 4-morpholino
636 Cl 2 , 6-diF-phenyl 2- (1 ' -CF3-tetrazol-2-yl)phenyl
637 Cl 2 , 6-diF-phenyl 4-morpholinocarbonyl
638 Cl 2 , 6-diF-phenyl 2-methyl-l-imidazolyl
639 Cl 2 , 6-diF-phenyl 5-methyl-1-imidazolyl
640 Cl 2 , 6-diF-phenyl 2-methylsulfonyl-l-imidazolyl
641 F phenyl 2- (aminosulfonyl)phenyl
642 F phenyl 2- (methylammosulfonyl)phenyl
643 F phenyl 1-pyrrolidinocarbonyl
644 F phenyl 2- (methylsulfonyl)phenyl
645 F phenyl 4-morpholino
646 F phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl
647 F phenyl 4-morpholinocarbonyl
648 F phenyl 2-methyl-l-imidazolyl
649 F phenyl 5-methyl-l-imidazolyl
650 F phenyl 2-methylsulfonyl-l-imidazolyl
651 F 2-pyridyl 2- (aminosulfonyl)phenyl
652 F 2-pyridyl 2- (methylaminosulfonyl)phenyl
653 F 2-pyridyl 1-pyrro1idinocarbony1
654 F 2-pyridyl 2- (methylsulfonyl)phenyl
655 F 2-pyridyl 4-morpholino
656 F 2-pyridyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl
657 F 2-pyridyl 4-morpholinocarbonyl
658 F 2-pyridyl 2-methyl-l-imidazolyl
659 F 2-pyridyl 5-methyl-l-imidazolyl
660 F 2-pyridyl 2-methylsulfonyl-l-imidazolyl
661 F 3-pyridyl 2- (aminosulfonyl) phenyl
662 F 3-pyridyl 2- (methylammosulfonyl) phenyl
663 F 3-pyridyl 1-pyrrolidinocarbonyl
664 F 3-pyridyl 2- (methylsulfonyl) phenyl
665 F 3-pyridyl 4-morpholino
666 F 3-pyridyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl
667 F 3-pyridyl 4-morpholinocarbonyl
668 F 3-pyridyl 2-methyl-l-imidazolyl
669 F 3-pyridyl 5-methyl-l-imidazolyl
670 F 3-pyridyl 2-methylsulfonyl-l-imidazolyl
671 F 2-pyrimidyl 2- (aminosulfonyl) phenyl
672 F 2-pyrimidyl 2- (methylaminosulfonyl) phenyl
673 F 2-pyrimidyl 1-pyrrolidinocarbonyl
674 F 2-pyrimidyl 2- (methylsulfonyl) phenyl
675 F 2-pyrimidyl 4-morpholino
676 F 2-pyrimidyl 2- (l'-CF3-tetrazol-2-yl) phenyl
677 F 2-pyrimidyl 4-morpholinocarbonyl
678 F 2-pyrimidyl 2-methyl-1-imidazolyl
679 F 2-pyrimidyl 5-methyl-l-imidazolyl
680 F 2-pyrimidyl 2-methylsulfonyl-l-imidazolyl
681 F 5-pyrimidyl 2- (aminosulfonyl) phenyl 682 F 5-pyrimidyl 2- (methylaminosulfonyl) phenyl
683 F 5-pyrimidyl 1-pyrrolidinocarbonyl
684 F 5-pyrimidyl 2- (methylsulfonyl)phenyl
685 F 5-pyrimidyl 4-morpholino
686 F 5-pyrimidyl 2- ( 1 ' -CF3 -tetrazol-2 -yD phenyl
687 F 5-pyrimidyl 4-morpholinocarbonyl
688 F 5-pyrimidyl 2-methyl-l-imidazolyl
689 F 5-pyrimidyl 5-methyl-l-imidazolyl
690 F 5-pyrimidyl 2-methylsulfonyl-l-imidazolyl
691 F 2-Cl-phenyl 2- (aminosulfonyl)phenyl
692 F 2-Cl-phenyl 2- (methylaminosulfonyl)phenyl
693 F 2-Cl-phenyl 1-pyrrolidinocarbonyl
694 F 2-Cl-phenyl 2- (methylsulfonyl)phenyl
695 F 2-Cl-phenyl 4-morpholino
696 F 2-Cl-phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl
697 F 2-Cl-phenyl 4-morpholinocarbonyl
698 F 2-Cl-phenyl 2-methyl-l-imidazolyl
699 F 2-Cl-phenyl 5-methyl-l-imidazolyl
700 F 2-Cl-phenyl 2-methylsulfonyl-l-imidazolyl
701 F 2-F-phenyl 2- (aminosulfonyl)phenyl
702 F 2-F-phenyl 2- (methylaminosulfonyl) phenyl
703 F 2-F-phenyl 1-pyrrolidinocarbonyl
704 F 2-F-phenyl 2- (methylsulfonyl)phenyl
705 F 2-F-phenyl 4-morpholino
706 F 2-F-phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl
707 F 2-F-phenyl 4-morpholinocarbonyl
708 F 2-F-phenyl 2-methyl-l-imidazolyl
709 F 2-F-phenyl 5-methyl-l-imidazolyl
710 F 2-F-phenyl 2-methylsulfonyl-l-imidazolyl
711 F 2, 6-diF-phenyl 2- (aminosulfonyl)phenyl
712 F 2, 6-diF-phenyl 2- (methylammosulfonyl)phenyl
713 F 2 , 6-diF-phenyl 1-pyrrolidinocarbonyl
714 F 2, 6-diF-phenyl 2- (methylsulfonyl)phenyl
715 F 2, 6-diF-phenyl 4-morpho1ino
716 F 2 , 6-diF-phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl
717 F 2, 6-diF-phenyl 4-morpholinocarbonyl
718 F 2, 6-diF-phenyl 2-methyl-l-imidazolyl
719 F 2, 6-diF-phenyl 5-methyl-l-imidazolyl
720 F 2, 6-diF-phenyl 2-methylsulfonyl-l-imidazolyl
721 C02CH3 phenyl 2- (aminosulfonyl)phenyl
722 C02CH3 phenyl 2- (methylaminosulfonyl)phenyl
723 C02CH3 phenyl 1-pyrrolidinocarbonyl
724 C02CH3 phenyl 2- (methylsulfonyl)phenyl
725 C02CH3 phenyl 4-morpholino
726 Cθ2CH3 phenyl 2- (1 ' -CF3-tetrazol-2-yl)phenyl
727 C02CH3 phenyl 4-morpholinocarbonyl
728 C02CH3 phenyl 2-methyl-l-imidazolyl
729 C02CH3 phenyl 5-methyl-l-imidazolyl
730 C02CH3 phenyl 2-methylsulfonyl-l-imidazolyl
731 C02CH3 2-pyridyl 2- (aminosulfonyl)phenyl
732 C02CH3 2-pyridyl 2- (methylaminosulfonyl)phenyl
733 C02CH3 2-pyridyl 1-pyrrolidinocarbonyl
734 C02CH3 2-pyridyl 2- (methylsulfonyl)phenyl
735 C02CH3 2-pyridyl 4-morpholino
736 C02CH3 2-pyridyl 2- (1 ' -CF3-tetrazol-2-yl)phenyl 737 C02CH3 2-pyridyl 4-morpho1inocarbony1
738 C02CH3 2-pyridyl 2-methyl-l-imidazolyl
739 C02CH3 2-pyridyl 5-methyl-1-imidazolyl
740 C02CH3 2-pyridyl 2-methylsulfonyl-l-imidazolyl
741 C02CH3 3 -pyridyl 2- (aminosulfonyl)phenyl
742 C02CH3 3-pyridyl 2- (methylaminosulfonyl) phenyl
743 C02CH3 3-pyridyl 1-pyrrolidinocarbonyl
744 C02CH3 3 -pyridyl 2- (methylsulfonyl) phenyl
745 C02CH3 3 -pyridyl 4-morpho1ino
746 C02CH3 3-pyridyl 2- ( l ' -CF3 -tetrazol-2 -yD phenyl
747 C02CH3 3 -pyridyl 4-morpholinocarbonyl
748 C02CH3 3-pyridyl 2-methyl-1-imidazolyl
749 C02CH3 3-pyridyl 5-methyl-l-imidazolyl
750 C02CH3 3-pyridyl 2-methylsulfonyl-l-imidazolyl
751 C02CH3 2-pyrimidyl 2- (aminosulfonyl)phenyl
752 CO2CH3 2-pyrimidyl 2- (methylaminosulfonyl)phenyl
753 C02CH3 2-pyrimidyl 1-pyrrolidinocarbonyl
754 C0 CH3 2-pyrimidyl 2- (methylsulfonyl)phenyl
755 C02CH3 2-pyrimidyl 4-morpholino
756 C02CH3 2-pyrimidyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl
757 C02CH3 2-pyrimidyl 4-morpholinocarbonyl
758 Cθ2CH3 2-pyrimidyl 2-methyl-l-imidazolyl
759 C02CH3 2-pyrimidyl 5-methyl-l-imidazolyl
760 C02CH3 2-pyrimidyl 2-methylsulfonyl-l-imidazolyl
761 CO2CH3 5-pyrimidyl 2- (aminosulfonyl)phenyl
762 CO2CH3 5-pyrimidyl 2- (methylaminosulfonyl) phenyl
763 Cθ2CH3 5-pyrimidyl 1-pyrrolidinocarbonyl
764 C02CH3 5-pyrimidyl 2- (methylsulfonyl)phenyl
765 C02CH3 5-pyrimidyl 4-morpholino
766 C02CH3 5-pyrimidyl 2- (1 ' -CF3 -tetrazol-2 -yD phenyl
767 Cθ2CH3 5-pyrimidyl 4-morpholinocarbonyl
768 C02CH3 5-pyrimidyl 2-methyl-l-imidazolyl
769 C02CH3 5-pyrimidyl 5-methyl-l-imidazolyl
770 C02CH3 5-pyrimidyl 2-methylsulfonyl-l-imidazolyl
771 C02CH3 2-Cl-phenyl 2- (aminosulfonyl)phenyl
772 C02CH3 2-Cl-phenyl 2- (methylammosulfonyl) phenyl
773 C02CH3 2-Cl-phenyl 1-pyrrolidinocarbonyl
774 C02CH3 2-Cl-phenyl 2- (methylsulfonyl)phenyl
775 C02CH3 2-Cl-phenyl 4-morpholino
776 C02CH3 2-Cl-phenyl 2- (1' -CF3-tetrazol-2-yDphenyl
777 C02CH3 2-Cl-phenyl 4-morpholinocarbonyl
778 C02CH3 2-Cl-phenyl 2-methyl-l-imidazolyl
779 C02CH3 2-Cl-phenyl 5-methyl-l-imidazolyl
780 C02CH3 2-Cl-phenyl 2-methylsulfonyl-l-imidazolyl
781 C02CH3 2-F-phenyl 2- (aminosulfonyl)phenyl
782 C02CH3 2-F-phenyl 2- (methylaminosulfonyl) phenyl
783 C02CH3 2-F-phenyl 1-pyrrolidinocarbonyl
784 C02CH3 2-F-phenyl 2- (methylsulfonyl)phenyl
785 C02CH3 2-F-phenyl 4-morpholino
786 C02CH3 2-F-phenyl 2- ( 1 ' -CF3 - tetrazol-2 -yD phenyl
787 C02CH3 2-F-phenyl 4-morpholinocarbonyl
788 C02CH3 2-F-phenyl 2-methyl-l-imidazolyl 789 C0 CH3 2-F-phenyl 5-methyl-l-imidazolyl 790 C02CH3 2-F-phenyl 2-methylsulfonyl-l-imidazolyl 791 C02CH3 2 , 6-diF-phenyl 2- (aminosulfonyl) phenyl 792 C02CH3 2 , 6-diF-phenyl 2- (methylammosulfonyl) phenyl 793 C02CH3 2, 6-diF-phenyl 1-pyrrolidinocarbonyl 794 C02CH3 2, 6-diF-phenyl 2- (methylsulfonyl) phenyl 795 CO2CH3 2 , 6-diF-phenyl 4-morpho1ino 796 CO2CH3 2, 6-diF-phenyl 2- ( 1 ' -CF3-tetrazol-2-yl ) phenyl 797 CO2CH3 2 , 6-diF-phenyl 4-morpho1inocarbony1 798 CO2CH3 2 , 6-diF-phenyl 2-methyl-l-imidazolyl 799 CO2CH3 2, 6-diF-phenyl 5-methyl-l-imidazolyl 800 CO2CH3 2 , 6-diF-phenyl 2-methylsulfonyl-l-imidazolyl 801 CH2OCH3 phenyl 2- (aminosulfonyl) phenyl 802 CH2OCH3 phenyl 2- (methylaminosulfonyl ) phenyl 803 CH2OCH3 phenyl 1-pyrro1idinocarbony1 804 CH2OCH3 phenyl 2- (methylsulfonyl) phenyl 805 CH2OCH3 phenyl 4-morpholino 806 CH2OCH3 phenyl 2- ( 1 ' -CF3-tetrazol-2-yl ) phenyl 807 CH2OCH3 phenyl 4-morpholinocarbonyl 808 CH2OCH3 phenyl 2-methyl-l-imidazolyl 809 CH2OCH3 phenyl 5-methyl-l-imidazolyl 810 CH2OCH3 phenyl 2-methylsulfonyl-l-imidazolyl 811 CH2OCH3 2-pyridyl 2- (aminosulfonyl) phenyl 812 CH2OCH3 2-pyridyl 2- (methylaminosulfonyl ) phenyl 813 CH2OCH3 2-pyridyl 1-pyrrolidinocarbonyl 814 CH2OCH3 2-pyridyl 2- (methylsulfonyl)phenyl 815 CH2OCH3 2-pyridyl 4-morpholino 816 CH2OCH3 2-pyridyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 817 CH2OCH3 2-pyridyl 4-morpholinocarbonyl 818 CH2OCH3 2-pyridyl 2-methyl-l-imidazolyl 819 CH2OCH3 2-pyridyl 5-methyl-l-imidazolyl 820 CH2OCH3 2-pyridyl 2-methylsulfonyl-l-imidazolyl 821 CH2OCH3 3-pyridyl 2- (aminosulfonyl ) phenyl 822 CH2OCH3 3-pyridyl 2- (methylaminosulfonyl ) phenyl 823 CH2OCH3 3-pyridyl 1-pyrro1idinocarbony1 824 CH2OCH3 3-pyridyl 2- (methylsulfonyl ) phenyl 825 CH2OCH3 3-pyridyl 4-morpho1ino 826 CH2OCH3 3-pyridyl 2- (1 ' -CF3-tetrazol-2-yDphenyl 827 CH2OCH3 3-pyridyl 4-morpho1inocarbony1 828 CH2OCH3 3-pyridyl 2-methyl-l-imidazolyl 829 CH2OCH3 3-pyridyl 5-methyl-l-imidazolyl 830 CHOCH3 3-pyridyl 2-methylsulfonyl-l-imidazolyl 831 CH2θCH3 2-pyrimidyl 2- (aminosulfonyl) phenyl 832 CH2OCH3 2-pyrimidyl 2- (methylaminosulfonyl) phenyl 833 CH2OCH3 2-pyrimidyl 1-pyrrolidinocarbonyl 834 CH2OCH3 2-pyrimidyl 2- (methylsulfonyl ) phenyl 835 CH2OCH3 2-pyrimidyl 4-morpholino 836 CH2OCH3 2-pyrimidyl 2- (D-CF3-tetrazol-2-yl) phenyl 837 CH2OCH3 2-pyrimidyl 4-morpholinocarbonyl 838 CHOCH3 2-pyrimidyl 2-methyl-l-imidazolyl 839 CH2OCH3 2-pyrimidyl 5-methyl-l-imidazolyl 840 CH2OCH3 2-pyrimidyl 2-methylsulfonyl-1-imidazolyl 841 CH2OCH3 5-pyrimidyl 2- (aminosulfonyl) phenyl
842 CH2OCH3 5-pyrimidyl 2- (methylaminosulfonyl) phenyl
843 CH2OCH3 5-pyrimidyl 1-pyrrolidinocarbonyl
844 CH2OCH3 5-pyrimidyl 2 - (methylsulfonyl ) phenyl
845 CH2OCH3 5-pyrimidyl 4-morpho1ino
846 CH2OCH3 5-pyrimidyl 2- (1 ' -CF3 -tetrazol-2-yl) phenyl
847 CH2OCH3 5-pyrimidyl 4-morpholinocarbonyl
848 CH2OCH3 5-pyrimidyl 2-methyl-l-imidazolyl
849 CH2OCH3 5-pyrimidyl 5-methyl-l-imidazolyl
850 CH2OCH3 5-pyrimidyl 2-methylsulfonyl-l-imidazolyl
851 CH2OCH3 2-Cl-phenyl 2- (aminosulfonyl) phenyl
852 CH2OCH3 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl
853 CH2OCH3 2-Cl-phenyl 1-pyrrolidinocarbonyl
854 CH2OCH3 2-Cl-phenyl 2- (methylsulfonyl)phenyl
855 CH2OCH3 2-Cl-phenyl 4-morpholino
856 CH2OCH3 2-Cl-phenyl 2- ( 1 ' -CF3 -tetrazol-2-yl) phenyl
857 CH2OCH3 2-Cl-phenyl 4-morpholinocarbonyl
858 CH2OCH3 2-Cl-phenyl 2-methyl-l-imidazolyl
859 CH2OCH3 2-Cl-phenyl 5-methyl-l-imidazolyl
860 CH2OCH3 2-Cl-phenyl 2-methylsulfonyl-l-imidazolyl
861 CH2OCH3 2-F-phenyl 2- (aminosulfonyl) phenyl
862 CH2OCH3 2-F-phenyl 2- (methylaminosulfonyl)phenyl
863 CH2OCH3 2-F-phenyl 1-pyrrolidinocarbonyl
864 CH2OCH3 2-F-phenyl 2- (methylsulfonyl) phenyl
865 CH2OCH3 2-F-phenyl 4-morpholino
866 CH2OCH3 2-F-phenyl 2-( 1 ' -CF3 -tetrazol-2-yl) phenyl
867 CH2OCH3 2-F-phenyl 4-morpholinocarbonyl
868 CH2OCH3 2-F-phenyl 2-methyl-l-imidazolyl
869 CH2OCH3 2-F-phenyl 5-methyl-l-imidazolyl
870 CH2OCH 2-F-phenyl 2-methylsulfonyl-l-imidazolyl
871 CH2OCH3 2 , 6-diF-phenyl 2- (aminosulfonyl) phenyl
872 CH2OCH3 2 , 6-diF-phenyl 2- (methylaminosulfonyl) phenyl
873 CH2OCH3 2, 6-diF-phenyl 1-pyrrolidinocarbonyl
874 CH2OCH3 2, 6-diF-phenyl 2- (methylsulfonyl) phenyl
875 CH2OCH3 2 , 6-diF-phenyl 4-morpho1ino
876 CH2OCH3 2 , 6-diF-phenyl 2- ( 1 ' -CF3 -tetrazol-2 -yD phenyl
877 CH2OCH3 2 , 6-diF-phenyl 4-morpholinocarbonyl
878 CH2OCH3 2, 6-diF-phenyl 2-methyl-l-imidazolyl
879 CH2OCH3 2 , 6-diF-phenyl 5-methyl-l-imidazolyl
880 CH OCH3 2 , 6-diF-phenyl 2-methylsulfonyl-l-imidazolyl
881 CO H2 phenyl 2- (aminosulfonyl) phenyl
882 CONH2 phenyl 2- (methylaminosulfonyl ) phenyl
883 CO H2 phenyl 1-pyrrolidinocarbony1
884 CONH2 phenyl 2- (methylsulfonyl) phenyl
885 CONH2 phenyl 4-morpholino
886 CONH2 phenyl 2- ( 1 ' -CF3 -tetrazol-2-yl) phenyl
887 CONH2 phenyl 4-morpholinocarbonyl
888 CONH2 phenyl 2-methyl-l-imidazolyl
889 CONH2 phenyl 5-methyl-l-imidazolyl
890 CONH2 phenyl 2-methylsulfonyl-l-imidazolyl
891 CONH2 2-pyridyl 2- (aminosulfonyl)phenyl
892 CO H2 2-pyridyl 2- (methylaminosulfonyl) phenyl 893 CONH2 2-pyridyl 1-pyrrolidinocarbony1
894 CONH2 2-pyridyl 2- (methylsulfonyl ) phenyl
895 CONH2 2-pyridyl 4-morpholino
896 CONH2 2-pyridyl 2- (l'-CF3-tetrazol-2-yl) phenyl
897 CONH2 2-pyridyl 4-morpholinocarbonyl
898 CO H2 2-pyridyl 2-methyl-1-imidazolyl
899 CONH2 2-pyridyl 5-methyl-1-imidazolyl
900 CONH2 2-pyridyl 2-methylsulfonyl-1-imidazoly1
901 CO H2 3-pyridyl 2- (aminosulfonyl)phenyl
902 CONH2 3-pyridyl 2- (methylaminosulfonyl) phenyl
903 CONH2 3 -pyridyl 1-pyrrolidinocarbonyl
904 CO H2 3-pyridyl 2- (methylsulfonyl) phenyl
905 CONH2 3-pyridyl 4-morpholino
906 CONH2 3-pyridyl 2- (l'-CF3-tetrazol-2-yl) phenyl
907 CO H2 3-pyridyl 4-morpholinocarbonyl
908 CONH2 3-pyridyl 2-methyl-1-imidazolyl
909 CO H2 3-pyridyl 5-methyl-l-imidazolyl
910 CONH2 3 -pyridyl 2-methylsulfonyl-l-imidazolyl
911 CONH2 2-pyrimidyl 2- (aminosulfonyl) phenyl
912 CONH2 2-pyrimidyl 2- (methylaminosulfonyl)phenyl
913 CO H2 2-pyrimidyl 1-pyrrolidinocarbonyl
914 CONH2 2-pyrimidyl 2- (methylsulfonyl)phenyl
915 CONH2 2-pyrimidyl 4-morpholino
916 CONH2 2-pyrimidyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl
917 CO H2 2-pyrimidyl 4-morpholinocarbonyl
918 CONH2 2-pyrimidyl 2-methyl-1-imidazolyl
919 CO H2 2-pyrimidyl 5-methyl-l-imidazolyl
920 CO H2 2-pyrimidyl 2-methylsulfonyl-l-imidazolyl
921 CO H2 5-pyrimidyl 2- (aminosulfonyl) phenyl
922 CONH2 5-pyrimidyl 2- (methylaminosulfonyl)phenyl
923 CONH2 5-pyrimidyl 1-pyrrolidinocarbonyl
924 CO H2 5-pyrimidyl 2- (methylsulfonyl)phenyl
925 CONH2 5-pyrimidyl 4-morpho1ino
926 CONH2 5-pyrimidyl 2- ( l ' -CF3- tetrazol-2 -yD phenyl
927 CONH2 5-pyrimidyl 4-morpholinocarbonyl
928 CO H2 5-pyrimidyl 2-methyl-l-imidazolyl
929 CO H2 5-pyrimidyl 5-methyl-l-imidazolyl
930 CO H2 5-pyrimidyl 2-methylsulfonyl-l-imidazolyl
931 CONH2 2-Cl-phenyl 2- (aminosulfonyl) phenyl
932 CO H2 2-Cl-phenyl 2- (methylammosulfonyl)phenyl
933 CONH2 2-Cl-phenyl 1-pyrrolidinocarbonyl
934 CONH2 2-Cl-phenyl 2- (methylsulfonyl)phenyl
935 CONH2 2-Cl-phenyl 4-morpholino
936 CONH2 2-Cl-phenyl 2-(l'-CF3-tetrazol-2-yl)phenyl
937 CONH2 2-Cl-phenyl 4-morpholinocarbonyl
938 CONH2 2-Cl-phenyl 2-methyl-l-imidazolyl
939 CONH2 2-Cl-phenyl 5-methyl-l-imidazolyl
940 CO H2 2-Cl-phenyl 2-methylsulfonyl-l-imidazolyl
941 CONH2 2-F-phenyl 2- (aminosulfonyl)phenyl
942 CONH2 2-F-phenyl 2- (methylaminosulfonyl) phenyl
943 CONH2 2-F-phenyl 1-pyrrolidinocarbonyl
944 CO H2 2-F-phenyl 2- (methylsulfonyl)phenyl 945 CO H2 2--F-phenyl 4-morpholino
946 CO H2 2- -F-phenyl 2- (1 ' -CF3-tetrazol-2-yl) henyl
947 CONH2 2- -F-phenyl 4-morpholinocarbonyl
948 CONH2 2- -F-phenyl 2-methyl-l-imidazolyl
949 CONH2 2- -F-phenyl 5-methyl-l-imidazolyl
950 CONH2 2- -F-phenyl 2-methylsulfonyl-l-imidazolyl
951 CONH2 2 , , 6-diF-phenyl 2- (aminosulfonyl) phenyl
952 CONH2 2, , 6-diF-phenyl 2- (methylammosulfonyl) phenyl
953 CONH2 2, , 6-diF-phenyl 1-pyrrolidinocarbonyl
954 CONH2 2, , 6-diF-phenyl 2- (methylsulfonyl)phenyl
955 CONH2 2, , 6-diF-phenyl 4-morpholino
956 CONH2 2, , 6-diF-phenyl 2-(l'-CF3-tetrazol-2-yl)phenyl
957 CONH2 2, , 6-diF-phenyl 4-morpholinocarbonyl
958 CONH2 2, , 6-diF-phenyl 2-methyl-l-imidazolyl
959 CO H2 2 , , 6-diF-phenyl 5-methyl-l-imidazolyl
960 CO H2 2, , 6-diF-phenyl 2-methylsulfonyl-l-imidazolyl
Table 3
Figure imgf000156_0001
Figure imgf000157_0001
hh
Figure imgf000158_0001
zz aaa bbb
Figure imgf000159_0001
m m nnn
Figure imgf000159_0002
rrr sss. ttt
Figure imgf000160_0001
uuu vw www
Figure imgf000160_0002
XXX yyy
Figure imgf000160_0003
zzz aaaa bbbb
A phenyl 2 - (aminosulfonyl ) phenyl phenyl 2- (methylaminosulf onyl) phenyl phenyl 1-pyrrolidinocarbonyl phenyl 2 - (methylsulfonyl ) phenyl phenyl 4 -mo rpho 1 ino phenyl 2 - ( 1 ' -CF3 -tetrazol-2 -yD phenyl phenyl 4-morpholinocarbonyl phenyl 2-methyl-l-imidazolyl phenyl 5-methyl-l-imidazolyl phenyl 2-methylsulfonyl-l-imidazolyl
2-pyridyl 2- (aminosulfonyl)phenyl
2-pyridyl 2- (methylaminosulfonyl) phenyl
2-pyridyl 1-pyrrolidinocarbonyl
2-pyridyl 2- (methylsulfonyl)phenyl
2-pyridyl 4-morpholino
2-pyridyl 2- (l'-CF3-tetrazol-2-yl) phenyl
2-pyridyl 4-morpho1inocarbony1
2-pyridyl 2-methyl-l-imidazolyl
2-pyridyl 5-methyl-l-imidazolyl
2-pyridyl 2-methylsulfonyl-l-imidazolyl
3-pyridyl 2- (aminosulfonyl) phenyl
3-pyridyl 2- (methylaminosulfonyl) phenyl
3-pyridyl 1-pyrrolidinocarbonyl
3-pyridyl 2- (methylsulfonyl)phenyl
3-pyridyl 4-morpho1ino
3-pyridyl 2- (l'-CF3-tetrazol-2-yl) phenyl
3-pyridyl 4-morpholinocarbonyl 3-pyridyl 2-methyl-l-imidazolyl
3-pyridyl 5-methyl-l-imidazolyl
3-pyridyl 2-methylsulfonyl-l-imidazolyl
2-pyrimidyl 2- (aminosulfonyl) phenyl
2-pyrimidyl 2- (methylammosulfonyl) phenyl
2-pyrimidyl 1-pyrrolidinocarbonyl
2-pyrimidyl 2- (methylsulfonyl) phenyl
2-pyrimidyl 4-morpholino
2-pyrimidyl 2-(l'-CF3-tetrazol-2-yl)phenyl
2-pyrimidyl 4-morpholinocarbonyl
2-pyrimidyl 2-methyl-l-imidazolyl
2-pyrimidyl 5-methyl-l-imidazolyl
2-pyrimidyl 2-methylsulfonyl-l-imidazolyl
5-pyrimidyl 2- (aminosulfonyl) phenyl
5-pyrimidyl 2- (methylaminosulfonyl)phenyl
5-pyrimidyl 1-pyrrolidinocarbonyl
5-pyrimidyl 2- (methylsulfonyl) phenyl
5-pyrimidyl 4-morpholino
5-pyrimidyl 2- (1 ' -CF3 -tetrazol-2-yl) phenyl
5-pyrimidyl 4-morpho1inocarbony1
5-pyrimidyl 2-methyl-l-imidazolyl
5-pyrimidyl 5-methyl-l-imidazolyl
5-pyrimidyl 2-methylsulfonyl-l-imidazolyl
2-Cl-phenyl 2- (aminosulfonyl)phenyl
2-Cl-phenyl 2- (methylaminosulfonyl) phenyl
2-Cl-phenyl 1-pyrrolidinocarbonyl
2-Cl-phenyl 2- (methylsulfonyl) phenyl
2-Cl-phenyl 4-morpholino
2-Cl-phenyl 2- (l'-CF3-tetrazol-2-yl) phenyl
2-Cl-phenyl 4-morpholinocarbonyl
2-Cl-phenyl 2-methyl-l-imidazolyl
2-Cl-phenyl 5-methyl-l-imidazolyl
2-Cl-phenyl 2-methylsulfonyl-l-imidazolyl
2-F-phenyl 2- (aminosulfonyl) phenyl
2-F-phenyl 2- (methylaminosulfonyl ) phenyl
2-F-phenyl 1-pyrrolidinocarbonyl
2-F-phenyl 2- (methylsulfonyl) phenyl
2-F-phenyl 4-morpholino
2-F-phenyl 2- (l'-CF3-tetrazol-2-yl) phenyl
2-F-phenyl 4-morpho1inocarbony1
2-F-phenyl 2-methyl-1-imidazolyl
2-F-phenyl 5-methyl-l-imidazolyl
2-F-phenyl 2-methylsulfonyl-l-imidazolyl
2 , 6-diF-phenyl 2- (aminosulfonyl)phenyl
2, 6-diF-phenyl 2- (methylaminosulfonyl) phenyl
2, 6-diF-phenyl 1-pyrrolidinocarbonyl
2 , 6-diF-phenyl 2- (methylsulfonyl) phenyl
2 , 6-diF-phenyl 4-morpholino
2 , 6-diF-phenyl 2- (l'-CF3-tetrazol-2-yl) phenyl
2 , 6-diF-phenyl 4-morpholinocarbonyl
2 , 6-diF-phenyl 2-methyl-1-imidazolyl
2, 6-diF-phenyl 5-methyl-l-imidazolyl
2 , 6-diF-phenyl 2-methylsulfonyl-l-imidazolyl Table 4
Figure imgf000162_0001
Figure imgf000163_0001
hh ϋ Ji
Figure imgf000164_0001
zz aaa bbb
Figure imgf000165_0001
ggg hhh
Ex # Rl a A B
I CH3 phenyl 2- (aminosulfonyl) phenyl 2 CH3 phenyl 2- (methylaminosulfonyl)phenyl
3 CH3 phenyl 1-pyrrolidinocarbonyl
4 CH3 phenyl 2- (methylsulfonyl)phenyl
5 CH3 phenyl 4-morpholino
6 CH3 phenyl 2- (1' -CF3-tetrazol-2-yDphenyl 7 CH3 phenyl 4-morpholinocarbonyl
8 CH3 phenyl 2-methyl-l-imidazolyl
9 CH3 phenyl 5-methyl-l-imidazolyl
10 CH3 phenyl 2-methylsulfonyl-l-imidazolyl
II CH3 2-pyridyl 2- (aminosulfonyl) phenyl 12 CH3 2-pyridyl 2- (methylaminosulfonyl)phenyl
13 CH3 2-pyridyl 1-pyrrolidinocarbonyl
14 CH3 2-pyridyl 2- (methylsulfonyl)phenyl
15 CH3 2-pyridyl 4-morpholino
16 CH3 2-pyridyl 2- (1' -CF3-tetrazol-2-yDphenyl 17 CH3 2-pyridyl 4-morpholinocarbonyl
18 CH3 2-pyridyl 2-methyl-l-imidazolyl
19 CH3 2-pyridyl 5-methyl-l-imidazolyl
20 CH3 2-pyridyl 2-methylsulfonyl-l-imidazolyl
21 CH3 3-pyridyl 2- (aminosulfonyl) phenyl 22 CH3 3-pyridyl 2- (methylammosulfonyl)phenyl
23 CH3 3-pyridyl 1-pyrrolidinocarbonyl
24 CH3 3-pyridyl 2- (methylsulfonyl)phenyl
25 CH3 3-pyridyl 4-morpholino
26 CH3 3-pyridyl 2- (1' -CF3-tetrazol-2-yDphenyl 27 CH3 3-pyridyl 4-morpholinocarbonyl
28 CH3 3-pyridyl 2-methyl-l-imidazolyl
29 CH3 3-pyridyl 5-methyl-l-imidazolyl
30 CH3 3-pyridyl 2-methylsulfonyl-l-imidazolyl
31 CH3 2-pyrimidyl 2- (aminosulfonyl) phenyl 32 CH3 2-pyrimidyl 2- (methylaminosulfonyl) phenyl
33 CH3 2-pyrimidyl 1-pyrrolidinocarbonyl CH3 2-pyrimidyl 2- (methylsulfonyl ) phenyl CH3 2 -pyrimidyl 4-morpho1ino CH3 2 -pyrimidyl 2 - ( 1 ' -CF3 -tetrazol-2-yl ) phenyl CH3 2-pyrimidyl 4-morpholinocarbonyl CH3 2-pyrimidyl 2-methyl-l-imidazolyl CH3 2-pyrimidyl 5-methyl-l-imidazolyl CH3 2-pyrimidyl 2-methylsulfonyl-l-imidazolyl CH3 5-pyrimidyl 2 - (aminosulfonyl ) phenyl CH3 5-pyrimidyl 2- (methylaminosulfonyl) phenyl CH3 5-pyrimidyl 1-pyrrolidinocarbonyl CH3 5-pyrimidyl 2- (methylsulfonyl) phenyl CH3 5-pyrimidyl 4-morpho1ino CH3 5-pyrimidyl 2 - ( 1 ' -CF3 -tetrazol-2 -yl ) phenyl CH3 5-pyrimidyl 4-morpho1inocarbony1 CH3 5-pyrimidyl 2-methyl-l-imidazolyl CH3 5-pyrimidyl 5-methyl-l-imidazolyl CH3 5-pyrimidyl 2-methylsulfonyl-l-imidazolyl CH3 2-Cl-phenyl 2- (aminosulfonyl) phenyl CH3 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl CH3 2-Cl-phenyl 1-pyrrolidinocarbonyl CH3 2-Cl-phenyl 2- (methylsulfonyl) phenyl CH3 2-Cl-phenyl 4-morpho1ino CH3 2-Cl-phenyl 2- (1 ' -CF3 -tetrazol-2-yDphenyl CH3 2-Cl-phenyl 4-morpholinocarbonyl CH3 2-Cl-phenyl 2-methyl-l-imidazolyl CH3 2-Cl-phenyl 5-methyl-l-imidazolyl CH3 2-Cl-phenyl 2-methylsulfonyl-l-imidazolyl CH3 2-F-phenyl 2- (aminosulfonyl ) phenyl CH3 2-F-phenyl 2- (methylaminosulfonyl) phenyl CH 2-F-phenyl 1-pyrrolidinocarbonyl CH3 2-F-phenyl 2- (methylsulfonyl ) phenyl CH3 2-F-phenyl 4-morpho1ino CH3 2-F-phenyl 2 -( 1 ' -CF3 -tetrazol-2-yl) phenyl CH3 2-F-phenyl 4-morpholinocarbonyl CH3 2-F-phenyl 2-methyl-l-imidazolyl CH3 2-F-phenyl 5-methyl-l-imidazolyl CH3 2-F-phenyl 2-methylsulfonyl-l-imidazolyl CH3 2,6-diF-phenyl 2- (aminosulfonyl ) phenyl CH3 2,6-diF-phenyl 2- (methylaminosulfonyl) phenyl CH3 2,6-diF-phenyl 1-pyrrolidinocarbonyl CH3 2,6-diF-phenyl 2- (methylsulfonyl ) phenyl CH3 2,6-diF-phenyl 4-morpholino CH3 2,6-diF-phenyl 2 - ( 1 ' -CF3 -tetrazol-2-yl ) phenyl CH3 2,6-diF-phenyl 4-morpholinocarbonyl CH3 2,6-diF-phenyl 2-methyl-l-imidazolyl CH3 2,6-diF-phenyl 5-methyl-l-imidazolyl CH3 2,6-diF-phenyl 2-methylsulfonyl-l-imidazolyl CH2CH3 phenyl 2 - (aminosulfonyl ) phenyl CH2CH3 phenyl 2 - (methylaminosulfonyl ) phenyl CH2CH3 phenyl 1-pyrrolidinocarbonyl CH2CH3 phenyl 2- (methylsulfonyl) phenyl CH2CH3 phenyl 4-morpholino 86 CH2CH3 phenyl 2 - ( 1 ' -CF3 - tetrazol-2 -yD phenyl
87 CH2CH3 phenyl 4-morpholinocarbonyl
88 CH2CH3 phenyl 2-methyl-l-imidazolyl
89 CH2CH3 phenyl 5-methyl-l-imidazolyl
90 CH2CH3 phenyl 2-methylsulfonyl-l-imidazolyl
91 CH2CH3 2-pyridyl 2- (.aminosulfonyl ) phenyl
92 CH2CH3 2-pyridyl 2- (methylaminosulfonyl) phenyl
93 CH2CH3 2-pyridyl 1-pyrrolidinocarbonyl
94 CH2CH3 2-pyridyl 2- (methylsulfonyl ) phenyl
95 CH2CH3 2-pyridyl 4-morpholino
96 CH2CH3 2-pyridyl 2- (l'-CF3-tetrazol-2-yl) phenyl
97 CH2CH3 2-pyridyl 4-morpho1inocarbony1
98 CH2CH3 2-pyridyl 2-methyl-l-imidazolyl
99 CH2CH3 2-pyridyl 5-methyl-l-imidazolyl
100 CH2CH3 2-pyridyl 2-methylsulfonyl-l-imidazolyl
101 CH2CH3 3-pyridyl 2- (aminosulfonyl) phenyl
102 CH2CH3 3-pyridyl 2- (methylaminosulfonyl) phenyl
103 CH2CH3 3-pyridyl 1-pyrrolidinocarbonyl
104 CH2CH3 3-pyridyl 2- (methylsulfonyl) phenyl
105 CH2CH3 3-pyridyl 4-morpholino
106 CH2CH3 3-pyridyl 2- (1' -CF3-tetrazol-2-yl) phenyl
107 CH2CH3 3-pyridyl 4-morpholinocarbonyl
108 CH2CH3 3-pyridyl 2-methyl-l-imidazolyl
109 CH2CH3 3-pyridyl 5-methyl-l-imidazolyl
110 CH2CH3 3-pyridyl 2-methylsulfonyl-l-imidazolyl
111 CH2CH3 2-pyrimidyl 2- (aminosulfonyl) phenyl
112 CH2CH3 2-pyrimidyl 2- (methylammosulfonyl) phenyl
113 CH2CH3 2-pyrimidyl 1-pyrrolidinocarbonyl
114 CH2CH3 2-pyrimidyl 2- (methylsulfonyl) phenyl
115 CH2CH3 2-pyrimidyl 4-morpho1ino
116 CH2CH3 2-pyrimidyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl
117 CH2CH3 2-pyrimidyl 4-morpholinocarbonyl
118 CH2CH3 2-pyrimidyl 2-methyl-l-imidazolyl
119 CH2CH3 2-pyrimidyl 5-methyl-l-imidazolyl
120 CH2CH3 2-pyrimidyl 2-methylsulfonyl-l-imidazolyl
121 CH2CH3 5-pyrimidyl 2- (aminosulfonyl) phenyl
122 CH2CH3 5-pyrimidyl 2- (methylaminosulfonyl) phenyl
123 CH2CH3 5-pyrimidyl 1-pyrrolidinocarbonyl
124 CH2CH3 5-pyrimidyl 2- (methylsulfonyl ) phenyl
125 CH2CH3 5-pyrimidyl 4-morpho1ino
126 CH2CH3 5-pyrimidyl 2- ( 1 ' -CF3 -tetrazol-2 -yD phenyl
127 CH2CH3 5-pyrimidyl 4-morpholinocarbonyl
128 CH2CH3 5-pyrimidyl 2-methyl-l-imidazolyl
129 CH2CH3 5-pyrimidyl 5-methyl-l-imidazolyl
130 CH2CH3 5-pyrimidyl 2-methylsulfonyl-l-imidazolyl
131 CH2CH3 2-Cl-phenyl 2- (aminosulfonyl) phenyl
132 CH2CH3 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl
133 CH2CH3 2-Cl-phenyl 1-pyrrolidinocarbonyl
134 CH2CH3 2-Cl-phenyl 2- (methylsulfonyl) phenyl
135 CH2CH3 2-Cl-phenyl 4-morpholino
136 CH2CH3 2-Cl-phenyl 2-(l'-CF3-tetrazol-2-yl)phenyl
137 CH2CH3 2-Cl-phenyl 4-morpholinocarbonyl 138 CH2CH3 2-Cl-phenyl 2-methyl-1-imidazolyl
139 CH2CH3 2-Cl-phenyl 5-methyl-1-imidazolyl
140 CH2CH3 2-Cl-phenyl 2-methylsulfonyl-l-imidazolyl
141 CH2CH3 2-F-phenyl 2- (aminosulfonyl) phenyl
142 CH2CH3 2-F-phenyl 2- (methylaminosulfonyl) phenyl
143 CH2CH3 2-F-phenyl 1-pyrrolidinocarbonyl
144 CH2CH3 2-F-phenyl 2- (methylsulfonyl) phenyl
145 CH2CH3 2-F-phenyl 4-morpholino
146 CH2CH3 2-F-phenyl 2-(l'-CF3-tetrazol-2-yl)phenyl
147 CH2CH3 2-F-phenyl 4-morpholinocarbonyl
148 CH2CH3 2-F-phenyl 2-methyl-l-imidazolyl
149 CH2CH3 2-F-phenyl 5-methyl-l-imidazolyl
150 CH2CH3 2-F-phenyl 2-methylsulfonyl-l-imidazolyl
151 CH2CH3 2 , 6-diF-phenyl 2- (aminosulfonyl)phenyl
152 CH2CH3 2 , 6-diF-phenyl 2- (methylaminosulfonyl) phenyl
153 CH2CH3 2 , 6-diF-phenyl 1-pyrrolidinocarbonyl
154 CH2CH3 2 , 6-diF-phenyl 2- (methylsulfonyl) phenyl
155 CH2CH3 2 , 6-diF-phenyl 4-morpholino
156 CH2CH3 2 , 6-diF-phenyl 2- ( 1 ' -CF3 -tetrazol-2-yl) phenyl
157 CH2CH3 2 , 6-diF-phenyl 4-morpho1inocarbony1
158 CH2CH3 2 , 6-diF-phenyl 2-methyl-l-imidazolyl
159 CH2CH3 2 , 6-diF-phenyl 5-methyl-1-imidazolyl
160 CH2CH3 2, 6-diF-phenyl 2-methylsulfonyl-l-imidazolyl
161 CF3 phenyl 2- (aminosulfonyl ) phenyl
162 CF3 phenyl 2- (methylammosulfonyl) phenyl
163 CF3 phenyl 1-pyrro1idinocarbony1
164 CF3 phenyl 2- (methylsulfonyl) phenyl
165 CF3 phenyl 4-morpho1ino
166 CF3 phenyl 2- (l'-CF3-tetrazol-2-yDphenyl
167 CF3 phenyl 4-morpholinocarbonyl
168 CF3 phenyl 2-methyl-l-imidazolyl
169 CF3 phenyl 5-methyl-l-imidazolyl
170 CF3 phenyl 2-methylsulfonyl-l-imidazolyl
171 CF3 2-pyridyl 2- (aminosulfonyl) phenyl
172 CF3 2-pyridyl 2- (methylaminosulfonyl) phenyl
173 CF3 2-pyridyl 1-pyrrolidinocarbonyl
174 CF3 2-pyridyl 2- (methylsulfonyl) phenyl
175 CF3 2-pyridyl 4-morpholino
176 CF3 2-pyridyl 2-(l'-CF3-tetrazol-2-yl)phenyl
177 CF3 2-pyridyl 4-morpholinocarbonyl
178 CF3 2-pyridyl 2-methyl-l-imidazolyl
179 CF3 2-pyridyl 5-methyl-l-imidazolyl
180 CF3 2-pyridyl 2-methylsulfonyl-l-imidazolyl
181 CF3 3-pyridyl 2- (aminosulfonyl)phenyl
182 CF3 3-pyridyl 2- (methylammosulfonyl) phenyl
183 CF3 3-pyridyl 1-pyrrolidinocarbonyl
184 CF3 3-pyridyl 2- (methylsulfonyl) phenyl
185 CF3 3-pyridyl 4-morpho1ino
186 CF3 3-pyridyl 2- (1' -CF3-tetrazol-2-yl) phenyl
187 CF3 3-pyridyl 4-morpholinocarbonyl
188 CF3 3-pyridyl 2-methyl-l-imidazolyl
189 CF3 3-pyridyl 5-methyl-l-imidazolyl 190 CF3 3-pyridyl 2-methylsulfonyl-1-imidazolyl
191 CF3 2-pyrimidyl 2- (aminosulfonyl) phenyl
192 CF3 2-pyrimidyl 2- (methylammosulfonyl) phenyl
193 CF3 2-pyrimidyl 1-pyrrolidinocarbonyl
194 CF3 2-pyrimidyl 2- (methylsulfonyl) phenyl
195 CF3 2-pyrimidyl 4-morpholino
196 CF3 2-pyrimidyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl
197 CF3 2-pyrimidyl 4-morpholinocarbonyl
198 CF3 2-pyrimidyl 2-methyl-l-imidazolyl
199 CF3 2-pyrimidyl 5-methyl-l-imidazolyl
200 CF3 2-pyrimidyl 2-methylsulfonyl-l-imidazolyl
201 CF3 5-pyrimidyl 2- (aminosulfonyl) phenyl
202 CF3 5-pyrimidyl 2- (methylaminosulfonyl) phenyl
203 CF3 5-pyrimidyl 1-pyrrolidinocarbonyl
204 CF3 5-pyrimidyl 2- (methylsulfonyl) phenyl
205 CF3 5-pyrimidyl 4-morpholino
206 CF3 5-pyrimidyl 2- ( 1 ' -CF3 -tetrazol-2-yl ) phenyl
207 CF3 5-pyrimidyl 4-morpholinocarbonyl
208 CF3 5-pyrimidyl 2-methyl-l-imidazolyl
209 CF3 5-pyrimidyl 5-methyl-l-imidazolyl
210 CF3 5-pyrimidyl 2-methylsulfonyl-l-imidazolyl
211 CF3 2-Cl-phenyl 2- (aminosulfonyl ) phenyl
212 CF3 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl
213 CF3 2-Cl-phenyl 1-pyrrolidinocarbonyl
214 CF3 2-Cl-phenyl 2- (methylsulfonyl ) phenyl
215 CF3 2-Cl-phenyl 4-morpholino
216 CF3 2-Cl-phenyl 2- (l'-CF3-tetrazol-2-yl) phenyl
217 CF3 2-Cl-phenyl 4-morpholinocarbonyl
218 CF3 2-Cl-phenyl 2-methyl-l-imidazolyl
219 CF3 2-Cl-phenyl 5-methyl-l-imidazolyl
220 CF3 2-Cl-phenyl 2-methylsulfonyl-l-imidazolyl
221 CF3 2-F-phenyl 2- (aminosulfonyl) phenyl
222 CF3 2-F-phenyl 2 - (methylaminosulfonyl ) phenyl
223 CF3 2-F-phenyl 1-pyrrolidinocarbonyl
224 CF3 2-F-phenyl 2- (methylsulfonyl ) phenyl
225 CF3 2-F-phenyl 4-morpholino
226 CF3 2-F-phenyl 2- (l'-CF3-tetrazol-2-yl)phenyl
227 CF3 2-F-phenyl 4-morpholinocarbonyl
228 CF3 2-F-phenyl 2-methyl-l-imidazolyl
229 CF3 2-F-phenyl 5-methyl-l-imidazolyl
230 CF3 2-F-phenyl 2-methylsulfonyl-l-imidazolyl
231 CF3 2, 6-diF-phenyl 2- (aminosulfonyl) phenyl
232 CF3 2 , 6-diF-phenyl 2- (methylaminosulfonyl) phenyl
233 CF3 2, 6-diF-phenyl 1-pyrrolidinocarbonyl
234 CF3 2 , 6-diF-phenyl 2- (methylsulfonyl ) phenyl
235 CF3 2 , 6-diF-phenyl 4-morpholino
236 CF3 2, 6-diF-phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl
237 CF3 2, 6-diF-phenyl 4-morpholinocarbonyl
238 CF3 2 , 6-diF-phenyl 2-methyl-l-imidazolyl
239 CF3 2, 6-diF-phenyl 5-methyl-l-imidazolyl
240 CF3 2, 6-diF-phenyl 2-methylsulfonyl-l-imidazolyl
241 SCH3 phenyl 2- (aminosulfonyl) phenyl 242 SCH3 phenyl 2- (methylaminosulfonyl) phenyl
243 SCH3 phenyl 1-pyrrolidinocarbonyl
244 SCH3 phenyl 2- (methylsulfonyl) phenyl
245 SCH3 phenyl 4-morpholino
246 SCH3 phenyl 2-(l'-CF3-tetrazol-2-yl)phenyl
247 SCH3 phenyl 4-morpholinocarbonyl
248 SCH3 phenyl 2-methyl-l-imidazolyl
249 SCH3 phenyl 5-methyl-l-imidazolyl
250 SCH3 phenyl 2-methylsulfonyl-l-imidazolyl
251 SCH3 2-pyridyl 2- (aminosulfonyl) phenyl
252 SCH3 2-pyridyl 2- (methylaminosulfonyl) phenyl
253 SCH3 2-pyridyl 1-pyrrolidinocarbonyl
254 SCH3 2-pyridyl 2- (methylsulfonyl) phenyl
255 SCH3 2-pyridyl 4-morpholino
256 SCH3 2-pyridyl 2- (1' -CF3-tetrazol-2-yl) phenyl
257 SCH3 2-pyridyl 4-morpholinocarbonyl
258 SCH3 2-pyridyl 2-methyl-l-imidazolyl
259 SCH3 2-pyridyl 5-methyl-l-imidazolyl
260 SCH3 2-pyridyl 2-methylsulfonyl-l-imidazolyl
261 SCH3 3 -pyridyl 2- (aminosulfonyl) phenyl
262 SCH3 3 -pyridyl 2- (methylaminosulfonyl)phenyl
263 SCH3 3 -pyridyl 1-pyrrolidinocarbonyl
264 SCH3 3-pyridyl 2- (methylsulfonyl)phenyl
265 SCH3 3-pyridyl 4-morpholino
266 SCH3 3-pyridyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl
267 SCH3 3-pyridyl 4-morpholinocarbonyl
268 SCH 3-pyridyl 2-methyl-1-imidazolyl
269 SCH3 3-pyridyl 5-methyl-l-imidazolyl
270 SCH3 3-pyridyl 2-methylsulfonyl-l-imidazolyl
271 SCH3 2-pyrimidyl 2- (aminosulfonyl ) phenyl
272 SCH3 2-pyrimidyl 2- (methylaminosulfonyl)phenyl
273 SCH3 2-pyrimidyl 1-pyrrolidinocarbonyl
274 SCH3 2-pyrimidyl 2- (methylsulfonyl)phenyl
275 SCH3 2-pyrimidyl 4-morpho1ino
276 SCH3 2-pyrimidyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl
277 SCH3 2-pyrimidyl 4-morpho1inocarbony1
278 SCH3 2-pyrimidyl 2-methyl-l-imidazolyl
279 SCH3 2-pyrimidyl 5-methyl-l-imidazolyl
280 SCH3 2-pyrimidyl 2-methylsulfonyl-l-imidazolyl
281 SCH3 5-pyrimidyl 2- (aminosulfonyl) phenyl
282 SCH3 5-pyrimidyl 2- (methylaminosulfonyl) phenyl
283 SCH3 5-pyrimidyl 1-pyrrolidinocarbonyl
284 SCH3 5-pyrimidyl 2- (methylsulfonyl)phenyl
285 SCH3 5-pyrimidyl 4-morpho1ino
286 SCH3 5-pyrimidyl 2- (1 ' -CF3-tetrazol-2-yl)phenyl
287 SCH3 5-pyrimidyl 4-morpholinocarbonyl
288 SCH3 5-pyrimidyl 2-methyl-l-imidazolyl
289 SCH3 5-pyrimidyl 5-methyl-l-imidazolyl
290 SCH3 5-pyrimidyl 2-methylsulfonyl-l-imidazolyl
291 SCH3 2-Cl-phenyl 2- (aminosulfonyl) phenyl
292 SCH3 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl
293 SCH3 2-Cl-phenyl 1-pyrrolidinocarbonyl 294 SCH3 2-Cl-phenyl 2- (methylsulfonyl) phenyl
295 SCH3 2-Cl-phenyl 4-morpholino
296 SCH3 2-Cl-phenyl 2 - ( 1 ' -CF3 -tetrazol-2 -yl ) phenyl
297 SCH3 2-Cl-phenyl 4-morpholinocarbonyl 298 SCH3 2-Cl-phenyl 2-methyl-l-imidazolyl
299 SCH3 2-Cl-phenyl 5-raethyl-l-imidazolyl
300 SCH3 2-Cl-phenyl 2-methylsulfonyl-l-imidazolyl
301 SCH3 2-F-phenyl 2 - ( aminosulfonyl) phenyl
302 SCH3 2-F-phenyl 2 - (methylaminosulfonyl ) phenyl 303 SCH3 2-F-phenyl 1-pyrrolidinocarbonyl
304 SCH3 2-F-phenyl 2- (methylsulfonyl) phenyl
305 SCH3 2-F-phenyl 4-morpho1ino
306 SCH3 2-F-phenyl 2 - ( 1 ' -CF3 -tetrazol-2 -yl ) phenyl
307 SCH3 2-F-phenyl 4-morpholinocarbonyl 308 SCH3 2-F-phenyl 2-methyl-l-imidazolyl
309 SCH3 2-F-phenyl 5-methyl-l-imidazolyl
310 SCH3 2-F-phenyl 2-methylsulfonyl-l-imidazolyl
311 SCH3 2,6-diF-phenyl 2- (aminosulfonyl) phenyl
312 SCH3 2,6-diF-phenyl 2- (methylaminosulfonyl ) phenyl 313 SCH3 2,6-diF-phenyl 1-pyrrolidinocarbonyl
314 SCH3 2,6-diF-phenyl 2 - (methylsulfonyl ) phenyl
315 SCH3 2,6-diF-phenyl 4-morpholino
316 SCH3 2,6-diF-phenyl 2- (l ' -CF3 -tetrazol-2 -yD phenyl
317 SCH3 2,6-diF-phenyl 4-morpholinocarbonyl 318 SCH3 2,6-diF-phenyl 2-methyl-l-imidazolyl
319 SCH3 2,6-diF-phenyl 5-methyl-l-imidazolyl
320 SCH3 2,6-diF-phenyl 2-methylsulfonyl-l-imidazolyl
321 SOCH3 phenyl 2- (aminosulfonyl) phenyl
322 SOCH3 phenyl 2 - (methylaminosulfonyl ) phenyl 323 SOCH3 phenyl 1-pyrrolidinocarbonyl
324 SOCH3 phenyl 2- (methylsulfonyl) phenyl
325 SOCH3 phenyl 4-morpholino
326 SOCH3 phenyl 2 - ( 1 ' -CF3 -tetrazol-2-yl ) phenyl
327 SOCH3 phenyl 4-morpholinocarbonyl 328 SOCH3 phenyl 2-methyl-l-imidazolyl
329 SOCH3 phenyl 5-methyl-l-imidazolyl
330 SOCH3 phenyl 2-methylsulfonyl-l-imidazolyl
331 SOCH3 2-pyridyl 2- (aminosulfonyl) phenyl
332 SOCH3 2-pyridyl 2- (methylaminosulfonyl) phenyl 333 SOCH3 2-pyridyl 1-pyrrolidinocarbonyl
334 SOCH3 2-pyridyl 2- (methylsulfonyl) phenyl
335 SOCH3 2-pyridyl 4-morpholino
336 SOCH3 2-pyridyl 2 - ( 1 ' -CF3 -tetrazol-2-yl ) phenyl
337 SOCH3 2-pyridyl 4-morpholinocarbonyl 338 SOCH3 2-pyridyl 2-methyl-l-imidazolyl
339 SOCH3 2-pyridyl 5-methyl-l-imidazolyl
340 SOCH3 2-pyridyl 2-methylsulfonyl-l-imidazolyl
341 SOCH3 3-pyridyl 2- (aminosulfonyl) phenyl
342 SOCH3 3-pyridyl 2- (methylaminosulfonyl ) phenyl 343 SOCH3 3-pyridyl 1-pyrrolidinocarbonyl
344 SOCH3 3-pyridyl 2- (methylsulfonyl) phenyl
345 SOCH3 3-pyridyl 4-morpholino 346 SOCH3 3-pyridyl 2- (l'-CF3-tetrazol-2-yl) phenyl
347 SOCH3 3-pyridyl 4-morpho1inocarbony1
348 SOCH3 3-pyridyl 2-methyl-l-imidazolyl
349 SOCH3 3-pyridyl 5-methyl-l-imidazolyl 350 SOCH3 3-pyridyl 2-methylsulfonyl-1-imidazolyl
351 SOCH3 2-pyrimidyl 2- (.aminosulfonyl ) phenyl
352 SOCH3 2-pyrimidyl 2- (methylaminosulfonyl) phenyl
353 SOCH3 2-pyrimidyl 1-pyrrolidinocarbonyl
354 SOCH3 2-pyrimidyl 2- (methylsulfonyl ) phenyl 355 SOCH3 2-pyrimidyl 4-morpholino
356 SOCH3 2-pyrimidyl 2 - ( 1 ' -CF3 -tetrazol-2 -yl) phenyl
357 SOCH3 2-pyrimidyl 4-morpho1inocarbonyl
358 SOCH3 2-pyrimidyl 2-methyl-l-imidazolyl
359 SOCH3 2-pyrimidyl 5-methyl-l-imidazolyl 360 SOCH3 2-pyrimidyl 2-methylsulfonyl-l-imidazolyl
361 SOCH3 5-pyrimidyl 2- (aminosulfonyl) phenyl
362 SOCH3 5-pyrimidyl 2- (methylaminosulfonyl) phenyl 363 SOCH3 5-pyrimidyl 1-pyrrolidinocarbonyl 364 SOCH3 5-pyrimidyl 2- (methylsulfonyl) phenyl 365 SOCH3 5-pyrimidyl 4-morpholino
366 SOCH 5-pyrimidyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl
367 SOCH3 5-pyrimidyl 4-morpholinocarbonyl
368 SOCH3 5-pyrimidyl 2-methyl-l-imidazolyl
369 SOCH3 5-pyrimidyl 5-methyl-l-imidazolyl 370 SOCH3 5-pyrimidyl 2-methylsulfonyl-l-imidazolyl
371 SOCH3 2-Cl-phenyl 2- (aminosulfonyl ) phenyl
372 SOCH3 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl
373 SOCH3 2-Cl-phenyl 1-pyrrolidinocarbonyl
374 SOCH3 2-Cl-phenyl 2- (methylsulfonyl) phenyl 375 SOCH3 2-Cl-phenyl 4-morpholino
376 SOCH3 2-Cl-phenyl 2-(l'-CF3-tetrazol-2-yl)phenyl
377 SOCH3 2-Cl-phenyl 4-morpholinocarbonyl
378 SOCH3 2-Cl-phenyl 2-methyl-l-imidazolyl
379 SOCH3 2-Cl-phenyl 5-methyl-l-imidazolyl 380 SOCH3 2-Cl-phenyl 2-methylsulfonyl-l-imidazolyl
381 SOCH3 2-F-phenyl 2- (aminosulfonyl ) phenyl
382 SOCH3 2-F-phenyl 2 - (methylaminosulfonyl ) phenyl
383 SOCH3 2-F-phenyl 1-pyrrolidinocarbonyl
384 SOCH3 2-F-phenyl 2 - (methylsulfonyl ) phenyl 385 SOCH3 2-F-phenyl 4-morpholino
386 SOCH3 2-F-phenyl 2- (l'-CF3-tetrazol-2-y phenyl
387 SOCH3 2-F-phenyl 4-morpholinocarbonyl
388 SOCH3 2-F-phenyl 2-methyl-l-imidazolyl
389 SOCH3 2-F-phenyl 5-methyl-l-imidazolyl 390 SOCH3 2-F-phenyl 2-methylsulfonyl-l-imidazolyl
391 SOCH3 2,6-diF-phenyl 2 - (aminosulfonyl ) phenyl
392 SOCH3 2,6-diF-phenyl 2- (methylaminosulfonyl) phenyl
393 SOCH3 2,6-diF-phenyl 1-pyrrolidinocarbonyl
394 SOCH3 2,6-diF-phenyl 2- (methylsulfonyl ) phenyl 395 SOCH3 2,6-diF-phenyl 4-morpholino
396 SOCH3 2,6-diF-phenyl 2 - ( 1 ' -CF3 -tetrazol-2-yl ) phenyl
397 SOCH3 2,6-diF-phenyl 4-morpho1inocarbony1 398 SOCH3 2 , 6-diF-phenyl 2-methyl-l-imidazolyl 399 SOCH3 2 , 6-diF-phenyl 5-methyl-l-imidazolyl 400 SOCH3 2 , 6-diF-phenyl 2-methylsulfonyl-1-imidazolyl 401 SO2CH3 phenyl 2- (aminosulfonyl) phenyl 402 S02CH3 phenyl 2- (methylaminosulfonyl) phenyl 403 S02CH3 phenyl 1-pyrrolidinocarbonyl 404 Sθ2CH3 phenyl 2- (methylsulfonyl) phenyl 405 SO2CH3 phenyl 4-morpholino 406 SO2CH3 phenyl 2- (1 ' -CF3-tetrazol-2-yl ) phenyl 407 SO2CH3 phenyl 4-morpholinocarbonyl 408 Sθ2CH3 phenyl 2-methyl-l-imidazolyl 409 S02CH3 phenyl 5-methyl-l-imidazolyl 410 S0 CH3 phenyl 2-methylsulfonyl-l-imidazolyl 411 S02CH3 2-pyridyl 2- (aminosulfonyl) phenyl 412 S02CH3 2-pyridyl 2- (methylaminosulfonyl) phenyl 413 Sθ2CH3 2-pyridyl 1-pyrrolidinocarbonyl 414 SO2CH3 2-pyridyl 2- (methylsulfonyl ) phenyl 415 SO2CH3 2-pyridyl 4-morpholino 416 Sθ2CH3 2-pyridyl 2- (l'-CF3-tetrazol-2-yl) phenyl 417 S02CH3 2-pyridyl 4-morpholinocarbonyl 418 Sθ2CH3 2-pyridyl 2-methyl-l-imidazolyl 419 SO2CH3 2-pyridyl 5-methyl-l-imidazolyl 420 SO2CH3 2-pyridyl 2-methylsulfonyl-l-imidazolyl 421 SO2CH3 3-pyridyl 2- (aminosulfonyl ) phenyl 422 SO2CH3 3-pyridyl 2- (methylaminosulfonyl) phenyl 423 SO2CH3 3-pyridyl 1-pyrrolidinocarbonyl 424 SO2CH3 3-pyridyl 2- (methylsulfonyl) phenyl 425 Sθ2CH3 3-pyridyl 4-morpho1ino 426 Sθ2CH3 3-pyridyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 427 S0 CH3 3-pyridyl 4-morpholinocarbonyl 428 SO2CH3 3-pyridyl 2-methyl-l-imidazolyl 429 SO2CH3 3-pyridyl 5-methyl-l-imidazolyl 430 SO2CH3 3-pyridyl 2-methylsulfonyl-1-imidazolyl 431 SO2CH3 2-pyrimidyl 2- (aminosulfonyl) phenyl 432 SO2CH3 2-pyrimidyl 2- (methylaminosulfonyl) phenyl 433 SO2CH3 2-pyrimidyl 1-pyrrolidinocarbonyl 434 S02CH3 2-pyrimidyl 2- (methylsulfonyl) phenyl 435 SO2CH3 2-pyrimidyl 4-morpholino 436 S0CH3 2-pyrimidyl 2- ( 1 ' -CF3 -tetrazol-2-yl) phenyl 437 S02CH3 2-pyrimidyl 4-morpholinocarbonyl 438 Sθ2CH3 2-pyrimidyl 2-methyl-l-imidazolyl 439 SO2CH3 2-pyrimidyl 5-methyl-l-imidazolyl 440 S02CH3 2-pyrimidyl 2-methylsulfonyl-l-imidazolyl 441 SO2CH3 5-pyrimidyl 2- (aminosulfonyl) phenyl 442 SO2CH3 5-pyrimidyl 2- (methylammosulfonyl) phenyl 443 S02CH3 5-pyrimidyl 1-pyrrolidinocarbonyl 444 SO2CH3 5-pyrimidyl 2- (methylsulfonyl ) phenyl 445 SO2CH3 5-pyrimidyl 4-morpho1ino 446 SO2CH3 5-pyrimidyl 2- (1 ' -CF3 -tetrazol-2-yl) phenyl 447 SO2CH3 5-pyrimidyl 4-morpholinocarbonyl 448 SO2CH3 5-pyrimidyl 2-methyl-l-imidazolyl 449 SO2CH3 5-pyrimidyl 5-methyl-l-imidazolyl 450 S02CH3 5-pyrimidyl 2-methylsulfonyl-1-imidazolyl
451 S02CH3 2-Cl-phenyl 2- (aminosulfonyl) phenyl
452 SO2CH3 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl
453 Sθ2CH3 2-Cl-phenyl 1-pyrrolidinocarbonyl
454 S02CH3 2-Cl-phenyl 2- (methylsulfonyl) phenyl
455 S02CH3 2-Cl-phenyl 4-morpholino
456 S02CH3 2-Cl-phenyl 2- ( 1 ' -CF3 -tetrazol-2-yl ) phenyl
457 SO2CH3 2-Cl-phenyl 4-morpholinocarbonyl
458 SO2CH3 2-Cl-phenyl 2-methyl-1-imidazolyl
459 S02CH3 2-Cl-phenyl 5-methyl-1-imidazolyl
460 S02CH3 2-Cl-phenyl 2-methylsulfonyl-l-imidazolyl
461 S02CH3 2-F-phenyl 2- (aminosulfonyl) phenyl
462 S02CH3 2-F-phenyl 2- (methylaminosulfonyl) phenyl
463 S02CH3 2-F-phenyl 1-pyrrolidinocarbonyl
464 S02CH3 2-F-phenyl 2- (methylsulfonyl) phenyl
465 SO2CH3 2-F-phenyl 4-morpholino
466 SO2CH3 2-F-phenyl 2- ( 1 ' -CF3 -tetrazol-2-yl ) phenyl
467 SO2CH3 2-F-phenyl 4-morpholinocarbonyl
468 SO2CH3 2-F-phenyl 2-methyl-1-imidazolyl
469 S02CH3 2 -F-phenyl 5-methyl-l-imidazolyl
470 SO2CH3 2-F-phenyl 2-methylsulfonyl-l-imidazolyl
471 SO2CH3 2 , 6-diF-phenyl 2- (aminosulfonyl) phenyl
472 SO2CH3 2 , 6-diF-phenyl 2- (methylaminosulfonyl) phenyl
473 SO2CH3 2, 6-diF-phenyl 1-pyrrolidinocarbonyl
474 SO2CH3 2, 6-diF-phenyl 2- (methylsulfonyl) phenyl
475 S02CH3 2 , 6-diF-phenyl 4-morpholino
476 SO2CH3 2, 6-diF-phenyl 2- (l'-CF3-tetrazol-2-yl) phenyl
477 SO2CH3 2, 6-diF-phenyl 4-morpholinocarbonyl
478 S02CH3 2 , 6-diF-phenyl 2-methyl-l-imidazolyl
479 SO2CH3 2, 6-diF-phenyl 5-methyl-l-imidazolyl
480 SO2CH3 2, 6-diF-phenyl 2-methylsulfonyl-1-imidazolyl
481 CH2NH phenyl 2- (aminosulfonyl) phenyl -SO2CH3
482 CH2NH phenyl 2- (methylammosulfonyl) phenyl -SO2CH3
483 CH2NH phenyl 1-pyrrolidinocarbonyl -SO2CH3
484 CH2NH phenyl 2- (methylsulfonyl ) phenyl -SO2CH3
485 CH2NH phenyl 4-morpholino -S02CH3
486 CH2NH phenyl 2- (1 ' -CF3 -tetrazol-2-yl) phenyl -S02CH3
487 CH2 H phenyl 4-morpho1inocarbony1 -SO2CH3
488 CH2NH phenyl 2-methyl-1-imidazolyl -SO2CH3
489 CH2NH phenyl 5-methyl-l-imidazolyl -SO2CH3
490 CH2 H phenyl 2-methylsulfonyl-l-imidazolyl -SO2CH3
491 CH2NH 2-pyridyl 2- (aminosulfonyl) phenyl -S0 CH3
492 CH2NH 2-pyridyl 2- (methylaminosulfonyl) phenyl -S02CH3
493 CH2NH 2-pyridyl 1-pyrrolidinocarbonyl -S02CH3
494 CH2NH 2-pyridyl 2 - (methylsulfonyl ) henyl -SO2CH3
495 CH2NH 2-pyridyl 4-morpholino -SO2CH3
496 CH2 H 2-pyridyl 2- ( 1 ' -CF3 -tetrazol-2-yl ) phenyl -S02CH3
497 CH2NH 2-pyridyl 4-morpholinocarbonyl -S02CH3
498 CH2NH 2-pyridyl 2-methyl-l-imidazolyl -SO2CH3
499 CH2NH 2-pyridyl 5-methyl-l-imidazolyl
500 CH2NH 2-pyridyl 2-methylsulfonyl-l-imidazolyl -SO2CH3
501 CH2 H 3-pyridyl 2- (aminosulfonyl) phenyl -S02CH3
502 CH2NH 3-pyridyl 2- (methylaminosulfonyl) phenyl -Sθ2CH3
503 CH2NH 3-pyridyl 1-pyrrolidinocarbonyl -S02CH3
504 CH2 H 3-pyridyl 2- (methylsulfonyl) phenyl -S02CH3
505 CH2NH 3-pyridyl 4-morpholino -S02CH3
506 CH2 H 3-pyridyl 2- ( 1 ' -CF3-tetrazol-2-yl) phenyl -S02CH3
507 CH2 H 3-pyridyl 4-morpholinocarbonyl -SO2CH3
508 CH2NH 3-pyridyl 2-methyl-l-imidazolyl -SO2CH3
509 CH2 H 3-pyridyl 5-methyl-l-imidazolyl -SO2CH3
510 CH2 H 3-pyridyl 2-methylsulfonyl-l-imidazolyl -SO2CH3
511 CH2NH 2-pyrimidyl 2- (aminosulfonyl)phenyl -S02CH3
512 CH2NH 2-pyrimidyl 2- (methylaminosulfonyl ) phenyl -S02CH3
513 CH2NH 2-pyrimidyl 1-pyrrolidinocarbonyl -S02CH3
514 CH H 2-pyrimidyl 2 - (methylsulfonyl ) phenyl -Sθ2CH3
515 CH2NH 2-pyrimidyl 4-morpho1ino -S02CH3
516 CH2 H 2-pyrimidyl 2- ( 1 ' -CF3-tetrazol-2-yl ) phenyl -S02CH3
517 CH2 H 2-pyrimidyl 4-morpholinocarbonyl -S02CH3 518 CH2NH 2-pyrimidyl 2-methyl-l-imidazolyl -S02CH3
519 CH2 H 2-pyrimidyl 5-methyl-1-imidazolyl -SO2CH3
520 CH2 H 2-pyrimidyl 2-methylsulfonyl-l-imidazolyl -SO2CH3
521 CH2NH 5-pyrimidyl 2- (aminosulfonyl) phenyl -SO2CH3
522 CH2NH 5-pyrimidyl 2- (methylaminosulfonyl) phenyl -S02CH3
523 CH2NH 5-pyrimidyl 1-pyrrolidinocarbonyl -S02CH3
524 CH2NH 5-pyrimidyl 2- (methylsulfonyl) phenyl -S02CH3
525 CH2NH 5-pyrimidyl 4-morpho1ino -SO2CH3
526 CH2 H 5-pyrimidyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl -SO2CH3
527 CH2NH 5-pyrimidyl 4-morpholinocarbonyl -S02CH3
528 CH2 H 5-pyrimidyl 2-methyl-l-imidazolyl -S02CH3
529 CH2NH 5-pyrimidyl 5-methyl-l-imidazolyl -S02CH3
530 CH2NH 5-pyrimidyl 2-methylsulfonyl-l-imidazolyl -S02CH3
531 CH2NH 2-Cl-phenyl 2- (aminosulfonyl) phenyl -S02CH3
532 CH2NH 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl -S02CH3
533 CH2 H 2-Cl-phenyl 1-pyrrolidinocarbonyl -S02CH3
534 CH2NH 2-Cl-phenyl 2- (methylsulfonyl) phenyl -S02CH3
535 CH2 H 2-Cl-phenyl 4-morpho1ino -S02CH3
536 CH2NH 2-Cl-phenyl 2- ( 1 ' -CF3 -tetrazol-2 -yD phenyl -S02CH3
537 CH2 H 2-Cl-phenyl 4-morpholinocarbonyl -SO2CH3
538 CH2NH 2-Cl-phenyl 2-methyl-l-imidazolyl -S02CH3
539 CH2NH 2-Cl-phenyl 5-methyl-1-imidazoly1 -S02CH3
540 CH2NH 2-Cl-phenyl 2-methylsulfonyl-l-imidazolyl -S0CH3
541 CH2NH 2-F-phenyl 2- (aminosulfonyl) phenyl -S02CH3
542 CH2NH 2-F-phenyl 2- (methylammosulfonyl) phenyl -S02CH3
543 CH2NH 2-F-phenyl 1-pyrrolidinocarbonyl -SO2CH3 544 CH2NH 2-F-phenyl 2 - (methylsulfonyl ) phenyl -S02CH3
545 CH2NH 2-F-phenyl 4-morpholino -SO2CH3
546 CH2NH 2-F-phenyl 2- ( 1 ' -CF3 - tetrazol-2 -yD phenyl -SO2CH3
547 CH2 H 2-F-phenyl 4-morpholinocarbonyl -SO2CH3
548 CH2 H 2-F-phenyl 2-methyl-l-imidazolyl -SO2CH3
549 CH2 H 2-F-phenyl 5-methyl-l-imidazolyl -SO2CH3
550 CHNH 2-F-phenyl 2-methylsulfonyl-l-imidazolyl -SO2CH3
551 CH2 H 2, 6-diF-phenyl 2- (aminosulfonyl) phenyl -SO2CH3
552 CH2NH 2, 6-diF-phenyl 2- (methylaminosulfonyl) phenyl -S02CH3
553 CH2NH 2, 6-diF-phenyl 1-pyrrolidinocarbonyl -S02CH3
554 CH2 H 2, 6-diF-phenyl 2- (methylsulfonyl) phenyl -SO2CH3
555 CH2NH 2, 6-diF-phenyl 4-morpho1ino -SO2CH3
556 CH2NH 2, 6-diF-phenyl 2- ( 1 ' -CF3 -tetrazol-2-yl ) phenyl -SO2CH3
557 CH2 H 2, 6-diF-phenyl 4-morpholinocarbonyl -SO2CH3
558 CH H 2,6-diF-phenyl 2-methyl-l-imidazolyl -SO2CH3
559 CH2NH 2, 6-diF-phenyl 5-methyl-l-imidazolyl -SO2CH3
560 CH2NH 2, 6-diF-phenyl 2-methylsulfonyl-l-imidazolyl -SO2CH3
561 Cl phenyl 2- (aminosulfonyl)phenyl
562 Cl phenyl 2- (methylaminosulfonyl ) phenyl
563 Cl phenyl 1-pyrrolidinocarbonyl
564 Cl phenyl 2- (methylsulfonyl) phenyl
565 Cl phenyl 4-morpho1ino
566 Cl phenyl 2- ( 1 ' -CF3 -tetrazol-2 -yD phenyl
567 Cl phenyl 4-morpholinocarbonyl
568 Cl phenyl 2-methyl-l-imidazolyl
569 Cl phenyl 5-methyl-l-imidazolyl
570 Cl phenyl 2-methylsulfonyl-l-imidazolyl
571 Cl 2-pyridyl 2- (aminosulfonyl) phenyl
572 Cl 2-pyridyl 2- (methylammosulfonyl) phenyl
573 Cl 2-pyridyl 1-pyrrolidinocarbonyl
574 Cl 2-pyridyl 2- (methylsulfonyl)phenyl
575 Cl 2-pyridyl 4-morpholino
576 Cl 2-pyridyl 2- ( 1 ' -CF3 -tetrazol-2-yl) phenyl
577 Cl 2-pyridyl 4-morpho1inocarbonyl
578 Cl 2-pyridyl 2-methyl-l-imidazolyl
579 Cl 2-pyridyl 5-methyl-l-imidazolyl 580 Cl 2-pyridyl 2-methylsulfonyl-1-imidazolyl
581 Cl 3-pyridyl 2- (aminosulfonyl) phenyl
582 Cl 3-pyridyl 2- (methylaminosulfonyl)phenyl
583 Cl 3-pyridyl 1-pyrrolidinocarbonyl
584 Cl 3-pyridyl 2- (methylsulfonyl) phenyl
585 Cl 3-pyridyl 4-morpholino
586 Cl 3-pyridyl 2- ( ' -CF3-tetrazol-2-yDphenyl
587 Cl 3-pyridyl 4-morpholinocarbonyl
588 Cl 3-pyridyl 2-methyl-1-imidazolyl
589 Cl 3-pyridyl 5-methyl-l-imidazolyl
590 Cl 3-pyridyl 2-methylsulfonyl-l-imidazolyl
591 Cl 2-pyrimidyl 2- (aminosulfonyl) phenyl
592 Cl 2-pyrimidyl 2- (methylaminosulfonyl)phenyl
593 Cl 2-pyrimidyl 1-pyrrolidinocarbonyl
594 Cl 2-pyrimidyl 2- (methylsulfonyl) phenyl
595 Cl 2-pyrimidyl 4-morpholino
596 Cl 2-pyrimidyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl
597 Cl 2-pyrimidyl 4-morpho1inocarbony1
598 Cl 2-pyrimidyl 2-methyl-l-imidazolyl
599 Cl 2-pyrimidyl 5-methyl-l-imidazolyl
600 Cl 2-pyrimidyl 2-methylsulfonyl-l-imidazolyl
601 Cl 5-pyrimidyl 2- (aminosulfonyl) phenyl
602 Cl 5-pyrimidyl 2- (methylaminosulfonyl)phenyl
603 Cl 5-pyrimidyl 1-pyrrolidinocarbonyl
604 Cl 5-pyrimidyl 2- (methylsulfonyl) phenyl
605 Cl 5-pyrimidyl 4-morpholino
606 Cl 5-pyrimidyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl
607 Cl 5-pyrimidyl 4-morpho1inocarbony1
608 Cl 5-pyrimidyl 2-methyl-l-imidazolyl
609 Cl 5-pyrimidyl 5-methyl-l-imidazolyl
610 Cl 5-pyrimidyl 2-methylsulfonyl-l-imidazolyl
611 Cl 2-Cl-phenyl 2- (aminosulfonyl)phenyl
612 Cl 2-Cl-phenyl 2- (methylammosulfonyl)phenyl
613 Cl 2-Cl-phenyl 1-pyrrolidinocarbonyl
614 Cl 2-Cl-phenyl 2- (methylsulfonyl) phenyl
615 Cl 2-Cl-phenyl 4-morpholino
616 Cl 2-Cl-phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl
617 Cl 2-Cl-phenyl 4-morpholinocarbonyl
618 Cl 2-Cl-phenyl 2-methyl-l-imidazolyl
619 Cl 2-Cl-phenyl 5-methyl-l-imidazolyl
620 Cl 2-Cl-phenyl 2-methylsulfonyl-l-imidazolyl
621 Cl 2-F-phenyl 2- (aminosulfonyl) phenyl
622 Cl 2-F-phenyl 2- (methylaminosulfonyl)phenyl
623 Cl 2-F-phenyl 1-pyrrolidinocarbonyl
624 Cl 2-F-phenyl 2- (methylsulfonyl) phenyl
625 Cl 2-F-phenyl 4-morpholino
626 Cl 2-F-phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl
627 Cl 2-F-phenyl 4-morpho1inocarbony1
628 Cl 2-F-phenyl 2-methyl-l-imidazolyl
629 Cl 2-F-phenyl 5-methyl-l-imidazolyl
630 Cl 2-F-phenyl 2-methylsulfonyl-1-imidazolyl
631 Cl 2, 6-diF-phenyl 2- (aminosulfonyl) phenyl
632 Cl 2 , 6-diF-phenyl 2- (methylaminosulfonyl)phenyl
633 Cl 2 , 6-diF-phenyl 1-pyrrolidinocarbonyl
634 Cl 2 , 6-diF-phenyl 2- (methylsulfonyl) phenyl
635 Cl 2 , 6-diF-phenyl 4-morpholino 636 Cl 2 , 6-diF-phenyl 2 - ( 1 ' -CF3 -tetrazol-2 -yl ) phenyl
637 Cl 2 , 6-diF-phenyl 4-morpholinocarbonyl
638 Cl 2, 6-diF-phenyl 2-methyl-l-imidazolyl
639 Cl 2 , 6-diF-phenyl 5-methyl-1-imidazolyl
640 Cl 2, 6-diF-phenyl 2-methylsulfonyl-l-imidazolyl
641 F phenyl 2- (aminosulfonyl) phenyl
642 F phenyl 2- (methylaminosulfonyl ) phenyl
643 F phenyl 1-pyrrolidinocarbonyl
644 F phenyl 2- (methylsulfonyl) phenyl
645 F phenyl 4-morpho1ino
646 F phenyl 2 - ( 1 ' -CF3 -tetrazol-2 -yD phenyl
647 F phenyl 4-morpholinocarbonyl
648 F phenyl 2-methyl-l-imidazolyl
649 F phenyl 5-methyl-l-imidazolyl
650 F phenyl 2-methylsulfonyl-l-imidazolyl
651 F 2-pyridyl 2- (aminosulfonyl) phenyl
652 F 2-pyridyl 2- (methylaminosulfonyl) phenyl
653 F 2-pyridyl 1-pyrrolidinocarbonyl
654 F 2-pyridyl 2- (methylsulfonyl) phenyl
655 F 2-pyridyl 4-morpholino
656 F 2-pyridyl 2- ( 1 ' -CF3 -tetrazol-2-yl ) phenyl
657 F 2-pyridyl 4-morpholinocarbonyl
658 F 2-pyridyl 2-methyl-1-imidazolyl
659 F 2-pyridyl 5-methyl-l-imidazolyl
660 F 2-pyridyl 2-methylsulfonyl-l-imidazolyl
661 F 3-pyridyl 2- (aminosulfonyl) phenyl
662 F 3 -pyridyl 2- (methylaminosulfonyl) phenyl
663 F 3-pyridyl 1-pyrrolidinocarbonyl
664 F 3 -pyridyl 2- (methylsulfonyl) phenyl
665 F 3-pyridyl 4-morpho1ino
666 F 3-pyridyl 2- (1 ' -CF3-tetrazol-2-yDphenyl
667 F 3 -pyridyl 4-morpholinocarbonyl
668 F 3 -pyridyl 2-methyl-l-imidazolyl
669 F 3-pyridyl 5-methyl-l-imidazolyl
670 F 3-pyridyl 2-methylsulfonyl-l-imidazolyl
671 F 2-pyrimidyl 2- (aminosulfonyl) phenyl
672 F 2-pyrimidyl 2- (methylaminosulfonyl) phenyl
673 F 2-pyrimidyl 1-pyrrolidinocarbonyl
674 F 2-pyrimidyl 2- (methylsulfonyl) phenyl
675 F 2-pyrimidyl 4-morpholino
676 F 2-pyrimidyl 2- (1 ' -CF3 -tetrazol-2-yDphenyl
677 F 2-pyrimidyl 4-morpholinocarbonyl
678 F 2-pyrimidyl 2-methyl-l-imidazolyl
679 F 2-pyrimidyl 5-methyl-l-imidazolyl
680 F 2-pyrimidyl 2-methylsulfonyl-l-imidazolyl
681 F 5-pyrimidyl 2- (aminosulfonyl) phenyl
682 F 5-pyrimidyl 2- (methylaminosulfonyl) phenyl
683 F 5-pyrimidyl 1-pyrrolidinocarbony1
684 F 5-pyrimidyl 2- (methylsulfonyl) phenyl
685 F 5-pyrimidyl 4-morpholino
686 F 5-pyrimidyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl
687 F 5-pyrimidyl 4-morpholinocarbonyl
688 F 5-pyrimidyl 2-methyl-1-imidazolyl
689 F 5-pyrimidyl 5-methyl-1-imidazolyl
690 F 5-pyrimidyl 2-methylsulfonyl-l-imidazolyl
691 F 2-Cl-phenyl 2- (aminosulfonyl) phenyl 692 F 2-Cl-phenyl 2- (methylammosulfonyl) phenyl 693 F 2-Cl-phenyl 1-pyrrolidinocarbonyl 694 F 2-Cl-phenyl 2- (methylsulfonyl) phenyl 695 F 2-Cl-phenyl 4-morpholino 696 F 2-Cl-phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 697 F 2-Cl-phenyl 4-morpholinocarbonyl 698 F 2-Cl-phenyl 2-methyl-1-imidazolyl 699 F 2-Cl-phenyl 5-methyl-l-imidazolyl 700 F 2-Cl-phenyl 2-methylsulfonyl-1-imidazolyl 701 F 2-F-phenyl 2- (aminosulfonyl) phenyl 702 F 2-F-phenyl 2- (methylaminosulfonyl ) phenyl 703 F 2-F-phenyl 1-pyrrolidinocarbonyl 704 F 2-F-phenyl 2- (methylsulfonyl) phenyl 705 F 2-F-phenyl 4-morpholino 706 F 2-F-phenyl 2 - ( 1 ' -CF3 -tetrazol-2-yl ) phenyl 707 F 2-F-phenyl 4-morpho1inocarbonyl 708 F 2-F-phenyl 2-methyl-l-imidazolyl 709 F 2-F-phenyl 5-methyl-1-imidazolyl 710 F 2-F-phenyl 2-methylsulfonyl-l-imidazolyl 711 F 2, 6-diF-phenyl 2- (aminosulfonyl)phenyl 712 F 2, 6-diF-phenyl 2 - (methylaminosulfonyl ) phenyl 713 F 2, 6-diF-phenyl 1-pyrrolidinocarbonyl 714 F 2, 6-diF-phenyl 2- (methylsulfonyl) phenyl 715 F 2 , 6-diF-phenyl 4-morpho1ino 716 F 2 , 6-diF-phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 717 F 2, 6-diF-phenyl 4-morpholinocarbonyl 718 F 2, 6-diF-phenyl 2-methyl-l-imidazolyl 719 F 2, 6-diF-phenyl 5-methyl-l-imidazolyl 720 F 2, 6-diF-phenyl 2-methylsulfonyl-l-imidazolyl 721 C02CH3 phenyl 2- (aminosulfonyl) phenyl 722 C02CH3 phenyl 2- (methylaminosulfonyl ) phenyl 723 C02CH3 phenyl 1-pyrrolidinocarbonyl 724 C02CH3 phenyl 2- (methylsulfonyl) phenyl 725 CO2CH3 phenyl 4-morpholino 726 CO2CH3 phenyl 2- ( 1 ' -CF3-tetrazol-2-yl ) phenyl 727 CO2CH3 phenyl 4-morpholinocarbonyl 728 CO2CH3 phenyl 2 -methyl-1-imidazolyl 729 CO2CH3 phenyl 5-methyl-l-imidazolyl 730 CO2CH3 phenyl 2-methylsulfonyl-l-imidazolyl 731 CO2CH3 2-pyridyl 2- (aminosulfonyl) phenyl 732 C02CH3 2-pyridyl 2- (methylaminosulfonyl) phenyl 733 C02CH3 2-pyridyl 1-pyrrolidinocarbonyl 734 C02CH3 2-pyridyl 2- (methylsulfonyl) phenyl 735 CO2CH3 2-pyridyl 4-morpholino 736 CO2CH3 2-pyridyl 2- ( 1 ' -CF3-tetrazol-2-yl) phenyl 737 CO2CH3 2-pyridyl 4-morpholinocarbonyl 738 CO2CH3 2-pyridyl 2-methyl-l-imidazolyl 739 CO2CH3 2-pyridyl 5-methyl-l-imidazolyl 740 C02CH3 2-pyridyl 2-methylsulfonyl-l-imidazolyl 741 Cθ2CH3 3-pyridyl 2- (aminosulfonyl)phenyl 742 Cθ2CH3 3-pyridyl 2- (methylaminosulfonyl ) phenyl 743 C02CH3 3-pyridyl 1-pyrrolidinocarbonyl 744 C02CH3 3-pyridyl 2- (methylsulfonyl) phenyl 745 CO2CH3 3-pyridyl 4-morpho1ino 746 C02CH3 3 -pyridyl 2- (l'-CF3-tetrazol-2-yl)phenyl
747 C02CH3 3 -pyridyl 4-morpholinocarbonyl
748 C02CH3 3 -pyridyl 2-methyl-1-imidazolyl
749 C02CH3 3 -pyridyl 5-methyl-1-imidazolyl
750 CO2CH3 3 -pyridyl 2-methylsulfonyl-l-imidazolyl
751 CO2CH3 2-pyrimidyl 2- (aminosulfonyl)phenyl
752 C02CH3 2 -pyrimidyl 2- (methylaminosulfonyl)phenyl
753 CO2CH3 2-pyrimidyl 1-pyrro1idinocarbony1
754 CO2CH3 2-pyrimidyl 2- (methylsulfonyl)phenyl
755 CO2CH3 2-pyrimidyl 4-morpholino
756 CO2CH3 2-pyrimidyl 2- (l'-CF3-tetrazol-2-yl) phenyl
757 CO2CH3 2-pyrimidyl 4-morpholinocarbonyl
758 CO2CH3 2-pyrimidyl 2-methyl-l-imidazolyl
759 CO2CH3 2 -pyrimidyl 5-methyl-1-imidazolyl
760 CO2CH3 2-pyrimidyl 2-methylsulfonyl-l-imidazolyl
761 C02CH3 5-pyrimidyl 2- (aminosulfonyl) phenyl
762 C02CH3 5-pyrimidyl 2- (methylaminosulfonyl) phenyl
763 C02CH3 5-pyrimidyl 1-pyrrolidinocarbonyl
764 CO2CH3 5-pyrimidyl 2- (methylsulfonyl)phenyl
765 CO2CH3 5-pyrimidyl 4-morpholino
766 C02CH3 5-pyrimidyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl
767 C02CH3 5-pyrimidyl 4-morpholinocarbonyl
768 C02CH3 5-pyrimidyl 2-methyl-1-imidazolyl
769 C02CH3 5-pyrimidyl 5-methyl-1-imidazolyl
770 CO2CH3 5-pyrimidyl 2-methylsulfonyl-l-imidazolyl
771 CO2CH3 2-Cl-phenyl 2- (aminosulfonyl)phenyl
772 CO2CH3 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl
773 CO2CH3 2-Cl-phenyl 1-pyrrolidinocarbonyl
774 CO2CH3 2-Cl-phenyl 2- (methylsulfonyl)phenyl
775 CO2CH3 2-Cl-phenyl 4-morpholino
776 CO2CH3 2-Cl-phenyl 2-(l'-CF3-tetrazol-2-yl)phenyl
777 C02CH3 2-Cl-phenyl 4-morpho1inocarbony1
778 C02CH3 2-Cl-phenyl 2-methyl-l-imidazolyl
779 C02CH3 2-Cl-phenyl 5-methyl-1-imidazolyl
780 C02CH3 2-Cl-phenyl 2-methylsulfonyl-l-imidazolyl
781 C02CH3 2-F-phenyl 2- (aminosulfonyl) phenyl
782 C02CH3 2-F-phenyl 2- (methylaminosulfonyl)phenyl
783 C02CH3 2-F-phenyl 1-pyrrolidinocarbonyl
784 C02CH3 2-F-phenyl 2- (methylsulfonyl)phenyl
785 C02CH3 2-F-phenyl 4-morpho1ino
786 C02CH3 2-F-phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl
787 C02CH3 2-F-phenyl 4-morpho1inocarbony1
788 C02CH3 2-F-phenyl 2-methyl-l-imidazolyl
789 C02CH3 2-F-phenyl 5-methyl-1-imidazolyl
790 C02CH3 2-F-phenyl 2-methylsulfonyl-l-imidazolyl
791 CO2CH3 2, 6-diF-phenyl 2- (aminosulfonyl) phenyl
792 C02CH3 2, 6-diF-phenyl 2- (methylaminosulfonyl)phenyl
793 C02CH3 2, 6-diF-phenyl 1-pyrrolidinocarbonyl
794 C02CH3 2, 6-diF-phenyl 2- (methylsulfonyl)phenyl
795 C02CH3 2, 6-diF-phenyl 4-morpholino
796 C02CH3 2, 6-diF-phenyl 2- (l'-CF3-tetrazol-2-yl) phenyl
797 CO2CH3 2, 6-diF-phenyl 4-morpholinocarbonyl 798 C02CH3 2 , 6-diF-phenyl 2-methyl-1-imidazolyl 799 CO2CH3 2 , 6-diF-phenyl 5-methyl-l-imidazolyl 800 CO2CH3 2 , 6-diF-phenyl 2-methylsulfonyl-l-imidazolyl 801 CH2OCH3 phenyl 2- (aminosulfonyl) phenyl 802 CH2OCH3 phenyl 2- (methylaminosulfonyl) phenyl 803 CH2OCH3 phenyl 1-pyrrolidinocarbonyl 804 CH2OCH3 phenyl 2- (methylsulfonyl) phenyl 805 CH2OCH3 phenyl 4-morpholino 806 CH2OCH3 phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 807 CH2OCH3 phenyl 4-morpholinocarbonyl 808 CH2OCH3 phenyl 2-methyl-l-imidazolyl 809 CH2OCH3 phenyl 5-methyl-1-imidazolyl 810 CH2OCH3 phenyl 2-methylsulfonyl-l-imidazolyl 811 CH2OCH3 2-pyridyl 2- (aminosulfonyl) phenyl 812 CH2OCH3 2-pyridyl 2 - (methylaminosulfonyl ) phenyl 813 CH2OCH3 2-pyridyl 1-pyrrolidinocarbonyl 814 CH2OCH3 2-pyridyl 2- (methylsulfonyl ) phenyl 815 CH2OCH3 2-pyridyl 4-morpholino 816 CH2OCH3 2-pyridyl 2- ( 1 ' -CF3 -tetrazol-2 -yD phenyl 817 CH2OCH3 2-pyridyl 4-morpholinocarbonyl 818 CH2OCH3 2-pyridyl 2-methyl-l-imidazolyl 819 CH2OCH3 2-pyridyl 5-methyl-l-imidazolyl 820 CH2OCH3 2-pyridyl 2-methylsulfonyl-l-imidazolyl 821 CH2OCH3 3-pyridyl 2- (aminosulfonyl) phenyl 822 CH2OCH3 3-pyridyl 2- (methylaminosulfonyl) phenyl 823 CH2OCH3 3-pyridyl 1-pyrrolidinocarbonyl 824 CH2OCH3 3-pyridyl 2- (methylsulfonyl) phenyl 825 CH2OCH3 3-pyridyl 4-morpholino 826 CH2OCH3 3-pyridyl 2- ( 1 ' -CF3-tetrazol-2-yl) phenyl 827 CH2OCH3 3-pyridyl 4-morpholinocarbonyl 828 CH2OCH3 3-pyridyl 2-methyl-l-imidazolyl 829 CH2OCH3 3-pyridyl 5-methyl-l-imidazolyl 830 CH2OCH3 3-pyridyl 2-methylsulfonyl-l-imidazolyl 831 CH2OCH3 2-pyrimidyl 2- (aminosulfonyl) phenyl 832 CH2OCH3 2-pyrimidyl 2- (methylaminosulfonyl)phenyl 833 CH2OCH3 2-pyrimidyl 1-pyrrolidinocarbonyl 834 CH2OCH3 2-pyrimidyl 2- (methylsulfonyl) phenyl 835 CH2OCH3 2-pyrimidyl 4-morpholino 836 CH2OCH3 2-pyrimidyl 2-(l'-CF3-tetrazol-2-yl)phenyl 837 CH2OCH3 2-pyrimidyl 4-morpholinocarbonyl 838 CH2OCH3 2-pyrimidyl 2-methyl-l-imidazolyl 839 CH2OCH3 2-pyrimidyl 5-methyl-l-imidazolyl 840 CH2OCH3 2-pyrimidyl 2-methylsulfonyl-l-imidazolyl 841 CH2OCH3 5-pyrimidyl 2- ( minosulfonyl) phenyl 842 CH2OCH3 5-pyrimidyl 2- (methylaminosulfonyl) phenyl 843 CH2OCH3 5-pyrimidyl 1-pyrrolidinocarbonyl 844 CH2OCH3 5-pyrimidyl 2- (methylsulfonyl) phenyl 845 CH2OCH3 5-pyrimidyl 4-morpholino 846 CH2OCH3 5-pyrimidyl 2- ( 1 ' -CF3 -tetrazol-2-yl) phenyl 847 CH2OCH3 5-pyrimidyl 4-morpholinocarbonyl 848 CH2OCH3 5-pyrimidyl 2-methyl-l-imidazolyl 849 CH2OCH3 5-pyrimidyl 5-methyl-l-imidazolyl 850 CH2OCH3 5-pyrimidyl 2-methylsulfonyl-l-imidazolyl
851 CH2OCH3 2-Cl-phenyl 2- (aminosulfonyl ) phenyl
852 CH2OCH3 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl
853 CH2OCH3 2-Cl-phenyl 1-pyrrolidinocarbonyl
854 CH2OCH3 2-Cl-phenyl 2- (methylsulfonyl) phenyl
855 CH2OCH3 2-Cl-phenyl 4-morpholino
856 CH2OCH3 2-Cl-phenyl 2- ( l ' -CF3 -tetrazol-2 -yD phenyl
857 CH2OCH3 2-Cl-phenyl 4-morpholinocarbonyl
858 CH2OCH3 2-Cl-phenyl 2-methyl-l-imidazolyl
859 CH2OCH3 2-Cl-phenyl 5-methyl-l-imidazolyl
860 CH2OCH3 2-Cl-phenyl 2-methylsulfonyl-l-imidazolyl
861 CH2OCH3 2-F-phenyl 2- (aminosulfonyl) phenyl
862 CH2OCH3 2-F-phenyl 2- (methylaminosulfonyl) phenyl
863 CH2OCH3 2-F-phenyl 1-pyrrolidinocarbonyl
864 CH2OCH3 2-F-phenyl 2- (methylsulfonyl) phenyl
865 CH2OCH3 2-F-phenyl 4-morpholino
866 CH2OCH3 2-F-phenyl 2- ( 1 ' -CF3 -tetrazol-2 -yD phenyl
867 CH2OCH3 2-F-phenyl 4-morpholinocarbonyl
868 CH2OCH3 2-F-phenyl 2-methyl-l-imidazolyl
869 CH2OCH3 2-F-phenyl 5-methyl-l-imidazolyl
870 CH2OCH3 2-F-phenyl 2-methylsulfonyl-l-imidazolyl
871 CH2OCH3 2 , 6-diF-phenyl 2- (aminosulfonyl ) phenyl
872 CH2OCH3 2 , 6-diF-phenyl 2- (methylaminosulfonyl ) phenyl
873 CH2OCH3 2 , 6-diF-phenyl 1-pyrrolidinocarbonyl
874 CH2OCH3 2 , 6-diF-phenyl 2- (methylsulfonyl ) phenyl
875 CH2OCH3 2 , 6-diF-phenyl 4-morpholino
876 CH2OCH3 2 , 6-diF-phenyl 2- (1 ' -CF3 -tetrazol-2-yDphenyl
877 CH2OCH3 2 , 6-diF-phenyl 4-morpholinocarbonyl
878 CH2OCH3 2, 6-diF-phenyl 2-methyl-1-imidazolyl
879 CH2OCH3 2 , 6-diF-phenyl 5-methyl-1-imidazolyl
880 CH2OCH3 2 , 6-diF-phenyl 2-methylsulfonyl-l-imidazolyl
881 CO H2 phenyl 2- (aminosulfonyl) phenyl
882 CONH2 phenyl 2- (methylaminosulfonyl) phenyl
883 CONH2 phenyl 1-pyrrolidinocarbonyl
884 CO H2 phenyl 2- (methylsulfonyl ) phenyl
885 CONH2 phenyl 4-morpholino
886 CONH2 phenyl 2- (1 ' -CF3-tetrazol-2-yDphenyl
887 CONH2 phenyl 4-morpholinocarbonyl
888 CONH2 phenyl 2-methyl-l-imidazolyl
889 CONH2 phenyl 5-methyl-l-imidazolyl
890 CONH2 phenyl 2-methylsulfonyl-l-imidazolyl
891 CONH2 2-pyridyl 2- (aminosulfonyl) phenyl
892 CONH2 2-pyridyl 2- (methylaminosulfonyl) phenyl
893 CONH2 2-pyridyl 1-pyrrolidinocarbonyl
894 CONH2 2-pyridyl 2- (methylsulfonyl) phenyl
895 CO H2 2-pyridyl 4-morpholino
896 CONH2 2-pyridyl 2-(l'-CF3-tetrazol-2-yl)phenyl
897 CO H2 2-pyridyl 4-morpholinocarbonyl
898 CONH2 2-pyridyl 2-methyl-l-imidazolyl
899 CONH2 2-pyridyl 5-methyl-l-imidazolyl
900 CONH2 2-pyridyl 2-methylsulfonyl-l-imidazolyl
901 CONH2 3-pyridyl 2- (aminosulfonyl) phenyl 902 CO H2 3-pyridyl 2- (methylaminosulfonyl) phenyl
903 CONH2 3-pyridyl 1-pyrro1idinocarbony1
904 CONH2 3-pyridyl 2- (methylsulfonyl) phenyl
905 CONH2 3-pyridyl 4-morpholino 906 CONH2 3-pyridyl 2- ( 1 ' -CF3 -tetrazol-2-yl ) phenyl
907 CONH2 3-pyridyl 4-morpholinocarbonyl
908 CONH2 3-pyridyl 2-methyl-l-imidazolyl
909 CONH2 3-pyridyl 5-methyl-l-imidazolyl
910 CONH2 3-pyridyl 2-methylsulfonyl-l-imidazolyl 911 CONH2 2-pyrimidyl 2- (aminosulfonyl) phenyl
912 CONH2 2-pyrimidyl 2- (methylaminosulfonyl) phenyl
913 CONH2 2-pyrimidyl 1-pyrrolidinocarbonyl
914 CONH2 2-pyrimidyl 2- (methylsulfonyl) phenyl
915 CO H2 2-pyrimidyl 4-morpholino 916 CONH2 2-pyrimidyl 2- (1 ' -CF3-tetrazol-2-yl ) phenyl
917 CONH2 2-pyrimidyl 4-morpholinocarbonyl
918 CONH2 2-pyrimidyl 2 -methyl-1-imidazolyl
919 CO H2 2-pyrimidyl 5-methyl-1-imidazolyl
920 CONH2 2-pyrimidyl 2 -methylsulfonyl-1-imidazolyl 921 CO H2 5-pyrimidyl 2- (aminosulfonyl) phenyl
922 CONH2 5-pyrimidyl 2- (methylaminosulfonyl) phenyl
923 CONH2 5-pyrimidyl 1-pyrrolidinocarbonyl
924 CO H2 5-pyrimidyl 2 - (methylsulfonyl) phenyl
925 CONH2 5-pyrimidyl 4-morpholino 926 CONH2 5-pyrimidyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl
927 CONH2 5-pyrimidyl 4-morpho1inocarbony1
928 CONH2 5-pyrimidyl 2-methyl-l-imidazolyl
929 CO H2 5-pyrimidyl 5-methyl-l-imidazolyl
930 CONH2 5-pyrimidyl 2-methylsulfonyl-l-imidazolyl 931 CO H2 2-Cl-phenyl 2- (aminosulfonyl) phenyl
932 CONH2 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl
933 CO H2 2-Cl-phenyl 1-pyrrolidinocarbonyl
934 CO H2 2-Cl-phenyl 2- (methylsulfonyl) phenyl
935 CO H2 2-Cl-phenyl 4-morpholino 936 CONH2 2-Cl-phenyl 2- (l'-CF3-tetrazol-2-yl) phenyl
937 CONH2 2-Cl-phenyl 4-morpholinocarbonyl
938 CO H2 2-Cl-phenyl 2-methyl-l-imidazolyl
939 CONH2 2-Cl-phenyl 5-methyl-l-imidazolyl
940 CONH2 2-Cl-phenyl 2-methylsulfonyl-l-imidazolyl 941 CONH2 2-F-phenyl 2- (aminosulfonyl) phenyl
942 CONH2 2-F-phenyl 2- (methylaminosulfonyl) phenyl
943 CO H2 2-F-phenyl 1-pyrrolidinocarbonyl
944 CONH2 2-F-phenyl 2- (methylsulfonyl)phenyl
945 CO H2 2-F-phenyl 4-morpho1ino 946 CONH2 2-F-phenyl 2- ( 1 ' -CF3 -tetrazol-2-yl) phenyl
947 CONH2 2-F-phenyl 4-morpholinocarbonyl
948 CONH2 2-F-phenyl 2-methyl-l-imidazoly1
949 CO H2 2-F-phenyl 5-methyl-l-imidazolyl
950 CONH2 2-F-phenyl 2-methylsulfonyl-l-imidazolyl 951 CONH2 2,6-diF-phenyl 2- (aminosulfonyl) phenyl
952 CO H2 2,6-diF-phenyl 2- (methylammosulfonyl) phenyl
953 CONH2 2,6-diF-phenyl 1-pyrro1idinocarbony1 954 CONH2 2, .6-diF-phenyl 2- (methylsulfonyl) phenyl
955 CONH2 2, , 6-diF-phenyl 4-morpho1ino
956 CO H2 2, , 6-diF-phenyl 2- ( 1 ' -CF3 -tetrazol-2-yl ) phenyl
957 CO H2 2, .6-diF-phenyl 4-morpho1inocarbony1
958 CONH2 2, .6-diF-phenyl 2-methyl-l-imidazolyl
959 CONH2 2, .6-diF-phenyl 5-methyl-l-imidazolyl
960 CONH2 2, .6-diF-phenyl 2-methylsulfonyl-l-imidazolyl
Table 5
Figure imgf000186_0001
q
Figure imgf000187_0001
b cc dd
Figure imgf000187_0002
ee gg
Figure imgf000187_0003
hh jj
Figure imgf000188_0001
AVCH2-NHGBIy
Figure imgf000188_0002
Figure imgf000188_0003
zz aaa bbb
Figure imgf000189_0001
fff ggg hhh
Ex # A
I phenyl 2- (aminosulfonyl) phenyl 2 phenyl 2- (methylaminosulfonyl) phenyl
3 phenyl 1-pyrrolidinocarbonyl
4 phenyl 2- (methylsulfonyl ) phenyl
5 phenyl 4-morpholino
6 phenyl 2- (1 ' -CF3-tetrazol-2-yDphenyl 7 phenyl 4-morpholinocarbonyl
8 phenyl 2-methyl-l-imidazolyl
9 phenyl 5-methyl-l-imidazolyl
10 phenyl 2-methylsulfonyl-l-imidazolyl
II 2-pyridyl 2- (aminosulfonyl) phenyl 12 2-pyridyl 2- (methylaminosulfonyl) phenyl
13 2-pyridyl 1-pyrrolidinocarbony1
14 2-pyridyl 2- (methylsulfonyl) phenyl
15 2-pyridyl 4-morpholino
16 2-pyridyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 17 2-pyridyl 4-morpholinocarbonyl
18 2-pyridyl 2-methyl-l-imidazolyl
19 2-pyridyl 5-methyl-l-imidazolyl
20 2-pyridyl 2-methylsulfonyl-l-imidazolyl
21 3-pyridyl 2- (aminosulfonyl) phenyl 22 3-pyridyl 2- (methylaminosulfonyl) phenyl
23 3-pyridyl 1-pyrrolidinocarbonyl
24 3-pyridyl 2- (methylsulfonyl)phenyl
25 3-pyridyl 4-morpholino
26 3-pyridyl 2- (1' -CF3-tetrazol-2-yl) phenyl 27 3-pyridyl 4-morpholinocarbonyl
28 3-pyridyl 2-methyl-l-imidazolyl
29 3-pyridyl 5-methyl-1-imidazolyl
30 3-pyridyl 2-methylsulfonyl-l-imidazolyl
31 2-pyrimidyl 2- (aminosulfonyl) phenyl 32 2-pyrimidyl 2- (methylaminosulfonyl) phenyl
33 2-pyrimidyl 1-pyrrolidinocarbonyl
34 2-pyrimidyl 2- (methylsulfonyl) phenyl
35 2-pyrimidyl 4-morpholino
36 2-pyrimidyl 2- ( 1 ' -CF3 -tetrazol-2-yl) phenyl 37 2-pyrimidyl 4-morpholinocarbonyl 2-pyrimidyl 2-methyl-1-imidazolyl
2-pyrimidyl 5-methyl-l-imidazolyl
2-pyrimidyl 2-methylsulfonyl-l-imidazolyl
5-pyrimidyl 2- (aminosulfonyl) phenyl
5-pyrimidyl 2- (methylaminosulfonyl) phenyl
5-pyrimidyl 1-pyrrolidinocarbonyl
5-pyrimidyl 2- (methylsulfonyl) phenyl
5-pyrimidyl 4-morpholino
5-pyrimidyl 2- ( 1 ' -CF3 -tetrazol-2-yl ) phenyl
5-pyrimidyl 4-morpholinocarbonyl
5-pyrimidyl 2-methyl-l-imidazolyl
5-pyrimidyl 5-methyl-l-imidazolyl
5-pyrimidyl 2-methylsulfonyl-l-imidazolyl
2-Cl-phenyl 2- (aminosulfonyl) phenyl
2-Cl-phenyl 2- (methylaminosulfonyl) phenyl
2-Cl-phenyl 1-pyrrolidinocarbonyl
2-Cl-phenyl 2 - (methylsulfonyl) phenyl
2-Cl-phenyl 4-morpholino
2-Cl-phenyl 2- (1 ' -CF3 -tetrazol-2-yl) phenyl
2-Cl-phenyl 4-morpholinocarbonyl
2-Cl-phenyl 2-methyl-l-imidazolyl
2-Cl-phenyl 5-methyl-l-imidazolyl
2-Cl-phenyl 2-methylsulfonyl-1-imidazolyl
2-F-phenyl 2 - (aminosulfonyl ) phenyl
2-F-phenyl 2 - (methylaminosulfonyl) phenyl
2-F-phenyl 1-pyrrolidinocarbony1
2-F-phenyl 2- (methylsulfonyl) phenyl
2-F-phenyl 4-morpholino
2-F-phenyl 2- (l'-CF3-tetrazol-2-yDphenyl
2-F-phenyl 4-morpholinocarbonyl
2-F-phenyl 2-methy1-1-imidazoly1
2-F-phenyl 5-methyl-l-imidazolyl
2-F-phenyl 2-methylsulfonyl-l-imidazolyl
2, 6-diF-phenyl 2- (aminosulfonyl ) phenyl
2, 6-diF-phenyl 2- (methylaminosulfonyl) phenyl
2, 6-diF-phenyl 1-pyrrolidinocarbonyl
2 , 6-diF-phenyl 2- (methylsulfonyl) phenyl
2, 6-diF-phenyl 4-morpholino
2 , 6-diF-phenyl 2- (1 ' -CF3-tetrazol-2-yl ) phenyl
2 , 6-diF-phenyl 4-morpholinocarbonyl
2 , 6-diF-phenyl 2-methyl-l-imidazolyl
2 , 6-diF-phenyl 5-methyl-l-imidazolyl
2 , 6-diF-phenyl 2-methylsulfonyl-l-imidazolyl
Utility The compounds of this invention are useful as anticoagulants for the treatment or prevention of thromboembolic disorders in mammals. The term "thromboembolic disorders" as used herein includes "arterial or venous cardiovascular or cerebrovascular thromboembolic disorders, including, for example, unstable angina, first or recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary and cerebral arterial thrombosis, cerebral embolism, kidney embolisms, and pulmonary embolisms. The anticoagulant effect of compounds of the present invention is believed to be due to inhibition of factor Xa or thrombin. The effectiveness of compounds of the present invention as inhibitors of factor Xa was determined using purified human factor Xa and synthetic substrate. The rate of factor Xa hydrolysis of chromogenic substrate S2222 (Kabi Pharmacia, Franklin, OH) was measured both in the absence and presence of compounds of the present invention. Hydrolysis of the substrate resulted in the release of pNA, which was monitored spectrophotometrically by measuring the increase in absorbance at 405 nM. A decrease in the rate of absorbance change at 405 nm in the presence of inhibitor is indicative of enzyme inhibition. The results of this assay are expressed as inhibitory constant, Ki .
Factor Xa determinations were made in 0.10 M sodium phosphate buffer, pH 7.5, containing 0.20 M NaCI, and 0.5 % PEG 8000. The Michaelis constant, Km, for substrate hydrolysis was determined at 25°C using the method of
Lineweaver and Burk. Values of Ki were determined by allowing 0.2-0.5 nM human factor Xa (Enzyme Research Laboratories, South Bend, IN) to react with the substrate (0.20 ιtιM-1 mM) in the presence of inhibitor. Reactions were allowed to go for 30 minutes and the velocities (rate of absorbance change vs time) were measured in the time frame of 25-30 minutes. The following relationship was used to calculate Ki values :
(v0-vs)/vs = I/(Ki (1 + S/K )) where : v0 is the velocity of the control in the absence of inhibitor; vs is the velocity in the presence of inhibitor; I is the concentration of inhibitor;
Ki is the dissociation constant of the enzyme: inhibitor complex; S is the concentration of substrate; K is the Michaelis constant . Using the methodology described above, a number of compounds of the present invention were found to exhibit a Ki of <10 μM, thereby confirming the utility of the compounds of the present invention as effective Xa inhibitors.
The antithrombotic effect of compounds of the present invention can be demonstrated in a rabbit arterio-venous (AV) shunt thrombosis model. In this model, rabbits weighing 2-3 kg anesthetized with a mixture of xylazine (10 mg/kg i.m.) and ketamine (50 mg/kg i.m.) are used. A saline-filled AV shunt device is connected between the femoral arterial and the femoral venous cannulae. The AV shunt device consists of a piece of 6-cm tygon tubing which contains a piece of silk thread. Blood will flow from the femoral artery via the AV- shunt into the femoral vein. The exposure of flowing blood to a silk thread will induce the formation of a significant thrombus. After forty minutes, the shunt is disconnected and the silk thread covered with thrombus is weighed. Test agents or vehicle will be given (i.v., i.p., s.c, or orally) prior to the opening of the AV shunt. The percentage inhibition of thrombus formation is determined for each treatment group. The ID50 values (dose which produces 50% inhibition of thrombus formation) are estimated by linear regression. The compounds of formula (I) may also be useful as inhibitors of serine proteases, notably human thrombin, plasma kallikrein and plas in. Because of their inhibitory action, these compounds are indicated for use in the prevention or treatment of physiological reactions, blood coagulation and inflammation, catalyzed by the aforesaid class of enzymes. Specifically, the compounds have utility as drugs for the treatment of diseases arising from elevated thrombin activity such as myocardial infarction, and as reagents used as anticoagulants in the processing of blood to plasma for diagnostic and other commercial purposes . Some compounds of the present "invention were shown to be direct acting inhibitors of the serine protease thrombin by their ability to inhibit the cleavage of small molecule substrates by thrombin in a purified system. In vitro inhibition constants were determined by the method described by Kettner et al . in J. Biol . Chem . 265, 18289-18297 (1990), herein incorporated by reference. In these assays, thrombin- mediated hydrolysis of the chromogenic substrate S2238 (Helena Laboratories, Beaumont, TX) was monitored spectrophotometrically. Addition of an inhibitor to the assay mixture results in decreased absorbance and is indicative of thrombin inhibition. Human thrombin (Enzyme Research Laboratories, Inc., South Bend, IN) at a concentration of 0.2 nM in 0.10 M sodium phosphate buffer, pH 7.5, 0.20 M NaCI, and 0.5% PEG 6000, was incubated with various substrate concentrations ranging from 0.20 to 0.02 mM. After 25 to 30 minutes of incubation, thrombin activity was assayed by monitoring the rate of increase in absorbance at 405 nm which arises owing to substrate hydrolysis. Inhibition constants were derived from reciprocal plots of the reaction velocity as a function of substrate concentration using the standard method of Lineweaver and Burk. Using the methodology described above, some compounds of this invention were evaluated and found to exhibit a K of less than 10 μm, thereby confirming the utility of the compounds of the present invention as effective thrombin inhibitors.
The compounds of the present invention can be administered alone or in combination with one or more additional therapeutic agents. These include other anticoagulant or coagulation inhibitory agents, anti-platelet or platelet inhibitory agents, thrombin inhibitors, or thrombolytic or fibrinolytic agents .
The compounds are administered to a mammal in a therapeutically effective amount. By "therapeutically effective amount" it is meant an amount of a compound of Formula I that, when administered alone or in combination with an additional therapeutic agent to a mammal, is effective to prevent or ameliorate the thromboembolic disease condition or the progression of the disease.
By "administered in combination" or "combination therapy" it is meant that the compound of Formula I and one or more additional therapeutic agents are administered concurrently to the mammal being treated. When administered in combination each component may be administered at the same time or sequentially in any order at different points in time. Thus, each component may be administered separately but sufficiently closely in time so as to provide the desired therapeutic effect. Other anticoagulant agents (or coagulation inhibitory agents) that may be used in combination with the compounds of this invention include warfarin and heparin, as well as other factor Xa inhibitors such as those described in the publications identified above under Background of the Invention. The term anti-platelet agents (or platelet inhibitory agents) , as used herein, denotes agents that inhibit platelet function such as by inhibiting the aggregation, adhesion or granular secretion of platelets. Such agents include, but are not limited to, the various known non-steroidal anti- inflammatory drugs (NSAIDS) such as aspirin, ibuprofen, naproxen, sulindac, indomethacin, mefenamate, droxicam, diclofenac, sulfinpyrazone, and piroxicam, including pharmaceutically acceptable salts or prodrugs thereof . Of the NSAIDS, aspirin (acetylsalicyclic acid or ASA) , and piroxicam are preferred. Other suitable anti-platelet agents include ticlopidine, including pharmaceutically acceptable salts or prodrugs thereof. Ticlopidine is also a preferred compound since it is known to be gentle on the gastro-intestinal tract in use. Still other suitable platelet inhibitory agents include Ilb/IIIa antagonists, thromboxane-A2-receptor antagonists and thromboxane-A2-synthetase inhibitors, as well as pharmaceutically acceptable salts or prodrugs thereof . The term thrombin inhibitors (or anti-thrombin agents) , as used herein, denotes inhibitors of the serine protease thrombin. By inhibiting thrombin, various thrombin-mediated processes, such as thrombin-mediated platelet activation (that is, for example, the aggregation of" platelets, and/or the granular secretion of plasminogen activator inhibitor-1 and/or serotonin) and/or fibrin formation are disrupted. A number of thrombin inhibitors are known to one of skill in the art and these inhibitors are contemplated to be used in combination with the present compounds. Such inhibitors include, but are not limited to, boroarginine derivatives, boropeptides, heparins, hirudin and argatroban, including pharmaceutically acceptable salts and prodrugs thereof. Boroarginine derivatives and boropeptides include N-acetyl and peptide derivatives of boronic acid, such as C-terminal a-aminoboronic acid derivatives of lysine, ornithine, arginine, homoarginine and corresponding isothiouronium analogs thereof . The term hirudin, as used herein, includes suitable derivatives or analogs of hirudin, referred to herein as hirulogs, such as disulfatohirudin. Boropeptide thrombin inhibitors include compounds described in Kettner et al., U.S. Patent No. 5,187,157 and European Patent Application Publication Number 293 881 A2, the disclosures of which are hereby incorporated herein by reference. Other suitable boroarginine derivatives and boropeptide thrombin inhibitors include those disclosed in PCT Application Publication Number 92/07869 and European Patent Application Publication Number 471,651 A2 , the disclosures of which are hereby incorporated herein by reference. The term thrombolytics (or fibrinolytic) agents (or thrombolytics or fibrinolytics) , as used herein, denotes agents that lyse blood clots (thrombi) .. Such agents include tissue plasminogen activator, anistreplase, urokinase or streptokinase, including pharmaceutically acceptable salts or prodrugs thereof. The term anistreplase, as used herein, refers to anisoylated plasminogen streptokinase activator complex, as described, for example, in European Patent Application No. 028,489, the disclosure of which is hereby incorporated herein by reference herein. The term urokinase, as used herein, is intended to denote both dual and single chain urokinase, the latter also being referred to herein as prourokinase . Administration of the compounds of Formula I of the invention in combination with such additional therapeutic agent, may afford an efficacy advantage over the compounds and agents alone, and may do so while permitting the use of lower doses of each. A lower dosage minimizes the potential of side effects, thereby providing an increased margin of safety.
The compounds of the present invention are also useful as standard or reference compounds, for example as a quality standard or control, in tests or assays involving the inhibition of factor Xa. Such compounds may be provided in a commercial kit, for example, for use in pharmaceutical research involving factor Xa. For example, a compound of the present invention could be used as a reference in an assay to compare its known activity to a compound with an unknown activity. This would ensure the experimenter that the assay was being performed properly and provide a basis for comparison, especially if the test compound was a derivative of the reference compound. When developing new assays or protocols, compounds according to the present invention could be used to test their effectiveness. The compounds of the present invention may also be used in diagnostic assays involving factor Xa. For example, the presence of factor Xa in an unknown sample could be determined by addition of chromogenic substrate S2222 to a series of solutions containing test sample and optionally one of the compounds of the present invention. If production of pNA is observed in the solutions containing test sample, but not in the presence of a compound of the present invention, then one would conclude factor Xa was present.
Dosaσe and Formulation
The compounds of this invention can be administered in such oral dosage forms as tablets, capsules (each of which includes sustained release or timed release formulations) , pills, powders, granules, elixirs, tinctures, suspensions, syrups, and emulsions. They may also be administered in intravenous (bolus or infusion) , intraperitoneal, subcutaneous, or intramuscular form, all using dosage forms well known to those of ordinary skill in the pharmaceutical arts. They can be administered alone, but generally will be administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice. The dosage regimen for the compounds of the present invention will, of course, vary depending upon known factors, such as the pharmacodynamic characteristics of the particular agent and its mode and route of administration; the species, age, sex, health, medical condition, and weight of the recipient; the nature and extent of the symptoms; the kind of concurrent treatment; the frequency of treatment; the route of administration, the renal and hepatic function of the patient, and the effect desired. A physician or veterinarian can determine and prescribe the effective amount of the drug required to prevent, counter, or arrest the progress of the thromboembolic disorder.
By way of general guidance, the daily oral dosage of each active ingredient, when used for the indicated effects, will range between about 0.001 to 1000 mg/kg of body weight, preferably between about 0.01 to 100 mg/kg of body weight per day, and most preferably between about 1.0 to 20 mg/kg/day. Intravenously, the most preferred doses will range from about 1 to about 10 mg/kg/minute during a constant rate infusion. Compounds of this invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three, or four times daily.
Compounds of this invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using transdermal skin patches. When administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen. The compounds are typically administered in admixture with suitable pharmaceutical diluents, excipients, or carriers (collectively referred to herein as pharmaceutical carriers) suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixirs, syrups and the like, and consistent with conventional pharmaceutical practices .
For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl callulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like; for oral administration in liquid form, the oral drug components can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents, and coloring agents can also be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth, or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes, and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum, and the like.
The compounds of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles . Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine, or phosphatidylcholines . Compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide-phenol, polyhydroxyethylaspartamidephenol, or polyethyleneoxide- polylysine substituted with palmitoyl residues. Furthermore, the compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacylates, and crosslinked or amphipathic block copolymers of hydrogels .
Dosage forms (pharmaceutical compositions) suitable for administration may contain from about 1 milligram to about 100 milligrams of active ingredient per dosage unit. In these pharmaceutical compositions the active ingredient will ordinarily be present in an amount of about 0.5-95% by weight based on the total weight of the composition.
Gelatin capsules may contain the active ingredient and powdered carriers, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract.
Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance. In general, water, a suitable oil, saline, aqueous dextrose (glucose) , and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions . Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances. Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents. Also used are citric acid and its salts and sodium EDTA. In addition, parenteral solutions can contain preservatives, such as benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol .
Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences", Mack Publishing Company, a standard reference text in this field.
Representative useful pharmaceutical dosage-forms for administration of the compounds of this invention can be illustrated as follows: Capsules
A large number of unit capsules can be prepared by filling standard two-piece hard gelatin capsules each with 100 milligrams of powdered active ingredient, 150 milligrams of lactose, 50 milligrams of cellulose, and 6 milligrams magnesium stearate.
Soft Gelatin Capsules
A mixture of active ingredient in a digestable oil such as soybean oil, cottonseed oil or olive oil may be prepared and injected by means of a positive displacement pump into gelatin to form soft gelatin capsules containing 100 milligrams of the active ingredient. The capsules should be washed and dried. Tablets
Tablets may be prepared by conventional procedures so that the dosage unit is 100 milligrams of active ingredient, 0.2 milligrams of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 275 milligrams of microcrystalline cellulose, 11 milligrams of starch and 98.8 milligrams of lactose. Appropriate coatings may be applied to increase palatability or delay absorption. Injectable
A parenteral composition suitable for administration by injection may be prepared by stirring 1.5% by weight of active ingredient in 10% by volume propylene glycol and water. The solution should be made isotonic with sodium chloride and sterilized. Suspension
An aqueous suspension can be prepared for oral administration so that each 5 mL contain 100 mg of finely divided active ingredient, 200 mg of sodium carboxymethyl cellulose, 5 mg of sodium benzoate," 1.0 g of sorbitol solution, U.S. P., and 0.025 mL of vanillin.
Where the compounds of this invention are combined with other anticoagulant agents, for example, a daily dosage may be about 0.1 to 100 milligrams of the compound of Formula I and about 1 to 7.5 milligrams of the second anticoagulant, per kilogram of patient body weight. For a tablet dosage form, the compounds of this invention generally may be present in an amount of about 5 to 10 milligrams per dosage unit, and the second anti-coagulant in an amount of about 1 to 5 milligrams per dosage unit .
Where the compounds of Formula I are administered in combination with an anti-platelet agent, by way of general guidance, typically a daily dosage may be about 0.01 to 25 milligrams of the compound of Formula I and about 50 to 150 milligrams of the anti-platelet agent, preferably about 0.1 to 1 milligrams of the compound of Formula I and about 1 to 3 milligrams of antiplatelet agents, per kilogram of patient body weight .
Where the compounds of Formula I are adminstered in combination with thrombolytic agent, typically a daily dosage may be about 0.1 to 1 milligrams of the compound of Formula I, per kilogram of patient body weight and, in the case of the thrombolytic agents, the usual dosage of the thrombolyic agent when administered alone may be reduced by about 70-80% when administered with a compound of Formula I.
Where two or more of the foregoing second therapeutic agents are administered with the compound of Formula I, generally the amount of each component in a typical daily dosage and typical dosage form may be reduced relative to the usual dosage of the agent when administered alone, in view of the additive or synergistic effect of the therapeutic agents when administered in combination. Particularly when provided as a single dosage unit, the potential exists for a chemical interaction between the combined active ingredients. For this reason, when the compound of Formula I and a second therapeutic agent are combined in a single dosage unit they are formulated such that although the active ingredients are combined in a single dosage unit, the physical contact between the active ingredients is minimized (that is, reduced) . For example, one active ingredient may be enteric coated. By enteric coating one of the active ingredients, it is possible not only to minimize the contact between the combined active ingredients, but also, it is possible to control the release of one of these components in the gastrointestinal tract such that one of these components is not released in the stomach but rather is released in the intestines . One of the active ingredients may also be coated with a material which effects a sustained- release throughout the gastrointestinal tract and also serves to minimize physical contact between the combined active ingredients. Furthermore, the sustained-released component can be additionally enteric coated such that the release of this component occurs only in the intestine. Still another approach would involve the formulation of a combination product in which the one component is coated with a sustained and/or enteric release polymer, and the other component is also coated with a polymer such as a lowviscosity grade of hydroxypropyl methylcellulose (HPMC) or other appropriate materials as known in the art, in order to further separate the active components . The polymer coating serves to form an additional barrier to interaction with the other component. These as well as other ways of minimizing contact between the components of combination products of the present invention, whether administered in a single dosage form or administered in separate forms but at the same time by the same manner, will be readily apparent to those skilled in the art, once armed with the present disclosure.
Obviously, numerous modifications and variations of the present invention are possible in light of the above teachings. It is therefore to be understood that within the scope of the appended claims, the invention may be practiced otherwise that as specifically described herein.

Claims

WHAT IS CLAIMED IS ;
A compound of formula I :
Figure imgf000204_0001
I or a stereoisomer or pharmaceutically acceptable salt thereof, wherein;
ring M contains, in addition to J, 0-3 N atoms, provided that if M contains 2 N atoms then Rlb is not present and if M contains 3 N atoms then Rla and Rlb are not present;
J is N or NH;
D is selected from CN, C (=NR8)NR7R9 , NHC (=NR8)NR7R9,
NR8CH(=NR7), C(0)NR7R8, and (CR8R9) tNR7R8, provided that D is substituted ortho to G on E;
E is selected from phenyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, and piperidinyl substituted with 1-2 R;
R is selected from H, Cl, F, Br, I, (CH2)tOR3, Cι_4 alkyl,
OCF3, CF3, C(0)NR7R8, and (CR8R9) NR7R8;
G is absent or is selected from NHCH2, OCH2, and SCH2, provided that when s is 0, then G is attached to a carbon atom on ring M;
Z is selected from a C1-4 alkylene, (CH2) rO (CH2) r
(CH2)rNR3(CH2)r- (CH2) rC (O) (CH2) r» (CH2) rC (0) 0 (CH2) r, (CH2)r0C(0) (CH2)r, (CH2) rC (0) NR3 (CH2) r, (CH2)rNR3C(0) (CH2)r, (CH2 ) rOC (0) 0 (CH2) r, (CH2)rOC(0)NR3(CH2)r, (CH2) r R3C (O) 0 (CH2) r, (CH2)rNR3C(0)NR (CH2)r, (CH2) rS (O) p (CH2) r, (CH2)rS02NR (CH2)r, (CH2 ) rNR3S02 (CH2 ) r and (CH2)r R32NR3 (CH2)r» provided that Z does not form a N- N, N-0, N-S, NCH2N, NCH20, or NCH2S bond with ring M or group A;
Rla and Rlb are independently absent or selected from -(CH2)r-R10 -CH=CH-R10 NCH2R1", OCH2R1", SCH2R1", NH(CH2)2 (CH2)tR10 O(CH2)2(CH2)tR10 and S (CH2 ) 2 (CH2 ) tR1';
alternatively, Rla and Rlb, when attached to adjacent carbon atoms, together with the atoms to which they are attached form a 5-8 membered saturated, partially saturated or unsaturated ring substituted with 0-2 R4 and which contains from 0-2 heteroatoms selected from the group consisting of N, 0, and S;
R1' is selected from H, Cι_3 alkyl, F, Cl, Br, I, -CN, -CHO, (CF2)rCF3, (CH2)rOR2, NR2R2a, C(0)R2c, OC(0)R2, (CF2)rC02R2c, S(0)pR2b, NR2(CH2)rOR2, CH (=NR2c)NR2R2a, NR2C(0)R2b, NR2C(0)NHR2b, NR2C(0)2R2a, OC (O) NR2aR2b,
C(0)NR2R2a, C(0)NR2(CH2)rOR2, S02NR2R2a, NR2S02R2b, C3_6 carbocyclic residue substituted with 0-2 R4, and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R4;
R1" is selected from H, CH(CH2OR2)2, C(0)R2c, C(0)NR2R2a, S(0)R2b, S(0)2R2b, and S02NR2R2a;
R2, at each occurrence, is selected from H, CF3, -Q alkyl, benzyl, C _6 carbocyclic residue substituted with 0-2 Rb, and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 Rb;
R2a, at each occurrence, is selected from H, CF3 , Cι_6 alkyl, benzyl, C3_6 carbocyclic residue substituted with 0-2 Rb, and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R4b;
R2b, at each occurrence, is selected from CF , Cι_4 alkoxy, Cι_6 alkyl, benzyl, C3_6 carbocyclic residue substituted with 0-2 Rb, and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R4b;
R2c, at each occurrence, is selected from CF3, OH, C1-4 alkoxy, C1-6 alkyl, benzyl, C3_6 carbocyclic residue substituted with 0-2 Rb, and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R4b;
alternatively, R2 and R2a combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring substituted with 0-2 R4b which contains from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;
alternatively, R2 and R2a, together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring substituted with 0-2 R4b and containing from 0-1 additional heteroatoms selected from the group consisting of N, 0, and S;
R3, at each occurrence, is selected from H, Cι_4 alkyl, and phenyl;
R3a, at each occurrence, is selected from H, Cι_4 alkyl, and phenyl;
R3b, at each occurrence, is selected from H, C1-4 alkyl, and phenyl ; R3c, at each occurrence, is selected from C3.-4 alkyl, and phenyl ;
A is selected from: C3_ιo carbocyclic residue substituted with 0-2 R4, and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R4;
B is selected from:
X-Y, NR2R2a, C(=NR2)NR2R2a, NR2C (=NR2 ) NR2R2a, C3-10 carbocyclic residue substituted with 0-2 R4 , and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R a;
X is selected from Cι_ alkylene, -CR2 (CR2R2b) (CH2) -, -C(O)-, -C(=NR1")-, -CR2(NR1"R2)-, -CR2(OR2)-, -CR2(SR2)-, -C(0)CR2R2a-, -CR2R2aC(0), -S(0)p-, -S (0)pCR2R2a- , -CR2R2aS(0)p-, -S(0)2NR2-, -NR2S(0)2-, -NR2S (O) 2CR2R2a- , -CR2R2aS(0)2NR2-, -NR2S(0)2NR2-, -C(0)NR2-, -NR2C(0)-, -C(0)NR2CR2R2 -, -NR2C(0)CR2R2a-, -CR2R2aC (O)NR2-, -CR2R2aNR2C(0)-, -NR2C(0)0-, -0C(0)NR2-, -NR2C (O)NR2- , -NR2-, -NR2CR2R2a-, -CR2R2aNR2-, O, -CR2R2a0-, and -0CR2R2a-;
Y is selected from:
(CH2)rNR2R2a, provided that X-Y do not form a N-N, 0-N, or S-N bond, C3_ιo carbocyclic residue substituted with 0-2 R4 , and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R4a;
R4, at each occurrence, is selected from H, =0, (CH )rOR2, F, Cl, Br, I, Cι_4 alkyl, -CN, N02, (CH2)rNR2R2a, (CH2)rC(0)R2c, NR2C(0)R2b, C(0)NR2R2a, NR2C (0)NR2R2a, CH(=NR2)NR2R2a, CH(=NS(0)2R5)NR2R2a, NHC (=NR2 ) NR2R2 , C(0)NHC(=NR2)NR2R2a, S0NR2R2a, NR2S02NR2R2a, NR2S02-Cι_ alkyl, NR2S02R5, S(0)pR5, (CF2)rCF3, NCH2R1", OCH2R1", SCH2R1", N(CH2 )2(CH2)tR10 O(CH2)2(CH2)tR10 and
Figure imgf000208_0001
alternatively, one R4 is a 5-6 membered aromatic heterocycle containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S;
R4a, at each occurrence, is selected from H, =0, (CH2)rOR2,
(CH2)r"F, (CH2)r-Br, (CH2)r-Cl, Cl, Br, F, I, C1-4 alkyl, -CN, N02, (CH2)r R2R2a, (CH2) rC (0) R2c, NR2C(0)R2b, C(0)NR2R2a, C(0)NH(CH2)2NR2R2a, NR2C (0) NR2R2a, CH(=NR2)NR2R2a, NHC(=NR2)NR2R2a, S02NR2R2a, NR2S02NR2R2a, NR2S02-Cι_4 alkyl, C (0)NHS02-Cι_ alkyl, NR2S02R5, S(0)pR5, and (CF2)rCF3;
alternatively, one R4a is a 5-6 membered aromatic heterocycle containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-1 R5;
R4b, at each occurrence, is selected from H, =0, (CH2)rOR3, F, Cl, Br, I, C1-4 alkyl, -CN, N02 , (CH2) rNR3R3a, (CH2)rC(0)R3, (CH2)rC(0)OR3c, NR3C(0)R3a, C(0)NR3R3a, NR3C(0)NR3R3a, CH (=NR3)NR3R3a, NR3C (=NR3 ) NR3R3a, S02NR3R3a, NR3S02NR3R3a, NR3S02-Ci_4 alkyl, NR3S02CF3, NR3S02-phenyl , S(0)pCF3, S(0)p-Ci-4 alkyl, S (0)p-phenyl, and (CF2)rCF3;
R5, at each occurrence, is selected from CF , Cι_6 alkyl, phenyl substituted with 0-2 R6, and benzyl substituted with 0-2 R6;
R6, at each occurrence, is selected from H, OH, (CH2)rOR2, halo, Cι_4 alkyl, CN, N02, (CH2)rNR2R2a, (CH2) rC (0)R2b, NR2C(0)R2b, NR2C(0)NR2R2a, CH(=NH)NH2, NHC(=NH)NH2, S02NR2R2 , NR2S02NR2R2a, and NR2S02Cι_4 alkyl; R7, at each occurrence, is selected from H, OH, Cι_6 alkyl, Ci-e alkylcarbonyl, C -Q alkoxy, Cχ_4 alkoxycarbonyl, (CH2) n-phenyl, Cδ-io aryloxy, C6_ιo aryloxycarbonyl, Cβ-10 arylmethylcarbonyl , C1-4 alkylcarbonyloxy C1-4 alkoxycarbonyl, Cβ-io arylcarbonyloxy Cχ_4 alkoxycarbonyl, Cι_6 alkylaminocarbonyl , phenylaminocarbony1 , and phenyl Cχ_4 alkoxycarbonyl;
R8, at each occurrence, is selected from H, C -Q alkyl and (CH2) n-phenyl;
alternatively, R7 and R8 combine to form a 5 or 6 membered saturated, ring which contains from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;
R9, at each occurrence, is selected from H, Cι_6 alkyl and (CH2)n-phenyl;
n, at each occurrence, is selected from 0, 1, 2, and 3 ;
m, at each occurrence, is selected from 0, 1, and 2;
p, at each occurrence, is selected from 0, 1, and 2;
r, at each occurrence, is selected from 0, 1, 2, and 3;
s, at each occurrence, is selected from 0, 1, and 2; and,
t, at each occurrence, is selected from 0, 1, 2, and 3;
provided that D-E-G- (CH2) s- and -Z-A-B are not both benzamidines .
2. A compound according to Claim 1, wherein the compound is of formulae Ia-Ih:
Figure imgf000210_0001
wherein, groups D-E- and -Z-A-B are attached to adjacent atoms on the ring;
R is selected from H, Cl, F, Br, I, (CH2) OR3, C1-4 alkyl, OCF3, CF3, C(0)NR7R8, and (CR8R9) tNR7R8 ;
Z is selected from a CH20, 0CH2, CH2NH, NHCH2 , C(0), CH2C(0), C(0)CH2, NHC(O), C(0)NH, CH2S(0)2, S(0)2(CH2), S02NH, and NHSO2, provided that Z does not form a N-N, N-O, NCH2N, or NCH2O bond with ring M or group A;
A is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R4; phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, 1, 2, 3 -oxadiazolyl, 1,2, 4-oxadiazolyl, 1, 2, 5-oxadiazolyl, 1, 3 , 4-oxadiazolyl, 1,2, 3-thiadiazolyl, 1, 2, 4-thiadiazolyl,
1,2, 5-thiadiazolyl, 1, 3 , 4-thiadiazolyl, 1, 2, 3-triazolyl, 1,2, 4-triazolyl, 1, 2, 5-triazolyl, 1, 3 , 4-triazolyl, benzofuranyl, benzothiofuranyl, indolyl, benzimidazolyl, benzoxazolyD benzthiazolyl, indazolyl, benzisoxazolyl, benzisothiazolyl, and isoindazolyl; B is selected from: Y, χ-γ, NR R2S c (=NR2)NR2R2a, and NR2C(=NR2)NR2R2a;
X is selected from Cι_ alkylene, -C(O)-, -C(=NR)-,
-CR2(NR2R2a)-, -C(0)CR2R2a-, -CR2R2aC(0), -C(0)NR2-, -NR2C(0)-, -C(0)NR2CR2R2a-, -NR2C (O) CR2R2a-, -CR2R2aC(0)NR2-, -CR2R2aNR2C(0)-, -NR2C (O)NR2- , -NR2-, -NR2CR2R2a-, -CR2R2aNR2-, 0, -CR2R2aO-, and -OCR2R2a-;
Y is NR2R2a, provided that X-Y do not form a N-N or 0-N bond;
alternatively, Y is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R4a; cylcopropyl, cyclopentyl, cyclohexyl, phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, isoxazolinyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, 1, 2, 3-oxadiazolyl, 1,2, 4-oxadiazolyl, 1, 2 , 5-oxadiazolyl, 1, 3 , 4-oxadiazolyl, 1,2, 3-thiadiazolyl, 1,2, 4-thiadiazolyl, 1,2, 5-thiadiazolyl, 1, 3 , 4-thiadiazolyl, 1, 2, 3-triazolyl, 1,2, 4-triazolyl, 1, 2 , 5-triazolyl, 1, 3, 4-triazolyl, benzofuranyl, benzothiofuranyl, indolyl, benzimidazolyl, benzoxazolyl , benzthiazolyl, indazolyl, benzisoxazolyl, benzisothiazolyl, and isoindazolyl;
alternatively, Y is selected from the following bicyclic heteroaryl ring systems :
Figure imgf000211_0001
K is selected from 0, S, NH, and N.
3. A compound according to Claim 2 , wherein the compound is of formulae Ila-IIf:
Figure imgf000212_0001
wherein;
Z is selected from a C(0), CH2C(0), C(0)CH2, NHC(O), C(0)NH, C(0)N(CH3) , CH2S(0)2, S(0)2(CH2), S02NH, and NHS02 , provided that Z does not form a N-N or NCH2N bond with ring M or group A.
4. A compound according to Claim 3, wherein;
E is phenyl substituted with R or 2-pyridyl substituted with R;
D is selected from NH2, NHCH3, CH2NH2, CH2NHCH3 , CH(CH3)NH2, and C(CH3)2NH2, provided that D is substituted ortho to ring M on E; and,
R is selected from H, OCH , Cl, and F.
5. A compound according to Claim 4, wherein;
D-E is selected from 2-aminophenyl, 2-methylaminophenyl, 2- aminomethylphenyl , 4-methoxy-2-aminophenyl, 4-methoxy-2- (methylamino) phenyl, 4-methoxy-2-aminomethylphenyl, 4- methoxy-2- (methylaminomethyl) phenyl, 4-methoxy-2- (1- aminoethyl)phenyl , 4-methoxy-2- (2-amino-2-propyl)phenyl, 4-Cl-2-aminophenyl, 4-Cl-2- (methylamino) phenyl, 4-C1-2- aminomethylphenyl , 4-C1-2- (methylaminomethyl) phenyl, 4- Cl-2-(l-aminoethyl)phenyl, 4-C1-2- (2-amino-2- propyl) phenyl , 4-F-2-aminophenyl, 4-F-2- (methylamino) phenyl, 4-F-2-aminomethylphenyl, 4-F-2- (methylaminomethyl)phenyl, 4-F-2- (1-aminoethyl) phenyl, and 4-F-2- (2-amino-2-propyl)phenyl .
6. A compound according to Claim 3, wherein;
Z is C(0)CH2 and CONH, provided that Z does not form a N-N bond with group A;
A is selected from phenyl, pyridyl, and pyrimidyl, and is substituted with 0-2 R4; and,
B is selected from X-Y, phenyl, pyrrolidino, morpholino,
1,2, 3-triazolyl, and imidazolyl, and is substituted with 0-1 Ra;
R4, at each occurrence, is selected from OH, (CH2)rOR2, halo, Cι-4 alkyl, (CH2) rNR2R , and (CF2)rCF3;
R4a s selected from Cι_ alkyl, CF3, S(Q)pR5, S02NR2R2a, and l-CF3-tetrazol-2-yl;
R5, at each occurrence, is selected from CF3, Cι_6 alkyl, phenyl, and benzyl;
X is CH2 or C(O); and, Y is selected from pyrrolidino and morpholino.
7. A compound according to Claim 6, wherein;
A is selected from the group: phenyl, 2-pyridyl, 3-pyridyl, 2-pyrimidyl, 2-Cl-phenyl, 3-Cl-phenyl, 2-F-phenyl, 3-F- phenyl, 2-methylphenyl, 2-aminophenyl, and 2- methoxyphenyl; and,
B is selected from the group: 2-CF3-phenyl, 2-
(aminosulfonyl) phenyl, 2- (methylaminosulfonyl)phenyl , 2- (dimethylaminosulfonyl)phenyl, 1-pyrrolidinocarbonyl, 2- (methylsulfonyl) phenyl, 4-morpholino, 2- (1 ' -CF3-tetrazol- 2-yl)phenyl, 4-morpholinocarbonyl, 2-methyl-l-imidazolyl, 5-methyl-l-imidazolyl, 2-methylsulfonyl-l-imidazolyl and, 5-methyl-1, 2 , 3-triazolyl .
8. A compound according to Claim 3, wherein;
E is phenyl substituted with R or 2-pyridyl substituted with
R;
D is selected from NH2, NHCH3, CH2NH2, CH2NHCH3 , CH(CH3)NH2, and
C(CH3)2NH2, provided that D is substituted ortho to ring M on E; and,
R is selected from H, OCH3, Cl, and F;
Z is C(0)CH2 and CONH, provided that Z does not form a N-N bond with group A;
A is selected from phenyl, pyridyl, and pyrimidyl, and is substituted with 0-2 R4; and, B is selected from X-Y, phenyl, pyrrolidino, morpholino,
1, 2, 3 -triazolyl, and imidazolyl, and is substituted with 0-1 R4a;
R4, at each occurrence, is selected from OH, (CH2)rOR2' halo, Cι-4 alkyl, (CH2) rNR2R2a, and (CF2)rCF3;
R4a iΞ selected from Cι_ alkyl, CF3, S(0)pR5, S02NR2R2a, and l-CF -tetrazol-2-yl;
R5, at each occurrence, is selected from CF3 , Cι-6 alkyl, phenyl, and benzyl;
X is CH2 or C(O) ; and,
Y is selected from pyrrolidino and morpholino.
9. A compound according to Claim 8, wherein;
D-E is selected from 2-aminophenyl, 2-methylaminophenyl, 2- aminomethylphenyl , 4-methoxy-2-aminophenyl, 4-methoxy-2- (methylamino) phenyl, 4-methoxy-2-aminomethylphenyl, 4- methoxy-2- (methylaminomethyl ) phenyl , 4-methoxy-2- ( 1- aminoethyl) phenyl, 4-methoxy-2- (2-amino-2-propyl) phenyl, 4-Cl-2-aminophenyl, 4-Cl-2- (methylamino) phenyl, 4-C1-2- aminomethylphenyl, 4-C1-2- (methylaminomethyl) phenyl, 4- Cl-2- (1-aminoethyl) phenyl, 4-C1-2- (2-amino-2- propyl) phenyl , 4-F-2-aminophenyl, 4-F-2- (methylamino) phenyl, 4-F-2-aminomethylphenyl, 4-F-2-
(methylaminomethyl) phenyl , 4-F-2- ( 1-aminoethyl) phenyl , and 4-F-2- (2-amino-2-propyl) phenyl;
A is selected from the group: phenyl, 2-pyridyl, 3-pyridyl, 2-pyrimidyl, 2-Cl-phenyl, 3-Cl-phenyl, 2-F-phenyl, 3-F- phenyl, 2-methylphenyl , 2-aminophenyl, and 2- methoxyphenyl ; and, B is selected from the group: 2-CF3-phenyl , 2-
(aminosulfonyl)phenyl, 2- (methylaminosulfonyl)phenyl, 2- (dimethylaminosulfonyl)phenyl, 1-pyrrolidinocarbonyl, 2- (methylsulfonyl)phenyl, 4-morpholino, 2- (1 ' -CF3-tetrazol- 2-yl)phenyl, 4-morpholinocarbdnyl, 2-methyl-l-imidazolyl, 5-methyl-l-imidazolyl, 2-methylsulfonyl-l-imidazolyl and, 5-methyl-l,2, 3-triazolyl.
10. A compound according to Claim 9, wherein the compound is of formula Ila.
11. A compound according to Claim 9, wherein the compound is of formula lib.
12. A compound according to Claim 9 , wherein the compound is of formula lie .
13. A compound according to Claim 9 , wherein the compound is of formula lid.
14. A compound according to Claim 9 , wherein the compound is of formula lie.
15. A compound according to Claim 9, wherein the compound is of formula Ilf.
16. A compound according to Claim 3, wherein;
D is selected from -CN, C (=NR8)NR7R9 , C(0)NR7R8, NR7R8, and
CH2NR7R8, provided that D is substituted ortho to ring M on E; E is phenyl substituted with R or pyridyl substituted with R;
R is selected from H, Cl, F, OR3, CH3 , CH2CH3 , OCF3 , CF3 , NR7R8 , and CH2NR7R8 ;
Z is selected from C(O), CH2C(0), C(0)CH2, NHC (0) , and C(0)NH, provided that Z does not form a N-N bond with ring M or group A;
Rla and Rlb are independently absent or selected from
-(CH2)r-R10 NCH2R1", OCH2R1", SCH2R1", N(CH2 )2(CH2 )tR10 O(CH2)2(CH2)tR10 and S (CH2) 2 (CH2) tR1', or combined to form a 5-8 membered saturated, partially saturated or unsaturated ring substituted with 0-2 R4 and which contains from 0-2 heteroatoms selected from the group consisting of N, O, and S;
R10 at each occurrence, is selected from H, Cχ_3 alkyl, halo, (CF2)rCF3, OR2, NR2R2a, C(0)R2c, (CF2 ) rC02R2c , S(0)pR2b, NR2 (CH2)rOR2, NR2C(0)R2b, NR2C(0)2R2b, C(0)NR2R2a, S02NR2R2a, and NR2S02R2b;
A is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R4,- phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, and imidazolyl;
B is selected from: Y, X-Y, NR2R2a, C (=NR2)NR2R2a, and NR2C(=NR2)NR2R2a;
X is selected from CH2, -CR2 (CR2R2b) (CH2) t" -C(0)-, -C(=NR)-, -CH(NR2R2a)-, -C(0)NR2-, -NR2C(0)-, -NR2C (O)NR2-, -NR2-, and O;
Y is NR2R2a, provided that X-Y do not form a N-N or 0-N bond; alternatively, Y is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R4a; phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, isoxazolinyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, 1, 2 , 3-oxadiazolyl, 1, 2, 4-oxadiazolyl, 1, 2 , 5-oxadiazolyl, 1, 3, 4-oxadiazolyl, 1,2, 3-thiadiazolyl , 1,2, 4-thiadiazolyl,
1, 2, 5-thiadiazolyl, 1, 3 , 4-thiadiazolyl, 1, 2, 3-triazolyl, 1, 2, 4-triazolyl, 1, 2 , 5-triazolyl, and 1, 3 , 4-triazolyl;
R4, at each occurrence, is selected from =0, OH, Cl, F, C1-4 alkyl, (CH2) rNR2R2a, (CH2) rC (0) R2b, NR2C(0)R2b, C(0)NR2R2a, CH(=NH)NH2, NHC(=NH)NH2, S02NR2R2a, NR2S02-Cι_4 alkyl, NR2S02R5, S(0)pR5, and (CF2)rCF3;
R4a, at each occurrence, is selected from =0, OH, Cl, F, Cι_4 alkyl, (CH2) rNR2R2a, (CH2) rC (0) R2b, NR2C(0)R2b, C(0)NR2R2a, CH(=NH)NH2, NHC(=NH)NH2, S02NR2R2a, NR2S02-Cι_ alkyl, NR2S02R5, S(0)pR5, (CF2)rCF3, and l-CF3-tetrazol-2-yl;
R5, at each occurrence, is selected from CF3 , Cχ-6 alkyl, phenyl substituted with 0-2 R6, and benzyl substituted with 0-2 R6;
R6, at each occurrence, is selected from H, =0, OH, OR2, Cl, F, CH3, CN, N02, (CH2)rNR2R2a, (CH2) rC (0) R2b, NR2C(0)R2b, CH(=NH)NH2, NHC(=NH)NH2, and S02NR2R2a;
R7, at each occurrence, is selected from H, OH, Cχ_6 alkyl, Cχ_6 alkylcarbonyl , C _6 alkoxy, Cι_4 alkoxycarbonyl, benzyl, C6-10 aryloxy, Ce-io aryloxycarbonyl, C6-10 arylmethylcarbonyl , Cι_4 alkylcarbonyloxy Cι_4 alkoxycarbonyl, Cβ-io arylcarbonyloxy Cχ_4 alkoxycarbonyl, Cχ_6 alkylaminocarbonyl, phenylaminocarbonyl , and phenyl Cχ_4 alkoxycarbonyl;
R8, at each occurrence, is selected from H, Cχ_6 alkyl and benzyl; and
alternatively, R7 and R8 combine to form a morpholino group; and,
R9, at each occurrence, is selected from H, Cχ_6 alkyl and benzyl .
17. A compound according to Claim 16, wherein;
E is phenyl substituted with R or 2-pyridyl substituted with R;
R is selected from H, Cl, F, OCH3 , CH3 , OCF3 , CF3, NH2 , and CH2NH2;
Z is selected from a C(0)CH2 and C(0)NH, provided that Z does not form a N-N bond with group A;
Rla is selected from H, CH3 , CH2CH3, Cl, F, CF3, 0CH3/ NR2R2a, S(0)pR2 , CH2S(0)pR2b, CH2NR2S(0)pR2b, C(0)R2c, CH2C(0)R2c, C(0)NR2R2a, and S02NR2R2a;
Rlb s selected from H, CH3, CH2CH3, Cl, F, CF3, 0CH3, NR2R2a, S(0)pR2b, CH2S(0)pR2b, CH2NR2S (0)pR2b, C(0)R2c, CH2C(0)R2 , C(0)NR2R2a, and S02NR2R2a;
A is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R4; phenyl, pyridyl, pyrimidyl, furanyl, thiophenyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, and imidazolyl; B is selected from: Y and X-Y;
X is selected from CH , -CR2 (CR2R2b) -, -C(0)-, -C(=NR)-,
-CH(NR2R2a)-, -C(0)NR2-, -NR2C(0)-, -NR2C (O)NR2- , -NR2-, and O;
Y is NR2R2a, provided that X-Y do not form a N-N or 0-N bond;
alternatively, Y is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R4a; phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, isoxazolinyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, 1, 2, 3-oxadiazolyl,
1,2, 4-oxadiazolyl, 1, 2 , 5-oxadiazolyl, 1, 3 , 4-oxadiazolyl,
1,2, 3-thiadiazolyl, 1, 2 , 4-thiadiazolyl,
1,2,5-thiadiazolyl, 1, 3 , 4-thiadiazolyl, 1, 2, 3-triazolyl, 1,2, 4-triazolyl, 1, 2, 5-triazolyl , and 1, 3 , 4-triazolyl;
R2, at each occurrence, is selected from H, CF3, CH3, benzyl, and phenyl;
R2a, at each occurrence, is selected from H, CF3, CH3, benzyl, and phenyl;
R2b, at each occurrence, is selected from CF3, OCH3, CH , benzyl, and phenyl;
R2c, at each occurrence, is selected from CF3, OH, OCH3, CH3, benzyl, and phenyl;
alternatively, R2 and R2a combine to form a 5 or 6 membered saturated, partially unsaturated, or unsaturated ring which contains from 0-1 additional heteroatoms selected from the group consisting of N, 0, and S; R3, at each occurrence, is selected from H, CH3 , CH2CH , and phenyl;
R3a, at each occurrence, is selected from H, CH , CH2CH3, and phenyl;
R4, at each occurrence, is selected from OH, Cl, F, CH3 ,
CH2CH3, NR2R2a, CH2NR2R2a, C(0)R2b, NR2C(0)R2b, C(0)NR2R2a, and CF3;
R4a, at each occurrence, is selected from OH, Cl, F, CH3 ,
CH2CH3, NR2R2a, CH2NR2R2a, C(0)R2b, C(0)NR2R2a, S02NR2R2a,
S(0)pR5, CF3, and l-CF3-tetrazol-2-yl;
R5, at each occurrence, is selected from CF3, Cχ_6 alkyl, phenyl substituted with 0-2 R6, and benzyl substituted with 1 R6;
R6, at each occurrence, is selected from H, OH, OCH3 , Cl, F, CH3, CN, N02, NRR , CH2NR2R2a, and S02NR2R2a;
R7, at each occurrence, is selected from H and Cχ_3 alkyl;
R8, at each occurrence, is selected from H, CH3, and benzyl;
R9, at each occurrence, is selected from H, CH , and benzyl; and,
t, at each occurrence, is selected from 0 and 1.
18. A compound according to Claim.17, wherein;
D is selected from NR7R8, and CH2NR7R8, provided that D is substituted ortho to ring M on E; Rla is absent or is selected from H, CH3 , CHCH3 , Cl, F, CF3 , OCH3, NR2R2a, S(0)pR2b, C(0)NR2R2a, CH2S(0)pR2b, CH2NR2S(0)pR2b, C(0)R2c, CH2C(0)R2c, and S02NR2R2a;
Rlb is absent or is selected from H", CH3, CH2CH3, Cl, F, CF3 , OCH3, NR2R2a, S(0)pR2b, C(0)NR2R2a, CH2S(0)pR2b, CH2NR2S(0)pR2b, C(0)R2b, CH2C(0)R2b, and S02NR2R2a;
A is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R4; phenyl, pyridyl, and pyrimidyl;
B is selected from: Y and X-Y;
X is selected from -C(O)- and O;
Y is NR2R2a, provided that X-Y do not form a O-N bond;
alternatively, Y is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R4 ; phenyl, piperazinyl, pyridyl, pyrimidyl, morpholinyl, pyrrolidinyl, imidazolyl, and 1,2,3- triazolyl ;
R2, at each occurrence, is selected from H, CF3, CH3, benzyl, and phenyl;
R2a, at each occurrence, is selected from H, CF3, CH3, benzyl, and phenyl;
R2b, at each occurrence, is selected from CF3, OCH3, CH3, benzyl, and phenyl;
R2c, at each occurrence, is selected from CF3, OH, OCH3, CH3, benzyl, and phenyl; alternatively, R2 and R2a combine to form a ring system selected from pyrrolidinyl, piperazinyl and morpholino;
R4, at each occurrence, is selected from Cl, F, CH3 , NR2R2a, and CF3;
R4a, at each occurrence, is selected from Cl, F, CH3, S02NR2R2a, S(0)pR5, and CF3 ;
R5, at each occurrence, is selected from CF3 and CH3;
R7, at each occurrence, is selected from H, CH3, and CH2CH ; and,
R8, at each occurrence, is selected from H and CH3.
19. A compound according to Claim 1, wherein the compound is selected from:
3-Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (2 ' -sulfamido- [1,1'] -biphen-4-yl) ) carboxyamide;
3-Ethyl-l- (2-aminomethyl-4-methoxyphenyl) -IH-pyrazole-5- (N- (2 ' -sulfamido- [1,1'] -biphen-4-yl) ) carboxyamide;
3-Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (2 ' -sulfamido- [1, 1 ' ] -biphen-4- yl) ) carboxyamide;
3-Methyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (2 ' -sulfamido- [1, 1 ' ] -biphen-4- yl) ) carboxyamide; 3-Ethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -IH-pyrazole- 5- (N- (2 ' -sulfamido- [1,1'] -biphen-4-yl) ) carboxyamide;
3-Trifluoromethyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) - IH-pyrazole-5- (N- (2 ' -sulfamido- [1, 1 ' ] -biphen-4- yl) ) carboxyamide;
3-Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (2 ' -methylsulfonyl- [1,1'] -biphen-4-yl) ) carboxyamide; 3-Ethyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (2 ' -methylsulfonyl- [1,1'] -biphen-4-yl) ) carboxyamide; -Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (2 ' -methylsulfonyl- [1,1'] -biphen-4- yl) ) carboxyamide; -Methyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (2 ' -methylsulfonyl- [1,1'] -biphen-4- yl) ) carboxyamide; -Ethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -lH-pyrazole- 5- (N- (2 ' -methylsulfonyl- [1, 1' ] -biphen-4-yl) ) carboxyamide;-Trifluoromethyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (2 ' -methylsulfonyl- [1, 1 ' ] -biphen-4- yl) ) carboxyamide; -Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (3-fluoro-2 ' -sulfamido- [1,1'] -biphen-4-yl) ) carboxyamide;-Ethyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (3- fluoro-2 ' -sulfamido- [1,1'] -biphen-4-yl) ) carboxyamide;-Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -sulfamido- [1,1'] -biphen-4- yl) ) carboxyamide; -Methyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -sulfamido- [1,1'] -biphen-4- yl) ) carboxyamide; -Ethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -lH-pyrazole- 5- (N- (3-fluoro-2 ' -sulfamido- [1,1'] -biphen-4- yl) ) carboxyamide; -Trifluoromethyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (3-fluoro-2 ' -sulfamido- [1, 1 ' ] -biphen-4- yl) ) carboxyamide; -Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1'] -biphen-4- yl) ) carboxyamide; -Ethyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (3- fluoro-2 ' -methylsulfonyl- [1,1'] -biphen-4- yl) ) carboxyamide; -Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1'] -biphen-
4-yl) ) carboxyamide; -Methyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1'] -biphen- 4-yl) ) carboxyamide; -Ethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -lH-pyrazole- 5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1'] -biphen-4- yl) ) carboxyamide; -Trifluoromethyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1']- biphen-4-yl) ) carboxyamide; -Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (4- ( 1-pyrrolidinocarbonyl)phenyl) carboxyamide; -Ethyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (4- (1-pyrrolidinocarbonyl) phenyl) carboxyamide; -Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (4- (1- pyrrolidinocarbonyl) phenyl) carboxyamide; -Methyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (4- (1- pyrrolidinocarbonyl)phenyl) carboxyamide; -Ethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -lH-pyrazole- 5- (N- (4- (1-pyrrolidinocarbonyl)phenyl) carboxyamide,--Trifluoromethyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (4- (1- pyrrolidinocarbonyl)phenyl) carboxyamide; -Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (2-fluoro-4- (1-pyrrolidinocarbonyl) phenyl) carboxyamide;-Ethyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (2- fluoro-4- (1-pyrrolidinocarbonyl)phenyl) carboxyamide; -Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (2-fluoro-4- (1- pyrrolidinocarbonyl)phenyl) carboxyamide; -Methyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (2-fluoro-4- (1- pyrrolidinocarbony1)phenyl) carboxyamide; -Ethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -IH-pyrazole-
5- (N- (2-fluoro-4- (1-pyrrolidinocarbonyl) carboxyamide, -Trifluoromethyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) - IH-pyrazole-5- (N- (2-fluoro-4- (1- pyrrolidinocarbonyl)phenyl) carboxyamide; -Methyl-l- (2-aminomethyl-4-methoxyphenyl) -IH-pyrazole-5- (N- (5- ( (2-sulfamido)phenyl)pyridin-2-yl) carboxyamide; -Ethyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (5- ( (2-sulfamido) phenyl)pyridin-2-yl) carboxyamide; -Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (5- ( (2-sulfamido)phenyl)pyridin-2- yl) carboxyamide; -Methyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (5- ( (2-sulfamido) phenyl) pyridin-2- yl) carboxyamide; -Ethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -lH-pyrazole- 5- (N- (5- ( (2-sulfamido) phenyl) pyridin-2-yl) carboxyamide; -Trifluoromethyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (5- ( (2-sulfamido)phenyl)pyridin-2- yl) carboxyamide; -Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (5- ( (2-methylsulphonyl) phenyl)pyridin-2-yl) carboxyamide;-Ethyl-l- (2-aminomethyl-4-methoxyphenyl) -IH-pyrazole-5- (N- (5- (2-methylsulphonyl) phenyl)pyridin-2-yl ) carboxyamide; -Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (5- ( (2-methylsulphonyl) phenyl)pyridin-2- yl) carboxyamide; -Methyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (5- ( (2-methylsulphonyl) phenyl) pyridin-2- yl) carboxyamide; -Ethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -lH-pyrazole-
5- (N- (5- ( (2-methylsulphonyl)phenyl)pyridin-2- yl) carboxyamide; -Trifluoromethyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (5- ( (2-methylsulphonyl)phenyl)pyridin-2- yl) carboxyamide; -Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (5- ( (2-sulfamido)phenyl)pyrimidin-2-yl) carboxyamide; -Ethyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (5- ( (2-sulfamido)phenyl)pyrimidin-2-yl) carboxyamide; -Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (5- ( (2-sulfamido)phenyl)pyrimidin-2- yl) carboxyamide; -Methyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5-(N- (5- ( (2-sulfamido)phenyl)pyrimidin-2- yl) carboxyamide; -Ethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -lH-pyrazole- 5- (N- (5- ( (2-sulfamido)phenyl)pyrimidin-2-yl) carboxyamide; -Trifluoromethyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) - IH-pyrazole-5- (N- (5- ( (2-sulfamido)phenyl)pyrimidin-2- yl) carboxyamide; -Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (5- ( (2-methylsulphonyl)phenyl)pyrimidin-2- yl) carboxyamide; -Ethyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (5- (2-methylsulphonyl)phenyl)pyrimidin-2-yl) carboxyamide; -Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (5- ( (2-methylsulphonyl)phenyl)pyrimidin-2- yl) carboxyamide; -Methyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (5- ( (2-methylsulphonyl)phenyl)pyrimidin-2- yl) carboxyamide; -Ethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -lH-pyrazole-
5- (N- (5- ( (2-methylsulphonyl)phenyl)pyrimidin-2- yl) carboxyamide; -Trifluoromethyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (5- ( (2-methylsulphonyl)phenyl)pyrimidin- 2-yl) carboxyamide; -Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (4- ( (2-methyl) imidazo-1-yl) phenyl) carboxyamide; -Ethyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (4- ( (2-methyl) imidazo-1-yl)phenyl) carboxyamide; -Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (4- ( (2-methyl) imidazo-1- yl)phenyl) carboxyamide; -Methyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (4- ( (2-methyl) imidazo-1- yl)phenyl) carboxyamide; -Ethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -lH-pyrazole- 5- (N- (4- ( (2-methyl) imidazo-1-yl)phenyl) carboxyamide; -Trifluoromethyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (4- ( (2-methyl) imidazo-1- yl)phenyl) carboxyamide; -Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (4- ( (5-methyl) imidazo-1-yl) phenyl ) carboxyamide; -Ethyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (4- ( (5-methyl) imidazo-1-yl)phenyl) carboxyamide; -Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (4- ( (5-methyl) imidazo-1- yl)phenyl) carboxyamide; 3-Methyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (4- ( (5-methyl) imidazo-1- yl) phenyl) carboxyamide; 3-Ethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -lH-pyrazole- 5- (N- (4- ( (5-methyl) imidazo-1-yl)phenyl) carboxyamide;
3-Trifluoromethyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (4- ( (5-methyl) imidazo-1- yl) phenyl) carboxyamide;
3-Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (2-fluoro-4- ( (2-methyl) imidazo-1-yl)phenyl) carboxyamide; 3-Ethyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (2- fluoro-4- ( (2-methyl) imidazo-1-yl)phenyl) carboxyamide;
3-Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (2-fluoro-4- ( (2-methyl) imidazo-1- y1) phenyl) carboxyamide;
3-Methyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (2-fluoro-4- ( (2-methyl) imidazo-1- yl) phenyl) carboxyamide;
3-Ethyl-l- (2-N-methylaminomethy1-4-methoxyphenyl) -lH-pyrazole-
5- (N- (2-fluoro-4- ( (2-methyl) imidazo-1- yl) phenyl) carboxyamide; 3-Trifluoromethyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (2-fluoro-4- ( (2-methyl) imidazo-1- y1)phenyl) carboxyamide;
3-Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (2-fluoro-4- ( (5-methyl) imidazo-1-yl)phenyl) carboxyamide;
3-Ethyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (2- fluoro-4- ( (5-methyl) imidazo-1-yDphenyl) carboxyamide; 3-Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (2-fluoro-4- ( (5-methyl) imidazo-1- yl)phenyl) carboxyamide;
3-Methyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (2-fluoro-4- ( (5-methyl) imidazo-1- yl)phenyl) carboxyamide;
3-Ethyl-l- (2-N-methylaminomethyl-4-methoxyphenyl) -lH-pyrazole- 5- (N- (2-fluoro-4- ( (5-methyl) imidazo-1- y1)phenyl) carboxyamide; and,
3-Trifluoromethyl-1- (2-N-methylaminomethyl-4-methoxyphenyl) - lH-pyrazole-5- (N- (2-fluoro-4- ( (5-methyl) imidazo-1- yl)phenyl) carboxyamide;
and pharmaceutically acceptable salts thereof.
20. A compound according to Claim 1, wherein the compound is selected from:
3-Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-5- (N- (2' -sulfamido- [1,1'] -biphen-4-yl) ) carboxyamide;
5-Methyl-l- (2-aminomethyl-4-methoxyphenyl) -lH-pyrazole-3- (N- (2 ' -sulfamido- [1, 1' ] -biphen-4-yl) ) carboxyamide;
3-Methyl-l- (2-N,N-dimethylaminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (2 ' -N-methylsulfamido- [1, 1 ' ] -biphen-4- yl) ) carboxyamide;
3-Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5-(N- (3-fluoro-2' -sulfamido- [1, 1] -biphen-4- yl) ) carboxyamide; 3-Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5-(N- (3-fluoro-2' -methylsulfonyl- [1, l]-biphen-4- yl) ) carboxyamide,-
3-Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (2' -methylsulfonyl- [1, 1] -biphen-4- yl) ) carboxyamide;
3-Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (2 ' -sulfamido- [1, 1] -biphen-4- yl) ) carboxyamide;
3-Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (4-N- pyrrolidinocarbonyl)phenyl) carboxyamide;
N-Benzylsulfonyl-4- (3-trifluoromethyl-1- (2-aminomethyl-4- methoxyphenyl) -lH-pyrazole-5-carboxyamido) piperidine;
3-Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (5- (2 ' -sulfonamido)phenyl)pyrid-2- yl) carboxyamide;
3-Trifluoromethyl-1- (2-aminomethyl-4-methoxyphenyl) -1H- pyrazole-5- (N- (5- (pyrid-2-yl) )pyrid-2-yl) carboxyamide;
N-Benzyl-4- (3-trifluoromethyl-1- (2-aminomethyl-4- methoxyphenyl) -lH-pyrazole-5-carboxyamido)piperidine;
N-Phenylsulfonyl-4- (3-trifluoromethyl-1- (2-aminomethyl-4- methoxyphenyl) -lH-pyrazole-5-carboxyamido) piperidine;
3-Trifluoromethyl-1- (2-aminomethyl-4-chlorophenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1'] -biphen- 4-yl) ) carboxyamide; -Trifluoromethyl-1- (2-aminomethyl-4-chlorophenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -sulfamido- [1,1'] -biphen-4- yl) ) carboxyamide; -Trifluoromethyl-1- (2-aminomethyl-5-chlorophenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1'] -biphen-
4-yl ) ) carboxyamide; -Trifluoromethyl-1- (2-aminomethyl-4-chlorophenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -sulfamido- [1,1'] -biphen-4- yl) ) carboxyamide; -Trifluoromethyl-1- (2-aminomethyl-4-fluorophenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1'] -biphen- 4-yl) ) carboxyamide; -Trifluoromethyl-1- (2-aminomethyl-4-fluorophenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -sulfamido- [1,1' ] -biphen-4- y1) ) carboxyamide; -Trifluoromethyl-1- (2-aminomethyl-5-fluorophenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1'] -biphen-
4-yl) ) carboxyamide; -Trifluoromethyl-1- (2-aminomethyl-5-fluorophenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -sulfamido- [1,1'] -biphen-4- yl) ) carboxyamide; -Trifluoromethyl-1- (2-aminomethyl-4, 5-difluorophenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1'] -biphen- 4-yl) ) carboxyamide; -Trifluoromethyl-1- (2-aminomethyl-4, 5-difluorophenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -sulfamido- [1, 1 ' ] -biphen-4- yl) ) carboxyamide; -Trifluoromethyl-1- (2-aminomethyl-3-fluorophenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1'] -biphen- 4-yl) ) carboxyamide; -Trifluoromethyl-1- (2-aminomethyl-3-fluorophenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -sulfamido- [1,1'] -biphen-4- yl) ) carboxyamide; -Trifluoromethyl-1- (2-aminomethyl-4-fluorophenyl) -1H- pyrazole-5- (N- (4- (2-methylsulfonyl- [1,1'] -biphen-4- yl) ) carboxyamide; -Trifluoromethyl-1- (2-aminomethyl-4-fluorophenyl) -1H- pyrazole-5- (N- (4- (2-sulfamido- [1,1'] -biphen-4- yl) ) carboxyamide; -Trifluoromethyl-1- (2-aminomethyl-4-fluorophenyl) -1H- pyrazole-5- (N- (4- (N- ( (N'- methylsulfonyl) iminoly)pyrrolidino) )phenyl) carboxyamide; -Trifluoromethyl-1- (2- (N-glycyl) aminomethyl-4-methoxyphenyl) lH-pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1']- biphen-4-yl) ) carboxyamide; -Trifluoromethyl-1- (2- (N-phenylacetyl) aminomethyl-4- methoxyphenyl) -lH-pyrazole-5- (N- (3-fluoro-2 ' - methylsulfonyl- [1,1'] -biphen-4-yl) ) carboxyamide; - (Trifluoromethyl) -1- (2- (aminomethyl)phenyl) -lH-pyrazole-5- (N- (2 ' -methylsulfonyl- [1, 1 ' ] -biphen-4-yl) ) carboxyamide;-Trifluoromethyl-1- (2- (aminomethyl)phenyl) -lH-pyrazole-5- (N- (2 ' -aminosulfonyl- [1,1' ] -biphen-4-yl) ) carboxyamide; -Trifluoromethyl-1- (2- (aminomethyl)phenyl) -lH-pyrazole-5- (N- (3-fluoro-2 ' -aminosulfonyl- [1,1'] -biphen-4- yl) ) carboxyamide; -Trifluoromethyl-1- (2- (aminomethyl)phenyl) -lH-pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1, 1 ' ] -biphen-4- yl) ) carboxyamide; -Trifluoromethyl-1- (2- (N- (glycyl) aminomethyl)phenyl) -1H- pyrazole-5- (N- (3-fluoro-2 ' -methylsulfonyl- [1,1'] -biphen- 4-yl) ) carboxyamide; -Trifluoromethyl-1- (2- ( (N-(N- methylglycyl) aminomethyl)phenyl) -lH-pyrazole-5- (N- (3- fluoro-2 ' -methylsulfonyl- [1,1'] -biphen-4- yl) ) carboxyamide; -Trifluoromethyl-1- (2-carboxamidophenyl) -lH-pyrazole-5- (N- (3- fluoro-2 ' -methylsulfonyl- [1,1'] -biphen-4- yl) ) carboxyamide; -Trifluoromethyl-1- (2-cyanophenyl) -lH-pyrazole-5- (N- (3- fluoro-2 ' -methylsulfonyl- [1,1'] -biphen-4- yl) ) carboxyamide; - (2 ' -Aminomethylphenyl) -5- [ [ (2 ' -methylsulfonyl) -3-fluoro- [1,1'] -biphen-4-yl] aminocarbonyl] -tetrazole; - (2 ' -Aminomethylphenyl) -5- [ (2 ' -aminosulfonyl- [1,1'] -biphen-4- yl) aminocarbonyl] -tetrazole; - [2- (Aminomethyl)phenyl] -3-thiomethoxy-5- [ (2-fluoro) - (2 ' - methylsulfonyl- [1,1'] -biphen-4-yl) aminocarbonyl]pyrazole;- [2- (Aminomethyl)phenyl] -3-methysulfonyl-5- [ (2-fluoro) - (2 ' - methylsulfonyl- [1,1'] -biphen-4-yl) minocarbonyl]pyrazole;- [2- (Aminomethyl)phenyl] -5- [ (2-fluoro) - (2 ' -methylsulfonyl- [1,1'] -biphen-4-yl) aminocarbonyl] triazole; 1- [2- (AminomethyDphenyl] -5- [ (2-fluoro) - (2 ' -methylsulfonyl- [1,1'] -biphen-4-yl) aminocarbonyl]pyrazole;
1- [2- (AminomethyDphenyl] -3-trifluoromethyl-5- [ ( (2-fluoro) - (2 ' -pyrrolidinomethyl) - [1, 1 ' ] -biphen-4- yl) aminocarbonyl]pyrazole; and,
1- [2- (AminomethyDphenyl] -3-trifluoromethyl-5- [ ( (2-fluoro) - (2 ' -hydroxymethyl) - [1, 1 ' ] -biphen-4- yl) aminocarbonyl]pyrazole; and pharmaceutically acceptable salts thereof.
21. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to Claim 1 or a pharmaceutically acceptable salt thereof.
22. A method for treating or preventing a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound according to Claim 1 or a pharmaceutically acceptable salt thereof .
PCT/US1998/026427 1997-12-22 1998-12-11 Nitrogen containing heteroaromatics with ortho-substituted p1's as factor xa inhibitors WO1999032454A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU17244/99A AU1724499A (en) 1997-12-22 1998-12-11 Nitrogen containing heteroaromatics with ortho-substituted p1's as factor xa inhibitors
IL13663798A IL136637A0 (en) 1997-12-22 1998-12-11 Nitrogen containing heteroaromatics with ortho-substituted pi's as factor xa inhibitors
CA002314401A CA2314401A1 (en) 1997-12-22 1998-12-11 Nitrogen containing heteroaromatics with ortho-substituted p1's as factor xa inhibitors
BR9813835-9A BR9813835A (en) 1997-12-22 1998-12-11 Compound, pharmaceutical composition and method of treatment or prevention of a thromboembolic disorder
JP2000525391A JP2001526268A (en) 1997-12-22 1998-12-11 Nitrogen-containing heterocyclic aromatic compounds having ortho-substituted P1 as factor Xa inhibitors
EP98962082A EP1042299A1 (en) 1997-12-22 1998-12-11 Nitrogen containing heteroaromatics with ortho-substituted p1's as factor xa inhibitors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US99644797A 1997-12-22 1997-12-22
US08/996,447 1997-12-22
US10107598P 1998-09-18 1998-09-18
US60/101,075 1998-09-18

Publications (2)

Publication Number Publication Date
WO1999032454A1 WO1999032454A1 (en) 1999-07-01
WO1999032454A9 true WO1999032454A9 (en) 2001-05-31

Family

ID=26797877

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/026427 WO1999032454A1 (en) 1997-12-22 1998-12-11 Nitrogen containing heteroaromatics with ortho-substituted p1's as factor xa inhibitors

Country Status (7)

Country Link
EP (1) EP1042299A1 (en)
JP (1) JP2001526268A (en)
AU (1) AU1724499A (en)
BR (1) BR9813835A (en)
CA (1) CA2314401A1 (en)
IL (1) IL136637A0 (en)
WO (1) WO1999032454A1 (en)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2380727A1 (en) 1999-07-16 2001-01-25 Bristol-Myers Squibb Pharma Company Nitrogen containing heterobicycles as factor xa inhibitors
US6329527B1 (en) 1999-10-21 2001-12-11 Bristol-Myers Squibb Pharma Company Synthesis of 1,3,5-trisubstituted pyrazoles
WO2001032628A1 (en) * 1999-11-03 2001-05-10 Bristol-Myers Squibb Pharma Company Cyano compounds as factor xa inhibitors
US6407256B1 (en) 1999-11-03 2002-06-18 Bristol Myers Squibb Co Cyano-pyrrole, cyano-imidazole, cyano-pyrazole, and cyano-triazole compounds as factor Xa inhibitors
ATE373655T1 (en) 2000-06-23 2007-10-15 Bristol Myers Squibb Pharma Co 1-(HETEROARYL-PHENYL)-CONDENSED PYRAZOLE DERIVATIVES AS FACTOR XA INHIBITORS
MEP58108A (en) 2001-09-21 2011-05-10 Bristol Myers Squibb Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
TWI331526B (en) 2001-09-21 2010-10-11 Bristol Myers Squibb Pharma Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
PE20030547A1 (en) 2001-09-24 2003-08-18 Bayer Corp IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF OBESITY
WO2003048081A2 (en) 2001-12-04 2003-06-12 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
TW200302225A (en) 2001-12-04 2003-08-01 Bristol Myers Squibb Co Substituted amino methyl factor Xa inhibitors
AU2003273179A1 (en) 2002-05-10 2003-12-12 Bristol-Myers Squibb Company 1,1-disubstituted cycloalkyl derivatives as factor xa inhibitors
AU2003302238A1 (en) 2002-12-03 2004-06-23 Axys Pharmaceuticals, Inc. 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors
EP1479678A1 (en) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Pyrazole-derivatives as factor xa inhibitors
US7429581B2 (en) 2002-12-23 2008-09-30 Sanofi-Aventis Deutschland Gmbh Pyrazole-derivatives as factor Xa inhibitors
JP4585448B2 (en) * 2002-12-23 2010-11-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Pyrazole derivatives as factor Xa inhibitors
EP1433788A1 (en) * 2002-12-23 2004-06-30 Aventis Pharma Deutschland GmbH Pyrazole-derivatives as factor Xa inhibitors
US7122557B2 (en) * 2003-03-18 2006-10-17 Bristol-Myers Squibb Company Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors
EP1620405A2 (en) * 2003-05-01 2006-02-01 Abbott Laboratories Pyrazole-amides and sulfonamides as sodium channel modulators
US20040220170A1 (en) * 2003-05-01 2004-11-04 Atkinson Robert N. Pyrazole-amides and sulfonamides as sodium channel modulators
US7223780B2 (en) 2003-05-19 2007-05-29 Sanofi-Aventis Deutschland Gmbh Triazole-derivatives as blood clotting enzyme factor Xa inhibitors
EP1479679A1 (en) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Triazole-derivatives as factor Xa inhibitors
BRPI0412259B1 (en) 2003-07-22 2019-08-20 Astex Therapeutics Limited 3,4-Disubstituted 1H-pyrazole compounds as cyclin-dependent kinase (CDK) modulators, their uses, process for their preparation and pharmaceutical composition
JP4979378B2 (en) * 2003-07-23 2012-07-18 シンタ ファーマシューティカルズ コーポレーション Compounds for inflammation and immune related uses
US20070060629A1 (en) * 2003-10-17 2007-03-15 Yasuhiro Imanishi Large conductance calcium-activated k channel opener
EP1568698A1 (en) * 2004-02-27 2005-08-31 Aventis Pharma Deutschland GmbH Pyrrole-derivatives as factor Xa inhibitors
TWI357901B (en) * 2004-03-12 2012-02-11 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivati
KR20070107022A (en) 2005-01-07 2007-11-06 신타 파마슈티칼스 코프. Compounds for inflammation and immune-related uses
AR054425A1 (en) 2005-01-21 2007-06-27 Astex Therapeutics Ltd PIPERIDIN ADDITION SALTS 4-IL-ACID AMID 4- (2,6-DICLORO-BENZOILAMINO) 1H-PIRAZOL-3-CARBOXILICO.
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
WO2006109846A1 (en) 2005-04-06 2006-10-19 Takeda Pharmaceutical Company Limited Triazole derivative and the use thereof
WO2008051405A1 (en) 2006-10-20 2008-05-02 Merck & Co., Inc. Substituted imidazoles as bombesin receptor subtype-3 modulators
CA2666310C (en) 2006-10-20 2012-07-31 Merck & Co., Inc. Substituted imidazoles as bombesin receptor subtype-3 modulators
JP2010506916A (en) 2006-10-20 2010-03-04 メルク エンド カムパニー インコーポレーテッド Substituted imidazoles as bombesin receptor subtype 3 modulators
CN101583593A (en) 2006-11-13 2009-11-18 辉瑞产品公司 Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
AU2007332867B2 (en) 2006-12-11 2012-02-16 Merck Sharp & Dohme Corp. Substituted diazepine sulfonamides as bombesin receptor subtype-3 modulators
EP2132196A1 (en) 2007-02-26 2009-12-16 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
AU2010363329A1 (en) 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
KR20150033678A (en) 2012-06-26 2015-04-01 사니오나 에이피에스 A phenyl triazole derivative and its use for modulating the gabaa receptor complex
EP2885290B1 (en) 2012-06-26 2017-10-18 Saniona A/S A phenyl triazole derivative and its use for modulating the gabaa receptor complex
NZ746490A (en) 2012-10-02 2018-12-21 Bayer Cropscience Ag Heterocyclic compounds as pesticides
EP2970121B1 (en) * 2013-03-15 2017-12-13 Araxes Pharma LLC Covalent inhibitors of kras g12c
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
JO3805B1 (en) 2013-10-10 2021-01-31 Araxes Pharma Llc Inhibitors of kras g12c
NZ724250A (en) * 2014-03-07 2022-02-25 Biocryst Pharm Inc Human plasma kallikrein inhibitors
CN104072436B (en) * 2014-07-23 2015-10-14 张远强 The tetrazole acetophenone compound of para-orientation, Preparation Method And The Use
CN104086502B (en) * 2014-07-23 2015-10-14 张远强 Halo tetrazole acetophenone compound, Preparation Method And The Use
CN104072439B (en) * 2014-07-23 2015-11-04 张远强 The tetrazole acetophenone compound of halogen substiuted, Preparation Method And The Use
CN104072438B (en) * 2014-07-23 2015-10-14 张远强 Dialkoxy is for tetrazole acetophenone compound, Preparation Method And The Use
JP2018513853A (en) 2015-04-10 2018-05-31 アラクセス ファーマ エルエルシー Substituted quinazoline compounds and methods of use thereof
CA2982360A1 (en) 2015-04-15 2016-10-20 Liansheng Li Fused-tricyclic inhibitors of kras and methods of use thereof
WO2016202935A1 (en) 2015-06-19 2016-12-22 Bayer Pharma Aktiengesellschaft Glucose transport inhibitors
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
EP3356349A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017058728A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10875842B2 (en) 2015-09-28 2020-12-29 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058805A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058792A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10689356B2 (en) 2015-09-28 2020-06-23 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10647703B2 (en) 2015-09-28 2020-05-12 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
AU2016355433C1 (en) 2015-11-16 2021-12-16 Araxes Pharma Llc 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
WO2018064510A1 (en) 2016-09-29 2018-04-05 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3523289A1 (en) 2016-10-07 2019-08-14 Araxes Pharma LLC Heterocyclic compounds as inhibitors of ras and methods of use thereof
EP3573970A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
US11279689B2 (en) 2017-01-26 2022-03-22 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
US11059819B2 (en) 2017-01-26 2021-07-13 Janssen Biotech, Inc. Fused hetero-hetero bicyclic compounds and methods of use thereof
WO2018140512A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
US11358959B2 (en) 2017-01-26 2022-06-14 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
EP3630747A1 (en) 2017-05-25 2020-04-08 Araxes Pharma LLC Quinazoline derivatives as modulators of mutant kras, hras or nras
AU2018271990A1 (en) 2017-05-25 2019-12-12 Araxes Pharma Llc Covalent inhibitors of KRAS
CN110869357A (en) 2017-05-25 2020-03-06 亚瑞克西斯制药公司 Compounds and methods of use thereof for treating cancer
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104311A (en) * 1992-02-05 1997-07-13 Fujisawa Pharmaceutical Co Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
US5612353A (en) * 1995-06-07 1997-03-18 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds
SI20017A (en) * 1996-12-23 2000-02-29 Dupont Pharmaceuticals Company NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS
JP2002507968A (en) * 1997-06-19 2002-03-12 デュポン ファーマシューティカルズ カンパニー Factor Xa inhibitor having a neutral P1 specific group

Also Published As

Publication number Publication date
CA2314401A1 (en) 1999-07-01
JP2001526268A (en) 2001-12-18
AU1724499A (en) 1999-07-12
BR9813835A (en) 2000-10-10
EP1042299A1 (en) 2000-10-11
WO1999032454A1 (en) 1999-07-01
IL136637A0 (en) 2001-06-14

Similar Documents

Publication Publication Date Title
US6271237B1 (en) Nitrogen containing heteromatics with ortho-substituted P1s as factor Xa inhabitors
WO1999032454A9 (en) Nitrogen containing heteroaromatics with ortho-substituted p1&#39;s as factor xa inhibitors
ES2331860T3 (en) HETEROAROMATIC COMPOUNDS CONTAINING NITROGEN AS INHIBITORS OF FACTOR XA.
US6602895B2 (en) Inhibitors of factor Xa with a neutral P1 specificity group
AU756755B2 (en) Novel guanidine mimics as factor Xa inhibitors
US6020357A (en) Nitrogen containing heteroaromatics as factor Xa inhibitors
US6339099B1 (en) Guanidine mimics as factor Xa inhibitors
EP0991625B1 (en) Inhibitors of factor xa with a neutral p1 specificity group
US6548512B1 (en) Nitrogen containing heteroaromatics as factor Xa inhibitors
MXPA00006159A (en) Nitrogen containing heteroaromatics with ortho-substituted p1&#39;s as factor xa inhibitors
LT4673B (en) Nitrogen containing heteroaromatics as factor xa inhibitors
MXPA99005878A (en) NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 136637

Country of ref document: IL

AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR CA CN CZ EE HU IL JP KR LT LV MX NO NZ PL RO SG SI SK UA VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1998962082

Country of ref document: EP

Ref document number: 17244/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 505081

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2314401

Country of ref document: CA

Ref document number: 2314401

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/006159

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2000 525391

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 98813765.8

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1998962082

Country of ref document: EP

AK Designated states

Kind code of ref document: C2

Designated state(s): AU BR CA CN CZ EE HU IL JP KR LT LV MX NO NZ PL RO SG SI SK UA VN

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGE 231, CLAIM, ADDED

WWW Wipo information: withdrawn in national office

Ref document number: 1998962082

Country of ref document: EP